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Abstract 
 
Cane toads (Bufo marinus) were introduced to Australia as a biocontrol agent for the beetle pests of 
sugarcane. An ill-advised attempt at biocontrol, the cane toad experiment proved remarkably 
unsuccessful. Not only did cane toads fail to control the beetles, they became an invasive poisonous 
pest and threat to many native predator species and ecosystems across northern Australia. All 
subsequent attempts to control the cane toad invasion have proved unsuccessful. In an attempt to 
address this challenge we recently set out to investigate cane toad chemical ecology – arguing that 
better knowledge of cane toad toxins and pheromones would reveal weaknesses that might be 
exploited for control. 
 
In preliminary investigations into cane toad toxins Capon group reported that the chemical 
composition of cane toad toxin secretions was more complex than previously reported and that 
bacteria isolated from the cane toad parotoid gland were capable of in vitro biotransformation of 
cane toad toxins. In our current investigations we have (i) characterized an array of bufadienolides 
and arginyl amides, and developed analytical methods for quantification in cane toad toxins  (ii) 
Analysis of cane toad toxins determined the variation of chemical diversity based on various 
handling methods (iii) cane toad toxins are hydrolysed by BtH during secretion from conjugates 
(bufotoxins) to non-conjugates (bufagenins), (iv) there are two types of microbes present in 
parotoid gland, a former that can degrade bufagenins and a latter that can biotransform bufagenins 
to other analogues (vii) cane toad eggs contains bufagenins and bufolipins (conjugates with fatty 
acids) and (viii) evaluation of pharmacological toxicity of cane toad toxins (an SAR study) using in 
vitro cytotoxicity against mammalian cells and bacteria and activation of mNOS pathway by arginyl 
amides. 
 
Cane toad toxin as always been identified as a single entity and the mystery (such as protoxin to 
toxin conversion of cane toad toxins, role of BtH and relationship between biotransformation and 
degradation bacteria) has been elaborated in the current thesis. Knowledge of the full story behind 
cane toad toxins, inclusive of bufagenins and bufotoxins, and the role of biotransforming enzymes 
and bacteria, is the first step in “knowing the enemy”. We are hopeful that this knowledge will 
inform future control solutions. 
ii	  
Declaration by author 
 
This thesis is composed of my original work, and contains no material previously published or 
written by another person except where due reference has been made in the text. I have clearly 
stated the contribution by others to jointly-authored works that I have included in my thesis. 
 
I have clearly stated the contribution of others to my thesis as a whole, including statistical 
assistance, survey design, data analysis, significant technical procedures, professional editorial 
advice, and any other original research work used or reported in my thesis. The content of my thesis 
is the result of work I have carried out since the commencement of my research higher degree 
candidature and does not include a substantial part of work that has been submitted to qualify for 
the award of any other degree or diploma in any university or other tertiary institution. I have 
clearly stated which parts of my thesis, if any, have been submitted to qualify for another award. 
 
I acknowledge that an electronic copy of my thesis must be lodged with the University Library and, 
subject to the General Award Rules of The University of Queensland, immediately made available 
for research and study in accordance with the Copyright Act 1968. 
 
I acknowledge that copyright of all material contained in my thesis resides with the copyright 
holder(s) of that material. Where appropriate I have obtained copyright permission from the 
copyright holder to reproduce material in this thesis. 
iii	  
Publications during candidature 
 
 No publications 
 
Publications included in this thesis 
 
 No publications included 
iv	  
Contributions by others to the thesis  
 
I acknowledge that MALDI imaging discussed in Chapter 4 was performed in collaboration with 
Dr. Brett Hamilton (Prof Deon Ventor group, Mater Hospital, Brisbane) while I provided the 
necessary tissue samples dissected from cane toads. Electron microscopy discussed in Chapter 4 
was performed in collaboration with Dr. Kathryn Green (IMB). Ion Torrent Sequencing of toad 
RNA was performed in collaboration with Dr. Darren Korbie (IMB) and shotgun sequencing with 
Dr. Eivind Undheim. In-house mNOS activation assay was performed in collaboration with Dr. 
Zeinab Khalil and cytotoxicity assay with Dr Xiaocong Huang. All the above experiments were 
planned (with all the necessary samples including tissues or cells, natural or synthetic compounds), 
conceptualized and outcomes processed by me for better understanding of cane toad toxins.  
 
Statement of parts of the thesis submitted to qualify for the award of another degree 
 
None
v	  
Acknowledgements 
 
I would like to thank my supervisor Prof Rob Capon for giving me a wonderful opportunity to work 
with his esteemed group on an interesting research project. I would also like to thank my co-
supervisor Dr. Andrew Piggott for being a good mentor, a great friend and for those nostalgic 
coffee times. I would like to extend my thanks to Dr. Angela Salim for her help with bufolipins and 
for reviewing the thesis even on the weekend. Dr Xiaocong Huang and Dr. Zeinab Khalil for your 
support with assays. I would also like to thank all the Capon group members for being good friends 
and for all the timely help especially towards the end of the project and I wish you guys all the best 
for your future. Dr John Griffin for your help with confocal imaging. 
 
I would like to thank my friend Nausad for his help with protein purification, especially for sharing 
your precious column. Those car drives and your awesome culinary skills contributed a lot to my 
physically heaviest phase of my life. To my housemates, Karthik and Anki, big thanks for providing 
those joyous moments and keeping me light even during those stressful times. Rakesh, you have 
been a great friend and thank you very much for your support especially with software stuff (all 
those Adobes!). My friends at IMB, Andrea, Victor, Xue, Pritesh, Pravir and Dan, you guys are 
awesome and thanks for all those great conversations.  
 
My parents, Dr. Kamalakkannan and Dr. Meenakshi Kamalakkannan, I don’t really have words to 
express my gratitude and emotions. Thanks for making my life better as you have always stood by 
my side. Although you were not physically present here you made your presence felt every minute 
of my life. I would like to thank my sister Vardhini for her understanding and support during my 
tough times. My grandparents, Mr. Kannan and Mrs. Dhakshayani, a big thanks for all the good 
times I have shared with you two. My family members especially Manickkam and Vedhan, you 
guys are awesome and thanks for all the support. This list wouldn’t be complete if not for my 
partner and fiancé, Soumya. You have been the greatest find of my life and will always be. Thanks 
for being my better half and putting up with all those emotional moments. All the trouble that 
you’ve gone through and the support that you’ve given can never be expressed with just few words. 
I am glad that we’ve worked our way out and soon to be starting our life together! 
 
“Though fate is against fulfilment one’s effort has ready payment” 
- Thirukkural 
vi	  
Keywords 
Cane toad toxins, parotoid glands, bufadienolides, arginyl amides, chemical diversity of toxins, 
steroidal toxins, microbial biotransformation, hydrolase, post secretory processing of toxins 
 
Australian and New Zealand Standard Research Classifications (ANZSRC) 
 
030101 Analytical Spectrometry, 45% 
060107, Enzymes, 35% 
030502, Natural Products chemistry, 20% 
 
Fields of Research (FoR) Classification 
 
0601, Biochemistry and Cell Biology, 50% 
0301, Analytical Chemistry, 40% 
0605 Microbiology, 10% 
 
vii	  
Table of contents  
 
Abstract                                                                                                                                               i 
 
Acknowledgements                                                                                                                             v 
 
Table of contents                                                                                                            vii 
 
List of figures                                                                                                                xiii 
 
List of tables                                                                                                                xviii 
 
List of schemes                                                                                                              xix 
 
Abbreviations                                                                                                                 xx 
 
Chapter 1  
Cane toad introduction in Australia and its aftermath 
 
1.1 B. marinus in Australia 2 
1.2 Chemistry of Bufo sp parotoid glands 4 
    1.2.1 Catecholamines  4 
    1.2.2 Indolealkylamines 4 
1.2.3 Bufadienolides 5 
    1.2.3.1 Bufagenins 6 
1.2.3.2 Bufotoxins 7 
    1.2.3.3 Bufolipins 8 
    1.2.3.4 Bufagenin sulfates 9 
    1.2.3.5 Bufagenin glycosides 10 
    1.2.4 Bufadienolides from B. marinus 10 
    1.2.4.1 Parotoid secretions 10 
    1.2.4.2 Skin 11 
    1.2.4.3 Plasma and bile 11 
    1.2.4.4 Eggs/oviducts 11 
    1.2.4.5 Tadpoles 12 
    1.2.5 Pharmacology of cane toad bufadienolides 16 
    1.2.5.1 Inhibition of Na+/K+ ATPase 16 
    1.2.5.2 Cytotoxicity studies of B. marinus bufadienolides 19 
    1.2.5.3 Other biological activities of B. marinus bufadienolides 20 
    1.2.6 Control strategies for cane toad 21 
    1.2.6.1 Physical 21 
    1.2.6.2 Biological 22 
    1.2.6.3 Chemical 23 
1.3 PhD research project 25 
    1.3.1 Aims 25 
    1.3.2 Objectives 25 
1.4 References 26 
viii	  
Chapter 2 
Full characterization, identification and quantification of the cane toad parotoid 
toxins 
 
2.1 Introduction  33 
2.2 Results and discussion 34 
   2.2.1 Generate a library of bufagenin standards 34 
    2.2.1.1 HSQC signature analysis for bufagenin 38 
    2.2.2 Generate a library of bufotoxin standards 41 
    2.2.2.1 HSQC signature analysis for bufotoxins 44 
    2.2.2.2 HSQC fingerprints for 5-OH vs 5-H bufagenins 46 
    2.2.2.3 HSQC fingerprints for 14-epoxy vs 14-OH bufagenins 47 
    2.2.3 HPLC-DAD methodology to analyse bufagenins 50 
    2.2.3.1 Quantification of bufagenins 52 
    2.2.4 HPLC-DAD methodology to analyse bufotoxins 52 
    2.2.4.1 Quantification of bufotoxins 54 
    2.2.5 Analysis of bufadienolides from live cane toads parotoid secretions 54 
 
 
    2.2.5.1 Approach 1 55 
    2.2.5.2 Approach 2 55 
   2.2.6 Analytical methodology to identify arginine 57 
   2.2.7 Analytical methodology to identify bufagenin suberates 59 
   2.2.8 Generate a library of diacid arginyl amides standards 60 
   2.2.9 Analytical methodology to analyse arginyl amides 63 
   2.2.9.1 Analytical methodology 1 for arginyl amides – HPLC-DAD-MS 63 
  2.2.9.2 Analytical methodology 2 for detection of arginyl amides 64 
  2.2.9.3 Quantification of arginyl amides 65 
2.3 Conclusion 68 
2.4 Experimental 69 
2.4.1 Equipment 69 
2.4.2 Isolation of bufagenins from parotoid secretions 69 
2.4.3 Synthesis of bufagenin esters 70 
2.4.3.1 Synthesis of bufalin-3-suberate  70 
2.4.3.2 Synthesis of bufalin-3-pimelate  70 
2.4.3.3 Synthesis of bufalin-3-acetate 71 
2.4.3.4 Synthesis of telocinobufagenin-3-suberate  71 
2.4.3.5 Synthesis of marinobufagenin-3-suberate 71 
2.4.3.6 Synthesis of marinobufagenin-3-pimelate 72 
2.4.3.7 Synthesis of marinobufagenin-3-succinate 72 
2.4.3.8 Synthesis of marinobufagenin-3-acetate 72 
2.4.4 Synthesis of bufotoxins 73 
2.4.4.1 Synthesis of bufalitoxin 73 
2.4.4.2 Synthesis of bufalin pimeloyl-L-arginine 73 
2.4.4.3 Synthesis of telocinobufotoxin 73 
2.4.4.4 Synthesis of marinobufotoxin 73 
2.4.4.5 Synthesis of marinobufagenin pimeloyl-L-arginine 74 
2.4.5 Synthesis of amides 75 
2.4.5.1 Synthesis of suberic anhydride 75 
2.4.5.2 Synthesis of pimelic anhydride 75 
2.4.5.3 Synthesis of suberoyl-L-arginine 75 
  
ix	  
2.4.5.4 Synthesis of pimeloyl-L-arginine 75 
2.4.5.5 Synthesis of azeloyl-L-arginine 76 
2.4.5.6 Synthesis of adipoyl-L-arginine 76 
2.4.6 Synthesis of derivatized amide standards 76 
2.4.7 Analytical methodology for detection of various structure classes of cane toad toxins 77 
2.4.8 Derivatization of amides from parotoid toxin/secretion as pyrimidines  78 
2.5 Appendix 79 
2.6 References 122 
 
Chapter 3 
Chemo-anatomy: Bufadienolide composition in cane toad parotoid toxin and 
parotoid secretion 
 
3.1 Introduction  125 
3.2 Results and discussion  127 
    3.2.1 Micro-dissection of parotoid microglands 127 
    3.2.2 Chemical analysis and quantification of parotoid secretions, parotoid toxins and parotoid microglands 131 
    3.2.2.1 Secretion A – parotoid secretion squeezed onto a glass plate 131 
    3.2.2.2 Secretion B – parotoid secretions squeezed into MeOH 135 
    3.2.2.3 Secretion C – parotoid secretions squeezed into H2O 140 
    3.2.2.4 Toxin A – microgland extracted with MeOH 143 
    3.2.2.5 Toxin B – microgland extracted into H2O 148 
    3.2.3 Rate of hydrolysis of bufotoxins 151 
    3.2.3.1 Rate of hydrolysis of bufotoxins – Secretion D 151 
    3.2.4 Identification of bufotoxin hydrolysis in parotoid microglands – chemical approach 154 
    3.2.4.1 Toxin C – investigation of co-localization of hydrolase 154 
    3.2.5 Why bufotoxins? – Multi-faceted stability investigations 156 
    3.2.6 Physical stability - Storage of toxins and their particle stability 157 
    3.2.6.1 Physical properties of cane toad of parotoid toxins 157 
    3.2.7 Chemical stability of toxins to plasma and saliva 161 
    3.2.7.1 Stability of toxins to plasma 162 
    3.2.7.2 Stability of toxins to saliva 164 
    3.2.8 Discussion – parotoid secretions vs parotoid toxins 165 
3.3 Conclusion 170 
3.4 Experimental 172 
    3.4.1 Micro-dissection of parotoid microglands 172 
 3.4.2 Secretion A – parotoid secretion squeezed onto glass plate 172 
    3.4.3 Secretion B – parotoid secretions squeezed into MeOH 172 
    3.4.4 Secretion C – parotoid secretions squeezed into H2O 172 
    3.4.5 Toxin A – microgland extracted in MeOH 173 
    3.4.6 Toxin B - microgland extracted in H2O 173 
    3.4.7 Secretion D – rate of hydrolysis of bufotoxin 173 
    3.4.8 Toxin C – co-localization of hydrolase within microgland 173 
    3.4.9 Imaging in situ parotoid toxin in parotoid microglands (Confocal imaging) 174 
    3.4.10 Imaging in situ parotoid toxin in parotoid microglands (Electron microscopy) 174 
    3.4.11 Stability of marinobufotoxin in plasma  174 
    3.4.12 Half-life of marinobufotoxin in plasma 174 
    3.4.13 Stability of marinobufotoxin in saliva 175 
3.5 References 
 
 
176 
x	  
Chapter 4 
Isolation, identification and characterization of enzyme mediating toxin 
hydrolysis                                    
 
4.1 Introduction 179 
4.2 Results and discussion 181 
   4.2.1 Fluorescein aided detection of hydrolase activity in parotoid secretions 181 
   4.2.2 Identification of BtH 182 
   4.2.2.1 Structure of parotoid gland and microglands 182 
   4.2.2.2 Localization of BtH 186 
   4.2.3 MALDI imaging on parotoid glands 187 
   4.2.4 Isolation of BtH from B. marinus parotoid secretions 189 
   4.2.5 Hypotheses 194 
   4.2.5.1 Hypothesis 1 194 
   4.2.5.2 Hypothesis 2 194 
   4.2.6 Identification of BtH – a proteomic/transcriptomic approach 195 
   4.2.6.1 Transcriptomics of parotoid gland 195 
   4.2.6.2 Tandem mass spectrometry sequencing of BtH 201 
4.2.6.3 Further purification of A62b 205 
4.2.7 Phylogenetic analysis 206 
   4.2.8 Kinetics of BtH – measurement of Vmax and Km values for the hydrolysis of bufotoxins by in situ 
hydrolase 
210 
   4.2.9 Structure-activity-related studies on BtH 212 
   4.2.9.1 Inhibition of hydrolase activity by suberoyl-L-arginine 214 
   4.2.10 Formation of bufotoxins by BtH (a hydrolase acting as an esterase) 216 
4.3 Conclusion 217 
4.4 Experimental 219 
   4.4.1 Reaction with fluorescein diacetate 219 
   4.4.2 Histology of parotoid gland 219 
   4.4.2.1 Imaging of BtH 219 
   4.4.3 Imaging mass spectrometry 219 
   4.4.4 Isolation of BtH from parotoid secretions 220 
   4.4.5 Kinetics of BtH 220 
4.4.5.1 Optimization of BtH concentration 220 
   4.4.5.2 Determination of Vmax and Kd values for BtH 221 
   4.4.6 Inhibition of BtH by amides 221 
   4.4.7 Transcriptomics of parotoid gland 221 
   4.4.8 Tandem mass spectrometry sequencing of BtH 222 
   4.4.9 Phylogenetic analysis 222 
4.5 References 223 
 
Chapter 5 
The ecological role of microbial biotransformation of cane toad toxins 
 
5.1 Introduction 225 
5.2 Results and discussion 230 
    5.2.1 Biotransformation of marinobufagenin 230 
    5.2.2 Biotransformation of marinobufotoxin (1c) 232 
    5.2.3 Biotransformation of marinobufagenin-3-suberate (1b) 235 
    5.2.4 Biotransformation of other bufagenins 237 
  
xi	  
    5.2.4.1 Biotransformation of telocinobufagenin (2a) 237 
    5.2.4.2 Biotransformation of bufalin (3a) 239 
    5.2.4.3 Discussion – biotransformation of bufagenins, bufotoxins and bufagenin-3-suberate 241 
    5.2.5 Identification of new bufagenin transforming microbes from parotoid gland and secretions 241 
5.3 Conclusion 247 
5.4 Experimental 249 
    5.4.1 Biotransformation of bufadienolides 249 
    5.4.1.1 Materials 249 
    5.4.1.2 Growth of previously isolated biotransforming strains 249 
    5.4.1.3 Growth of bacterial strains in liquid medium 249 
    5.4.2 Biotransformation of marinobufagenin (1a) 249 
    5.4.3 Biotransformation of marinobufotoxin (1c) 249 
    5.4.4 Biotransformation of marinobufagenin hemisuberate (1b) 250 
    5.4.5. Biotransformation of telocinobufagenin (2a) 250 
    5.4.6 Biotransformation of bufalin (3a) 250 
    5.4.7 Isolation of microbes from the surface and the interior of the parotoid gland 250 
    5.4.8 Biotransformation of marinobufagenin (1a) using micro bioreactors 251 
5.5 References 252 
 
Chapter 6 
Characterization of the cane toad egg extracts, with the emphasis on 
bufadienolides (bufolipins) 
 
6.1 Introduction 255 
6.2 Results and discussion 258 
    6.2.1 Analytical methodology for bufagenin esters 258 
    6.2.2 Partitioning of egg extracts 260 
    6.2.3 Identification of bufadienolides based on HPLC-DAD-MS analysis 261 
    6.2.4 Isolation of bufagenins 264 
    6.2.5 Identification of bufolipins 267 
    6.2.6 Discussion on bufadienolides from B. marinus eggs 269 
    6.2.7 Hydrolysis of bufolipins 269 
    6.2.8 Bufolipins as B. marinus tadpole attractants 271 
    6.2.8.1 Isolation of large amounts of bufagenins 272 
6.3 Conclusion 273 
6.4 Experimental 274 
    6.4.1 analytical methodologies for detection and isolation of bufolipins 274 
    6.4.2 Isolation and identification of bufagenins and bufolipins from B. marinus eggs 274 
    6.4.3 Synthesis of octanoic acid chloride 275 
    6.4.4 Synthesis of marinobufagenin-3-octanoate (6h) 275 
    6.4.5 Isolation of bufagenins from parotoid secretions 275 
6.5 References 276 
6.6 Appendix 277 
 
 
 
xii	  
Chapter 7 
Comparative analysis of the pharmacological properties of individual cane toad 
toxins 
 
7.1 Introduction 279 
7.1.1 Cane toad toxins and toxicity 279 
7.1.2 Conventional assays: a critic 279 
7.1.3 Cane toad toxicity – pharmacological or ecological 281 
7.2 Results and discussion  284 
7.2.1 Pharmacological toxicity studies on bufadienolides 284 
7.2.2 Cytotoxicity of bufadienolides – An SAR study 285 
7.2.2.1 Cytotoxicity of bufagenins 285 
7.2.2.2 Cytotoxicity of bufagenin esters 286 
7.2.2.3 Cytotoxicity of bufotoxins 287 
7.2.2.4 Cytotoxicity of bufolipins 288 
7.2.2.5 Discussion – SAR studies on cytotoxicity of bufadienolides 290 
7.2.2.6 Cytotoxicity of arginyl amides 291 
7.2.2.7 Synergism of bufagenins and suberoyl-L-arginine (1d) 292 
7.2.3 Possible role of nitric oxide synthase in cane toad toxicity 293 
7.2.4 mNOS activation of arginyl amides 293 
7.2.4.1 Effect of suberoyl-L-arginine and pimeloyl-L-arginine compared to L-arginine 294 
7.2.4.2 SAR studies on mNOS activation of arginyl amides 296 
7.2.4.3 Discussion – mNOS activation by arginyl amides 297 
7.2.5 Antimicrobial activity of bufadienolides and arginyl amides 298 
7.3 Conclusion 299 
7.4 Experimental 300 
7.4.1 Cytotoxicity 300 
7.4.1.1 Cell lines and Cell Culture 300 
7.4.1.2 Cytotoxicity Assay (MTT) 300 
7.4.2 mNOS activation assay 300 
7.4.2.1 Reagents preparation according to manufacturer’s instructions 300 
7.4.2.2 Cell Preparations 301 
7.4.3 Antimicrobial assay 301 
7.5 References  302 
8 Conclusion 303 
9. Future work 305 
 
  
xvii	  
List of Figures  
 
Figure 1.1 Adult male cane toad (Bufo marinus) 2 
Figure 1.2 B. marinus in wild 3 
Figure 1.3 Distribution of cane toads in Australia as of 2007 4 
Figure 1.4 Structure of major catecholamines reported from parotoid secretions of the cane toad 4 
Figure 1.5 Structure of major indole alkylamines reported from parotoid secretions of the cane toad 5 
Figure 1.6 Examples of bufagenins found in plants and animals 7 
Figure 1.7 Examples of bufotoxins found in toads and snakes  8 
Figure 1.8 Bufolipins found in eggs/ovaries of the cane toad  9 
Figure 1.9 Examples of bufagenin sulfates found in toads 9 
Figure 1.10 Examples of bufagenin glycosides from plants  10 
Figure 1.11 Bufagenins from B. marinus  14 
Figure 1.12 Bufotoxins from B. marinus  15 
Figure 1.13 Bufagenin sulfates from B. marinus  15 
Figure 1.14 Diagrammatic representation of the membrane bound Na+/K+ ATPase pump  17 
Figure 1.15 List of cane toad bufadienolides structure class based on inhibition of Na+/K+ ATPase  19 
Figure 1.16 Cane toad tadpoles flee in response to crushed conspecifics  23 
Figure 2.1 Scheme describing strategy for assembling a bufagenin/bufotoxin standard library 34 
Figure 2.2 Isolation scheme for bufagenins from cane toad parotoid gland secretions 35 
Figure 2.3 HPLC chromatogram (298 nm) of EtOAc solubles from cane toad parotoid secretion 36 
Figure 2.4 Bufagenins isolated from cane toad parotoid secretions 36 
Figure 2.5 Expansion of HSQC (CD3OD, 600 MHz) spectrum of marinobufagenin (1a)  39 
Figure 2.6 Expansion of HSQC (CD3OD, 600 MHz) spectrum of telocinobufagenin (2a)  39 
Figure 2.7 Expansion of HSQC (CD3OD, 600 MHz) spectrum of bufalin (3a)  40 
Figure 2.8 Expansion of HSQC (CD3OD, 600 MHz) spectrum of resibufagenin (4a)  40 
Figure 2.9 Synthesis of marinobufotoxin (1c)  41 
Figure 2.10 Expansion of HSQC (CD3OD, 600 MHz) spectrum of marinobufotoxin (1c)  45 
Figure 2.11 Expansion of HSQC (CD3OD, 600 MHz) spectrum of telocinobufotoxin (2c)  45 
Figure 2.12 Expansion of HSQC (CD3OD, 600 MHz) spectrum of bufalitoxin (3c)  46 
Figure 2.13 Expansion of HSQC (CD3OD, 600 MHz) fingerprint of 5-OH bufagenins  46 
Figure 2.14 Expansion of HSQC (CD3OD, 600 MHz) fingerprint of 5-H bufagenins  47 
Figure 2.15 Expansion of HSQC (CD3OD, 600 MHz) fingerprint of 14-OH bufagenins  47 
Figure 2.16 Expansion of HSQC (CD3OD, 600 MHz) fingerprint of 14-epoxy bufagenins  48 
Figure 2.17 Bufagenin esters synthesized from bufagenins  49 
Figure 2.18 Bufotoxins synthesized from bufagenin esters  50 
Figure 2.19 HPLC chromatograms (298 nm) and UV-Vis spectrum of bufagenins 51 
Figure 2.20 Concentration curve and UV-vis spectrum of marinobufagenin (1a)  52 
Figure 2.21 HPLC chromatograms (298 nm) and UV-vis spectrum of bufotoxins 53 
Figure 2.22 Concentration curve and UV-vis spectrum of marinobufotoxin (1c)    54 
Figure 2.23 HPLC profile (298 nm) of live cane toad parotoid secretion squeezed on a petridish  55 
Figure 2.24 HPLC profile (298 nm) of adult parotoid secretion squeezed into water  56 
Figure 2.25 Mechanism 1 – Transformation of marinobufotoxin (1c)  56 
Figure 2.26 Mechanism 2 – Transformation of marinobufotoxin (1c)  57 
Figure 2.27 HPLC chromatogram (320 nm) of C3 Marfey’s analysis on water soluble fraction  58 
Figure 2.28 Co-injection of organic fraction of parotoid secretion with bufagenin suberates  59 
Figure 2.29 Scheme of synthesis for arginyl amides standards with suberoyl-L-arginine (1d) as an example  60 
Figure 2.30 List of synthesized arginyl amides  62 
Figure 2.31 List of derivatized synthetic arginyl amides  62 
Figure 2.32 Single ion extraction of derivatized arginyl amides standards in positive ion ESI mode  63 
Figure 2.33 Single ion extraction of crude water solubles of parotoid secretion in positive ion ESI mode  64 
Figure 2.34 HPLC chromatogram (320 nm) and UV-vis spectrum of 2,4-pentanedione derivatized extract  65 
Figure 2.35 Concentration curve and UV-vis spectrum of derivatized suberoyl-L-arginine (1e)  67 
Figure S1 1H NMR (CD3OD, 600 MHz) data for marinobufagenin (1a)  93 
Figure S2 1H NMR (CD3OD, 600 MHz) data for telocinobufagenin (2a)  94 
Figure S3 1H NMR (CD3OD, 600 MHz) data for bufalin (3a)  95 
xvii	  
Figure S4 1H NMR (CD3OD, 600 MHz) data for hellebrigenin (5a)  96 
Figure S5 1H NMR (CD3OD, 600 MHz) data for bufalin-3-acetate (7a)  97 
Figure S6 1H NMR (CD3OD, 600 MHz) data for marinobufagenin-3-suberate (1b)  98 
Figure S7 1H NMR (CD3OD, 600 MHz) data for telocinobufagenin-3-suberate (2b)  99 
Figure S8 1H NMR (CD3OD, 600 MHz) data for bufalin-3-suberate (3b)  100 
Figure S9 1H NMR (CD3OD, 600 MHz) data for marinobufotoxin (1c)  101 
Figure S10 1H NMR (CD3OD, 600 MHz) data for telocinobufotoxin (2c)  102 
Figure S11 1H NMR (CD3OD, 600 MHz) data for bufalitoxin (3c)  103 
Figure S12 1H NMR (CD3OD, 600 MHz) data for adipoyl-L-arginine (2d)  104 
Figure S13 1H NMR (CD3OD, 600 MHz) data for pimeloyl-L-arginine (3d)  105 
Figure S14 1H NMR (CD3OD, 600 MHz) data for suberoyl-L-arginine (1d) 106 
Figure S15 1H NMR (CD3OD, 600 MHz) data for azeloyl-L-arginine (4d)  107 
Figure S16 1H NMR (CD3OD, 600 MHz) data for derivatized suberoyl-L-arginine (1e)  108 
Figure S17 1H NMR (CD3OD, 600 MHz) data for resibufagenin (4a)  109 
Figure S18 1H NMR (CD3OD, 600 MHz) data for derivatized azeloyl-L-arginine (4e)  110 
Figure S19 1H NMR (CD3OD, 600 MHz) data for derivatized adipoyl-L-arginine (2e)  111 
Figure S20 1H NMR (CD3OD, 600 MHz) data for marinobufagenin-3-succinate (9b)  112 
Figure S21 1H NMR (CD3OD, 600 MHz) data for marinobufagenin-3-pimelate (5b)  113 
Figure S22 1H NMR (CD3OD, 600 MHz) data for marinobufagenin-3-acetate (8b)  114 
Figure S23 1H NMR (CD3OD, 600 MHz) data for bufalin pimeloylarginine (9c)  115 
Figure S24 1H NMR (CD3OD, 600 MHz) data for marinobufagenin pimeloylarginine (8c)  116 
Figure S25 1H NMR (CD3OD, 600 MHz) data for derivatized pimeloyl-L-arginine (3e)  117 
Figure S26 1H NMR (CD3OD, 600 MHz) data for bufalin-3-pimelate (7b)  118 
Figure S27 HPLC chromatograms (298 nm) of natural bufagenins analysed using Method 1 119 
Figure S28 HPLC chromatograms (298 nm) of synthetic bufotoxins analysed using Method 2   119 
Figure S29a Concentration curves of bufagenins and bufotoxins 120 
Figure S29b Concentration curves of bufotoxins and derivatized amides 121 
Figure 3.1 Scheme of handling of parotoid gland contents  126 
Figure 3.2 Section of parotoid gland exhibiting dorsal portion covered with thick epithelium  127 
Figure 3.3 Light microscopy image of parotoid microglands  128 
Figure 3.4 3 Light microscopy image of parotoid microglands at different stages of compression 129 
Figure 3.5 Scanning electron microscopy images of an intact parotoid microgland filled with toxin 130 
Figure 3.6 Scanning electron microscopy images of a compressed parotoid microgland 130 
Figure 3.7 Secretion A – production of analytes A1 – A5 (n-BuOH)  132 
Figure 3.8 HPLC chromatogram (298 nm) of Secretion A analytes A1-A5 analysed using Method 2 133 
Figure 3.9 Bufotoxins identified in parotoid secretions in secretion A  133 
Figure 3.10 Bufagenins identified in parotoid secretions in secretion A  134 
Figure 3.11 Secretion B – production of analytes A6 – A8 (n-BuOH) and A6* – A8* (H2O)  136 
Figure 3.12 HPLC chromatogram (298 nm) of Secretion B analytes A6-A8 analysed using Method 2  137 
Figure 3.13 Derivatized arginyl amide identified in Secretion B preparation  138 
Figure 3.14 HPLC chromatogram (320 nm) of Secretion B analytes A6*-A8* analysed using Method 3 139 
Figure 3.15 Secretion C – production of analytes A9 – A11 (n-BuOH) and A9* – A11* (H2O)  140 
Figure 3.16 HPLC chromatogram (298 nm) of Secretion C analytes A9-A11 analysed using Method 1 141 
Figure 3.17 Derivatized arginyl amides detected in Secretion C preparation  142 
Figure 3.18 HPLC chromatogram (320 nm) of 2 Secretion C analytes A9*-A11* analysed using Method 3 143 
Figure 3.19 Toxin A – production of analytes A12 – A20 (n-BuOH) and A12’ – A20’ (H2O)  144 
Figure 3.20 HPLC chromatogram (298 nm) of Toxin A analytes A12-A20 analysed using Method 2 145 
Figure 3.21 Plot between mass of microgland (mg) and total bufadienolides per microgland (µg)  147 
Figure 3.22 HPLC chromatogram (298 nm) of Toxin A analytes A12*-A20* analysed using Method 3 148 
Figure 3.23 Toxin B – production of analytes A21 – A29 (n-BuOH)  149 
Figure 3.24 HPLC chromatogram (298 nm) of Toxin B analyets A21*-A29* analysed using Method 2 150 
Figure 3.25 Secretion D – production of analytes A30 – A50 (n-BuOH)  151 
Figure 3.26 HPLC chromatogram (298 nm) of Secretion D analytes A30-A50 analysed using Method 2 152 
Figure 3.27 Conversion of marinobufotoxin (1c) to marinobufagenin (1a) over 30 min  153 
Figure 3.28 Comparison of dissection strategies adopted in previous analyses 154 
Figure 3.29 Toxin C – production of analytes A51 – A54 (n-BuOH)  155 
Figure 3.30 Identification of hydrolase activity in different modes of dissection 155 
xvii	  
Figure 3.31 Storage of bufotoxins serves several benefits 157 
Figure 3.32 Parotoid toxin exiting from a parotoid microgland  158 
Figure 3.33 Confocal image of toxin stored within the parotoid microgland  159 
Figure 3.34 Lipid droplets observed within an individual parotoid microgland  160 
Figure 3.35 Cylindrical structures within lipid droplets 160 
Figure 3.36 HPLC chromatogram (298 nm) of 100 µM of marinobufotoxin (1c) 162 
Figure 3.37 Stability of 100 µM of marinobufotoxin (1c) in the presence of human plasma for 24 h  163 
Figure 3.38 Stability of 100 µM of marinobufotoxin (1c) (green) in the presence of human saliva for 1 h 164 
Figure 3.39 Summary on investigations of storage and delivery of cane toad parotoid toxins  166 
Figure 3.40 Scheme of analysis of parotoid secretions with different handling approaches  166 
Figure 3.41 Scheme of analysis of parotoid toxin with different handling approaches  167 
Figure 3.42 Chemical composition of parotoid toxins vs parotoid secretions 167 
Figure 3.43 Plausible oxidation-reduction in in situ parotoid glands to form various bufotoxin analogues  169 
Figure 3.44 A diagrammatic representation of storage and release of parotoid toxin  171 
Figure 4.1 Conversion of fluorescein diacetate to fluorescein by the hydrolase in the presence of H2O   181  
Figure 4.2 Reaction of crude parotoid secretions pellet with fluorescein diacetate  182 
Figure 4.3 Trichrome staining of B. marinus parotoid gland  183 
Figure 4.4 Differential staining of parotoid microglands exhibiting foam like appearances 185 
Figure 4.5 Imaging of parotoid micro glands using various stains  186 
Figure 4.6 Confocal image of differentiated granular glands in the parotoid gland  187 
Figure 4.7 Imaging mass spectrometry of parotoid glands with in situ parotoid toxin  188 
Figure 4.8 SDS PAGE analysis of analytes A55 – A58 in Tris buffer  190 
Figure 4.9 Chromatogram showing the absorbance of various proteins present in the parotoid secretions 
chromatography, S-200 column                    202 
191 
Figure 4.10 Fluorescence exhibited by A62 (left) and A61 (right) measured using FdA  191 
Figure 4.11 SDS PAGE analysis of A61 and A62 collected using gel filtration in Tris buffer 192 
Figure 4.12 Purification of the active protein (A62b) using gel filtration chromatography  192 
Figure 4.13 Summary of hypotheses 1 and 2 194 
Figure 4.14 Plausible role of BtH in hydrolysis and esterification  195 
Figure 4.15 Calculated nucleotide sequence of 100 kDa protein with high expression in A68  198 
Figure 4.16 Translated protein sequence of 100 kDa protein with high expression in A68  199 
Figure 4.17 Calculated nucleotide sequence of 50 kDa protein with high expression in A69 199 
Figure 4.18 Translated protein sequence of 50 kDa protein with high expression in A69 (contig 61) 199 
Figure 4.19 Blast of the highest expressed protein showing similarity to Bufo species  200 
Figure 4.20 Blast of the highest expressed protein showing similarity to Xenopus laevis 200 
Figure 4.21 Complete sequence of BtH identified from transcriptomics 202 
Figure 4.22 Complete sequence of 50 kDa protein identified from transcriptomic analysis  204 
Figure 4.23 Complete sequence of the 50 kDa protein identified from partial sequencing 205 
Figure 4.24 Purification of the active fraction of BtH 206 
Figure 4.25 First cluster of phylogenetic tree for BtH             207 
Figure 4.26 Second cluster of phylogenetic tree for BtH             207 
Figure 4.27 Third cluster of phylogenetic tree for BtH        208 
Figure 4.28 Phylogentic analysis of BtH showing matches with conserved sequences  209 
Figure 4.29 Rate kinetics of parotoid gland hydrolase (BtH)  211 
Figure 4.30 Calculation of Km and Vmax value for the BtH for the hydrolysis of marinobufotoxin (1c) 212 
Figure 4.31 Structure based hydrolase activity of BtH 1b and 1c 213 
Figure 4.32 Structure based hydrolase activity of BtH 8b 213 
Figure 4.33 Structure based hydrolase activity of BtH 9b and 1h 214 
Figure 4.34 Structure activity based relationship activity exhibited by BtH on various bufotoxin analogues 214 
Figure 4.35 Hypothesis – suberoyl-L-arginine influences the binding characteristics of bufotoxins on BtH  215 
Figure 4.36 Inhibition of BtH mediated hydrolysis of marinobufotoxin (1c) in the presence of 1d 216 
Figure 4.37 Summary on investigations of storage and delivery of cane toad toxins  217 
Figure 4.38 A diagrammatic representation of storage and release of parotoid toxin  218 
Figure 5.1 Biotransformation of cinobufagenin (31a) by Alternaria alternata and Mucor spinosus  226 
Figure 5.2 Modifications observed in biotransformation of bufagenins 228 
Figure 5.3 Biotransformation of marinobufagenin (1a) by Comamonas testosteronii 229 
Figure 5.4 HPLC traces (298 nm) of analytes A70 - A72 analysed using Method 1 231 
Figure 5.5 HPLC traces (298 nm) of analytes A73 - A75 analysed using Method 1 232 
xvii	  
Figure 5.6 HPLC traces (298 nm) of analytes A76 – A78 analysed using Method 1 233 
Figure 5.7 HPLC traces (298 nm) of analytes A79 – A81 analysed using Method 1 234 
Figure 5.8 HPLC traces (298 nm) analytes A82 – A84 analysed using Method 1 236 
Figure 5.9 HPLC traces (298 nm) of analytes A85 – A87 analysed using Method 1 237 
Figure 5.10 HPLC trace (298 nm) of analyte A88   238  
Figure 5.11 Single ion-extraction of analyte A88 238 
Figure 5.12 Proposed scheme and biotransformation products of telocinobufagenin (2a) by A. johnsonii 239 
Figure 5.13 HPLC traces (298 nm) of ethyl acetate fraction of bufalin (3a) added Acinetobacter johnsonii 240 
Figure 5.14a HPLC-DAD-MS analysis of TIC (negative reflectron mode) 240 
Figure 5.14b Single ion-extraction of analyte A89 240 
Figure 5.15 Proposed scheme and biotransformation products of bufalin (3a) by A. johnsonii 240 
Figure 5.16 Applikon bioreactor system 242 
Figure 5.17 HPLC traces (298 nm) of analytes A119 (green) and A148 (blue) analysed using Method 1 244 
Figure 5.18 HPLC trace (298 nm) of A109 analysed using Method 1 245 
Figure 5.19 HPLC trace (298 nm) of A124 analysed using Method 1 245 
Figure 5.20 Proposed role of biotransforming microbes in parotoid glands  246 
Figure 5.21 A diagrammatic representation of storage and release of parotoid toxin from a parotoid microgland 248 
Figure 6.1 Bufagenins and bufolipins found in eggs/ovaries of the cane toad 256 
Figure 6.2 HPLC chromatograms and UV-Vis spectrum of synthetic bufolipins analysed using Method 4 258 
Figure 6.3 HPLC chromatograms and UV-Vis spectrum of synthetic bufolipins analysed using Method 5 259 
Figure 6.4 HPLC chromatogram of A159 analysed using Method 4 261 
Figure 6.5 HPLC-DAD-MS chromatogram of A161 analysed using Method 4  262 
Figure 6.6a HPLC-DAD-ESI(+)-MS of A161 exhibiting single ion extraction of bufagenins 263 
Figure 6.6b HPLC-DAD-ESI(-)-MS of A161 exhibiting single ion extraction of bufolipins 264 
Figure 6.7 Purification of A161 using preparative HPLC-DAD  264 
Figure 6.8 Bufagenins identified in A161  267 
Figure 6.9 Bufolipins identified in A161  268 
Figure 6.10 HPLC-DAD-MS profile of analytes A187 and A188  268 
Figure 6.11 HPLC-DAD-MS profile of unknown bufolipins in fractions 4h and 5h 269 
Figure 6.12 HPLC chromatogram (298 nm) of A192 analysed using Method 1  270 
Figure 6.13 HPLC-DAD-MS analysis of A192 describing the single ion extraction  270 
Figure 6.14 HPLC chromatogram of marinobufagenin-3-octanoate (6h) analysed using Method 4 271 
Figure 6.15 HPLC traces (298nm) of analytes A192 – A195 analysed using Method 1 273 
Figure S30 1H NMR (CD3OD, 600 MHz) data for marinobufagenin-3-octanoate (6h) 277 
Figure 7.1 Bufagenins subjected to cytotoxicity assays 285 
Figure 7.2 Cytotoxicity (IC50) of bufagenins from parotoid secretions for SW 620 and SF-295 cell lines 285 
Figure 7.3 Bufagenin esters subjected to cytotoxicity assays 286 
Figure 7.4 Cytotoxicity (IC50) of bufagenin esters from parotoid secretions and synthetic analogues  287 
Figure 7.5 Bufotoxins subjected to cytotoxicity assays 288 
Figure 7.6 Cytotoxicity (IC50) of bufotoxins for SW 620 and SF-295 cell lines 288 
Figure 7.7 Bufolipins subjected to cytotoxicity assays 289 
Figure 7.8 Cytotoxicity (IC50) of bufolipins for SW 620 and SF-295 cell lines 289 
Figure 7.9 Structure activity relationship of bufadienolide structure classes based on cytotoxicity 291 
Figure 7.10 Arginyl amides subjected to cytotoxicity assays 291 
Figure 7.11 Cytotoxicity (IC50) of arginyl amides for SW 620 and SF-295 cell lines 292 
Figure 7.12 Cytotoxicity profiles of marinobufotoxin (1c) and its hydrolysis products 292 
Figure 7.13 Description of NOS pathway in an endothelial cell  293 
Figure 7.14  mNOS activation identified in KB31 cells 295 
Figure 7.15 mNOS activation identified in SW620 cells  295 
Figure 7.16 mNOS activation identified in KB-31 cells post treatment with 1mM arginyl amides 296 
Figure 7.17 Proposed scheme of events following a predatory attack on cane toads 297 
Figure 7.18 MIC (antilog) curve exhibited by bufalin (3a) on Pseudomonas aeruginosa 298 
Figure 8.1 Trends in understanding of cane toad parotoid glands 304 
	  
xviii	  
List of tables 
 
Table 1.1 List of bufadienolides from various tissues of B. marinus reported from various countries  13 
Table 1.2 List of pharmacological properties reported on various bufadienolide structure classes isolated  21 
Table 2.1 List of amino acids identified in water solubles of parotoid secretion using C3-Marfey’s analysis  59 
Table 2.2 List of synthesized diacid arginyl amides  62 
Table 2.3 List of all 2,4-pentanedione derivatized arginyl amides  63 
Table 2.4 Analytical methods for the detection of bufadienolides and amides  78 
Table S1 NMR (CD3OD, 600 MHz) data for marinobufagenin (1a) 79 
Table S2 NMR (600 MHz, CD3OD) data for telocinobufagenin (2a)  80 
Table S3 NMR (600 MHz, CD3OD) data for bufalin (3a) 81 
Table S4 NMR (600 MHz, CD3OD) data for resibufagenin (4a) 82 
Table S5 NMR (600 MHz, CD3OD) data for hellebrigenin (5a) 83 
Table S6 NMR (600 MHz, CD3OD) data for bufalin-3-acetate (7a) 84 
Table S7 NMR (CD3OD, 600 MHz) data for marinobufotoxin (1c) 86 
Table S8 NMR (600 MHz, CD3OD) data for synthetic telocinobufotoxin (2c) 87 
Table S9 NMR assignments (600 MHz, CD3OD) of synthetic bufalitoxin (3c) 88 
Table S10 NMR assignments (600 MHz, MeOD) of bufalin pimeloyl-L-arginine (9c) 89 
Table S11 NMR assignments (600 MHz, MeOD) of marinobufagenin pimeloyl-L-arginine (8c) 90 
Table S12 NMR (D2O, 600 MHz) data for suberoyl-L-arginine (1d) 91 
Table S13 NMR assignments (600 MHz, D2O) of azeloyl-L-arginine (4d) 91 
Table S14 NMR assignments (600 MHz, D2O) of pimeloyl-L-arginine (3d) 92 
Table S15 NMR assignments (600 MHz, D2O) of adipoyl-L-arginine (2d) 92 
Table 3.1 Relative composition (%) of bufadienolides in secretion A 134 
Table 3.2 Absolute amounts (mg) of bufadienolides in secretion A 135 
Table 3.3 Relative composition (%) of bufadienolides in secretion B 137 
Table 3.4 Absolute amounts of bufadienolides and arginyl amides in secretion B 139 
Table 3.5 Relative composition (%) of bufadienolides in secretion C 141 
Table 3.6 Absolute amounts (mg) of bufadienolides and arginyl amides in secretion C  143 
Table 3.7 Relative composition (%) of bufadienolides in toxin A 146 
Table 3.8 Total amounts (µg) of bufadienolides in toxin A 146 
Table 4.1 List of stains and specificity  183 
Table 4.2 List of anatomical structures in parotoid gland 184 
Table 4.3 Proteins that exhibited high expression levels in A68 (>2000 reads)  197 
Table 4.4 Proteins that exhibited high expression levels in A69 (>2000 reads) 198 
Table 4.5 List of peptides generated from tryptic digest of the 100 kDa protein from SDS-PAGE  202 
Table 4.6 List of peptides generated from tryptic digest of the 50 kDa protein from SDS-PAGE  204 
Table 5.1 List of bufagenins, biotransforming fungi and biotransformation products  227 
Table 5.2 List of bufagenins, biotransforming bacteria and biotransformation products 227 
Table 5.3 Biotransformation of marinobufagenin (1a) by newly isolated strains 251 
Table 6.1 Analytical methods for the detection of bufolipins 274 
Table 7.1 List of pharmacological properties reported on various bufadienolide structure classes  280 
Table 7.2 Prokaryotic and mammalian cell toxicities of bufadienolides 284 
Table 7.3 IC50 values of bufadienolides against mammalian cancer cells 290 
 
 
xix	  
List of Schemes 
 
Scheme 4.1 Scheme of identification and characterization of parotoid gland hydrolase  180 
Scheme 4.2 Preparation of analytes A55 – A58 189 
Scheme 4.3 Preparation of analytes A59 – A65 and their biochemical analysis 190 
Scheme 4.4 Analyses of A62b 193 
Scheme 4.5 Preparation of analytes A66 – A69 195 
Scheme 4.6 Scheme of identification of protein sequences exhibiting high expression profiles 196 
Scheme 4.7 MS/MS sequencing of 100 kDa and 50 kDa proteins obtained from A62b 201 
Scheme 5.1 Preparation of analytes A70 – A72      230 
Scheme 5.2 Preparation of analytes A73 – A75  231 
Scheme 5.3 Preparation of analytes A76 – A78 233 
Scheme 5.4 Preparation of analytes A79 – A81 234 
Scheme 5.5 Preparation of analytes A82 – A84  235 
Scheme 5.6 Preparation of analytes A85 – A87 236 
Scheme 5.7 Preparation of analyte A88 237 
Scheme 5.8 Preparation of analyte A89 239 
Scheme 5.9 Preparation of analytes A90 – A157 243 
Scheme 6.1 Preparation of analytes A158 – A190 260 
Scheme 6.2 Preparation of analytes A191 and A192 270 
Scheme 6.3 Synthesis of bufolipins with octanoic acid (5.1) as example 271 
Scheme 6.4 Preparation of analytes A193 – A198  272 
Scheme 7.1 Investigations of pharmacological activities of bufadienolides and arginyl amides 
 
283 
 
 
 
 
xx	  
Abbreviations 
 
BtH – Bufotoxin hydrolase 
 
DAPI – 4’,6’-diamidino-2-phenylindole 
 
FdA – fluorescein diacetate 
 
H&E – Haematoxylin Eosin 
 
MALDI – Matrix assisted laser desorption/ionization 
 
Na+/K+ ATPase – Sodium potassium ATPase 
 
PAS – Periodic acid-Schiff  
 
PBS – Phosphate buffer saline 
 
SDS PAGE – Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
 
1	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1: Cane toad introduction in Australia and its 
aftermath 
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1.1 B. marinus in Australia 
 
The cane toad belongs to the family Bufonidae, which consists of 33 genera and more than 470 
species, with 258 species belong to the genus Bufo.1 The cane toad and its relatives, among the most 
primitive groups of broad skulled toads,2 are generally found in the Americas, Africa and Eurasia. 
 
Figure 1.1 Adult male cane toad (Bufo marinus) Photograph by Alexis Barrett 
 
The snout to vent length (SVL) of the cane toads is 10 – 15 cm in the wild and in some cases larger, 
especially when in captivity. Female cane toads have been reported with a SVL of more than 20 cm 
and a weight of 1.5 kg.3 Cane toads possess a broad head with a truncated snout. Immediately 
behind the head of the cane toad are the parotoid glands, which secrete a milky-white toxin.  Cane 
toads have a characteristic dry warty skin and are usually brown to olive brown in colour with a 
pale whiter to yellowish belly (Figure 1.1).2 The life cycle of the cane toad comprises egg – tadpole 
– juvenile – adult – egg stages like other amphibians, with a clutch size varying depending on the 
size and age of the female cane toad, ranging from 4000 – 36000 eggs per adult.1 The egg/tadpole 
survival rate is generally low as cane toad tadpoles themselves are major predators of cane toad 
eggs, consuming more than 99% of laid eggs.4 The average life expectancy of a cane toad in the 
wild is 10 – 15 years.5 
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Parotoid glands are macroglands containing numerous vesicles or microglands (Figure 1.2A).6 They 
play a major role in chemical defence against predatory attacks and microorganisms.7 The parotoid 
secretions are stored in the microglands and are discharged upon manual compression of parotoid 
gland.8 The cane toads can inflate their lungs during a predatory attack to position the parotoid 
gland towards the source of danger and then secrete the toxin when exposed to physical pressure.6 
Dissected parotoid glands display large numbers of alveoli containing large bottle shaped glands 
with a narrow slit like opening lined by a thick epithelium through which the toxin passes when 
physical pressure is applied (Figure 1.2B).9 
 
Figure 1.2 B. marinus in wild. Toxin is stored in parotoid glands as indicated by an arrow (left). Parotoid microgland 
(PM) filled with toxin, toxin exit duct as indicated by black arrow (right). 
 
The cane toad (Bufo marinus) was introduced into various countries, including Australia, Fiji and 
Hawaii, as a biocontrol agent for the beetle pests of sugarcane. However, the introductions turned 
out to be largely unsuccessful as the cane toads failed to feed specifically on the beetle pests. For 
example, the cane toad was introduced in June 1935 from Hawaii to Cairns, Queensland, for the 
control of greyback cane beetle (Dermolepida albohirtum) and Frenchi beetle (Lepidiota frenchi).10 
Since then, the cane toad has been reported to have some significant effects on the native predator 
populations.3   The major concern is the threat to the Australian native predator populations from 
ingestion of the toxic cane toads.11 A large number of deaths have been reported among the native 
predators including lizards,12 snakes,13 quolls,14 crocodiles11 and domestic animals.15 Cane toads are 
the only species in Australia to deploy bufadienolides for defense and the local predators are more 
susceptible since they are not evolved to overcome bufadienolide poisoning. Moreover, the cane 
toad population has increased significantly, extending from Queensland to New South Wales 
colonising more than 1 million km2 and more importantly across the Northern Territory to the 
Western Australia.3 Therefore, the need for the control of cane toad populations is urgent and 
significant. Figure 1.3 illustrates the distribution of cane toads in Australia as of 2007.  
 
A 
PM 
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Figure 1.3 Distribution of cane toads in Australia as of 2007. (Reproduced from Shanmuganathan et al 2007).10 
1.2 Chemistry of Bufo sp parotoid glands 
 
The cane toad parotoid gland secretion contains a mixture of various classes of compounds.16 The 
major class of chemicals reported from the cane toad toxin are the bufadienolides17, 18 and biogenic 
amines (catecholamines, indolylalkylamines).19  
 
1.2.1 Catecholamines 
 
B. marinus parotoid secretions have been reported to contain catecholamines such as adrenaline 
(1.1), noradrenaline (1.2) and dopamine (1.3) (Figure 1.4).19 The catecholamines in the parotoid 
secretion are potent neurotransmitters and vasoconstrictors.6, 20  
 
                                  adrenaline (1.1)                 noradrenaline (1.2)               dopamine (1.3) 
Figure 1.4 Structure of major catecholamines reported from parotoid secretions of the cane toad 
 
1.2.2 Indolealkylamines 
 
More than twenty indolealkylamine derivatives have been attributed to Bufo species. 
Indolealkylamines such as bufotenine (1.4), bufotenidine (1.5), dehydrobufotenine (1.6), 
bufothionine (1.7) and serotonin (1.8) have been isolated from skin and parotoid gland secretions of 
and sexual maturity can be achieved within 1 year (depend-
ing upon environmental conditions). These attributes
together with a lack of natural predators and the ability
of adult toads to live for many years (Zug & Zug, 1979)
can result in toad densities in excess of 2000 animals ha!1
(Freeland, 1986). Another characteristic contributing to the
toads being successful invaders is their skin, which is resistant
to desiccation allowing them to inhabit arid conditions that
predominate in tropical Australia during the dry season
(Duellman & Trueb, 1986). Toads also have a prodigious
non-discriminatory appetite, including a wide variety of
invertebrates and small vertebrates including native frogs
(Easteal, 1993; Boland, 2004; Crossland et al., 2008).
Records from the 1970s suggest that B. marinus became a
serious predator of many native insect species (Zug & Zug,
1979). However, recent studies suggest that the principal
damage caused by the cane toad in Australia is its direct
toxic effect on predators that attempt to ingest it. Although
some native predators can successfully prey upon cane toads
(Mitchell, Jones & Hero, 1985), there are numerous reports
of death associated with ingestion or attempted ingestion of
a range of species such as lizards, crocodiles, snakes, quolls
and domestic animals (Covacevich & Archer, 1975; Phillips
& Fitzgerald, 2004; Letnic & Ward, 2005), and some studies
showed that B. marinus can cause the decline of native
amphibians (Crossland et al., 2008). Moreover, laboratory
experiments suggest low tolerance levels of some predators
(e.g. most species of Australian snakes) to toad toxins
(Phillips, Brown & Shine, 2004; Webb, Shine & Christian,
2005; Kidera & Ota, 2008).
The toad toxin is a complex mixture of compounds
comprised of a family of cardioactive steroids, collectively
known as bufadienolides (bufagins) and bufotoxins, the
catecholamines epinephrine and nor-epinephrine and indo-
lealkylamines (Chen & Kovarikova, 1967; Meyer & Linde,
1971). The toxicity generally associated with toad poisoning
results from the binding of the cardiotonic steroids to the
membrane-associated sodium–potassium pump (Na+ K+
ATPase). Disruption of the Na+ K+ ATPase results in a
positive inotropic effect or increased force of contraction of
the heart, which leads to cardiovascular constriction and
failure (Lim et al., 1997; Chi et al., 1998).
It has been reported that the combined effects result in
population-level declines (Phillips, Brown & Shine, 2003;
Oakwood, 2004). However, robust quantitative data on
declines in native predators associated with cane toad
arrival are scarce (Griffiths & McKay, 2007; Doody et al.,
2009; Letnic, Webb & Shine, 2008). Doody et al. (2009)
demonstrated severe declines ("80–90%) in three species of
lizards co-incident with toad arrival at two sites, contribut-
ing to the upgraded listing of two of these to ‘vulnerable’ in
the Northern Territory (Ward et al., 2006a,b). In contrast,
Doody et al. (2009) showed that individual effects did not
translate into population-level effects in freshwater croco-
diles. However, data presented by Letnic et al. (2008)
showed that B. marinus can cause declines of crocodile
populations indicating that the impact of B. marinus at
population levels is most likely a complex system of inter-
acting ecological factors. The character of ecological com-
munities is also changing in northern Australia as a direct
Figure 1 Imported toads Bufo marinus from
Hawaii (101) were bred at Gordonvale, Qld
(arrow), the progeny of which were released
into the surrounding districts of Hambelton and
Mulgrave (Lever, 2001). The above map shows
the range (grey shading) of cane toads as of
2007. Adapted from Urban et al. (2007).
Animal Conservation 13 Suppl.1 (2010) 16–23 c# 2009 The Authors. Journal compilation c# 2009 The Zoological Society of London 17
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B. marinus (Figure 1.5).21 Bufotenine is known for its hallucinogenic properties, an activity that has 
seen it became a drug of abuse, and a scheduled and restricted substance.22 
             
              bufotenine (1.4)      bufotenidine (1.5)       dehydrobufotenin (1.6)  bufothionine (1.7)       serotonin (1.8) 
 
Figure 1.5 Structure of major indole alkylamines reported from parotoid secretions of the cane toad 
 
1.2.3 Bufadienolides 
 
Since the biogenic amines from the cane toad, B. marinus have been well studied, the focus of my 
research was on the bufadienolides. Although several competing trivial nomenclatures for 
bufadienolides can be found in the literature, for the purpose of this thesis we adopt the sub-class 
nomenclature of bufagenins, bufotoxins, bufolipins, bufagenin sulfates and bufagenin glycosides. 
Following the convention, bufadienolides with an unsubstituted C-3 hydroxyl are termed as 
bufagenins and those bearing a C-3 ester linkage to a diacid aminoacid amide are termed 
bufotoxins. Bufagenins bearing a C-3 ester linkage to a fatty acid are termed bufolipins. Bufagenins 
bearing a C-3 sulfate are referred to as bufagenin sulfates, while bufagenins bearing a C-3 
glycosides are referred to as bufagenin glycosides.  
 
About 100 bufadienolides have been reported from Bufo species, of which only 30 have been 
attributed to B. marinus.18 Bufadienolides are known for their cardiotonic properties which have 
seen them used traditionally as a local anaesthetic.19 Bufadienolides like marinobufagenin are 
structurally similar to cardenolide cardioactive glycosides such as ouabain (found in milk weed, 
1.10) and digoxin (foxglove, 1.11). Biosynthesis of bufadienolides is still not well understood, but 
cholesterol is a well established precursor.23 Bufadienolides are reported to be inhibitors of the 
Na+/K+ ATPase pump found in heart muscle, an activity they have in common with cardioactive 
glycosides such as digitalis.24, 25 
 
                   cholesterol (1.9)                                                             ouabain (1.10) 
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digoxin (1.11) 
 
 
Bufadienolides have been isolated from various sources including plants and animals. The first 
report of a bufadienolide was scillarenin A (1.12) from the Egyptian Squill.26 Since then bufagenins 
have been reported from various plants sources such as Kalanchoe,27 Scilla,28 Melianthus,29 
Helleborous30 and animal sources including toads (Bufonidae),31 snakes (Rhabdopis spp)32 and 
fireflies (Photinus spp).33 Mammalian bufadienolides have been known for two decades and include 
marinobufagenin (1a), first reported in 1993 from human cataract and kidneys.34, 35 Mammalian 
bufadienolides also reported from Bufo species, include marinobufagenin (1a), marinobufotoxin 
(1c) and telocinobufagenin (2a).36, 37 This chapter will discuss more about bufadienolides reported 
from the Bufonidae, especially from B. marinus (also known as Rhinella marina).9 The species 
name for cane toads has been debated in the last 10 years but in this thesis we emphasized “Bufo 
marinus” as majority of the literature sources have adopted this species name. 
 
 
scillarenin A (1.12) 
 
1.2.3.1 Bufagenins 
Bufagenins possess steroidal A/B cis and C/D cis ring junctions with an α-pyrone ring at C-17, and 
a hydroxyl at C-3 (Figure 1.6). The first repeated bufagenin was acetylcinobufagenin (1.13), 
described in 1930 by Jensen et al., from B. marinus.38 Since then bufagenins have been reported 
from various plants and animal sources18 as well as cane toad parotoid secretions and include 
compounds such as bryophillin B (1.14), 12β-hydroxyscillirosidin (1.15) and  gamabufotalin 
(1.16).18, 39 Bufagenins have been reported to be potent inhibitors of Na+/K+ ATPase.25  
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Other known biological activities attributed to bufagenins include antimicrobial,40 antitumour,41 
antileishmanial and antitrypanosomal,7 anti-apoptotic,42 anti-angiogenic,43 and activation of the 
ClC-3 chloride channel (anti-metastasis).44  
 
   
                                                    acetylcinobufagenin (1.13)          bryophillin B (1.14)   
                                                        from B. marinus                          from K. gracilis         
 
                                             12β-hydroxyscillirosidin (1.15)         gamabufotalin (1.16)   
                                                    from Drimia robusta                    from R. tigrinus      
 
Figure 1.6 Examples of bufagenins found in plants and animals  
 
1.2.3.2 Bufotoxins 
The first reported bufotoxin was marinobufotoxin (1c), described from the American toad B. 
marinus by Chen et al in 1930 (Figure 1.7).38 Since the initial report approximately 35 bufotoxins 
have been reported from other Bufo spp.18 Bufotoxins from B. marinus are predominantly diacid 
arginyl esters however, bufotoxins containing other aminoacid variations, such as histidine and 
glutamine have also been reported from Bufo melanostictus and Bufo japonicas.45, 46 Parotoid 
secretions from Bufo spp have also been reported to contain trace amounts of bufotoxins with 
differing diacids, such as pimeloyl,17 succinoyl39 glutaroyl18 and adipoyl39 esters of arginine. 
Bufotoxins are also inhibitors of Na+/K+ ATPase with potencies ranging from sub micromolar to 
micromolar levels.25, 47 Marinobufotoxin (1c) has been reported to be biosynthesized in human Y1 
adrenal cells and it is the first bufadienolide to be identified from in vitro mammalian cell 
cultures.37 The role of bufotoxins in mammals is not well understood, however some reports 
suggest their role in sodium retention in kidneys.48  
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                         marinobufotoxin (1c) from B. marinus                    hellebritoxin (5c) from R. tigrinus 
                                 
                       
Figure 1.7 Examples of bufotoxins found in toads and snakes 
 
1.2.3.3 Bufolipins 
The first bufolipins to be reported were bufolipin A, bufolipin B and bufolipin C isolated and 
characterized (Note: Subsequent to this 1998 report, our laboratory coined the bufolipin 
terminology to provide a logical framework for describing this unique class of bufadienolides) from 
the ovaries of the cane toad B. marinus, by Matsukawa et al in 1998 (Figure 1.8).31  Unlike 
bufotoxins, bufolipins are composed of a mono-carboxylic acid ester side chain with a hydroxyl 
group attached to the terminal of the fatty acid. To date, there have been only two literature reports 
of bufolipins,31, 49 where bufolipin A was isolated from the eggs of B. marinus while the rest were 
isolated from ovaries.31,49 Bufolipins, like other bufadienolides, are inhibitors of Na+/K+ ATPase 
and are more potent than their counterparts, bufotoxins.31 More recently, in studies carried out in 
our laboratory, bufolipin A was reported to have an attractant pheromone effect on B. marinus 
tadpoles.49 
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bufolipin C (3h) 
 
Figure 1.8 Bufolipins found in eggs/ovaries of the cane toad 
 
1.2.3.4 Bufagenin sulfates 
 
The first reported bufagenin sulfate was bufalin-3-sulfate (3f) from B. vulgaris (Japanese toad), 
described in 1974 by Shimada et al (Figure 1.9).50 Sulfated bufadienolides have since been detected 
in Bufo spp plasma, bile and skin,51-53 and are weak inhibitors of Na+/K+ ATPase compared to 
bufagenins and bufotoxins.51 It has been postulated that sulphation of bufagenins in toads is a 
detoxification strategy,54 as the sulfates are more water soluble and more easily excreted.55  
 
  
bufalin 3- sulfate (3f) -                      hellebrigenol 3- O-sulfate 
from B. vulgaris                                from B. melanostictus (5f) 
 
Figure 1.9 Examples of bufagenin sulfates found in toads 
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1.2.3.5 Bufagenin glycosides 
 
Scillaren A (1.12) was the first bufagenin glycoside reported by Stoll et al in 1933.26 In plants, 
bufadienolides predominately occur as glycosides with sugar units at 3-OH of bufagenins (Figure 
1.10). Urginea maritima and Urginea altissima have been a great source of bufagenin glycosides.56 
Bufagenin glycosides were responsible for 33% of cattle deaths (12,000) annually, indicating the 
levels of toxicity and causing a great influence on agriculture industry in those regions native to 
bufagenin glycosides harbouring plants. More than 50 bufagenin glycosides have been reported 
from Crassulaceae (Kalanchoe tomentose, Tylecodon wallichii, etc) and Hyacinthaceae (Urginea 
spp.).18, 56 Shimada et al reported that doubly linked glycosides exhibited higher cardiotonic activity 
than their respective bufagenins.25 L-rhamnose promotes cardiotonic activity (eg scilliglaucosidin-
α-L-rhamnoside) while D-rhamnose subititution showed less/no activity (eg scilliglaucosidin-β-D-
rhamnoside).57 
 
                                              kalanchoside A (1.17)                                          scilliroside (1.18) 
                                           from Kalanchoe gracilis)                                   from Urginea maritima 
 
Figure 1.10 Examples of bufagenin glycosides from plants 
 
 
1.2.4 Bufadienolides from B. marinus 
 
The Bufonidae are a rich source of bufadienolides including bufagenins, bufotoxins, bufolipins and 
bufagenin sulfates, with bufagenins being the dominant structure class58, 59 Bufadienolides have 
been reported from various tissues of B. marinus such as skin, parotoid secretions, oviducts/eggs, 
plasma and tadpoles (Figures 1.11 – 1.13).31, 51, 52, 60 A list of B. marinus bufadienolides from 
various tissue sources and regions is summarized in Table 1.1.  
 
1.2.4.1 Parotoid secretions 
 
Parotoid secretions are a rich source of bufadienolides, consisting of bufagenins and minor amounts 
of bufotoxins.17,37,51 Seven bufagenins, marinobufagenin (1a), telocinobufagenin (2a), bufalin (3a), 
resibufogenin (4a), hellebrigenin (5a), arenobufagenin (6a) and marinoic acid (8a) and five 
bufotoxins, marinobufotoxin (1c), telocinobufotoxin (2c), bufalitoxin (3c), marinobufagenin 
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pimeloylarginine (8c) and bufalin pimeloylarginine (9c) have been reported from parotoid 
secretions of B. marinus.17, 61, 62 In some cases HPLC-DAD analysis of parotoid secretions  detected 
bufagenins as the dominant chemistry, with trace levels of bufotoxins.58 Whether bufotoxins are 
present in parotoid secretions remains unclear, and more work is required.19,35 Shimada et al, 
hypothesized that bufotoxins were the precursors of bufagenins.63 Curiously the relative and 
absolute bufagenins composition of parotoid secretion can vary, with B. marinus sampled in 
Australia exhibiting >30 bufadienolides with significant amounts of marinobufagenin (1a), 
telocinobufagenin (2a), bufalin (3a) and resibufagenin (4a), and traces of arenobufagenin (6a) and 
hellebrigenin (5a) and bufotoxins.17 
 
1.2.4.2 Skin 
 
B. marinus skin is a rich source of bufotoxins and bufagenin sulfates compared to parotoid 
secretions which are dominated by bufagenins.52 The reason for such a variation has never been 
investigated and is addressed in this thesis (Chapter 3). Bufotoxins found in B. marinus skin include 
marinobufotoxin (1c), telocinobufotoxin (2c) and marinobufagenin-3-pimeloylarginine (8c), while 
bufagenin sulfates include marinobufagenin-3-sulfate (1f) and resibufogenin-3-sulfate (4f).52 The 
only report of a bufagenin detected from the skin of B. marinus was that of marinosin (9a) by 
Matsukawa et al, in 1998.64 
 
1.2.4.3 Plasma and bile 
 
Distribution of bufadienolides in plasma is similar to that of the skin, as it predominantly contains 
bufotoxins and bufagenin sulfates. Two bufotoxins, telocinobufotoxin (2c) and arenobufotoxin (6c), 
and three bufagenin sulfates, telocinobufagenin-3-sulfate (2f), bufalin-3-sulfate (3f) and 
arenobufagenin-3-sulfate (6f) have been reported from the plasma of B. marinus.51,65 Interestingly, a 
bufagenin glucuronide was claimed, but as the identification of a glucuronyl bufadienolide structure 
was based solely on the HPLC-DAD retention time, this claim lacks credibility.51 Lichtstein et al, 
identified the bufagenin, resibufogenin (4a) in the plasma of B. marinus.65 To date the bufagenin 
sulfates, marinobufagenin-3-sulfate (1f) and 12β-hydroxytetrahydroresibufogenin (7f) have been 
identified in the bile of B. marinus. Sulfation and glucuronidation of xenobiotics are known to be 
mediated by cytochrome P450 enzymes during the phase two of xenobiotic metabolism, a process 
designed to facilitate excretion.66,67 Since sulfation improves plasma solubility, it is perhaps not 
surprising that bufagenin sulfates are detected in plasma and bile.55 
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1.2.4.4 Eggs/oviducts 
 
Eggs (pre-laying) were reported to contain bufagenins, however, compared to bufagenins found in 
adult B. marinus parotoid secretions, the bufagenins on the eggs are poly-hydroxylated.68 Poly-
hydroxylation of bufadienolides could provide better solubility characteristics for toxin on the 
surface of eggs. Surprisingly, oviducts contain polyhydroxylated bufagenins (such as eggs) and 
bufolipins.31 
Five bufagenins, 11α-hydroxymarinobufagenin (10a), 11α,19-dihydroxymarinobufagenin (11a), 
11α-hydroxytelocinobufagenin (12a), 19-hydroxytelocinobufagenin (13a) and 11α,19-
dihydroxytelocinobufagenin (14a) have been reported from pre-laid eggs of B. marinus, of which 
10a and 13a are also found in oviducts.31 Four other bufagenins, telocinobufagenin (2a), 
hellebrigenin (5a), arenobufagenin (6a) and 5β-hydroxyarenobufagenin (15a) and three bufolipins, 
bufolipin A (1h), bufolipin B (2h) and bufolipin C (3h) were isolated from oviducts of B. 
marinus.31 In a recent report, bufolipin A was isolated from laid eggs while several other bufolipins 
and bufagenins were also identified.49 It was also postulated that the defence mechanism in B. 
marinus eggs could be attributed to the bufadienolides passed on from the ovaries (since the 
composition of bufadienolides was similar in eggs and ovaries). It is also important to note the de 
novo biosynthesis of bufadienolides does not commence until the juvenile stages of the cane toad 
life cycle.60 
 
1.2.4.5 Tadpoles  
 
Tadpoles were reported to contain only bufagenins, but in lower amounts compared to egg or adult 
stages.60 Bufagenins that were identified in parotoid secretions, marinobufagenin (1a), 
telocinobufagenin (2a), resibufagenin (4a), hellebrigenin (5a) and arenobufagenin (6a) were also 
identified in tadpoles.60 Interestingly, bufagenin levels in tadpoles vary in concentration based on 
different developmental stages. For instance, stage 21 (early) showed moderate levels of 1a, 2a, 5a 
and 6a; while stage 25 (middle) showed low levels of 4a and 6a; but stage 44/45 (late) showed 
substantial levels of 2a, 4a and 6a and moderate levels of 1a and 5a.60 This pattern not only 
indicated the distribution of bufadienolides within the various developmental stages, but also lead to 
insights into the onset of bufadienolide biosynthesis as the metamorphic and juvenile stages showed 
restoration of bufadienolide composition found in parotoid secretions. 
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Table 1.1 List of bufadienolides from various tissues of B. marinus reported from various countries 
 
Tissue Country of origin bufagenins bufotoxins bufolipins 
bufagenin 
sulfates 
bufagenin 
glycosides 
parotoid Australia, Japan 
1a, 2a, 3a, 4a, 
5a, 6a, 8a 
1c, 2c, 3c, 
8c, 9c    
skin Japan 9a 1c, 8c, 2c  1f, 4f  
bile Japan, US    1f, 7f  
plasma Japan, US 4a 2c, 6c  2f, 3f, 6f 1g 
eggs/oviducts Japan, Australia 
2a, 5a, 6a, 
10a, 11a, 12a, 
13a, 14a, 15a 
 1h, 2h, 3h   
tadpoles Australia 1a, 2a, 4a, 5a, 6a     
  
 
marinobufagenin (1a)        telocinobufagenin (2a)                bufalin (3a) 
 
   
resibufagenin (4a)              hellebrigenin (5a)                  arenobufagenin (6a) 
 
 
 
        marinoic acid (8a)                 marinosin (9a)    11α- hydroxymarinobufagenin (10a) 
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                                 11α-hydroxy                      11α,19-dihydroxy                   11α,19-dihydroxy 
                            telocinobufagenin (11a)          marinobufagenin (12a)           telocinobufagenin (13a) 
 
  
                                                               19-hydroxy                5β-hydroxyarenobufagenin (15a) 
                                                      telocinobufagenin (14a) 
 
Figure 1.11 Bufagenins from B. marinus 
 
 
  
marinobufotoxin (1c)                                          telocinobufotoxin (2c) 
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arenobufotoxin (6c)                                     marinobufagenin-3-pimeloylarginine (8c) 
 
 
 
bufalin-3-pimeloylarginine (9c) 
 
Figure 1.12 Bufotoxins from B. marinus 
 
 
   
                     marinobufagenin-3-sulfate (1f)   telocinobufagenin-3-sulfate (2f)     bufalin-3-sulfate (3f) 
 
 
   
resibufagenin-3-sulfate (4f)    arenobufagenin-3-sulfate (6f)          12β-hydroxytetrahydro 
                                                                                                                  resibufagenin 3-sulfate (7f) 
 
Figure 1.13 Bufagenin sulfates from B. marinus 
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1.2.5 Pharmacology of cane toad bufadienolides 
 
Bufadienolides from B. marinus have been attributed various pharmacological properties. They are 
predominantly described as inhibitors of cardiac/kidney Na+/K+ ATPase, as well as antimicrobial,40 
antitumour,41 antileishmanial and antitrypanosomal,7 anti-apoptotic,42 anti-angiogenetic,43 chloride 
channel activators44 and anti-viral69. However, bufotoxins, bufolipins and bufagenin 
sulfates/glycosides have only been subjected to Na+/K+ ATPase inhibition in different cell types and 
no other pharmacological interactions have been described. One of the major challenges 
encountered in comparing the biological/ecological properties of different bufadienolides is the lack 
of consistent, quantifiable and relevant bioassay data. A list of pharmacological properties of cane 
toad bufadienolides is summarized in Table 1.2.  
 
1.2.5.1 Inhibition of Na+/K+ ATPase 
 
The sodium-potassium activated adenosine triphosphatase (Na+/K+ ATPase) is a plasma membrane 
spanning protein complex that utilizes the energy released during the hydrolysis of ATP for the 
transport of sodium and potassium ions across the cell membrane. The pump plays an essential role 
in maintaining the concentration of sodium and potassium ions across the cell membrane. The main 
function of this electrochemical gradient is to provide energy for the transport of metabolites and 
nutrients like glucose, amino acids and ions like H+, Ca+ and Cl- across the membrane and also for 
the regulation of cell volume and action potential of muscle.70  
 
The Na+/K+ ATPase contains two subunits (α and β) associated in a 1:1 ratio (Figure 1.14). 
Basically, four α subunit isoforms occur in association with three β subunit isoforms to generate 
various Na+/K+ ATPase isozymes with specific transport and pharmacological properties.71  The α 
subunit (110 kDa) provides the binding sites for the ligands to induce or inhibit the enzyme 
complex whereas the β (300 amino acids)72 subunit plays a vital role in orientation and stabilization 
of the α subunit.70 The γ subunit (10 kDa) of Na+/K+ ATPase was reported much later73 and its role 
is still uncertain, but there has been a recent report which describes the γ subunit as an activator of 
Na+/K+ ATPase in pig kidney outer medulla.74 
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Figure 1.14 Diagrammatic representation of the membrane bound Na+/K+ ATPase pump showing the binding of 
cardiotonic steroids to the transmembrane domains of α subunit. Green – dephosphorylation mediated by TGES motif, 
Orange – phosphorylation region, purple – ATP binding pocket (Taken from Bagrov et al. Pharm. Rev. 2009).75 
 
 
The inhibitory activity of the bufadienolides against Na+/K+ ATPase is reportedly similar to that of 
the plant derived ouabain (1.10) and digoxin (1.11).31 Ouabain (1.10) was reported to inhibit Na+/K+ 
ATPase by binding to the α subunit.76 Na+/K+ ATPase in humans contains three isoforms of α 
subunits, α1, α2 and α3 expressed at various levels in various individuals, but the affinity of ouabain 
to all the isoforms is uniform.77  
 
Marinobufagenin and ouabain exhibited highest affinity to different isoforms (α1 and α3) of Na+/K+ 
ATPase in rat aorta,78 although both resulted in comparable Na+/K+ ATPase inhibition in C7-
MDCK cells grown in the presence of marinobufagenin and ouabain.47 When the Na+/K+ ATPase 
pump is inhibited, the intracellular concentration of Na+ is slightly increased, which in turn affects 
the Na+/Ca2+ exchange pump leading to increased levels of intracellular Ca2+ in the sarcoplasm of 
myocytes, causing a positive inotropic effect (increased muscular contractions).79 Besides positive 
inotropy an increase in the extracellular concentrations of K+ (hyperkalemia) has also been 
reported.80 The genetic variations in the Na+/K+ isoforms are substantial as some species are 
immune to the cane toad toxin while others are highly susceptible. The bufadienolide diversity in 
the cane toad may play a significant role in antagonising a wide array of Na+/K+ isoforms thereby 
targeting a range of predators. 
 
member of the P-type ATPase family of membrane-in-
corporated proteins, and it is directly responsible for the
maintenance of the low intracellular Na!/K! ratio by the
active transport of these ions across the plasmamembrane
using the hydrolysis of ATP to provide the necessary en-
ergy (Skou and Esmann, 1992). The Na!/K!-ATPase con-
trols multiple essential cellular functions. Specifically, it
maintains the electrical membrane potential, which is nec-
essary for nerve transmission and muscle contraction, ex-
citability, andmany other cellular functions, which depend
on the necessary sodium-potassium gradients (Lingrel,
1992). The sodium pump can also drive secondary active
co-/countertransporters, which are coupled to the gradient
of extracellular to intracellular [Na!], such as the Na!/
Ca2!-exchanger (Blaustein, 1993). It logically follows that
the Na!/K!-ATPase, acting via ATP hydrolysis, deter-
mines a very substantial fraction of the cellular metabolic
rate of most tissues (Blanco and Mercer, 1998).
The Na!/K!-ATPase consists of two polypeptides in
equimolar ratios. The ! catalytic subunit has a molecu-
lar mass (Mr) of approximately 110 kDa and the glyco-
sylated " glycoprotein subunit has aMr of 31.5 kDa. The
! subunit has 10 transmembrane segments. It contains
the binding sites for Na! and CTS on the extracellular
segments and the binding sites for K! and ATP on the
intracellular loops. Asp369, in particular, is critical for the
binding of a phosphate group and is an essential site for
ATP hydrolysis (Lingrel, 1992). Two more residues, Lys501
and Asp586, may also participate in the binding of ATP
(Farley et al., 1997) (Fig. 1). The regulatory " subunit is
a single-transmembrane protein with a glycosylation
site controlling the activity of Na!/K!-ATPase (Blanco
and Mercer, 1998). At present, the !" complex is be-
lieved to form the functional dimeric units of the sodium
pump. These dimers may also be organized in tetramers
or possibly stack into ribbons (So¨derholm et al., 1988).
According to the Albers-Post model, the Na!/K!-ATPase
“pumps” sodium ions from the inside of the cell to the
outside while moving potassium ions in the opposite
direction, both against existing concentration gradients
in an energy-dependent process. The ! subunit, in the
presence of Na! and Mg2!, is phosphorylated by ATP,
followed by occlusion of three cytosolic Na! ions. This
high-energy E1P form of the enzyme, loaded with Na!
1 2 3 4 5 6 7 8 9 10
γ-subunit
(FXYD)
COOH
α-subunit
NH2
NH2
COOH
NH2
COOH
Cytoplasmic
Extra-cellular
ATP
TGES
P
Cardiotonic steroids
β-subunit
FIG. 1. Structure of Na!/K!-ATPase. Na!/K!-ATPase consists of two ! and " polypeptides in equimolar ratios. The ! catalytic subunit has 10
transmembrane segments, schematically presented in an “unfolded” disposition; in reality, there is a bungle around M4, M5, and M6 transmembrane
segments. The extracellular segments of ! subunit form a binding site for CTS (shown in red), which include TM1–TM2, TM5–TM6, and TM7–TM8
loops and several amino acids from the transmembrane regions M4, M6, and M10 (see the explanation in the text). The binding site for ATP is located
on the intracellular loop TM4–TM5 (shown in blue), which forms the “pocket” for this nucleotide. The phosphorylation domain (P; shown in orange)
located on the proximal and distal parts of intracellular loop TM4–TM5; phosphate of ATP is transiently transferred on the aspartyl residue 376 of
DKTGT motif. The actuator domain, specifically its TGES motif, is responsible for the dephosphorylation step; it is constituted by the cytoplasmic
NH2-terminal and TM2–TM3 intracellular loop (shown in green). The regulatory " glycoprotein subunit is a single-transmembrane protein with a
several glycosylation sites (two are shown). The extracellular part of " subunit interacts with a conserved motif SYGQ on the extracellular loop
TM7–TM8 of ! subunit. The !"-subunit complex of Na!/K!-ATPase associates with third subunit, which contains the conserved motif FXYD identical
for all s ven proteins from this f mily. FXYD2 protein is kn wn as the earlier described # subunit of N !/K!-ATPase. These proteins, including the
# subunit, are not an integral part of sodium pump, but they are associated with specific domains of !"-subunit complex and modulate catalytic
properties of the Na!/K!-ATPase.
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Although several pharmacological properties are described for cane toad bufadienolides, inhibition 
of Na+/K+ ATPase pump is of great significance as it appears to correlate to the ecological 
properties exhibited against predators. Several studies have been performed to understand the 
interaction of bufadienolides, especially bufagenins, against cardiac/kidney Na+/K+ ATPase.81,82 
However these studies were conducted on different cell types, in different assay systems using 
different readout technologies by different researchers at different time periods. In short, 
comparative structure activity relationship (SAR) data is simply not reliable. 
 
In 1985 Shimada et al reported the inhibition of Na+/K+ ATPase isolated from guinea pig heart 
using an HPLC-based quantification system.25,83 Forty-six bufadienolides, with variations in the 
steroid backbone and side chain conjugation were assessed as Na+/K+ ATPase inhibitors.7 Briefly, 
the guinea pig Na+/K+ ATPase was incubated with bufadienolides and ATP was added to the 
reaction mixture. After stopping the enzymatic reaction, the conversion of ATP to ADP was 
measured by HPLC analysis. Although, the assay was purported to quantify the enzyme activity, 
and suffered from a number of limitations, Shimada et al nevertheless concluded that bufotoxins 
were more toxic as Na+/K+ ATPase inhibitor than bufagenins, bufagenin sulfates or glycosides.25 
 
In another report, Akimova et al, employed a ouabain radioligand displacement assay using MDCK 
cells to measure the displacement properties of a range of bufadienolides.47 Contradicting Shimada 
et al, Akimova et al concluded the bufagenins exhibited more toxicity or higher Na+/K+ ATPase 
inhibition compared to bufotoxins, with bufalin (3a) showing the highest inhibition. Overall, 
marinobufagenin (1a), telocinobufagenin (2a) and bufalin (3a) showed high potencies against 
Na+/K+ ATPase isolated from various tissues (brain, kidney or heart).  
 
Na+/K+ ATPase inhibition of bufolipins has also been reported in dog kidney Na+/K+ ATPase using 
a calorimetric based assay system. Interestingly, bufolipins showed high potency by inhibiting 
Na+/K+ ATPase in sub micromolar concentrations (0.1 µM), which is comparable to bufalin (3a) 
reported from other research groups.31 Since different research group used different assay systems 
to report the Na+/K+ ATPase inhibition exhibited by various structure class of bufadienolides, it is 
difficult to suggest the hierarchy of potencies. However, based on the values of IC50, it could be 
suggested that bufagenins>bufolipins>bufotoxins>bufagenin sulfates/glycosides. However, the 
conclusion could also be disputed as bufotoxins in some assays showed more potency than 
bufagenins. A complete list of cane toad bufadienolides and their Na+/K+ ATPase inhibition profile 
has been summarized using a pie chart based on their potency and the available data in the literature 
(Figure 1.15). A majority of cane toad bufadienolides have not yet been investigated for Na+/K+ 
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ATPase inhibition assay. However, at least one member from each of the bufadienolide structure 
class has been investigated for the inhibition of Na+/K+ ATPase.  A standard quantification 
experiment for Na+/K+ ATPase inhibition including all the cane toad bufadienolide structure class 
would be significant to investigate the relative toxicity exhibited by cane toad toxins.  
 
 
Figure 1.15 List of cane toad bufadienolides structure class based on inhibition of Na+/K+ ATPase sorted from the 
published literature 
 
 
1.2.5.2 Cytotoxicity studies of B. marinus bufadienolides 
 
Bufadienolides have been reported to exhibit anti-cancer activity based on the cytotoxicity studies 
using human cancer cell lines.18 Cytotoxicity activities of B. marinus bufadienolides were 
conducted by researchers using various cell lines. Kamano et al, conducted a structure-activity 
relationship study of bufadienolides (bufagenins and bufagenin hemiesters), including B. marinus 
bufagenins using primary liver carcinoma cell line, PLC/PRF/5.84 Bufagenins were found to be 
more cytotoxic than bufagenin hemiesters, but no bufotoxins were included in this study. In another 
study, Cunha-Filho et al, performed cytotoxicity assays on marinobufagenin (1a), telocinobufagenin 
(2a), bufalin (3a) and hellebrigenin (5a) using MDA-MB435 (melanoma), HL-60 (leukaemia), 
HCT-8 (colon), SF295 (glioblastoma) and PBLs (peripheral blood lymphocytes).41 Interestingly in 
both studies bufalin (3a) exhibited the highest cytotoxicity (IC50 at sub nanomolar levels) while 
other bufagenins exhibited sub micromolar to 1 µM IC50 levels. Telocinobufagenin-3-sulfate was 
subjected to cytotoxicity studies using A549 (non-small-cell lung cancer), U373 (glioblastoma), 
HS683 (oligodendroglioma) and MCF-7 (breast cancer) cell lines and was reported to be non-
cytotoxic.54 In summary bufagenin sulfates appear to be the least cytotoxic bufadienolides followed 
active (1a, 2a, 3a, 1c, 1h, 
2h, 3h) 
non/inactive (1c, 2c, 8c, 
1f, 1g) 
no data (4a, 5a, 6a, 9a, 
4h, 9c, 2f-7f) 
Na+/K+&ATPase&ac-vity&
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by bufagenin hemiesters. Bufagenins exhibit the highest levels of cytotoxicity, while bufotoxins are 
less cytotoxic.  
 
1.2.5.3 Other biological activities of B. marinus bufadienolides 
 
Marinobufagenin (1a) and telocinobufagenin (2a) were reported to exhibit modest antibiotic 
activity against Escherichia coli (MIC 16 and 64 µg/mL) and weak to negligible antibiotic activity 
against Staphylococcous aureus (MIC 128 µg/mL).40 Anti-apoptotic activity of bufalin (3a) has 
been investigated in LNCaP (human Prostate Carcinoma) and MCF10A (human breast epithelial) 
cell lines. Following treatment with bufalin (3a), both cancer lines exhibited increased caspase 
mediated apoptotic modulation in androgen mediated and non-mediated cell types.42 Anti-protozoan 
activity of telocinobufagenin (2a) and hellebrigenin (5a) were investigated against Leishmania (L.) 
chagasi promastigotes and Trypanozoma cruzi trypomastigotes. Both the bufadienolides were 
active against Leishmania (L.) chagasi while only hellebrigenin (5a) was active against 
Trypanozoma cruzi.7 
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Table 1.2 List of pharmacological properties reported on various bufadienolide structure classes 
isolated from B. marinus reported from various countries 
 
Pharmacological 
properties (cell/tissue types) 
bufagenins bufotoxins bufolipins bufagenin 
sulfates 
bufagenin 
glycosides 
Na+/K+ ATPase inhibition      
human kidney82 1a, 2a     
C7-MDCK cells47 1a, 3a 1c, 2c    
dog kidney/pig brain85 3a     
guinea pig heart81 1a, 2a 1c, 2c, 8c    
guinea pig heart25 1a 1c  1f 1g 
dog kidney31   1h, 2h, 3h   
Cytotoxicity      
PLC/PRF/5 cells84 1a, 2a, 3a, 
4a, 5a 
    
HL-60, HCT-8, SF295, 
MDA-MB435, PBLS41 
1a, 2a, 3a, 
5a 
    
A549, U373, HS683, MCF-
754 
   2f  
Antibiotic – E. coli and S. 
aureus40 
1a, 2a     
Apoptotic activity      
LNCaP, MCF10A42 3a     
Anti-leishmania7 2a, 5a     
Anti-trypanosome86 5a     
 
1.2.6 Control strategies for cane toad 
 
The control strategies for cane toad can be divided into three major categories, physical, chemical 
and biological.  
1.2.6.1 Physical 
The physical control method is a comparatively low technology solution for the control of cane 
toads. It involves the use of traps87 or containers for capturing toads and fencing barriers to avoid 
the migration of the cane toad.88 Although the method offers temporary local control of cane toad 
populations, it cannot be regarded as a permanent solution. Moreover, the method is labour 
intensive and time consuming. Non-profit organisations, such as The Kimberley Toadbusters, 
support the physical control of the cane toads through various campaign programmes and creating 
awareness among the local people.89  
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1.2.6.2 Biological 
The biological control approach favours the use of recombinant viruses, bacteria or parasites that 
are lethal and self-replicating, to colonize the toad population. 
Viral delivery method 
It was postulated that recombinant strains of Bohle iridovirus containing foreign DNA encoding 
globin could be used to challenge tadpole with adult cane toad globin, leading to increased 
mortality rates (80%-100%) in the test population of cane toad metamorphs.90 This strategy proved 
to be scientifically and technically non-feasible, and arguably politically naïve, as it required the 
non-reliable, uncontrolled release of a genetically modified virus – with unknown ecological 
consequences. The approach was not surprisingly abandoned but not until it had diverted valuable 
resources away from the more ecologically responsible and scientifically feasible solutions. 
Daughterless toad strategy 
Daughterless toad technology involves a sex skewing strategy where the number of female toads is 
decreased drastically leading to accumulation of a male dominated population. Introducing the male 
sex-determining genes to the cane toad population would generate a genetically modified cane toad, 
which would be introduced into the environment.10 By incorporating these genes, the development 
of ovaries in the female cane toads would be blocked, leading to development of testes thereby 
generating male progeny.10 The resulting male tadpoles remain as males while the females will 
reverse sex and develop as males. The offspring of the daughterless toads would spread the 
incorporated gene to the following generation. In this way the female population is vastly reduced 
and on the other hand the male population is greatly increased and surpasses the former. As a result, 
the male toads will run out of their breeding partners and the cane toad population can be greatly 
controlled. Although the sex determining genes in cane toads have been reported91 this method was 
shown not to be applicable based on model studies which required a large number of genetically 
modified toads to be released into the environment.10 
Sterile male strategy 
The strategy involves the production of fertile males whose off springs are sterile males. Most of 
the animals are diploid (2n) in nature possessing two of each chromosome per nuclei. In this 
strategy, genetically modified male cane toads would be generated which are polyploid (4n), by 
duplication of their entire genome.92 These male cane toads survives as the level of duplication is 
even (balanced meiosis) and when interacts with diploid female cane toads, generates triploid 
progeny (3n) which are sterile in nature due to uneven number of chromosomes (disrupted meiosis). 
Thus, the F1 progeny are sterile male cane toad tadpoles. Moreover, the reproductive output of the 
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female cane toads is also greatly reduced.10,92 Again, as imaginative as the strategy appeared, it 
lacked feasibility and was abandoned. 
Discussion 
The biological approach has largely been abandoned. Two major problems involved are the 
scientific and technical ability to deliver, as well as safety of any implement. On the matter of 
safety, the use of recombinant viruses in the environment is risky as the viruses may revert 
pathogenicity and more importantly the specificity of the recombinant viruses must be fully 
investigated to prevent the infection of other organisms. Likewise, introduction of genetically 
modified toads may result in the transmission of foreign DNA among the toad population leading to 
mutations, which might affect the ecological balance. Quite apart from the failure of science to 
deliver, even with a biological solution in hand it would be questionable if deployment would be 
authorized.  
1.2.6.3 Chemical  
Given the risks and limitations of the biological control method, a number of chemical approaches 
were considered. To develop a chemical approach requires careful analysis of the cane toad toxins 
in an ecological context, to identify possible solutions for the cane toad control. The chemical 
approach is exemplified by recent developments from our laboratory in the area of alarm49 and 
attractant93 pheromones and the microbial biotransformation of bufadienolides.17  
Pheromones (Alarm) 
Pheromones are chemical substances that are secreted by an individual and are recognized by 
another individual of the same species, triggering a behavioural response.93 For example, cane toad 
tadpoles flee (Figure 1.16) when exposed to the water extract of crushed tadpole con-specifics 
suggesting the presence of alarm pheromones.94 An ability to identify such alarm would be 
significant for an individual to confront pressure induced by its environment or predators.94 
 
Figure 1.16 Cane toad tadpoles flee in response to crushed conspecifics (Taken from: Capon et al., 2009).95  
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Although cane toad tadpoles exhibit a stray flight response,96-98 the chemical composition of the 
alarm pheromone remained unknown. In a recent study, our lab in collaboration with the Shine lab 
(U Syd) explored the observation that chronic exposure of cane toad tadpoles to the alarm 
pheromones (water extract of crushed conspecific) leads to premature metamorphs with low 
survival rates. More importantly, the pheromone had no effect on the native frog species.98 This 
collaboration also explained and identified a tadpole attractant pheromone present in B. marinus 
eggs and used this to develop a bait/trap system.49 Insights into cane toad chemical ecology are 
pivotal to exploring and applying effective chemical control solutions. For instance, distributing the 
synthetic alarm pheromone through waterways like lakes, dams, etc during the breeding season may 
interrupt the development of cane toad tadpoles and thereby lead to reduction in their population. 
More information about B. marinus pheromones is discussed in further chapters (Chapter 5). 
Currently the bait system has been translated to field trials (in ponds) with various bufolipin 
ananlogues and their ability to attract tadpoles is being performed (unpublished).  
Biotransformation of bufadienolides 
The biotransformation of certain bufadienolides by bacteria99-101 and plant cells102 has already been 
reported. For instance, resibufagenin (4a) when exposed to the cultures of Mucor subtilissimus was 
converted into 11 products,99 while exposure to Pseudomonas aeruginosa produced a single 
product, 3-oxoresibufogenin (16a).100 The biotransformation of bufadienolides suggests the 
possibility of broadening of chemical diversity of the bufadienolides existing in the parotoid gland. 
In a recent report, the microbial biotransformation of marinobufagenin (a bufadienolide isolated 
from the cane toad parotoid secretion) was reported.17 Bacterial strains from the parotoid gland, 
ovary, tongue and stomach of a mature female cane toad were recovered and grown in liquid 
cultures in the presence of marinobufagenin (1a).  
 
3-oxoresibufogenin (16a) 
 
Comomonas testosteroni is a gram-negative bacterium that utilizes C19 - C27 steroids as its carbon 
source for growth.103-105 Exposure of marinobufagenin (1a) to liquid cultures of C. testosteroni for 
96 h was performed and the products were isolated by solvent extraction from the broth and were 
subjected to HPLC-DAD-MS analysis. This observation supports the hypothesis that bacteria 
present in the parotoid gland may manipulate bufadienolide diversity, either to make the toxin more 
O
OH
H
O
O
H
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effective against range of predators by diversifying the chemistry or by detoxifying B. marinus 
parotoid secretions by biotransforming the cardiac steroids into less toxic analogues. Further 
information on biotransformation of cane toad toxins is discussed in detail in successive chapter 
(Chapter 4).  
 
1.3 PhD research project 
 
1.3.1 Aims 
To better understand cane toad bufadienolides, including chemical diversity, stability and biology, 
as well as biosynthesis, distribution and ecology.  
 
1.3.2 Objectives  
To achieve the proposed aims several objectives were undertaken:  
Ø Develop analytical methodology capable of detecting all class of bufadienolides in 
quantifiable amounts (Chapter 2) 
Ø Carry out bufadienolide quantification in various cane toad tissues such as adult parotoid 
glands and eggs (Chapter 3&5) 
Ø Analysis of storage of toxins within the parotoid gland in situ (Chapter 3) 
Ø Stability of parotoid secretions against microbial biotransformation (Chapter 4) 
Ø Pharmacological properties of cane toad bufadienolides (Chapter 6) 
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Chapter 2: Full characterization, identification and 
quantification of cane toad bufadienolides 
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2.1 Introduction 
 
A principle objective of this aspect of my research project is to develop analytical methodology 
capable of identifying and quantifying bufadienolides from various tissues of cane toads. Although 
bufagenins have been reported as the dominant bufadienolides in cane toad parotoid secretions,1,2 
with bufotoxins sometimes acknowledged as minor constituents, these studies do not employ 
optimized analytical methodology.3 This chapter describes the development of analytical 
methodology to identify and quantify bufagenins and bufotoxins. Discussion on the analysis of 
bufolipins will be presented in chapter 6, and since bufagenin sulfates and glycosides are rare in 
cane toads,4 their analysis is not a priority for this project.  
 
Bufadienolides can be analysed by HPLC-DAD, although traditional methods such as prep-TLC5 
had been described in the literature. While normal phase silica HPLC has been investigated,6 
reverse phase HPLC has proved to be more effective.1,7 Detection of bufadienolides using a diode 
array detector (DAD) is greatly facilitated by a characteristic UV absorbance (300 nm) of the C-17 
α-pyrone ring. Different bufadienolides exhibit different retention times on reverse phase HPLC 
columns, with bufagenins appearing as sharp peaks8 while bufotoxins appearing as broad peaks due 
to the presence of the charged arginyl moiety.4 To unambiguously differentiate and quantify various 
bufadienolide classes from a given tissue sample (such as skin or parotoid secretion), requires 
analytical methodology optimized to detect specific bufadienolide structure classes.  
 
Specific objectives 
Ø To generate a bufadienolide standards library inclusive of bufagenins and bufotoxins 
Ø To develop highly sensitive analytical methods optimized to detect and quantify bufagenins 
and bufotoxins 
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Figure 2.1 Scheme describing strategy for assembling a bufagenin/bufotoxin standard library. Dissection of parotoid 
glands from cane toads followed by solvent partitioning to obtain a mixture of either (1) bufagenins or (2) bufotoxins. 
(3) – conversion of bufagenins to bufotoxins 
 
The approaches for the development of cane toad toxin library are based on factors such as the 
availability of resources, and the feasibility of the process (Figure 2.1). A reserve of > 500 frozen 
cane toads preserved at −20 °C provided a source of parotoid glands. Solvent partitioning and 
extraction followed by normal and reverse phase HPLC proved very successful at yielding 
bufagenins. Bufagenins obtained from adult parotoid secretions were then subjected to esterification 
with suberic and pimelic acid to obtain pure bufagenin esters, which were then coupled with L-
arginine to yield bufotoxins. A highly sensitive analytical method was developed to analyse these 
bufagenin and bufotoxin standards and to analyse the bufadienolide composition of various cane 
toad tissues (Chapter 3).  
 
2.2 Results and discussion 
2.2.1 To generate a library of bufagenin standards 
 
The first objective was to develop a library of standards for the detection and quantification of 
bufadienolides (and diacid arginyl amides) in cane toad tissues. The development of such a library 
includes the isolation, characterization and identification of a panel of bufagenins and bufotoxins. 
The parotoid glands from 120 frozen cane toads were dissected and extracted with ethyl acetate 
(EtOAc). After in vacuo concentration, the EtOAC solubles (a yellow oil) were triturated with n-
hexane followed by n-BuOH (Figure 2.2). The residual parotoid gland tissues were triturated with 
water to solubilize all polar compounds. The organic layer contained all the bufadienolides while 
the water layer contained amines and amides. The EtOAc solubles were subjected to normal phase 
HPLC (See Experimental Section 1.2) to yield marinobufagenin (1a) (3 g), telocinobufagenin (2a) 
Adult&parotoid&
secre/ons&
bufagenins&bufotoxins&
3 
2 1 
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(402 mg), bufalin (3a) (620 mg). The remaining crude extract retained by the column was eluted 
with 30% methanol/hexane, dried in vacuo, re-dissolved in methanol and was subjected to reverse 
phase HPLC purification to yield resibufagenin (4a) (7 mg), hellebrigenin (5a) (3.4 mg) and 
bufalin-3-acetate (7a) (2.8 mg). Marinobufagenin (1a) constituted 70% of the ethyl acetate fraction 
of the EtOAc solubles. Gao et al, previously reported the identification of bufagenins from the 
parotoid secretions of B. marinus and the present analysis is in agreement with that finding. The 
bufagenins isolated from the cane toad parotoid secretions were characterized using HPLC-DAD-
MS, NMR and HRMS and identified to be 1a, 2a, 3a, 4a, 5a and 7a, respectively (refer to 
Appendix), consistent with prior studies.1, 9, 10  
 
 
Figure 2.2 Isolation scheme for bufagenins from cane toad parotoid gland secretions 
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(a)
(b)
(a) Sequential solvent extraction [ EtOAc (-1-1), H2O (-1-2)]
(b) Sequential trituration  [ n-hexane (-1-1-1), n-butanol (-1-1-2)]
(c) Preparative NP-HPLC: 50 g SNAP cartridge (Flash chromatography silica column), eluting with 
10.0 mL/min 60-100% EtOAc/n-hexane
(d) Semi-preparative RP-HPLC: Zorbax C18column, 250 x 9.4 mm, 5 µm, 3.5 mL/min, eluting with
10-100% MeCN/H2O over 15 min
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Figure 2.3 HPLC chromatogram (298 nm) of EtOAc solubles from cane toad parotoid secretion. Marinobufagenin (1a), 
telocinobufagenin (2a), bufalin (3a), resibufagenin (4a), hellebrigenin (5a) bufalin-3-acetate (7a) and marinobufotoxin 
(1c) analysed using Method 1 
 
 
 
                              marinobufagenin (1a)            telocinobufagenin (2a)                bufalin (3a) 
 
resibufagenin (4a)         hellebrigenin (5a)                bufalin acetate (7a) 
 
Figure 2.4 Bufagenins isolated from cane toad parotoid secretions 
 
Characterization of 1a from Australian cane toad parotoid secretions has been previously reported.1 
In our study 1a was obtained as a pale white solid with HR(+)ESIMS analysis revealing a quasi-
molecular ion (m/z 401.2323 [M+H]+) consistent with the molecular formula C24H32O5 (Δmmu 
0.4).1 The 1H NMR and 13C NMR (CD3OD) data for 1a was identical to the literature data 
(Appendix Figure S1, Table S1).11 The UV-vis spectrum of 1a exhibited the characteristic α-pyrone 
ring absorbance. All of the above confirmed that 1a was marinobufagenin.  
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Characterization of 2a from Australian cane toad parotoid secretions has been previously reported.1 
In our study 2a was obtained as a pale white solid with HR(+)ESIMS analysis revealing a quasi-
molecular ion (m/z 403.2479 [M+H]+) consistent with the molecular formula C24H34O5 (Δmmu 
0.4).1 The 1H NMR and 13C NMR (CD3OD) data for 2a was identical to the literature data 
(Appendix Figure S2, Table S1).7 The UV-vis spectrum of 2a exhibited the characteristic α-pyrone 
ring absorbance. All of the above confirmed that 2a was telocinobufagenin. 
 
Characterization of 3a from Australian cane toad parotoid secretions has been previously reported.1 
In our study 3a was obtained as a pale white solid with HR(+)ESIMS analysis revealing a quasi-
molecular ion (m/z 387.2530 [M+H]+) consistent with the molecular formula C24H34O4 (Δmmu 
0.1).1 The 1H NMR and 13C NMR (CD3OD) data for 3a was identical to the literature data 
(Appendix Figure S3, Table S1).12 The UV-vis spectrum of 3a exhibited the characteristic α-pyrone 
ring absorbance. All of the above confirmed that 3a was bufalin. 
 
Characterization of 4a from Australian cane toad parotoid secretions has been previously reported.1 
In our study 4a was obtained as a pale white solid with HR(+)ESIMS analysis revealing a quasi-
molecular ion (m/z 407.2190 [M+H]+) consistent with the molecular formula C24H32O4 (Δmmu -
0.05).1 The 1H NMR and 13C NMR (CD3OD) data for 4a was identical to the literature data 
(Appendix Figure S17, Table S1).12 The UV-vis spectrum of 4a exhibited the characteristic α-
pyrone ring absorbance. All of the above confirmed that 4a was resibufagenin. 
 
Characterization of 5a from Australian cane toad parotoid secretions has been previously reported.1 
In our study 5a was obtained as a pale white solid with HR(+)ESIMS analysis revealing a quasi-
molecular ion (m/z 417.2272 [M+H]+) consistent with the molecular formula C24H32O6 (Δmmu 
0.2).1 The 1H NMR and 13C NMR (CD3OD) data for 5a was identical to the literature data 
(Appendix figure S4, Table S5).7 The UV-vis spectrum of 5a exhibited the characteristic α-pyrone 
ring absorbance. All of the above confirmed that 5a was hellebrigenin. 
 
Characterization of 7a from cane toad parotoid secretions has not been previously reported. In our 
study 7a was obtained as a pale white solid with HR(+)ESIMS analysis revealing a quasi-molecular 
ion (m/z 428.2272  [M+H]+) consistent with the molecular formula C26H36O5 (Δmmu −0.7). The 1H 
NMR and 13C NMR spectrum (CD3OD) of natural 7a was identical to the synthetic compound 
(Appendix Figure S5, Table S6). The UV-vis spectrum of 7a exhibited the characteristic α-pyrone 
ring absorbance. All of the above confirmed that 7a was bufalin-3-acetate. Bufalin-3-acetate was 
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synthesized from bufalin using a partial synthesis strategy (Sec 2.2.2). Synthetic bufalin-3-acetate 
was co-injected along with crude parotoid secretions to confirm 7a to be bufalin-3-acetate. 
2.2.1.1 HSQC signatures analysis for bufagenins 
 
Bufagenins, comprising of a typical steroidal A/B and C/D cis ring junctions exhibit a complicated 
and overlapping signals of methylenes which are difficult to identify using a standard 1H or 1H-1H 
COSY spectra. In our analyses on bufadienolides, we investigated the common signatures exhibited 
by the structural functionality of the bufagenins (such as carboxylations) using HSQC. These 
signatures would then represent a fingerprint for the specific functionality of the bufagenins. This 
analyses would also be applied to bufotoxins (Page 44) and possibly extended to other bufagenin 
structure classes such as bufolipins. The HSQC fingerprinting analysis would be significant in 
identifying bufadienolides that are present in lower quantities (in <500 µg).   
 
Bufagenins (such as 1a – 7a as shown above) exhibit varying levels of oxidation in a manner that is 
not immediately recognizable in standard 1H and 13C NMR spectra, this is particularly evident 
where functionalization occurs at quaternary carbons – for example hydroxylations at C-5 and C-
14. In an effect to provide better empirical spectroscopic tools to assist in the identification of 
common bufagenin scaffolds, we examined the HSQC spectra of 1a – 4a across δH 0.6 – 3.7 and δC 
14.0 – 67.0 to compare the upfield methylene envelop region to determine if the data could be used 
to fingerprint key structural features.  
 
As anticipated, HSQC fingerprinting analysis of bufagenins exhibited four distinct clustering of 
contours based on the substitutions at C-5 and C-14. The HSQC spectrum of bufagenins (1a – 4a) 
clearly indicated the presence of a α-pyrone ring  (δH 6.26 – 8.0; δC 149.6 – 164.6) and two tertiary 
methyls (δH 0.78 – 0.98; δC 17.2 – 24.5). All four bufagenins, 1a – 4a, differ in levels of oxidation, 
for example, marinobufagenin (1a) and telocinobufagenin (2a) possess a 5-OH substitution whereas 
bufalin (3a) and resibufagenin (4a) do not, leading to diagnostic HSQC signatures. These signatures 
are highlighted in Figures 2.5 – 2.8 with different colours; brown for 5-OH and magenta for 5-H 
(Figures 2.5 – 2.8).  
 
Another HSQC signature was attributed to the presence of C-14 epoxide vs hydroxylation. For 
example, whereas marinobufagenin (1a) and resibufagenin (4a) possessed a Δ14,15 epoxide, 
telocinobufagenin (2a) and bufalin (3a) possessed a C-14 hydroxyl, leading to diagnostic HSQC 
signatures. These signatures are highlighted in Figures 2.5 – 2.8.  
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Figure 2.5 Expansion of HSQC (CD3OD, 600 MHz) spectrum of marinobufagenin (1a) showing 5-OH (brown) and 
Δ14,15 epoxide (purple) signatures 
 
 
Figure 2.6 Expansion of HSQC (CD3OD, 600 MHz) spectrum of telocinobufagenin (2a) showing 5-OH (brown) and 
14-OH (green) signatures 
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Figure 2.7 Expansion of HSQC (CD3OD, 600 MHz) spectrum of bufalin (3a) showing 5-H (magenta) and 14-OH 
(green) signatures 
 
 
Figure 2.8 Expansion of HSQC (CD3OD, 600 MHz) spectrum of resibufagenin (4a) showing 5-H (magenta) and Δ14,15 
epoxide (purple) correlations 
 
HSQC fingerprinting does appear to provide a valuable means to recognize quarternary oxidation 
levels about C-5 and C-14, and could be useful in identifying both known and new bufagenins. This 
F2 [ppm] 3.5  3.0  2.5  2.0  1.5  1.0 
F
1 
[p
p
m
]
 6
0 
 5
0 
 4
0 
 3
0 
 2
0 
1b
2a 2b4a 4b
18
19
16a 16b
17
15a 15bHO
OH
H
O
O
H
H2
4
19 16
17
18
15
1
bufalin (3a)
5
5
F2 [ppm] 3.5  3.0  2.5  2.0  1.5  1.0 
F
1 
[p
p
m
]
 6
0 
 5
0 
 4
0 
 3
0 
 2
0 
1b
2a 2b
4a 4b
19
5
16b16a
18
17
15
HO
O
H
O
O
H
H2
4
19 16
17
18
15
1
resibufagenin (4a)
	   41	  
approach can also be extended to bufotoxins and bufolipins as discussed later in this thesis. Since 
hellebrigenin (5a) and bufalin-3-acetate (7a) exhibited differences about C-3 (acetate) and C-10 
(keto) they were not included in this current HSQC fingerprinting analysis. However, with a larger 
set of analogues to compare it is likely that additional HSQC signatures could be identified.  
 
2.2.2 To generate a library of bufotoxin standards 
 
Bufotoxins have previously been reported from the extraction of thousands of cane toad skins6,13 
and as minor components from the parotoid secretions.1 The (apparent) lack of a reliable natural 
source necessitated a semi-synthesis approach, where we converted bufagenins to pure bufotoxins. 
Bufotoxins were prepared from previously isolated bufagenins by a two-step synthetic strategy 
where a bufagenin ester of suberic acid (DMAP; 3 h at 60 °C in DCM) was coupled to L-arginine 
(iBuClCOO-, MeOH/TFA, (C2H5)3N for 4 h at – 10 °C) to form the bufotoxin14 (Figure 2.7).  
 
Figure 2.9 (a) marinobufagenin (1a) was treated with suberic anhydride and DMAP for 3 h at 60 °C in DCM (78%). (b) 
– The bufagenin suberate ester (1b) was treated with L-arginine monohydrochloride, triethylamine, isobutyl 
chloroformate and methanol in THF for 4 h at – 10 °C (77%). 
 
The bufagenin esters, 1b, 2b, 3b, 5b and 6b, were subjected to purification using a C18 SPE 
cartridge (20-100% MeCN) followed by semi-preparative HPLC (Zorbax SB C18 column, 250 × 
9.4 mm, 5 µm, 3.5 mL/min, gradient from 90% H2O/MeCN to 100% MeCN over 25 min, hold at 
100% MeCN for 5 min, with isocratic 0.01% modifier (TFA)), after which they were subjected to 
full spectroscopic characterization.   
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In our study, 1b was obtained as a pale white solid, with HR(+)ESIMS analysis revealing a quasi-
molecular ion (m/z 557.3138 [M+H]+) consistent with the molecular formula C32H44O8 (Δmmu 
−2.8). The 1H NMR spectra (CD3OD) of 1b showed the purity of the compound (Appendix Figure 
S6, Section 2.4.3.3). The UV-vis spectrum of 1b exhibited the characteristic α-pyrone ring 
absorbance. All of the above confirmed that 1a was marinobufagenin-3suberate. 
 
In our study 2b was obtained as a pale white solid with HR(+)ESIMS analysis revealing a quasi-
molecular ion (m/z 581.3110 [M+H]+) consistent with the molecular formula C34H44O8 (Δmmu 
−0.1). The 1H NMR spectra (CDCl3) of 2b showed the purity of the compound (Appendix Figure 
S7, Section 2.4.3.2). The UV-vis spectrum of 2b exhibited the characteristic α-pyrone ring 
absorbance. All of the above confirmed that 2b was telocinobufagenin-3-suberate. 
 
In our study 3b was obtained as a pale white solid with HR(+)ESIMS analysis revealing a quasi-
molecular ion (m/z 543.3313 [M+H]+) consistent with the molecular formula C32H46O7 (Δmmu 
0.6). The 1H NMR spectra (CD3OD) of 3b showed the purity of the compound (Appendix Figure 
S8, Section 2.4.3.1). The UV-vis spectrum of 3b exhibited the characteristic α-pyrone ring 
absorbance. All of the above confirmed that 3b was bufalin-3-suberate. 
 
In our study 5b was obtained as a pale white solid with HR(+)ESIMS analysis revealing a quasi-
molecular ion (m/z 543.3109  [M+H]+) consistent with the molecular formula C31H42O8 (Δmmu 
−0.8). The 1H NMR spectra (CD3OD) of 5b showed the purity of the compound (Appendix figure 
S21, Section 2.4.3.3). The UV-vis spectrum of 5b exhibited the characteristic α-pyrone ring 
absorbance. All of the above confirmed that 5b was marinobufagenin-3-pimelate. 
 
In our study 6b was obtained as a pale white solid with HR(+)ESIMS analysis revealing a quasi-
molecular ion (m/z 551.2992 [M+Na]+) consistent with the molecular formula C32H44O8 (Δmmu -
1.3). The 1H NMR spectra (CD3OD) of 6b showed the purity of the compound (Appendix Figure 
S25, Section 2.4.3.1). The UV-vis spectrum of 6b exhibited the characteristic α-pyrone ring 
absorbance. All of the above confirmed that 6b was bufalin-3-pimelate. 
 
The bufagenin esters were then coupled to L-arginine to form bufotoxins. Synthetic bufotoxins, 1c, 
2c, 3c, 8c and 9c, were purified using semi-preparative HPLC (Zorbax SB C18 column, 250 × 9.4 
mm, 5 µm, 3.5 mL/min, gradient from 90% H2O/MeCN to 100% MeCN over 25 min, hold at 100% 
MeCN for 5 min, with constant 0.01% modifier (TFA)) and dried in vacuo to yield an oily residue. 
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HPLC-DAD-MS analysis confirmed that marinobufotoxin (1c) was converted into its TFA adduct 
during handling, a transformation that could be avoided by eliminating TFA from the HPLC 
method. Purified bufotoxins were characterized using NMR spectroscopy (1H, 13C and HSQC) and 
HRMS (Appendix Figure S9, Table S7).  
 
Characterization of 1c from Australian cane toad parotoid secretions has been previously reported.1 
In our study, 1c was obtained as a pale white solid with HR(+)ESIMS analysis revealing a quasi-
molecular ion (m/z 713.4120 [M+H]+) consistent with the molecular formula C38H56N4O9 (Δmmu 
−0.3).1 The 1H NMR and 13C NMR spectrum (CD3OD) for 1c was identical to the literature data 
(Appendix Figure S9, Table S7).11 The UV-vis spectrum of 1c exhibited the characteristic α-pyrone 
ring absorbance. All of the above confirmed that 1c was marinobufotoxin. Moreover, as 1c was 
synthesized from marinobufagenin-3-suberate (1b), which was in turn prepared from authentic 
natural marinobufagenin (1a), we can be confident that the structure is as proposed.  
 
Characterization of 2c from Australian cane toad parotoid secretions has been previously reported 
(Figure 2.14).1 In our study 2c was obtained as a pale white solid with HR(+)ESIMS analysis 
revealing a quasi-molecular ion (m/z 715.4277 [M+H]+) consistent with the molecular formula 
C38H58N4O9 (Δmmu 0.3).1 The 1H NMR and 13C NMR spectrum (CD3OD) of 2c was identical to 
the literature data (Appendix Figure S10, Table S8).6 The UV-vis spectrum of 2c exhibited the 
characteristic α-pyrone ring absorbance. All of the above confirmed that 2c was telocinobufotoxin. 
Moreover, as 2c was synthesized from telocinobufagenin-3-suberate (2b), which was in turn 
prepared from authentic natural telocinobufagenin (2a), we can be confident that the structure is as 
proposed.  
 
Characterization of 3c from Australian cane toad parotoid secretions has been previously reported 
(Figure 2.14).1 In our study 3c was obtained as a pale white solid with HR(+)ESIMS analysis 
revealing a quasi-molecular ion (m/z 699.4327 [M+H]+) consistent with the molecular formula 
C37H58N4O8  (Δmmu −0.3).1 The 1H NMR and 13C NMR spectrum (CD3OD) of 3c was identical to 
the literature data (Appendix figure S11, Table S9).15 The UV-vis spectrum of 3c exhibited the 
characteristic α-pyrone ring absorbance. All of the above confirmed that 3c was bufalitoxin. 
Moreover, as 3c was synthesized from bufalin-3-suberate (3b), which was in turn prepared from 
authentic natural bufalin (3a), we can be confident that the structure is as proposed.  
 
Characterization of 8c from Australian cane toad parotoid secretions has been previously reported 
(Figure 2.14).1 In our study 8c was obtained as a pale white solid with HR(+)ESIMS analysis 
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revealing a quasi-molecular ion (m/z 699.3971 [M+H]+) consistent with the molecular formula 
C37H54N4O9 (Δmmu −0.05).1 The 1H NMR and 13C NMR spectrum (CD3OD) of 8c was identical to 
the literature data (Appendix figure S24, Table S11).6 The UV-vis spectrum of 8c exhibited the 
characteristic α-pyrone ring absorbance. All of the above confirmed that 8c was marinobufagenin 
pimeoyl-L-arginine. Moreover, as 8c was synthesized from marinobufagenin-3-pimelate (5b), 
which was in turn prepared from authentic natural marinobufagenin (1a), we can be confident that 
the structure is as proposed.  
 
Characterization of 9c from Australian cane toad parotoid secretions has been previously reported 
(Figure 2.14).1 In our study 9c was obtained as a pale white solid with HR(+)ESIMS analysis 
revealing a quasi-molecular ion (m/z 685.4172 [M+H]+) consistent with the molecular formula 
C36H54N4O8 (Δmmu −0.08).1 The 1H NMR and 13C NMR spectrum (CD3OD) of 9c was identical to 
the literature data (Appendix figure S23, Table S10).16 The UV-vis spectrum of 9c exhibited the 
characteristic α-pyrone ring absorbance. All of the above confirmed that 9c was bufalin pimeoyl-L-
arginine. Moreover, as 9c was synthesized from bufalin-3-pimelate (6b), which was in turn 
prepared from authentic natural bufalin (3a), we can be confident that the structure is as proposed.  
 
1H NMR spectrum of bufotoxins revealed more complicated signals compared to respective 
bufagenins due to the signals overlapping from C3-suberoyl-L-arginine conjugate. A search for 
complete NMR structure description for bufotoxins other than marinobufotoxin (1c) in literature 
revealed only non-detailed structure elucidation (with few distinct signals) from the 1970’s.6 
However, the 1H NMR spectrum for bufotoxins (1c, 2c, 3c, 8c and 9c) matched the data reported by 
Hayes et al in 2008.1  
 
2.2.2.1 An empirical HSQC signature analysis for bufotoxins 
 
Investigation of bufotoxin HSQC spectra was performed as described earlier for bufagenins, 
revealing comparable diagnostic signatures for marinobufotoxin (1c) telocinobufotoxin (2c) and 
bufalitoxin (3c).  
The 5-OH/5-H and Δ14,15 epoxide/14-OH motifs revealed diagnostic HSQC signatures across the 
methylene envelop region of the steroid framework. 
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Figure 2.10 Expansion of HSQC (CD3OD, 600 MHz) spectrum of marinobufotoxin (1c) showing 5-OH (brown) and 
Δ14,15 epoxy (purple) signatures 
 
Figure 2.11 Expansion of HSQC (CD3OD, 600 MHz) spectrum of telocinobufotoxin (2c) showing 5-OH (brown) and 
14-OH (green) signatures 
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Figure 2.12 Expansion of HSQC (CD3OD, 600 MHz) spectrum of bufalitoxin (3c) showing 5-H (magenta) and 14-OH 
(green) signatures 
 
2.2.2.2 HSQC fingerprints for 5-OH vs 5-H bufagenins 
 
Figure 2.13 Expansion of HSQC (CD3OD, 600 MHz) fingerprint of 5-OH bufagenins (brown) 
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Figure 2.14 Expansion of HSQC (CD3OD, 600 MHz) fingerprint of 5-H bufagenins (magenta) 
 
 
2.2.2.3 Empirical HSQC rules for 14-epoxy vs 14-OH 
 
Figure 2.15 Expansion of HSQC (CD3OD, 600 MHz) fingerprint of 14-OH bufagenins (green) 
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Figure 2.16 Expansion of HSQC (CD3OD, 600 MHz) fingerprint of 14-epoxy bufagenins (purple) 
 
These data suggests that HSQC fingerprinting analysis is not only applicable to identify bufagenins 
but also bufotoxins, and can potentially be extended to identify bufadienolides both known and new 
(Chapter 3).  
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                             telocinobufagenin-3-suberate (2b)                                bufalin-3-pimelate (7b) 
 
bufalin-3-suberate (3b) 
Figure 2.17 Bufagenin esters synthesized from bufagenins  
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bufalitoxin (3c) 
 
Figure 2.18 Bufotoxins synthesized from bufagenin esters 
 
 
2.2.3 HPLC-DAD methodology to analyse bufagenins 
 
An HPLC-DAD based analytical methodology was developed specifically for bufagenins by 
evaluating several reverse phase columns including C3, C8, C18, CN (cyano) and phenyl columns 
with C18 (Zorbax, SB, 4.6 × 150 mm, 5 µm) providing the best resolution. Solvent conditions 
including MeOH/H2O and MeCN/H2O, across varying gradients (linear/isocratic) with and without 
TFA (0.01%) were also evaluated (Figure 2.19). A linear gradient of MeCN/H2O with TFA (0.01%) 
showed high resolution of bufagenins (Method 1, refer section 2.) based on the peak area, peak 
height and the retention time of the respective bufagenin. 
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Figure 2.19 HPLC chromatograms (298 nm) and UV-Vis spectrum of marinobufagenin (1a), telocinobufagenin (2a) 
and bufalin (3a) respectively analysed using Method 1 (refer page 77) 
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2.2.3.1 Quantification of bufagenins 
 
Having assembled authentic standards of a range of bufagenins, and having developed an optimized 
HPLC-DAD analytical methodology, it was important to evaluate this method for its applicability 
for quantitation analyses. As the DAD response for the α-pyrone moiety was constant across all 
bufagenins, it was deemed sufficient to calibrate against marinobufagenin (1a) as a representative 
of all bufagenins. A series of pure standards concentrated solutions of 1a were prepared (3.9, 7.8, 
15.6, 31.2, 62.5, 125, 250, 500, 1000 and 2000 µM). Injection of 10 µL from each standard solution 
delivered fixed amounts of 1a (0.02, 0.04, 0.07, 0.13, 0.25, 0.5, 1, 2, 4 and 8 µg) (in triplicates). A 
plot of the DAD (298 nm) response (Figure 2.20) indicated a linear response across the range 0.02 
to 8 µg (r2=0.9978). This study provided a calibration curve that could be used to measure the 
concentration of 1a (or any bufagenin) in a sample of unknown concentration, provided the mass of 
bufagenin injected per analyses fell within the linear range of 0.02 – 8 µg/injection. 
 
 
Figure 2.20 Concentration curve and UV-vis spectrum of marinobufagenin (1a)  
 
 
2.2.4 HPLC-DAD methodology for bufotoxins  
 
Bufotoxins are more polar compared to bufagenins due to the presence of arginyl amide conjugate, 
which also results in broad peaks when analysed using HPLC-DAD.4, 10 Like the HPLC-DAD 
analytical methodology development with bufagenins, several reverse phase columns, such as C3, 
C8, C18, CN (cyano) and phenyl columns (Zorbax, SB, 4.6 × 150 mm, 5 µm) were evaluated as well 
as MeOH/H2O and MeCN/H2O, with or without TFA (0.01%) (Figure 2.21). A C18 column with a 
linear gradient of MeCN/H2O with TFA (0.01%) exhibited the best resolution (Method 2) based on 
the peak area, peak height and the retention time of the respective bufotoxin. 
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Figure 2.21 HPLC chromatograms (298 nm) and UV-vis spectrum of marinobufotoxin (1c), telocinobufotoxin (2c) and 
bufalitoxin (3c) using Method 2 (refer page 77) 
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2.2.4.1 Quantification of bufotoxins 
 
Having assembled authentic standards of a range of bufotoxins, and having developed an optimized 
HPLC-DAD analytical methodology, it was important to evaluate this method so as to permit 
quantitation analyses. As the DAD response for the α-pyrone moiety was constant across all 
bufotoxins, it was deemed sufficient to calibrate against marinobufotoxin (1c) as a representative of 
all bufotoxins. A series of pure standards concentrated solutions of 1a were prepared (3.9, 7.8, 15.6, 
31.2, 62.5, 125, 250, 500, 1000 and 2000 µM). Injection of 10 µL from each standard solution 
delivered fixed amounts of 1a (0.02, 0.04, 0.07, 0.13, 0.25, 0.5, 1, 2, 4 and 8 µg) (in triplicates). A 
plot of the DAD (298 nm) response (Figure 2.22) indicated a linear response across the range 0.02 
to 8 µg (r2=0.9994). This study provided a calibration curve that could be used to measure the 
concentration of 1c (or any bufotoxin) in a sample of unknown concentration, provided the mass of 
bufotoxin injected per analyses fell within the calculated range of 0.02 – 8 µg/injection. 
 
Figure 2.22 Concentration curve and UV-vis spectrum of marinobufotoxin(1c)  
 
2.2.5 Analysis of bufadienolides from live cane toad parotoid secretions  
 
Our pure bufagenin standards were isolated from frozen adult cane toad parotoid secretions, 
however, Hayes et al previously identified bufotoxins as minor components in parotoid secretions 
sourced from living cane toads. To explore this apparent contradiction we examined, parotoid 
secretions from live cane toads using our optimized analytical methodology specific for bufagenins 
and bufotoxins. Handling of parotoid secretions was of concern as the texture of toxin varies from 
sticky or pasty secretion to waxy solid if left to dry (data not shown). Two different approaches 
were investigated to handle the parotoid secretions. 
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2.2.5.1 Approach 1 
Parotoid secretions from the left parotoid gland of three adult cane toads were squeezed onto a 
petridish and left for an hour to turn into a waxy solid. A pipette tip was used to scrap off parotoid 
secretion from the petridish and was directly dropped into methanol, mixed until homogenous 
solution and evaporated to dryness under N2 at 40 °C. 
 
HPLC-DAD analysis of the parotoid secretions recovered from live cane toads was dominated by 
bufagenins 1a, 3a and 4a (66%), accompanied by significant amounts of bufotoxins 1c and 2c 
(34%). This analysis also detected dehydrobufotenin (1.6) (*) (Figure 2.23). 
 
Figure 2.23 HPLC profile (298 nm) of live cane toad parotoid secretion squeezed on a petridish. Dehydrobufotenin 
(1.6), marinobufagenin (1a), bufalin (3a), resibufagenin (4a), marinobufotoxin (1c) and telocinobufotoxin (2c) 
 
2.2.5.2 Approach 2 
Parotoid secretions from the right parotoid gland were squeezed directly onto water and let for one 
hour retaining the sticky nature of the toxin. Subsequently, an aliquot of parotoid secretion in water 
was dispensed and dried under N2 at 40 °C.  
 
HPLC-DAD analysis of the parotoid secretions recovered from live cane toads revealed a higher 
ratio of bufagenins (89%) to bufotoxins (11%) (Figure 2.24)  than measured in approach 1 (above).  
This observation suggests that post secretion and under certain conditions bufotoxins transformed 
into bufagenins. This was the first indication of such a transformation and has significant ecological 
implication given the very different levels of biological activity attributed to bufagenins vs 
bufotoxins. 
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Figure 2.24 HPLC profile (298 nm) of adult parotoid secretion squeezed into water. Dehydrobufotenin (1.6), 
marinobufagenin (1a), bufalin (3a), resibufagenin, (4a) and telocinobufotoxin (2c) 
 
The breakdown of bufotoxins to bufagenins could proceed by two plausible mechanisms 
1. Proteolysis of the arginyl amide followed by hydrolysis of the suberoyl ester, to deliver the 
corresponding bufagenin together with arginine and suberic acid (Mechansim 1) 
2. Hydrolysis of the suberoyl ester to deliver the corresponding bufagenin accompanied by 
intact suberoyl-L-arginine (Mechanism 2) 
 
 
Figure 2.25 Mechanism 1 – Transformation of marinobufotoxin (1c) to marinobufagenin-3-suberate (1b) and arginine 
followed by marinobufagenin (1a) and suberic acid 
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Figure 2.26 Mechanism 2 – Transformation of marinobufotoxin (1c) to marinobufagenin (1a) and suberoyl-L-arginine 
(1d) 
 
 
To differentiate between these two hypotheses we developed and applied analytical methods to 
detect arginine, bufagenin suberate and suberoyl-L-arginine.  
 
2.2.6 Analytical methodology to identify arginine 
 
Although there is extensive literature about the isolation and characterization of bufadienolides 
(including bufotoxins), the configuration in the arginine of C-3 suberoylarginine conjugates of 
bufotoxins has never been reported. However, bufotoxins have always been represented to contain 
L-arginine in all of the published reports.15, 17-19 Also, an analytical methodology to identify arginine 
in the parotoid secretions would be significant to determine the breakdown of bufotoxins through 
previously proposed mechanisms (Figure 2.25) during handling of the parotoid secretions.  To 
detect arginine in the parotoid secretions and to determine the configuration of arginine, C3-
Marfey’s analysis was performed on crude cane toad parotoid secretions. Since parotoid secretions 
directly squeezed into water showed high levels of bufagenins, it was chosen as a medium to 
identify arginine, as the lower the butotoxins, the higher the arginine level (Figure 2.23). Parotoid 
secretion was squeezed into water (5 mL), mixed using a vortex followed by partitioning with n-
BuOH (5 mL) to solubilize all the bufadienolides. The water-soluble fraction was then dried in 
vacuo and was subjected to acid hydrolysis using 6M HCl to hydrolyse all the conjugated amino 
acids followed by derivatization with C3-Marfey’s reagent in the presence of 1M NaHCO3. The 
reaction was stopped by the addition of 1M HCl, dried in vacuo, re-dissolved in MeCN (1 mg/mL) 
and was analysed using HPLC-DAD-MS co-injected with derivatized amino acid standards (Figure 
2.27).  
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Figure 2.27 HPLC chromatogram (320 nm) of C3 Marfey’s analysis on water soluble fraction of parotoid secretions.  
* - Marfey’s reagent (for peak annotation refer to Table 2.1) 
 
Table 2.1 List of amino acids identified in water solubles of parotoid secretion using C3-Marfey’s 
analysis 
 
Amino acid Retention time (min) 
L-histidine (H) 8.1 
L-lysine (K) 9.8, 13.6 
D-arginine (D-R) 10.2 
L-arginine (R) 11.7 
L-serine (S) 15.4 
L-glycine (G) 19.3 
L-aspartate (D) 20.8 
L-threonine (T) 22.4 
L-proline (P) 24.6 
L-glutamine (Q) 25.6 
L-alanine (A) 28.5 
L-tyrosine (Y) 34.5 
L-valine (V) 40.3 
L-phenylalanine (F) 43.6 
L-isoleucine (I) 46.4 
 
C3 Marfey’s analysis clearly indicated the presence of high amounts of L-arginine in the parotoid 
secretion based on HPLC-DAD analysis (Figure 2.27). The analysis also indicated that 
transformation of bufotoxins to bufagenins and arginyl amides could occur through mechanism 2 
(Figure 2.25) since no free L-arginine (or any amino acid) was detected in the water solubles of the 
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cane toad parotoid secretions, which is further, described in section 2.2.9. Analytical methodology 
to detect suberic acid would determine the hypothesis. A direct way of detecting suberic acid in the 
parotoid secretions would be to detect bufagenin suberates as cleavage of arginine from bufotoxin 
would significantly release bufagenin suberates. Interestingly, 14 other amino acids could also be 
identified indicating the presence of some source of peptides or proteins co-secreted with the 
parotoid secretions (Table 2.1). Bufotoxins with amino acid variations except arginine was not 
detected during previous analyses on B. marinus parotoid secretions. Hence, the source of amino 
acids could be from a peptide/protein. Moreover, D-arginine was also identified in low amounts 
based on UV detection while its function in parotoid secretions is unknown. 
 
2.2.7 Analytical methodology to detect bufagenin suberate 
 
Bufagenin suberates standards were synthesized previously during the synthesis of bufotoxin 
standards from pure bufagenins isolated from adult cane toad parotoid secretions. The standards 
were co-injected with the n-BuOH solubles of parotoid secretions squeezed into water (Section 
2.2.5) and analysed using analytical methodology for bufagenins (Figure 2.28). No bufagenin 
suberate could be detected in the parotoid secretions indicating that transformation of bufotoxin 
through mechanism 1 may not fit the hypothesis (Figure 2.25). In addition to HPLC-DAD based 
detection, a single ion extraction of masses specific for the bufagenin suberates and other diacid 
conjugates also confirmed their absence.  
 
 
Figure 2.28 HPLC-DAD traces of co-injection of organic fraction of parotoid secretion with bufagenin suberates. 
Marinobufagenin (1a), resibufagenin (4a), marinobufagenin-3-suberate (1b), bufalin-3-suberate (3b) 
 
The presence of substantial amounts of L-arginine in the parotoid secretion (C3 Marfey’s analysis) 
could be attributed to the presence of arginyl amides in substantial quantities in the water soluble 
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part of parotoid secretions. Arginyl amides, like the amino acid arginine must be water-soluble, 
hence, the detected L-arginine could be a hydrolysed product of suberoyl-L-arginine formed from 
mechanism 2. Hence, bufotoxins are proposed to undergo transformation by direct breakdown of 
suberoyl-L-arginine (1d) to form bufagenins (Figure 2.26). The observation also indicated the 
presence of free arginyl amides present in the parotoid secretions that had never been identified 
before using HPLC-DAD. Hence, it is hypothesized that there is a fourth structure class present in 
the B. marinus parotoid secretions other than bufadienolides, catecholamines and indole alkaloids, 
namely arginyl amides. It can also be concluded that arginine present in bufotoxins is L-arginine 
and the previous reports of the structure could be considered as correctly representing the 
configuration. A literature search on the arginyl amides returned only one hit where 1d was 
identified during the chemical analysis of the Chinese traditional medicine, Chansu, prepared from 
the skin of the parotoid glands of Bufo species.18 Mass corresponding to suberoyl-L-arginine (1d) 
was identified during an ESI-MS analysis of parotoid secretions from B. marinus.2 Bufagenin 
conjugates with suberoyl-L-arginine and pimeloyl-L-arginine have been described previously from 
parotoid secretions of Bufo species and from Chansu.9, 18 
 
2.2.8 To generate a library of diacid arginyl amides 
 
A major drawback in the detection of arginyl amides is the lack of a characteristic UV chromophore 
making it difficult to isolate and characterize using HPLC-DAD. Hence, the detection and 
quantification of arginyl amides in the parotoid secretions requires a chemical derivatization 
method that could introduce a UV chromophore for detection using DAD. A synthetic strategy was 
undertaken to synthesize arginyl amides standards and subsequent identification using a specific 
analytical methodology (Figure 2.29). Since arginyl amides have not been studied before, its 
biological activity is as yet unknown (will be discussed in later chapters).  
 
Figure 2.29 Scheme of synthesis for arginyl amides standards with suberoyl-L-arginine (1d) as an example. (a) – reflux 
for 2 h with acetic anhydride, (b) –coupling with L-arginine monohydrochloride at pH 8.2 at room temperature for 24 h, 
(e) – reflux for 7 h with 2,4-pentanedione and pyridine. 
CO2H
HO2C
OO O
H2N NH
H
N
NH2
Osuberic acid (2.1) CO2Hsuberic anhydride (2.2) suberoylarginine (1d)
(a) (b) CO2H
N
H
H
N
OCO2H
CO2H
N
N
derivatized suberoylarginine (1e)
(c)
	   61	  
From C3-Marfey’s analysis, it was determined that arginine of the daicid arginyl amide is L-arginine 
and hence arginyl amides were synthesized with diacids containing various chain lengths and L-
arginine. The amides were synthesized by coupling L-arginine with adipic, pimelic, suberic and 
azeloic anhydrides, respectively.20 The anhydrides were obtained by heating the dicarboxylic acids 
with acetic anhydride at reflux. Immediately after the synthesis, the anhydrides were dried in vacuo 
and were subjected to coupling with L-arginine monohydrochloride (Figure 2.29).  
 
The pKa values for the alpha amino group and the guanidino group of arginine are 9.04 and 12.48 
respectively. The reaction was maintained between pH 8 and 9 to permit the free amine (alpha 
amino group) to undergo nucleophilic addition to the anhydride to form an amide bond (Appendix 
Figure S14, Table S12). Arginyl amides with varying chain lengths (4, 5, 6 and 7 methylenes) were 
synthesized (Table 2.2) and the purification was performed using ion-exchange chromatography 
(Dowex 50WX2, strong cation exchange resin, 200-400 dry mesh, 1 mL/min) with a linear gradient 
of 0 – 2 M HCl. Characterization was performed with NMR spectroscopy (1H, 13C, HSQC, HMBC 
and COSY) and HRMS.  
Table 2.2 List of synthesized diacid arginyl amides 
 
Chain length (n) amide yield 
4 adipoyl-L-arginine (2d) 61% 
5 pimeloyl-L-arginine (3d) 57% 
6 suberoyl-L-arginine (1d) 58% 
7 azeloyl-L-arginine (4d) 55% 
 
A derivatization method was adopted to specifically modify the individual amides to be UV 
detectable (Figure 2.29).21 The amides were converted to their respective pyrimidine analogues by 
the cyclization of the guanidino group of the arginine in the presence of 2,4-pentanedione (Table 
2.3).  
 
The synthesized amides (Figure 2.30) were subjected to the 2,4-pentanedione derivatization 
reaction and pure pyrimidine analogues of amides were isolated and characterized by semi-
preparative HPLC, NMR spectroscopy (1H, 13C, HSQC, HMBC and COSY) and mass 
spectrometry.  
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Table 2.3 List of all 2,4-pentanedione derivatized arginyl amides 
 
Chain length (n) derivatized amide yield 
4 derivatized adipoyl-L-arginine (2e) 83% 
5 derivatized pimeloyl-L-arginine (3e) 72% 
6 derivatized suberoyl-L-arginine (1e) 90% 
7 derivatized azeloyl-L-arginine (4e) 88% 
 
All the derivatized diacid arginyl amides (Figure 2.31) would be used as standards to identify and 
quantify the presence of arginyl amides in any given tissue sample (such as parotoid secretion). An 
analytical methodology to specifically identify derivatized amides was developed which will be 
discussed in the next section. Quantification of arginyl amides standards would be performed using 
the analytical methodology and generate a standard concentration curve which would be used as a 
tool to calculate absolute amounts of arginyl amides in a given tissue sample.   
                          
                         adipoyl-L-arginine (2d)                                                                     pimeloyl-L-arginine (3d)
           
                        suberoyl-L-arginine  (1d)                                                                   azeloyl-L-arginine (4d) 
                                               
Figure 2.30 List of synthesized arginyl amides  
 
 
 
               
                  derivatized adipoyl-L-arginine (2e)                                      derivatized pimeloyl-L-arginine (3e) 
      
                   derivatized suberoyl-L-arginine  (1e)                                   derivatized azeloyl-L-arginine (4e) 
 
Figure 2.31 List of derivatized synthetic arginyl amides 
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2.2.9 Analytical methodology for arginyl amides  
 
2.2.9.1 Analytical methodology 1 for arginyl amides – HPLC-DAD-MS 
 
A primary analytical methodology (Method 3a, refer 2.4.7) for the detection of arginyl amides 
involves an HPLC-DAD-MS based approach based on the ionization of the derivatized amides. 
Following the derivatizaion of arginyl amide standards with 2,4-pentanedione, a single ion 
extraction analysis was performed based on the mass (m/z) of the derivatized amides and the search 
returned a distinct ionization pattern for all four different amides (Figure 2.32). This approach 
would be suitable for arginyl amides that are present in less amounts or difficult to identify using 
absorption measured by HPLC-DAD. 
 
Figure 2.32 Single ion extraction of derivatized arginyl amides standards in ESI positive ion reflectron mode analysed 
using Method 3a (refer page 77). 2e – derivatized adipoyl-L-arginine, 3e – derivatized pimeloyl-L-arginine, 1e – 
derivatized suberoylargiinne, 4e – derivatized azeloyl-L-arginine 
 
Surprisingly, the analytical methodology also revealed that derivatized arginyl amide standards 
showed a better resolution under HPLC-DAD-MS profile (Figure 2.33). A search for the suberoyl-
L-arginine (1d), the major arginyl amide, in crude water solubles of the parotoid secretion co-eluted 
with dehydrobufotenine (1.6, major indole alkaloid) as a broad peak. However, since the derivatized 
amide (1e) has a different retention time and a better resolution (narrow peak) under HPLC-DAD-
MS, the problem of co-eluting or complexing of arginyl amides with other derivatives would be 
avoided while detecting individual arginyl amides. The two arginyl amides that were identified 
using Method 3a on crude water solubles of parotoid secretion include pimeloyl-L-arginine (3d) 
and suberoyl-L-arginine (1d) while no free L-arginine was detected.  
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Figure 2.33 Single ion extraction chromatograms from crude water solubles of parotoid secretion in ESI positive ion 
mode analysed using Method 3a (refer page 77). TIC – total ion current, dehydrobufotenine (1.6), suberoyl-L-arginine 
(1d), derivatized suberoyl-L-arginine (1e) 
 
2.2.9.2 Analytical method for detection of arginyl amides 
 
Arginyl amides standards when analysed using HPLC-DAD did not elicit a good response, 
however, a small peak was observed at 210 nm but at higher concentrations (>2 mg/mL). 
Derivatized amides were subjected to HPLC-DAD analysis using several reverse phase columns 
including C3, C8, C18, CN (cyano) and phenyl with C18 (Zorbax, SB, 4.6 × 150 mm, 5 µm)  showing 
the best resolution based on the peak area, peak height and the retention time of the respective 
arginyl amide. MeCN/H2O solvent gave better resolution compared to MeOH/H2O with TFA 
(0.01%). The absorbance (DAD) elicited by the derivatized amides is attributed to the pyrimidine 
ring (320 nm) formed from the cyclization of guanidine group of the arginine. Since the derivatized 
amides have a distinctive and characteristic UV absorbance at 320 nm it is significant to identify 
arginyl amides among other structure classes such as bufadienolides (298 nm) and alkaloids (210 
nm) in a given tissue sample (Method 3b, refer 2.4.7). The derivatized amides are less polar and 
methanol soluble compared to arginyl amides that are water-soluble. Crude extract from a tissue 
sample would be partitioned with EtOAC/H2O or n-BuOH/H2O to separate bufadienolides and 
arginyl amides. The water solubles containing arginyl amides would be further subjected to 
derivatization with 2,4-pentanedione followed by analysis using HPLC-DAD (Figure 2.34).  
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Figure 2.34 HPLC chromatogram (320 nm) and UV-vis spectrum of 2,4-pentanedione derivatized arginyl amides (1 
mM; 10 µL) analysed using Method 3b (refer page 77). 1e – derivatized suberoyl-L-arginine, 2e –  derivatized adipoyl-
L-arginine and 4e – derivatized azeloyl-L-arginine  
 
 
2.2.9.3 Quantification of arginyl amides 
 
Free arginyl amides were identified in the B. marinus parotoid secretions leading to indication of 
presence of significant quantities based on ionization as identified using HPLC-DAD-MS (Figure 
2.33). Gao et al, reported the presence of suberoyl-L-arginine (1d) in the parotoid secretions of B. 
marinus based on the mass spectrometry analysis.3 Since arginyl amides are not detetcted using 
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DAD, derivatized amides were subjected to quantitation studies using the analytical method for 
arginyl amdies previously described. This means the crude extract from the tissue under study must 
be derivatized with 2,4-pentanedione followed by analysis using HPLC-DAD using analytical 
Method 3. 
 
Having assembled authentic standards of a range of pyrimidine derivatives, and having developed 
an optimized HPLC-DAD analytical methodology, it was important to evaluate this method so as to 
permit quantitation analyses. As the DAD response for the pyrimidine moiety was constant across 
all derivatized amides, it was deemed sufficient to calibrate against derivatized suberoyl-L-arginine 
(1e) as a representative of all bufagenins. A series of pure standards concentrated solutions of 1e 
were prepared (3.9, 7.8, 15.6, 31.2, 62.5, 125, 250, 500, 1000 and 2000 µM). Injection of 10 µL 
from each standard solution delivered fixed amounts of 1a (0.02, 0.04, 0.07, 0.13, 0.25, 0.5, 1, 2, 4 
and 8 µg) (in triplicates). A plot of the DAD (320 nm) response (Figure 2.35) indicated a linear 
response across the range 0.02 to 8 µg (r2=0.9960). This study provided a calibration curve that 
could be used to measure the concentration of 1e (or any pyrimidine derivative) in a sample of 
unknown concentration, provided the mass of pyrimidine derivatives injected per analyses fell 
within the linear range of 0.02 – 8 µg/injection. Another interesting observation about the 
derivatized  arginyl amides is that, unlike other bufadienolides, they can be detected by DAD at 320 
nm, which means that a specific detection method is now available to exclusively detect arginyl 
amides. (Figure 2.35).  
 
Concentration curves for other derivatized amides are described elsewhere (Appendix Figure S29). 
The current investigation of arginyl amides in the parotoid secretions has revealed interesting 
findings since identification of arginyl amides has not been reported previously. The quantification 
of arginyl amides in the parotoid secretions may be significant for the toxicity of the cane toad 
parotoid secretions. 2,4-pentanedione derivatized crude extracts from a given sample could 
therefore be analysed using method 3b. Quantification of concentration for specific arginyl amides 
identified by comparison with standards can be done using the standard concentration curve. 
Following the calculation of absolute amounts in the crude extract, the amount present in the given 
tissue sample could be accurately determined.  
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Figure 2.35 Concentration curve and UV-vis spectrum of derivatized suberoyl-L-arginine (1e)  
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2.3 Conclusion 
 
The chemical diversity in parotoid secretions obtained from frozen B. marinus corresponded to the 
previously published literature, however, only bufagenins and no bufotoxins were identified as 
mentioned in some previous reports. A cane toad toxin library consisting of bufagenins, bufotoxins 
and arginyl amides was developed by various approaches as mentioned earlier to obtain significant 
quantities of compounds for quantification of toxin in various tissues.  
 
Bufagenin standards were directly isolated from parotoid secretions while bufotoxin standards were 
partially synthesized from bufagenins. All the standards were characterized for their purity and 
structure using analytical HPLC-DAD, HPLC-DAD-MS, NMR and HRMS. Having developed 
standards, a specific analytical methodology for identification of bufagenins and bufotoxins was 
developed. Quantification of the standards was performed by employing the analytical 
methodologies specific for each structure class with known amounts. Concentration curves were 
generated using UV absorbance (area under the curve) and absolute amount of each standard. 
Having developed an analytical separation and quantification methodology, absolute amounts of 
bufadienolides in any given tissue sample (parotoid secretions, eggs) could be determined. A HSQC 
finger printing analysis of bufadienolides was developed to identify the key substitution patterns in 
the steroidal A and D rings of new/unknown bufagenins as well as bufotoxins.  
 
During the analysis of parotoid secretions from live cane toads, handling of the toxin was 
determined to have an effect on the chemical profiling of the bufadienolides in the parotoid 
secretions. Bufotoxins were identified in significant amounts from dried parotoid secretions while 
the amounts dropped in parotoid secretions stored in water, although bufagenins were identified to 
be the dominant class of bufadienolides in either ways of handling. The investigation clearly 
suggested that there is a transformation of bufotoxins to bufagenins and arginyl amides. The 
observations also led to the presence of a new structure class, diacid arginyl amides in the parotoid 
secretions. To identify and quantify diacid arginyl amides in the parotoid secretions, standards were 
synthesized and derivatized with 2,4-pentanedione facilitating a UV response when detected using 
HPLC-DAD. 
 
C3-Marfeys analysis on parotoid secretions indicated the presence of L-arginine, which not only 
confirmed the stereochemistry of arginine in bufotoxins but also indicated the presence of 
significant amounts of arginyl amide in the parotoid secretions. Investigations on the role of free 
arginyl amides in the parotoid secretions are explained in following chapter.   
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2.4 Experimental 
2.4.1 Equipment 
 
High Performance Liquid Chromatography (HPLC) was performed using an Agilent 1100 Series 
Separations Module equipped with Agilent 1100 series diode array and/or multiple wavelength 
detectors and Agilent 1100 series fraction collector, controlled using ChemStation Rev.9.03A. 
Electrospray Ionisation Mass Spectra (ESI-MS) were acquired using an Agilent 1100 Series 
separations module equipped with an Agilent 1100 Series LC/MSD mass detector in both positive 
and negative ion modes. NMR spectra was obtained on a Bruker Avance DRX600 spectrometer, in 
the solvents indicated and referenced to residual proton signals in deuterated solvents. 
2.4.2 Isolation of bufagenins from parotoid secretions 
 
Parotoid glands from 120 frozen toads were dissected and were manually disrupted in a beaker 
containing ethyl acetate to release all the secretions. The organic layer was collected and was dried 
in vacuo at 40 °C and subjected to purification by flash chromatography (Biotage) with a linear 
gradient of 60-100% EtOAc/n-hexane using 50 g normal phase silica column (SNAP cartridge). 
Each peak was collected in clean glass test tubes. Peaks corresponding to bufalin (3a) and 
telocinobufagenin (2a) were again subjected to purification by HPLC to isolate the minor peaks that 
was not detected by flash chromatography to yield hellebrigenin (5a) and bufalin-3-acetate (7a).  
 
marinobufagenin (1a): yellow solid; [α]21D +12.5 (c 0.2, CHCl3) (Reported: +12.2 (c 1.1, CHCl3); 
1H and 13C NMR (CD3OD, 600 MHz) see Table S1; HRESI(+)MS m/z 401.2323 (M+H)+ (calcd for 
C24H32O5, 401.2322). Zorbax C18 column, 250 × 9.4 mm, 5 µm, 3.5 mL/min, gradient from 10-
100% MeCN/H2O over 25 min, tR = 13.5 (Appendix Figure S1). Yield: 66.7% 
 
telocinobufagenin (2a): white solid; [α]21D −5.7 (c 0.16, MeOH) (Reported: −12.5 (c 0.9, MeOH); 
1H and 13C NMR (CD3OD, 600 MHz) see Table S2; HRESI(+)MS m/z 403.2479 (M+H)+ (calcd for 
C24H34O5, 403.2474). Zorbax C18 column, 250 × 9.4 mm, 5 µm, 3.5 mL/min gradient from 10-
100% MeCN/ H2O over 25 min, tR = 11.2 min (Appendix Figure S2). Yield: 8.9% 
 
bufalin (3a): white solid; [α]21D −7.7 (c 0.2, CHCl3) (Reported: −8.9 (c 1.2, CHCl3); 1H and 13C 
NMR (CD3OD, 600 MHz) see Table S3; HRESI(+)MS m/z 387.2530 (M+H)+ (calcd for C24H34O4, 
387.2527). Zorbax C18 column, 250 × 9.4 mm, 5 µm, 3.5 mL/min, gradient from 10-100% MeCN/ 
H2O over 25 min, tR = 14.4 min (Appendix Figure S3). Yield: 13.7% 
 
resibufagenin (4a): white solid; [α]21D +37.3 (c 0.15, CHCl3); 1H and 13C NMR (CD3OD, 600 
MHz) see Table S4; HRESI(+)MS m/z 407.2190 (M+Na)+ (calcd for C24H32O4, 407.2193). Zorbax 
C18 column, 250 × 9.4 mm, 5 µm, 3.5 mL/min, gradient from 10-100% MeCN/ H2O over 25 min, tR 
= 15.2 min (Appendix Figure S17). Yield: 1.5% 
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hellebrigenin (5a): white solid; [α]21D +13.2 (c 0.05, CHCl3) (Reported: +19.8 (c 1.074, CHCl3); 1H 
and 13C NMR (CD3OD, 600 MHz) see Table S5; HRESI(+)MS m/z 417.2272 (M+H)+ (calcd for 
C24H32O6, 417.2269). Zorbax C18 column, 250 × 9.4 mm, 5 µm, 3.5 mL/min, gradient from 10-
100% MeCN/ H2O over 25 min, tR = 9.7 min (Appendix Figure S4). Yield: 0.7% 
 
bufalin-3-acetate (7a): white solid; [α]21D +11.9 (c 0.095, CHCl3) (Reported: −7.5 (c 1.1, CHCl3); 
1H and 13C NMR (CD3OD, 600 MHz) see Table S6; HRESI(+)MS m/z 429.2272 (M+H)+ (calcd for 
C26H34O6, 429.2268). Zorbax C18 column, 250 × 9.4 mm, 5 µm, 3.5 mL/min, gradient from 10-
100% MeCN/ H2O over 25 min, tR = 14.3 min (Appendix Figure S5). Yield: 0.6% 
2.4.3 Synthesis of bufagenin esters 
2.4.3.1 Synthesis of bufalin-3-suberate 
A solution of bufalin (100 mg, 0.259 mmol), suberic anhydride (121 mg, 0.777 mmol) and 4-
(dimethylamino)pyridine (32.2 mg, 0.259 mmol) in CH2Cl2 (3 mL) stirred for 3 h at 60 °C. The 
reaction mixture was later dried under a stream of N2 at 40 °C and re-dissolved in MeOH for 
purification using a SPE C18 cartridge. The purification was performed using a stepwise gradient of 
20-100% MeOH/H2O. Bufalin-3-suberate (3b) was collected in the 60% MeOH/H2O fraction, dried 
under a stream of N2 at 40 °C and purified by semi-preparative HPLC-DAD (Zorbax SB C18 
column, 250 × 9.4 mm, 5 µm, 3.5 mL/min, gradient from 90% H2O/MeCN to 100% MeCN over 25 
min, hold at 100% MeCN for 5 min, with isocratic 0.01% modifier (TFA)). Yield 67 mg.  
1H NMR (CD3OD, 600 MHz) δH 0.72 (s, H-18), 0.98 (s, H-19), 1.65 (m, H-9), 1.73 (m, H-8), 2.28 
(t, J = 14.9, 7.5 Hz, H-7ʹ′), 2.33 (t, J = 7.3 Hz, H-2ʹ′), 6.28 (dd, J = 9.7, 0.8 Hz, H-23), 7.43 (dd, J = 
2.5, 0.9 Hz, H-21), 7.99 (dd, J = 9.7, 2.6 Hz, H-22) ppm.  
 
bufalin-3-suberate (3b): white solid; [α]21D −9.3 (c 0.2, CHCl3); 1H NMR (CD3OD, 600 MHz); 
HRESI(+)MS m/z 543.3313 (M+H)+ (calcd for C32H46O7, 543.3311) (Appendix Figure S8). 
2.4.3.2 Synthesis of bufalin-3-pimelate  
Bufalin-3-pimelate (was also synthesized and purified based on the above mentioned method except 
for the reactants, bufalin (10 mg, 0.026 mmol), pimelic anhydride (11 mg, 0.078 mmol) and 4-
(dimethylamino)pyridine (3.2 mg, 0.026 mmol) to yield 5.8 mg.  
1H NMR (CD3OD, 600 MHz) δH 0.72 (s, H-18), 0.98 (s, H-19), 1.64 (m, H-9), 1.73 (m, H-8), 2.27 
(t, J = 7.5 Hz, H-7ʹ′), 2.33 (t, J = 7.4 Hz, H-2ʹ′), 6.28 (d, J = 9.7 Hz, H-23), 7.43 (d, J = 2.2 Hz, H-
21), 7.99 (dd, J = 9.7, 2.5 Hz, H-22) ppm. 
 
bufalin-3-pimelate (7b): white solid; [α]21D −7.1 (c 0.06, CHCl3); 1H NMR (CD3OD, 600 MHz); 
HRESI(+)MS m/z 551.2992 (M+Na)+ (calcd for C31H44O7, 551.2979) (Appendix Figure S26). 
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2.4.3.3 Synthesis of bufalin-3-acetate 
Bufalin-3-acetate was also synthesized and purified based on the above mentioned method except 
for the reactants, bufalin (10 mg, 0.026 mmol), acetic anhydride (8 mg, 0.078 mmol) and 4-
(dimethylamino)pyridine (3.2 mg, 0.026 mmol) to yield 8.2 mg. (Appendix Figure S6, Table S5) 
2.4.3.4 Synthesis of telocinobufagenin-3-suberate 
A solution of telocinobufagenin (100 mg, 0.25 mmol), suberic anhydride (116 mg, 0.74 mmol) and 
4-(dimethylamino)pyridine (30.6 mg, 0.25 mmol) in CH2Cl2 stirred for 3 h at 60 °C with constant 
stirring. The reaction mixture was later dried under a stream of N2 at 40 °C and was re-dissolved in 
methanol for purification using a SPE C18 cartridge. The purification was performed using a 
stepwise gradient of 20-100% methanol/water. Telocinobufagenin-3-suberate was collected at 80% 
methanol fraction, dried under a stream of N2 at 40 °C and was purified using semi-preparative 
HPLC-DAD (Zorbax SB C18 column, 250 × 9.4 mm, 5 µm, 3.5 mL/min, gradient from 90% 
H2O/MeCN to 100% MeCN over 25 min, hold at 100% MeCN for 5 min, with isocratic 0.01% 
modifier (TFA)). Yield 86 mg. 
1H NMR (CDCl3, 600 MHz) δH 0.69 (s, H-18), 0.99 (s, H-19), 1.66 (m, H-9), 1.98 (d, J = 2.9 Hz, H-
15a), 2.18 (ddd, J = 12.4, 8.7, 3.7 Hz, H-7ʹ′), 2.32 (dd, J = 15.4, 7.9 Hz, H-2ʹ′), 6.25 (d, J = 9.8 Hz, 
H-23), 7.21 (dd, J = 2.3, 0.9 Hz, H-21), 7.90 (dd, J = 9.7, 2.6 Hz, H-22) ppm.  
 
Telocinobufagenin-3-suberate (2b): white solid; [α]21D +17.3 (c 0.07, CHCl3); 1H NMR (CDCl3, 
600 MHz); HRESI(+)MS m/z 581.3109 (M+H)+ (calcd for C34H44O8, 581.3108) (Appendix Figure 
S7). 
2.4.3.5 Synthesis of marinobufagenin-3-suberate 
A solution of marinobufagenin (200 mg, 0.500 mmol), suberic anhydride (156 mg, 1.00 mmol) and 
4-(dimethylamino)pyridine (61 mg, 0.50 mmol) in CH2Cl2 (5 mL) stirred for 3 h at 60 °C. The 
reaction mixture was later dried under a stream of N2 at 40 °C and was re-dissolved in acetonitrile 
for purification using a SPE C18 cartridge. The purification was performed using a stepwise gradient 
of 20-100% acteonitrile/water. Marinobufagenin-3-suberate (1b) was collected at 60% acetonitrile 
fraction, dried under a stream of N2 at 40 °C and was purified using semi-preparative HPLC-DAD 
(Zorbax SB C18 column, 250 × 9.4 mm, 5 µm, 3.5 mL/min, gradient from 90% H2O/MeCN to 
100% MeCN over 25 min, holding 100% MeCN for 5 min, isocratic 0.01% TFA). Yield 156 mg.  
1H NMR (CD3OD, 600 MHz) δH 0.79 (s, H-18), 0.99 (s, H-19), 1.65 (m, H-9), 2.01 (td, J = 12.1, 
3.9 Hz, H-8), 2.29 (t, J = 7.4 Hz, H-7ʹ′), 2.36 (ddd, J = 10.3, 7.6, 2.7 Hz, H-2ʹ′), 6.27 (dd, J = 9.8, 0.8 
Hz, H-23), 7.45 (d, J = 2.2, H-21), 7.90 (dd, J = 9.7, 2.5 Hz, H-22) ppm.  
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marinobufagenin-3-suberate (1b): white solid; [α]21D +27.3 (c 0.1, CHCl3); 1H NMR (CD3OD, 
600 MHz); HRESI(+)MS m/z 557.3109 (M+H)+ (calcd for C32H44O8, 557.3104) (Appendix Figure 
S6). 
2.4.3.6 Synthesis of marinobufagenin-3-pimelate 
Marinobufagenin-3-pimelate (5b) was synthesized and purified based on the above mentioned 
method except for the reactants, marinobufagenin (20 mg, 0.05 mmol), pimelic anhydride (14 mg, 
0.10 mmol) and 4-(dimethylamino)pyridine (6.1 mg, 0.05 mmol) to yield 14.6 mg.  
1H NMR (CD3OD, 600 MHz) δH 0.79 (s, H-18), 0.99 (s, H-19), 1.64 (m, H-9), 2.01 (td, J = 12.2, 
4.2 Hz, H-8), 2.32 (t, J = 7.5 Hz, H-2ʹ′), 2.35 (ddd, J = 10.1, 7.5, 2.8 Hz, H-7ʹ′), 6.26 (d, J = 9.8 Hz, 
H-23), 7.45 (d, J = 2.3 Hz, H-21), 7.90 (dd, J = 9.7, 2.3 Hz, H-22) ppm. 
 
marinobufagenin-3-pimelate (5b): white solid; [α]21D +27.8 (c 0.1, CHCl3); 1H NMR (CD3OD, 
600 MHz); HRESI(+)MS m/z 543.2778 (M+H)+ (calcd for C31H42O8, 543.2776) (Appendix Figure 
S21). 
2.4.3.7 Synthesis of marinobufagenin-3-succinate 
Marinobufagenin-3-succinate (9b) was synthesized and purified based on the above mentioned 
method except for the reactants, marinobufagenin (20 mg, 0.05 mmol), succinic anhydride (10 mg, 
0.10 mmol) and 4-(dimethylamino)pyridine (6.1 mg, 0.05 mmol) to yield 18.6 mg.  
1H NMR (CD3OD, 600 MHz) δH 0.79 (s, H-18), 0.99 (s, H-19), 1.66 (m, H-9), 2.01 (td, J = 12.2, 
4.0 Hz, H-8), 2.33 (dd, J = 15.8, 3.8 Hz, H-7ʹ′), 2.56 (m, H-2ʹ′), 6.27 (d, J = 9.8 Hz, H-23), 7.45 (d, J 
= 2.1 Hz, H-21), 7.90 (dd, J = 9.9, 2.4 Hz, H-22) ppm. 
 
marinobufagenin -3-succinate (9b): white solid; [α]21D  −85.9 (c 0.05, CHCl3); 1H NMR (CD3OD, 
600 MHz); HRESI(+)MS m/z 523.2313 (M+Na)+ (calcd for C28H36O8, 523.2302) (Appendix Figure 
S20). 
2.4.3.8 Synthesis of marinobufagenin-3-acetate 
Marinobufagenin-3-acetate (8b) was synthesized based on the above mentioned method except for 
the reactants, marinobufagenin (20 mg, 0.05 mmol), acetic anhydride (10.2 mg, 0.10 mmol) and 4-
(dimethylamino)pyridine (6.1 mg, 0.05 mmol) to yield 17.7 mg.  
1H NMR (CD3OD, 600 MHz) δH 0.79 (s, H-18), 0.99 (s, H-19), 2.05 (s, H-26), 2.59 (d, J =10.4 Hz, 
H-17), 3.62 (br s, H-15), 6.27 (dd, J =9.8, 0.7 Hz, H-23), 7.45 (d, J = 1.9 Hz, H-21), 7.90 (d, J = 1.9 
Hz, H-22) ppm. 
 
marinobufagenin-3-acetate (8b): white solid; [α]21D +79.9 (c 0.06, CHCl3) (Reported: +24.1 (c 
1.059, CHCl3); 1H NMR (CD3OD, 600 MHz); HRESI(+)MS m/z 465.2255 (M+Na)+ (calcd for 
C26H34O6, 465.2248) (Appendix Figure S22). 
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2.4.4 Synthesis of bufotoxins 
2.4.4.1 Synthesis of bufalitoxin 
A solution of bufalin-3-suberate (100 mg, 0.184 mmol) in THF (8 mL) containing triethylamine 
(0.14 mL) was stirred for 15 min at −10 °C followed by the addition of isobutylchloroformate (0.05 
mL) in THF (1 mL) and stirring was continued for further 40 min. Methanol (1 mL) was added to 
the reaction mixture followed by dropwise addition of freshly prepared L-arginine 
monohydrochloride solution (77 mg, 0.37 mmol) in a mixture of water (0.4 mL) and methanol (4 
mL) over 3 min. Stirring was continued for another 3 h at −5 °C to 0 °C. The reaction mixture was 
then concentrated under reduced pressure yielded an oily residue, which was purified using HPLC 
(Zorbax SB C18 column, 250 × 9.4 mm, 5 µm, 3.5 mL/min, gradient from 90% H2O/MeCN to 
100% MeCN over 25 min, hold at 100% MeCN for 5 min, tR = 11.5 min). Yield 82 mg. 
 
bufalitoxin (3c): white solid; [α]21D −5.8 (c 0.05, MeOH) (Reported: −5.2 (c 0.2, MeOH); 1H and 
13C NMR (CD3OD, 600 MHz) see Table S9; HRESI(+)MS m/z 699.4327 (M+H)+ (calcd for 
C37H56N4O8, 699.4318) (Appendix Figure S11). 
2.4.4.2 Synthesis of bufalin pimeloyl-L-arginine 
A solution of bufalin-3-pimelate (10 mg, 0.02 mmol) in THF (2 mL) containing triethylamine (0.02 
mL) was stirred for 15 min at −10 °C followed by the addition of isobutylchloroformate (0.01 mL) 
in THF (0.2 mL) and stirring was continued for further 40 min. Methanol (0.2 mL) was added to the 
reaction mixture followed by dropwise addition of freshly prepared L-arginine monohydrochloride 
solution (7.7 mg, 0.04 mmol) in a mixture of water (0.1 mL) and methanol (0.9 mL) over 3 min. 
Stirring was continued for another 3 h at −5 °C to 0 °C. The reaction mixture was then concentrated 
under reduced pressure yielded an oily residue, which was purified using HPLC (Zorbax SB C18 
column, 250 × 9.4 mm, 5 µm, 3.5 mL/min, gradient from 90% H2O/MeCN to 100% MeCN over 25 
min, hold at 100% MeCN for 5 min, tR = 10.9 min). Yield 7.3 mg. 
bufalin pimeloyl-L-arginine (9c): white solid; [α]21D +7.3 (c 0.07, MeOH) (Reported: −5.5 (c 0.18, 
CHCl3); 1H and 13C NMR (CD3OD, 600 MHz) see Table S10; HRESI(+)MS m/z 685.4172 (M+H)+ 
(calcd for C37H56N4O8, 685.4171) (Appendix Figure S23). 
2.4.4.3 Synthesis of telocinobufotoxin 
A solution of telocinobufagenin-3-suberate (100 mg, 0.179 mmol) in THF (8 mL) containing 
triethylamine (0.14 mL) was stirred for 15 min at −10 °C followed by the addition of 
isobutylchloroformate (0.05 mL) in THF (1 mL) and stirring was continued for further 40 min. 
Methanol (1 mL) was added to the reaction mixture followed by dropwise addition of freshly 
prepared L-arginine monohydrochloride solution (75 mg, 0.36 mmol) in a mixture of water (0.4 
mL) and methanol (4 mL) over 3 min. Stirring was continued for another 3 h at −5 °C to 0 °C. The 
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reaction mixture was then concentrated under reduced pressure yielded an oily residue, which was 
purified using HPLC (Zorbax SB C18 column, 250 × 9.4 mm, 5 µm, 3.5 mL/min, gradient from 
90% H2O/MeCN to 100% MeCN over 25 min, hold at 100% MeCN for 5 min, tR = 10.1 min). 
Yield 81 mg. 
 
telocinobufotoxin (2c): white solid; [α]21D +14.0 (c 0.05, MeOH); 1H and 13C NMR (CD3OD, 600 
MHz) see Table S8; HRESI(+)MS m/z 715.4327 (M+H)+ (calcd for C38H58N4O9, 715.4320) 
(Appendix Figure S10). 
2.4.4.4 Synthesis of marinobufotoxin 
A solution of marinobufagenin-3-suberate (100 mg, 0.182 mmol) in THF (8 mL) containing 
triethylamine (0.14 mL) was stirred for 15 min at −10 °C followed by the addition of 
isobutylchloroformate (0.05 mL) in THF (1 mL) and stirring was continued for further 40 min. 
Methanol (2 mL) was added to the reaction mixture followed by dropwise addition of freshly 
prepared L-arginine monohydrochloride solution (75 mg, 0.36 mmol) in a mixture of water (0.4 
mL) and methanol (4 mL) over 3 min. Stirring was continued for another 3 h at −5 °C to 0 °C. The 
reaction mixture was then concentrated under reduced pressure yielded an oily residue, which was 
purified using HPLC (Waters C18 column, 150 × 19 mm, 7 µm, 10 mL/min, gradient from 90% 
H2O/MeCN to 100% MeCN over 25 min, hold at 100% MeCN for 5 min, tR = 9.7 min). Yield 77 
mg. 
 
marinobufotoxin (1c): white solid; [α]21D +14.6 (c 0.1, MeOH); 1H and 13C NMR (CD3OD, 600 
MHz) see Table S7; HRESI(+)MS m/z 713.4120 (M+H)+ (calcd for C38H56N4O9, 713.4116) 
(Appendix Figure S9). 
2.4.4.5 Synthesis of marinobufagenin pimeloyl-L-arginine 
A solution of marinobufagenin-3-pimelate (10 mg, 0.02 mmol) in THF (2 mL) containing 
triethylamine (0.02 mL) was stirred for 15 min at −10 °C followed by the addition of 
isobutylchloroformate (0.01 mL) in THF (0.2 mL) and stirring was continued for further 40 min. 
Methanol (0.2 mL) was added to the reaction mixture followed by dropwise addition of freshly 
prepared L-arginine monohydrochloride solution (7.7 mg, 0.04 mmol) in a mixture of water (0.1 
mL) and methanol (0.9 mL) over 3 min. Stirring was continued for another 3 h at −5 °C to 0 °C. 
The reaction mixture was then concentrated under reduced pressure yielded an oily residue, which 
was purified using HPLC (Zorbax SB C18 column, 250 × 9.4 mm, 5 µm, 3.5 mL/min, gradient from 
90% H2O/MeCN to 100% MeCN over 25 min, hold at 100% MeCN for 5 min, tR = 9.1 min). Yield 
6.8 mg. 
marinobufagenin pimeloyl-L-arginine (8c): white solid; [α]21D +18.4 (c 0.05, MeOH) (Reported: 
+22 (c 0.23, MeOH); 1H and 13C NMR (CD3OD, 600 MHz) see Table S11; HRESI(+)MS m/z 
699.3971 (M+H)+ (calcd for C37H54N4O9, 699.3964) (Appendix Figure S24). 
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2.4.5 Synthesis of amides 
2.4.5.1 Synthesis of suberic anhydride 
A solution of suberic acid (1.0 g, 5.7 mmol) in acetic anhydride (5 mL) was heated at reflux for 4 h 
with constant stirring. The reaction mixture was then reduced in vacuo at 40 °C which yielded a 
pale yellow solid. Recrystallization from hexane/ethyl acetate yielded 750 mg (75%) of suberic 
anhydride. 
2.4.5.2 Synthesis of pimelic anhydride 
A solution of pimelic acid (1.0 g, 6.2 mmol) in acetic anhydride (5 mL) was heated at reflux for 4 h 
with constant stirring. The reaction mixture was then reduced in vacuo at 40 °C which yielded a 
pale yellow solid. Recrystallization from hexane/ethyl acetate yielded 640 mg (64%) of pimelic 
anhydride.  
2.4.5.3 Synthesis of suberoyl-L-arginine 
A solution of suberic anhydride (52 mg, 0.33 mmol) and L-arginine monohydrochloride (69 mg, 
0.33 mmol) in water was prepared and the pH of the solution was adjusted to 8 – 9 using NaOH 
(40% w/v) and was left stirring overnight at room temperature. The reaction mixture was dried 
under a stream of N2 at 40 °C and purification was performed using ion-exchange chromatography 
(Dowex 50WX2, strong cation exchange resin, 200-400 dry mesh, 1 mL/min) with a linear gradient 
of 0 – 2 M HCl. Pure arginyl amide eluted from 0.9 – 2 M HCl to yield 70 mg. 
 
suberoyl-L-arginine (1d): colourless oil ; [α]21D +2.1 (c 0.08, MeOH); 1H and 13C NMR (CD3OD, 
600 MHz) see Table S12; HRESI(+)MS m/z 331.1969 (M+H)+ (calcd for C14H27N4O5, 331.1968) 
(Appendix Figure S14). 
2.4.5.4 Synthesis of pimeloyl-L-arginine 
A solution of pimelic anhydride (50 mg, 0.35 mmol) and L-arginine monohydrochloride (73 mg, 
0.35 mmol) in water was prepared and the pH of the solution was adjusted to 8 – 9 using NaOH 
(40% wt/vol) and was left stirring overnight at room temperature. The reaction mixture was dried 
under a stream of N2 at 40 °C and purification was performed using ion-exchange chromatography 
(Dowex 50WX2, strong cation exchange resin, 200-400 dry mesh, 1 mL/min) with a linear gradient 
of 0 – 2 M HCl. Pure arginyl amide eluted from 0.9 – 2 M HCl to yield 71 mg. 
 
pimeloyl-L-arginine (3d): colourless oil ; [α]21D −5.9 (c 0.08, MeOH); 1H and 13C NMR (CD3OD, 
600 MHz) see Table S14; HRESI(+)MS m/z 339.1637 (M+Na)+ (calcd for C13H24N4O5Na, 
339.1635) (Appendix Figure S13). 
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2.4.5.5 Synthesis of azeloyl-L-arginine 
A solution of azelaic anhydride (57 mg, 0.33 mmol) and L-arginine monohydrochloride (69 mg, 
0.33 mmol) in water was prepared and the pH of the solution was adjusted to 8 – 9 using NaOH 
(40% wt/vol) and was left stirring overnight at room temperature. The reaction mixture was dried 
under a stream of N2 at 40 °C and purification was performed using ion-exchange chromatography 
(Dowex 50WX2, strong cation exchange resin, 200-400 dry mesh, 1 mL/min) with a linear gradient 
of 0 – 2 M HCl. Pure arginyl amide eluted from 0.9 – 2 M HCl to yield 69 mg. 
 
azeloyl-L-arginine (4d): colourless oil ; [α]21D −1.8 (c 0.05, MeOH); 1H and 13C NMR (CD3OD, 
600 MHz) see Table S13; HRESI(+)MS m/z 345.2144 (M+H)+ (calcd for C15H29N4O5, 345.2142) 
(Appendix Figure S15). 
2.4.5.6 Synthesis of adipoyl-L-arginine 
A solution of adipic anhydride (42 mg, 0.33 mmol) and L-arginine monohydrochloride (69 mg, 0.33 
mmol) in water (5 mL) adjusted to pH 8 – 9 using NaOH (40% wt/vol) was stirred overnight at 
room temperature. The reaction mixture was then dried under a stream of N2 at 40 °C and 
purification was performed using ion-exchange chromatography (Dowex 50WX2, strong cation 
exchange resin, 200-400 dry mesh, 1 mL/min) with a linear gradient of 0 – 2 M HCl to yield 
adipoyl-L-arginine (2d) (67 mg). 
 
adipoyl-L-arginine (2d): colourless oil ; [α]21D −6.4 (c 0.05, MeOH); 1H and 13C NMR (CD3OD, 
600 MHz) see Table S15; HRESI(+)MS m/z 303.1305 (M+H)+ (calcd for C12H23N4O5, 303.1302) 
(Appendix Figure S12). 
2.4.6 Synthesis of derivatized amide standards 
 
A known amount of pure arginyl amide (10 mg) was subjected to derivatization with 2,4-
pentanedione and pyridine (2:1) for a period of 12 h at reflux. The reaction mixture was later dried 
under a stream of N2 at 40 °C and was subjected to purification by HPLC (Zorbax C18 Semi-prep 
column, 250 × 9.4 mm, 5 µm, 3.0 mL/min, gradient from 10-100% MeCN over 25 min).  
 
Derivatized adipoyl-L-arginine (2e): 1H NMR (CD3OD, 600 MHz) δH 1.65 (m, H-3), 1.67 (m, H-
10), 2.28 (t, J = 13.8 Hz, H-5), 2.31 (t, J = 13.8 Hz, H-2), 2.40 (s, H-12), 3.52 (m, H-11), 4.46 (m, 
H-7), 6.64 (s, H-13) ppm. Yield: 9 mg (Appendix Figure S19). Slight brownish oil; [α]21D +1.6 (c 
0.05, MeOH); HRESI(+)MS m/z 367.1976 (M+H)+ (calcd for C17H26N4O5, 367.1976). 
 
Derivatized pimeloyl-L-arginine (3e): 1H NMR (CD3OD, 600 MHz) δH 1.63 (m, H-3), 2.26 (m, H-
2, H-6), 2.30 (s, H-13, H-15), 3.44 (m, H-12), 4.44 (m, H-8), 6.45 (s, H-14) ppm. Yield: 7.2 mg 
(Appendix Figure S25). Slight brownish oil; [α]21D +2.8 (c 0.06, MeOH); HRESI(+)MS m/z 
381.2132 (M+H)+ (calcd for C18H28N4O5, 381.2132). 
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Derivatized suberoyl-L-arginine (1e): 1H NMR (CD3OD, 600 MHz) δH 1.60 (m, H-3), 1.67 (m, H-
12), 2.17 (m, H-7), 2.20 (m, H-2), 2.40 (s, H-14), 3.49 (m, H-13), 4.46 (m, H-9), 6.64 (s, H-15) 
ppm. Yield: 8.3 mg (Appendix Figure S16). Slight brownish oil; [α]21D +2.3 (c 0.09, MeOH); 
HRESI(+)MS m/z 395.2289 (M+H)+ (calcd for C19H30N4O5, 395.2289). 
 
Derivatized azeloyl-L-arginine (4e): 1H NMR (CD3OD, 600 MHz) δH 1.60 (m, H-3), 1.66 (m, H-
13), 2.28 (m, H-8), 2.32 (m, H-2), 2.40 (s, H-15), 3.49 (m, H-14), 4.42 (m, H-10), 6.64 (s, H-16) 
ppm. Yield: 8.8 mg (Appendix Figure S18). Slight brownish oil; [α]21D +4.4 (c 0.08, MeOH); 
HRESI(+)MS m/z 409.2460 (M+H)+ (calcd for C20H32N4O5, 409.2458). 
 
2.4.7 Analytical methodology for detection of various structure classes of cane 
toad toxins 
 
Table 2.4 Analytical methods for the detection of bufadienolides and amides 
 
 Method Structure class Conditions 
HPLC-DAD Method 1 
bufagenins 
 
Zorbax C18 column, 150 × 4.6 mm, 5 µm, 1 mL/min, 
gradient from 90% H2O/ MeCN to 100% MeCN over 
15 min, hold at 100% MeCN over 5 min, with constant 
0.01% modifier (TFA). 
HPLC-DAD Method 2 
bufotoxins 
 
Zorbax C18 column, 150 × 4.6 mm, 5 µm, 1 mL/min, 
gradient from 90-50% H2O/ MeCN over 15 min, 50-
30% H2O/ MeCN over 5 min, 30% H2O/ MeCN to 
100% MeCN over 5 min, hold at 100% MeCN for 5 
min, with constant 0.01% modifier (TFA). 
HPLC-DAD-MS Method 3a 
amides 
 
Zorbax C18 column, 150 × 4.6 mm, 5 µm, 1 mL/min, 
gradient from 90% H2O/ MeCN to 70% H2O/ MeCN 
over 20 min, 90% H2O/ MeCN – 100% MeCN over 2 
min, hold at 100% MeCN over 3 min, with constant 
0.01% modifier (TFA). 
HPLC-DAD 
 
 
Method 3b 
 
 
amides 
 
Zorbax C18 column, 150 × 4.6 mm, 5 µm, 1 mL/min, 
gradient from 90% H2O/ MeCN to 70% H2O/ MeCN 
over 20 min, 90% H2O/ MeCN – 100% MeCN over 2 
min, hold at 100% MeCN over 3 min, with constant 
0.01% modifier (TFA). 
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2.4.8 Derivatization of amides from parotoid toxin/secretion as pyrimidines  
 
Parotoid glands from 10 frozen toads were dissected and manually disrupted in a beaker containing 
ethyl acetate to release all the secretions. The organic layer was collected and distilled water was 
added to the left over parotoid gland fractions and sonicated for 5 min. The aqueous extract was 
collected and was reduced to dryness under a stream of N2. The left over residue was heated at 
reflux with pyridine and 2,4-pentanedione for 7 h. The reaction mixture was then reduced to 
dryness under a stream of N2 at 40 °C. The residues were redissolved in methanol (1 mg/mL), 
filtered using 0.45 µm PTFE filter and was analysed using HPLC-DAD. 
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2.5 Appendix 
Table S1 NMR (CD3OD, 600 MHz) data for marinobufagenin (1a) 
 
                                                         Experimental data                                             Literature dataa 
Pos. δH (m, J in Hz) δC δCa δH (m, J in Hz)a 
1a 
1b 
1.83 (ddd, 14.5, 14.5, 4.1) 
 
26.2 26.2 1.83 (ddd, 14.3, 14.3 3.9), 
1.41* 
2a 
2b 
1.67* 
1.58* 
28.6 28.7 1.67*, 1.58* 
3 4.12 (m) 69.2 69.2 4.13 (m) 
4a 
4b 
2.22 (dd, 14.9, 3.2) 
1.79 (m) 
37.8 37.9 2.22 (dd, 14.8, 3.2) 
1.79* 
5  75.9 76.2 - 
6a 
6b 
 
1.31 (ddd, 13.1, 4.1, 3.1) 
35.3 35.3 1.68* 
1.31 (ddd, 13.2, 4.1, 3.0) 
7a 
7b 
1.62* 
0.99 (m) 
24.1 24.1 1.61* 
0.99 (m) 
8 2.01 (td, 12.3, 3.9) 33.9 34.3 2.00 (ddd, 12.1, 12.1, 3.1) 
9 1.65* 43.9 44.0 1.65* 
10  42.1 42.2 - 
11a 
11b 
1.60* 
 
22.8 22.8 1.60* 
1.41* 
12a 
12b 
 
1.51 (m) 
40.3 40.3 1.71* 
1.51* 
13  46.3 46.3 - 
14  76.2 75.9 - 
15 3.60 (br s) 61.3 61.3 3.60 (br s) 
16a 
16b 
2.43 (ddd, 15.4, 10.1, 1.3) 
             1.94 (d, 15.4) 
33.3 33.3 2.42 (ddd, 15.4, 10.1, 1.4) 
1.94 (d, 15.4) 
17 2.59 (d, 10.1) 48.6 48.6 2.60 (d, 10.1) 
18 0.78 (s) 17.2 17.2 0.78 (s) 
19 0.92 (s) 17.4 17.4 0.92 (s) 
20  124.6 124.6 - 
21 7.45 (dd, 2.5, 0.8) 151.9 151.9 7.45 (dd, 2.5, 0.8) 
22 7.90 (dd, 9.7, 2.5) 149.6 149.7 7.90 (dd, 9.7, 2.5) 
23 6.26 (dd, 9.7, 0.9) 115.5 115.5 6.26 (dd, 9.7, 0.8) 
24  164.6 164.6 - 
δH 1.4 – 1.9 – overlapping resonances 
* – J coupling constants could not be determined due to overlap with other signals 
a – structure comparison with the published literature, NMR (600 MHz, CD3OD)11 
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Table S2 NMR (600 MHz, CD3OD) data for telocinobufagenin (2a) 
 
 
                                               Experimental data                                     Literature dataa 
Pos. δH (m, J in Hz) δC δCa δH (m, J in Hz)a 
 
1a 
1b 
1.83 (ddd, 14.5, 14.5, 4.1) 
 
26.3 26.0            1.80 
1.38 
 
2a 
2b 
1.67* 
1.58 (m) 
28.6 28.3            1.69 
1.58 
 
3 4.13 (m) 69.2 68.8       4.13 (m)  
4a 
4b 
 37.9 37.5            2.21 
1.49 
 
5  76.3 76.0   
6a 
6b 
 
 
36.1 35.8            1.73 
1.38 
 
7a 
7b 
1.95 (m) 
1.25 (m) 
24.9 24.6            1.95 
1.26 
 
8 1.65* 42.1b1 41.8 1.65  
9 1.62 (d, 3.21) 40.5 40.1 1.62  
10  42.2b1 41.7   
11a 
11b 
 
1.28 (m) 
23.2 22.8            1.49 
1.28 
 
12a 
12b 
1.53 (m)  
1.46* 
42.1b1 41.8            1.53 
1.45 
 
13  49.7 49.5   
14  86.2 85.9   
15a 
15b 
2.07 (dd, 9.4, 2.2) 
1.70* 
33.3 32.9            2.07 
1.70 
 
16a 
16b 
 29.9 29.5            2.19 
1.73 
 
17 2.56 (d, 10.3) 52.3 51.9 2.56  
18 0.71 (s) 17.4b2 17.0 0.71  
19 0.93 (s) 17.4b2 17.1 0.93  
20  125.2 124.8   
21 7.43 (d, 2.5) 151.6 150.2 7.43  
22 7.99 (dd, 9.7, 2.5) 149.5 149.1 7.99  
23 6.28 (dd, 9.7, 0.9) 115.5 115.2 6.28  
24  164.9 164.7   
δH 1.2 – 1.8 – overlapping resonances 
* – J coupling constants could not be determined due to overlap with other signals 
a – structure comparison with the published literature, NMR (600 MHz, CD3OD)7 
b1,2 – signals are interchangeable 
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Table S3 NMR (600 MHz, CD3OD) data for bufalin (3a) 
 
                                                      Experimental data                                                    Literature dataa 
Pos. δH (m, J in Hz) δC δCa δH (m, J in Hz)a 
1b  30.9 29.7 1.50 
2a 
2b 
1.62* 
 
28.7 27.9 1.62 
1.52 
3 4.07 (m) 67.8 66.9 4.16 
4a 
4b 
1.98 (dd, 14.0, 3.1) 
 
34.3 33.4 1.93 
1.38 
5 1.76* 37.6 36.0 1.77 
6a 
6b 
1.94 (m) 
1.27 (m) 
28.1 26.6 1.90 
1.27  
7a 
7b 
1.81 (m) 
 
22.7b1 21.4 1.73 
1.29 
8 1.64*  43.2 42.5 1.55 
9 1.71* 36.6b2 35.8 1.62 
10  37.0b2 35.4  
11a 
11b 
 
1.22 (ddd, 16.1, 12.4, 3.9) 
22.7b1 21.5 1.44 
1.21 
12a 
12b 
1.52* 
 
42.1 40.9 1.52 
1.37 
13  49.9 48.4  
14  86.3 85.5  
15a 
15b 
2.11 (ddd, 11.6, 9.4, 2.2) 
1.71* 
33.3 32.8 2.06 
1.71 
16a 
16b 
2.20 (ddd, 15.5, 10.3, 1.3) 
1.73* 
30.1 28.8 2.20  
1.75 
17 2.56 (d, 10.3) 52.4 51.4 2.49 
18 0.73 (s) 17.5 16.6 0.72 
19 0.98 (s) 24.5 23.8 0.97 
20  125.2 122.7  
21 7.44 (d, 2.5) 150.6 148.6 7.25 
22 8.01 (dd, 9.8, 2.6) 149.5 146.8 7.83 
23 6.29 (dd, 9.8, 0.9) 115.6 115.4 6.29  
24  164.9 162.5  
δH 1.2 – 2.0 – overlapping resonances 
* – J coupling constants could not be determined due to overlap with other signals 
a – structure comparison with the published literature, NMR (500 MHz, CD3OD)12 
b1,2 – signals are interchangeable 
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Table S4 NMR (600 MHz, CD3OD) data for resibufagenin (4a) 
 
                                                                  Experimental data                             Literature dataa 
Pos. δH (m, J in Hz) δC δCa δH (m, J in Hz)a 
1b  30.9 29.6 1.51 
2a 
2b 
1.62* 
 
28.8 27.9 1.54 
 
3 4.07 (m) 67.8 66.9 4.13 
4a 
4b 
 
 
35.3 33.3 1.88 
1.35 
5  37.6b1 36.0 1.76 
6a 
6b 
1.89 (m) 
1.20 (m) 
 27.3 25.8 1.85 
1.20 
7a 
7b 
1.47* 
1.05 (ddd, 17.4, 13.3, 4.3) 
21.9b2 20.8 1.50 
0.95 
8   35.2 33.6 1.98 
9  37.5b1 39.4 1.60 
10   36.7 35.6  
11a 
11b 
1.56* 
 
22.4b2 21.1 1.51 
1.33c 
12a 
12b 
 
1.70 (m) 
40.2 39.5 1.38  
1.65 
13  46.5 45.3  
14  76.0 74.8  
15 3.60 (br s) 61.3 59.9 3.52 
16a 
16b 
2.43 (ddd, 15.4, 10.1, 1.3) 
             1.94 (m) 
33.4 32.5 2.36 
1.95 
17 2.59 (d, 10.1) 48.6 47.9 2.45 
18 0.78 (s) 17.3 16.9 0.78 
19 0.99 (s) 24.4 23.8 0.98 
20  124.7 122.3  
21 7.45 (dd, 2.5, 0.8) 151.9 149.7 7.23 
22 7.90 (dd, 9.7, 2.5) 149.8 147.1 7.78 
23 6.26 (dd, 9.7, 0.9) 115.6 115.4 6.24 
24  164.7 162.1  
δH 1.42 – 2.00 – overlapping resonances 
* – J coupling constants could not be determined due to overlap with other signals 
a – structure comparison with the published literature, NMR (500 MHz, CD3OD)12 
b1,2 – signals are interchangeable 
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Table S5 NMR (600 MHz, CD3OD) data for hellebrigenin (5a) 
 
                                             Experimental data                                                       Literature dataa 
Pos. δH (m, J in Hz) δC δCa δH (m, J in Hz)a 
1a 
1b 
  
 
18.7 18.4 1.70 
2.13 
2a 
2b 
1.72* 
1.65* 
27.7 27.3 1.72 
1.67 
3 4.14 (m) 68.1 67.7 4.14 
4a 
4b 
 
 
38.7 38.4 1.50 
2.20 
5  75.9 90.1  
6a 
6b 
 
2.10 (dd, 14.9, 3.2) 
37.6 37.2 1.67 
2.10  
7a 
7b 
1.37 (m) 
 
25.4 25.0 1.38 
2.15 
8 1.95 (dt, 12.6, 3.6) 43.2 42.7 1.95 (dt, 12.6, 3.6) 
9 1.70* 40.7 40.3 1.71c 
10  56.4 55.9  
11a 
11b 
1.55 (dd, 13.7, 3.4) 
1.19 (m) 
23.7 23.4 1.55 (dd, 13.7, 3.4) 
1.19 (m) 
12a 
12b 
1.42 (m) 
   
41.7 41.3 1.42 (m) 
  1.51d 
13  49.6 49.1  
14  85.8 85.3  
15a 
15b 
2.06 (ddd, 18.2, 14.5, 4.9) 
1.67* 
32.5 32.1 2.06 (ddd, 18.2, 14.5, 4.9) 
1.67a 
16a 
16b 
   
  1.74* 
29.9 29.4   2.20e 
  1.74c 
17 2.56 (d, 10.2) 52.1 51.7 2.56 (d, 10.2) 
18 0.68 (s) 17.2 17.0 0.68 (s) 
19 10.06 (s) 210.3 209.1 10.06 (s) 
20  125.2 124.5  
21 7.43 (d, 2.5) 150.7 150.3 7.43 (d, 2.5) 
22 7.99 (dd, 9.7, 2.5) 149.4 149.1 7.99 (dd, 9.7, 2.5) 
23 6.28 (d, 9.7) 115.6 115.2 6.28 (d, 9.7) 
24  164.9 164.3  
δH 1.2 – 1.8, 2.1 – 2.4 – overlapping resonances 
* – J coupling constants could not be determined due to overlap with other signals 
a – structure comparison with the published literature, NMR (600 MHz, CD3OD)7 
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Table S6 NMR (600 MHz, CD3OD) data for bufalin-3-acetate (7a) 
 
 
Pos. δH (m, J in Hz) δC 
1a 
1b 
2.01 (m) 
 
31.8b1 
2a 
2b 
1.66* 
 
26.1 
3 5.07 (br t) 72.5 
4a 
4b 
 
1.37 (ddd, 18.9, 15.1, 4.7) 
31.7b1 
5 1.68* 38.6 
6a 
6b 
1.93 (m) 
 
27.8 
7a 
7b 
1.83 (m) 
 
22.7b2 
8  43.1 
9  36.5b3 
10  37.1b3 
11a 
11b 
1.29* 
1.23 (ddd, 16.1, 12.4, 3.9) 
22.6b2 
12a 
12b 
1.51 (m) 
1.46* 
42.0 
13  49.9 
14  86.3 
15a 
15b 
2.13 (d, 11.8, 9.4, 2.5) 
1.71* 
33.3 
16a 
16b 
2.20  (ddd, 15.4, 10.2, 1.1) 
 
30.0 
17 2.56 (d, 10.2) 52.4 
18 0.71 (s) 17.5 
19 0.98 (s) 24.4 
20  125.2 
21 7.44 (d, 2.5) 150.6 
22 8.01 (dd, 9.8, 2.6) 149.5 
23 6.29 (dd, 9.8, 0.9) 115.6 
24  164.9 
25  172.7 
26 2.03 (s) 21.4 
δH 1.2 – 1.8 – overlapping resonances 
* – J coupling constants could not be determined due to overlap with other signals 
b1-3 – signals are interchangeable 
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marinobufotoxin (1c)                                       telocinobufotoxin (2c) 
 
 
bufalitoxin (3c)                                                 marinobufagenin pimeloyl-L-arginine (8c) 
 
 
bufalin pimeloyl-L-arginine (9c) 
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Table S7 NMR (CD3OD, 600 MHz) data for marinobufotoxin (1c) 
 
                                              Experimental data                                                            Literature dataa 
Pos. δH (m, J in Hz) δC δCa δH (m, J in Hz)a 
1a 
1b 
1.80 (ddd, 14.3, 14.3, 3.5) 
 
26.5b1 26.7 1.79 (ddd,14.2, 14.3, 3.5) 
1.42* 
2a 
2b 
1.73* 
1.61* 
25.9b1 25.6 1.74* 
1.61* 
3 5.14 (br t, 2.6) 72.0 72.3 5.14 (m) 
4a 
4b 
2.34 (d, 7.6) 
 
36.3b2 36.4 2.34 (dd, 15.4, 4.0) 
1.54* 
5  74.4 74.5  
6a 
6b 
 
1.32 (ddd, 13.5, 3.9, 3.2) 
35.6b3 35.6 1.72* 
1.32(ddd, 13.5, 4.0, 3.1) 
7a 
7b 
1.63* 
0.99 (s) 
24.4 24.5 1.63* 
0.99* (s) 
8 2.01 (td, 12.3, 3.9) 33.9 34.2 2.00 (td, 12.3, 3.9) 
9 1.66* 43.7 43.7 1.66* 
10  42.0b4 41.7  
11a 
11b 
1.56* 
 
22.5 22.5 1.56* 
1.42* 
12a 
12b 
1.70* 
 
40.1 40.1 1.70* 
1.52 (ddd, 13.3, 13.3, 3.3) 
13  46.2 46.2  
14  75.8 75.8  
15 3.61 (br s) 61.2 61.4 3.61 (s) 
16a 
16b 
2.41 (ddd, 15.5, 10.3, 1.3) 
 
33.3 33.3 2.41 (ddd, 15.4, 10.2, 1.3) 
1.93* 
17 2.59 (d, 10.3) 48.3 48.6 2.59 (d, 10.2) 
18 0.78 (s) 17.1b5 17.2 0.78 (s) 
19 0.98 (s) 17.2b5 17.3 0.98 (s) 
20  124.6 124.6  
21 7.44 (dd, 2.5, 0.9) 151.4 151.9 7.44 (dd, 2.4, 0.8) 
22 7.89 (dd, 9.7, 2.5) 149.6 149.7 7.89 (dd, 9.7, 2.4) 
23 6.26 (dd, 9.7, 0.9) 115.4 115.5 6.26 (dd, 9.7, 0.8) 
24  164.6 164.6  
1ʹ′  175.1b7 175.1  
2ʹ′ 2.35 (t, 7.7) 35.4b3 35.5 2.35 (t, 7.5) 
3ʹ′  26.4b1 26.5 1.63* 
4ʹ′ 1.36* 30.0b6 30.0 1.36* 
5ʹ′  30.0b6 30.0 1.36* 
6ʹ′  26.5b1 26.9 1.63* 
7ʹ′ 2.26 (ddd, 11.1, 7.4, 3.9) 36.8b2 36.8 2.26 (t, 7.4) 
2.25 (t, 7.4) 
8ʹ′  174.8b7 174.8  
9ʹ′ 4.43 (dd, 8.9, 5.1) 52.7 53.0 4.42 (dd, 9.1, 5.1) 
10ʹ′  176.5 176.5  
1ʹ′ʹ′a 
1ʹ′ʹ′b 
 29.8b6 30.0 1.93* 
1.72* 
2ʹ′ʹ′ 1.62* 26.3b1 26.0 1.62* 
3ʹ′ʹ′a 
3ʹ′ʹ′b 
3.23 (dd, 13.7, 7.2) 
3.19 (dd, 13.7, 7.2) 
42.0b4 42.0 3.24 (dd, 13.6, 7) 
3.19 (dd, 13.6, 7) 
4ʹ′ʹ′  158.8 158.8  
δH 1.2 – 1.8 – overlapping resonances 
* – J coupling constants could not be determined due to overlap with other signals 
a – structure comparison with the published literature NMR (600 MHz, CD3OD)11 
b1-7 – signals are interchangeable 
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Table S8 NMR (600 MHz, CD3OD) data for synthetic telocinobufotoxin (2c) 
 
Pos. δH (m, J in Hz) δCa  
1a 
1b 
 
 
26.9 
2a 
2b 
1.76* 
 
25.6b1 
3 5.17 (br t, 2.6) 72.5 
4a 
4b 
2.33 (d, 3.9) 
1.56 (m) 
36.4b2 
5  74.6 
6a 
6b 
 
 
36.4b2 
7a 
7b 
1.97 (m) 
1.24 (m) 
25.3b1 
8  42.0b3 
9 1.66 (m) 40.3 
10  42.1b3 
11a 
11b 
 
1.31 (d, 4.1) 
22.9 
12a 
12b 
1.53 (t, 7.5) 
 
41.7b3 
13  49.7 
14  86.2 
15a 
15b 
2.07 (d, 2.2) 
1.71* 
33.4 
16a 
16b 
2.20 (ddd, 15.4, 10.4, 1.3) 
 
29.9b4 
17 2.56 (d, 10.4) 52.3 
18 0.71 (s) 17.3b5 
19 0.93 (s) 17.4b5 
20  125.2 
21 7.45 (d, 2.5) 150.8 
22 7.90 (dd, 9.7, 2.5) 149.6 
23 6.26 (dd, 9.7, 0.9) 115.6 
24  164.9 
1ʹ′  175.2b6 
2ʹ′ 2.35 (t, 7.4) 35.5 
3ʹ′ 1.63* 26.5b1 
4ʹ′ 1.37* 30.0b4 
5ʹ′  30.0b4 
6ʹ′  26.8b1 
7ʹ′ 2.26 (ddd, 11.1, 7.4, 3.9) 36.8b2 
8ʹ′  174.9b6 
9ʹ′ 4.43 (dd, 8.9, 5.1) 53.0 
10ʹ′  176.7 
1ʹ′ʹ′a 
1ʹ′ʹ′b 
1.94 (m) 
 
29.8b4 
2ʹ′ʹ′  26.0b1 
3ʹ′ʹ′a 
3ʹ′ʹ′b 
3.24 (dd, 13.7, 7.2) 
3.19 (dd, 13.7, 7.2) 
41.9b3 
4’ʹ′ʹ′  158.8 
δH 1.2 – 1.8 – overlapping resonances 
* – J coupling constants could not be determined due to overlap with other signals 
a – structure comparison was performed with in house standard, NMR (600 MHz, CD3OD) 
b1-6 – signals are interchangeable 
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Table S9 NMR assignments (600 MHz, CD3OD) of synthetic bufalitoxin (3c) 
 
Pos. δH (m, J in Hz) δC δH (m, J in Hz)* 
 
1a 
1b 
 1.61* 
  
31.9b1  
 
2a 
2b 
  
  
26.9b2  
 
3 5.08 (br t, 2.6) 72.3 5.05 (m) 
4a 
4b 
2.02 (td, 16.6, 14.5, 3.0) 
  
31.7b1  
5 1.67* 38.7  
6a 
6b 
1.28 (m) 
 
27.9  
7a 
7b 
1.83 (m) 
   
22.6b3  
8   1.73* 36.9b4  
9    43.2    
10  37.1  
11a 
11b 
1.31* 
1.23 (ddd, 16.2, 12.3, 3.9) 
22.8b3  
12a 
12b 
1.46* 
1.52 (m) 
42.0b5  
13  49.9  
14  86.2  
15a 
15b 
2.13 (ddd, 11.8, 9.4, 2.5) 
 
33.3  
16a 
16b 
2.20 (ddd, 15.5, 10.3, 1.3) 
 
30.1b6  
17 2.56 (d, 10.3) 52.4b7  
18 0.71 (s) 17.5 0.72 (s) 
19 0.98 (s) 24.5 0.98 (s) 
20  125.2  
21 7.43 (d, 2.5) 150.6 7.22 (d, 2.5) 
22 7.99 (dd, 9.7, 2.5) 149.5 7.83 (dd, 9.5, 2.5 
23 6.28 (dd, 9.7, 1.0) 115.6 6.22 (d, 9.5) 
24  164.9  
1ʹ′  175.3b8  
2ʹ′ 2.33 (t, 7.4) 35.6  
3ʹ′  26.2b2  
4ʹ′ 1.37* 30.0b6  
5ʹ′  30.0b6  
6ʹ′  26.3b2  
7ʹ′ 2.26 (ddd, 10.5, 7.4, 3.0) 36.5b4  
8ʹ′ - 175.1b8  
9ʹ′ 4.43 (dd, 8.9, 5.1) 53.0b7 4.26 (m) 
10ʹ′  176.5  
1ʹ′ʹ′a 
1ʹ′ʹ′b 
 
 
30.0b6                             
 
2ʹ′ʹ′  26.5b2  
3ʹ′ʹ′a 
3ʹ′ʹ′b 
3.24 (dd, 13.7, 7.2) 
3.19 (dd, 13.7, 7.2) 
41.9b5  
4ʹ′ʹ′  158.8  
δH 1.2 – 1.8 – overlapping resonances 
* – J coupling constants could not be determined due to overlap with other signals 
a – structure comparison was performed with in house standard, NMR (600 MHz, CD3OD 
b1-8 – signals are interchangeable
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Table S10 NMR assignments (600 MHz, MeOD) of bufalin pimeloyl-L-arginine (9c) 
 
Pos. δH (m, J in Hz) δC 
1a 
1b 
 1.61* 
 
31.9b1 
2a 
2b 
 1.63* 
  
26.9b2 
3 5.08 (br t, 2.6) 72.3 
4a 
4b 
2.02 (td, 16.6, 14.5, 3.0) 
  
31.7b1 
5  38.7 
6a 
6b 
1.28 (m) 
1.94* 
27.9 
7a 
7b 
1.83 (m) 
   
22.6b3 
8  36.9b4 
9   1.65* 43.2 
10  37.1 
11a 
11b 
1.31* 
1.23 (ddd, 16.2, 12.3, 3.9) 
22.8b3 
12a 
12b 
1.46* 
1.52 (m) 
42.0b5 
13  49.9 
14  86.2 
15a 
15b 
2.13 (ddd, 11.8, 9.4, 2.5) 
1.72* 
33.3 
16a 
16b 
2.20 (ddd, 15.5, 10.3, 1.3) 
 
30.1b6 
17 2.56 (d, 10.3) 52.4b7 
18 0.71 (s) 17.5 
19 0.98 (s) 24.5 
20  125.2 
21 7.43 (d, 2.5) 150.6 
22 7.99 (dd, 9.7, 2.5) 149.5 
23 6.28 (dd, 9.7, 1.0) 115.6 
24  164.9 
1ʹ′  175.3b8 
2ʹ′ 2.33 (t, 7.4) 35.6 
3ʹ′  26.2b2 
4ʹ′ 1.38* 30.0b6 
5ʹ′  26.3b2 
6ʹ′ 2.26 (ddd, 10.5, 7.4, 3.0) 36.5b4 
7ʹ′ - 175.1b8 
8ʹ′ 4.43 (dd, 8.9, 5.1) 53.0b7 
9ʹ′  176.5 
1ʹ′ʹ′a 
1ʹ′ʹ′b 
 30.0b6 
2ʹ′ʹ′  26.5b2 
3ʹ′ʹ′a 
3ʹ′ʹ′b 
3.24 (dd, 13.7, 7.2) 
3.19 (dd, 13.7, 7.2) 
41.9b5 
4ʹ′ʹ′  158.8 
δH 1.2 – 1.8 – overlapping resonances 
* – J coupling constants could not be determined due to overlap with other signals 
a – structure comparison was performed with in house standard, NMR (600 MHz, CD3OD) 
b1-8 – signals are interchangeable 
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Table S11 NMR assignments (600 MHz, MeOD) of marinobufagenin pimeloyl-L-arginine (8c) 
 
Pos. δH (m, J in Hz) δC 
1a 
1b 
1.80 (ddd, 14.3, 14.3, 3.5) 
 
26.5b1 
2a 
2b 
 
1.61* 
25.9b1 
3 5.14 (br t, 2.6) 72.0 
4a 
4b 
2.34 (d, 7.6) 
 
36.3b2 
5  74.4 
6a 
6b 
 
1.32 (ddd, 13.5, 3.9, 3.2) 
35.6b3 
7a 
7b 
0.99 (s) 24.4 
8 2.01 (td, 12.3, 3.9) 33.9b4 
9 1.66* 43.7 
10  42.0b5 
11a 
11b 
1.56* 
 
22.5 
12a 
12b 
1.70* 
 
40.1 
13  46.2 
14  75.8 
15 3.61 (br s) 61.2 
16a 
16b 
2.41 (ddd, 15.5, 10.3, 1.3) 
 
33.3b4 
17 2.59 (d, 10.3) 48.3 
18 0.78 (s) 17.1b6 
19 0.98 (s) 17.2b6 
20  124.6 
21 7.44 (dd, 2.5, 0.9) 151.4 
22 7.89 (dd, 9.7, 2.5) 149.6 
23 6.26 (dd, 9.7, 0.9) 115.4 
24  164.6 
1ʹ′  175.1b6 
2ʹ′ 2.35 (t, 7.7) 35.4b3 
3ʹ′ 1.63* 26.4b1 
4ʹ′ 1.38* 30.0b7 
5ʹ′  26.5b1 
6ʹ′ 2.26 (ddd, 11.1, 7.4, 3.9) 36.8b2 
7ʹ′  174.8b6 
8ʹ′ 4.43 (dd, 8.9, 5.1) 52.7 
9ʹ′  176.5 
1ʹ′ʹ′a 
1ʹ′ʹ′b 
 29.8b7 
2ʹ′ʹ′  26.3b1 
3ʹ′ʹ′a 
3ʹ′ʹ′b 
3.23 (dd, 13.7, 7.2) 
3.19 (dd, 13.7, 7.2) 
42.0b5 
4ʹ′ʹ′  158.8 
δH 1.3 – 1.8 – overlapping resonances 
* – J coupling constants could not be determined due to overlap with other signals 
a – structure comparison was performed with in house standard, NMR (600 MHz, CD3OD) 
b1-7 – signals are interchangeable 
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Table S12 NMR (D2O, 600 MHz) data for suberoyl-L-arginine (1d) 
 
 
 
Pos. δH (m, J in Hz) δC 
1  179.2 
2 2.38 (t, 7.4) 33.7 
3 1.61* 24.1b1 
4 1.34* 27.6b2 
5  27.7b2 
6  24.3b1 
7 2.32 (ddd, 9.1, 7.6, 2.2) 35.3 
8  177.1 
9 4.35 (dd, 9.1, 5.1) 52.8 
10  176.3 
1ʹ′a 
1ʹ′b 
1.93 (m) 
1.77 (m) 
27.9b2 
2ʹ′ 1.67 (m) 25.0 
3ʹ′a 
3ʹ′b 
3.24 (dd, 13.7, 7.2) 
3.19 (dd, 13.7, 7.2) 
40.4 
4ʹ′  158.2 
δH 1.55 – 2.00 – overlapping resonances 
* – J coupling constants could not be determined due to overlap with other signals 
b1,2 – signals are interchangeable 
 
 
 
Table S13 NMR assignments (600 MHz, D2O) of azeloyl-L-arginine (4d) 
 
 
Pos. δH (m, J in Hz) δC 
1        181.3 
2 2.37 (t, 7.4)         35.6 
3 1.60* 25.8b1 
4 1.33* 29.4b2 
5  29.4b2 
6 
7 
         26.7 
29.6b2 
8 2.31(ddd, 9.1, 7.6, 2.2)         37.1 
9        179.2b3 
10 4.27 (dd, 9.1, 5.1)         55.3 
11        178.5b3 
1ʹ′a 
1ʹ′b 
1.90 (m) 
1.73 (m)  
        30.0b2 
2ʹ′ 1.63* 26.1b1 
3ʹ′ 3.22 (t, 7.2)         42.1 
4ʹ′        158.2 
δH 1.55 – 2.00 – overlapping resonances 
* – J coupling constants could not be determined due to overlap with other signals 
b1-3 – signals are interchangeable 
NH2
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H2N
H
N
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CO2H
1379
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Table S14 NMR assignments (600 MHz, D2O) of pimeloyl-L-arginine (3d) 
 
 
Pos. δH (m, J in Hz) δC 
1  179.2 
2 2.38 (t, 7.4) 33.5 
3 1.61* 23.9b1 
4 1.34 (m) 27.5b2 
5  24.3b1 
6 2.32 (ddd, 9.1, 7.6, 2.2)      35.3 
7  177.1 
8 4.35 (dd, 9.1, 5.1) 52.1 
9  176.3 
1ʹ′a 
1ʹ′b 
1.93 (m) 
1.78 (m) 
  27.6 b2 
2ʹ′ 1.66 (m) 24.9b1 
3ʹ′a 
3ʹ′b 
3.24 (dd, 13.7, 7.2) 
3.19 (dd, 13.7, 7.2) 
40.4 
4ʹ′  158.2 
 
δH 1.55 – 2.00 – overlapping resonances 
* – J coupling constants could not be determined due to overlap with other signals 
b1,2 – signals are interchangeable 
 
Table S15 NMR assignments (600 MHz, D2O) of adipoyl-L-arginine (2d) 
 
 
 
Pos. δH (m, J in Hz) δC 
1  178.5 
2 2.42 (t, 7.4) 33.4 
3   23.6b1 
4   24.3b1 
5 2.35 (ddd, 9.1, 7.6, 2.2) 35.0 
6  176.7 
7 4.39 (dd, 9.1, 5.1) 52.2 
8  175.5 
1ʹ′a 
1ʹ′b 
1.95 (m) 
1.79 (m) 
27.6  
2ʹ′ 1.67 (m)   24.6b1 
3ʹ′a 
3ʹ′b 
3.23 (dd, 13.7, 7.2) 
3.19 (dd, 13.7, 7.2) 
40.4 
4ʹ′  156.8 
 
δH 1.55 – 2.00 – overlapping resonances 
* – J coupling constants could not be determined due to overlap with other signals 
b1 – signals are interchangeable 
CO2HN
H
H
NH2N
OCO2H
NH2
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Figure S27. HPLC chromatograms (298 nm) of bufagenins from parotoid secretions analysed using Method 1 
 
 
Figure S28. HPLC chromatograms (298 nm) of synthetic bufotoxins analysed using Method 2 
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Figure S29a. Concentration curves of bufagenins and bufotoxins. Telocinobufagenin (2a) (r2=0.9987), bufalin (3a) 
(r2=0.9943) and telocinobufotoxin (2c) (r2=0.9993)  
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Figure S29b. Concentration curves of bufotoxins and derivatized amides. Bufalitoxin (3c) (r2=0.9985), der. adipoyl-L-
arginine (2e) (r2=0.9925), der. pimeloyl-L-arginine (3e) (r2=0.9960) and der. azeloyl-L-arginine (4e) (r2=0.9938) 
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Chapter 3: Chemo-anatomy: Bufadienolide composition in 
cane toad parotoid toxin and parotoid secretion 
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3.1 Introduction 
 
 
The aim of this section of my research is to analyse bufadienolide composition and levels within 
adult cane toad parotoid glands. Depending on experimental method, our investigations into the 
chemistry of secretions obtained from live cane toads resulted in variable results – yielding different 
proportions of bufagenins vs bufotoxins. This finding led to new insights into the composition and 
storage of bufadienolides in cane toad parotoid glands. Based on the handling procedures, the 
composition of bufadienolides in secretion varies. To better understand this phenomenon we 
investigated bufadienolide composition in secretions and in situ (within the parotoid gland). To 
differentiate toxins found within versus those secreted from the parotoid gland, we adopted a 
clarifying terminology. A “parotoid toxin” indicates the toxin present within the parotoid gland (in 
situ) while a “parotoid secretion” indicates the toxin secreted from the parotoid gland upon manual 
pressure (ex situ).  
 
Parotoid secretions were obtained by manual squeezing the parotoid gland onto a solid/liquid 
medium. As parotoid toxins are stored within the parotoid gland in numerous small microglands, 
parotoid toxins were obtained by micro-dissection of the parotoid gland followed by solvent 
extraction.  
 
The bufadienolides content in parotoid toxins and secretions were quantified by the methods 
developed in chapter 2. Our study into bufadienolide composition of the parotoid toxin provides 
insights into the in situ storage of bufadienolides in adult cane toads, extending across physical 
(formation of secondary structures such as liposomes), chemical (stability against biological fluids 
such as plasma), microbiological (susceptibility to biotransformation) and biological (cytotoxicity) 
aspects of bufadienolides.   
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Figure 3.1 Scheme of handling of parotoid gland contents with respect to investigations on storage and delivery of cane 
toad toxins 
 
Chemical analyses of ex situ parotoid secretions were performed by adopting various handling 
conditions, squeezing the parotoid secretions onto different media, glass (secretion A), MeOH 
(secretion B) and H2O (secretion C). Parotoid toxins were investigated by dissecting parotoid 
microglands into MeOH and/or H2O followed by analyzing for bufadienolides and arginyl amides 
using previously established analytical methodology. Composition of bufadienolides in parotoid 
secretions vs parotoid toxin would provide insights into storage and delivery of cane toad toxins. 
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3.2 Results and discussion 
 
3.2.1 Micro-dissection of parotoid microglands 
 
In situ parotoid toxin is stored in 60 – 100 small microgland like structures called parotoid 
microglands attached to the parotoid epithelium (Figure 3.2).1 Each microgland is about 0.5 – 1 mm 
diameter and is highly vascularized. During the manual compression of the parotoid gland, the 
stored toxin is pushed outwards via the opening of the microgland through to the pores of the 
parotoid skin. It has been reported that the synthesis and storage of toxin, including bufadienolides, 
biogenic amines and proteins, occurs in the microglands.2  
 
Figure 3.2 Section of parotoid gland exhibiting dorsal portion covered with thick epithelium and fine pores and the 
ventral portion exhibiting numerous microglands filled with parotoid toxin 
 
 
parotoid gland  
(dorsal) 
parotoid gland  
(ventral) 
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Figure 3.3 Light microscopy image of parotoid microglands (left). A parotoid microgland filled with toxin (right). Bars 
– black = 10 mm, white = 500 µM 
 
Parotoid microglands are yellow to orange when filled with toxin. After manual compression of the 
parotoid glands to release parotoid secretion, the deflated microgland is filled with blood. 
Compressed parotoid microglands are smaller in size (deflated) and are bright red. Another, 
interesting feature of the parotoid gland is all of the toxin cannot be expelled by a single 
compression leaving a mix of yellow and red microglands. A previous study by Morales et al 
determined that a single compression of a parotoid gland leaves approximately 50% of the 
microglands intact.3 The red microglands takes about 28 days to mature into a fully loaded yellow 
parotoid microgland (filled with toxin). This reluctance to fully deplete toxin levels during a 
secretion event (predatory attack) may be designed to ensure that the toad retains sufficient levels of 
toxin to protect against subsequent predatory attacks.3  
 
Micro-dissection involves dissecting individual parotoid microglands, with the aid of a microscope 
(Figure 3.5). Micro-scissors and micro-tweezers were used to cut individual microglands from the 
surrounding epithelium, which were secured by a strong basal attachment. Isolated microglands 
were examined under a light microscope (Carl Zeiss, Australia) to ensure that they were not 
damaged during dissection.  
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Figure 3.4 (a) Parotoid microgland filled with toxin before manual compression with evidence of toxin leakage, (b) 
filled with blood after manual compression of the parotoid gland and (c) partially filled with toxin and blood after 
manual compression of the parotoid gland, bar = 500 µm  
 
Parotoid microglands when filled with parotoid toxin have a diameter of a 500 µm with a well-
defined continuous myoepithelium (Figure 3.4). The entire parotoid microgland features a rich 
network of collagenous connective tissue, which was previously proposed to supply nutrients for 
the biosynthesis of parotoid toxin.4 The microgland toxin exit duct also features a dense network of 
connective tissue and epithelium, believed to facilitate contraction and toxin release during a 
predatory attack. Scanning electron microscopy of intact excised microglands reveal structural 
elements that aids in the storage and secretion of parotoid toxin (Figures 3.5 and 3.6), whereas 
scanning electron microscopy of compressed (deflated) parotoid microglands reveals a ruptured or 
shrunk myoepithelium (Figure 3.6) and an expanded exit duct (due to the passage of parotoid toxin 
during the compression). The connective tissue of compressed microglands is more transparent 
compared to intact microglands, and shows accumulation of epithelial cells with a rich network of 
collagen like fibrous connective tissue.  
 
 
a b c 
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Figure 3.5 Scanning electron microscopy images of an intact parotoid microgland filled with toxin. A – structural 
framework of parotoid microgland, TED – toxin exiting duct, MEp – myoepithelium, CT – connective tissue, B – 
epithelium with a network of connective tissue. 
 
 
 
Figure 3.6 Scanning electron microscopy images of a compressed parotoid microgland filled with blood. C – structural 
framework of parotoid microgland, arrows pointing to ruptured/shrunk myoepithelium, D – surface of microgland with 
a large number of myoepihtelial cells with a network of connective tissue. 
 
TED 
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3.2.2 Chemical analysis and quantification of parotoid secretions, parotoid 
toxins and parotoid microglands 
 
During preliminary analyses of parotoid secretions from live cane toads we observed that parotoid 
secretions squeezed into H2O contained predominantly bufagenins with minor amounts of 
bufotoxins, while parotoid secretions squeezed onto a glass plate contained mostly bufagenins but 
with significant amounts of bufotoxins. This observation suggested that, subject to handling, 
bufotoxins can undergo varying degrees of conversion to bufagenins. This hypothesis was 
supported by the observation that expression of parotoid secretion directly into MeOH yielded only 
bufotoxins, while expression into H2O followed by a short (10 – 20 min) incubation at room 
temperature yielded only bufagenins. All these observations were confirmed by quantitative 
analyses as detailed below. 
 
3.2.2.1 Secretion A – parotoid secretion squeezed onto a glass plate 
 
Manual compression of parotoid glands to release secretion directly on to a glass plate has been 
reported previously, and is often used as a standard method to obtain parotoid secretions.5, 6 
Following this strategy the parotoid gland secretions of five adult cane toads were squeezed on to a 
glass plate and were left for an hour during which the secretion turned into a dry waxy solid. All the 
toads selected for these analyses were within the mass range of 90 – 180 g, and included three 
female (181 g, 102 g and 149 g) and two male (103 g and 91 g) cane toads. The dry waxy parotoid 
secretion  from each toad was dissolved from the glass surface into MeOH (5 mL) and dried under 
N2 at 40 °C to yield 231 mg, 104 mg, 96 mg, 168 mg and 78 mg respectively. This result is 
consistent with our previous studies, where we observed that the mass of toads correlates with 
parotoid secretion mass yields. The dried MeOH extract was subjected to n-BuOH/ H2O partition, 
and the n-BuOH solubles were dried under N2 at 40 °C and weighed to generate 49 mg, 21 mg, 18 
mg, 36 mg and 15 mg, respectively. Based on prior experience in our laboratory the n-BuOH phase 
contains all bufadienolides, while various indole-alkaloids and catecholamine components are 
concentrated in the H2O soluble phase. The n-BuOH solubles were then re-dissolved in MeOH to a 
standard concentration (1 mg/mL) to generate analytes A1 – A5 which were analysed using Method 
2 (Chapter 2) specific for bufagenins and bufotoxins, respectively (Figure 3.7). 
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Figure 3.7 Secretion A – production of analytes A1 – A5 (n-BuOH)  
 
Aliquots (10 µL =10 µg) of A1 – A5 were analysed using HPLC Method 2 (see Chapter 2) to yield 
five HPLC traces (Figure 3.8). Comparison of HPLC retention times and HPLC-MS data for all 
peaks in the traces with authentic standards (See Chapter 2) confirmed the presence of bufagenins 
(1a, 2a, 3a, 4a and 5a) (Figure 3.9) and bufotoxins (1c, 2c, 3c and 5c) (Figure 3.10). The area under 
each peak was quantified to generate relative bufadienolide percentages in A1 – A5  (Table 3.1).  
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Figure 3.8 HPLC chromatogram (298 nm) of Secretion A analytes A1-A5 analysed using Method 2 (see Chapter 2). 
Bufotoxins (green) and bufagenins (blue). Marinobufotoxin (1c), telocinobufotoxin (2c), bufalitoxin (3c), hellebritoxin 
(5c), marinobufagenin (1a), telocinobufagenin (2a), bufalin (3a) and resibufagenin (4a). 
 
 
       marinobufotoxin (1c)                               telocinobufotoxin (2c)..                                      bufalitoxin (3c) 
 
 
heelbritoxin (3c)                                       marinobufagenin pimeloyl-L-arginine (8c) 
 
Figure 3.9 Bufotoxins identified in parotoid secretions in secretion A 
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                            marinobufagenin (1a)          telocinobufagenin (2a)                  bufalin (3a) 
 
 
                                                   resibufagenin (4a)               hellebrigenin (5a) 
 
Figure 3.10 Bufagenins identified in parotoid secretions in secretion A 
 
Table 3.1 Relative composition (%) of bufadienolides in secretion A (A1 – A5 are analytes) 
 
Compound 
no. 
A1  
(%) 
A2  
(%) 
A3  
(%) 
A4  
(%) 
A5  
(%) 
1c 41.4 34.2 33.8 38.5 37.4 
2c 5.3 3.8 1.7 6.0 3.7 
3c 4.4 2.7 5.3 3.7 4.7 
5c 3.0 2.1 4.7 3.8 2.7 
1a 33.6 46.6 43.5 34.1 40.0 
2a 5.9 4.0 4.9 5.1 4.4 
3a 3.0 4.2 4.8 4.1 4.5 
4a 0.4 1.3 1.3 0.8 1.0 
5a 3.0 1.1 <0.1 3.9 1.6 
 
Secretion A contains an approximately 1:1 composition of bufotoxins to bufagenins with 
marinobufotoxin (1c) as the dominant bufotoxin followed by bufalitoxin (3c), telocinobufotoxin 
(2c) and hellebritoxin (5c), and marinobufagenin (1a) as the dominant bufagenin followed by 
telocinobufagenin (2a), bufalin (3a) and hellebrigenin (5a).  
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The area under each peak in the HPLC traces (Figure 3.8) was also compared against standard 
curves for marinobufagenin (Chapter 2, Figure 2.16) and marinobufotoxin (Chapter 2, Figure 2.18), 
to calculate the µg/peak per HPLC trace per compound. Table 3.2 uses these qualitative measures to 
calculate the weight (mg) of each bufadienolide in each secretion A sample. 
 
Secretion A contains an approximately 1.8:1 weight composition of bufotoxins to bufagenins, with 
marinobufotoxin (1c) as the dominant bufotoxin followed by bufalitoxin (3c), telocinobufotoxin 
(2c) and hellebritoxin (5c), and marinobufagenin (1a) was the dominant bufagenin followed by 
telocinobufagenin (2a) and bufalin (3a). 
 
Table 3.2 Absolute amounts (mg) of bufadienolides in secretion A 
 
Compound 
no. 
A1  
(mg) 
A2  
(mg) 
A3  
(mg) 
A4  
(mg) 
A5  
(mg) 
1c 25.9 7.9 6.8 18.7 5.4 
2c 2.9 1.0 0.9 2.5 0.7 
3c 1.9 0.8 0.5 1.0 0.6 
5c 0.9 0.8 0.5 1.0 0.6 
1a 12.7 6.3 5.6 9.4 4.0 
2a 1.9 0.6 0.5 1.0 0.6 
3a 0.5 0.6 0.5 0.7 0.6 
4a <0.1 <0.1 <0.1 <0.1 <0.1 
5a <0.1 <0.1 <0.1 0.3 <0.1 
 
 
From the above analysis the total weight of bufadienolides per secretion A was calculated across 
toads 1 – 5 to be 46 mg, 18 mg, 15 mg, 34 mg and 12 mg respectively with the bufagenin to 
bufotoxin ratio in male and female toads being similar. Since cane toads deliver approximately half 
of their toxin content in the first compression of the parotoid gland, and possess two glands, we can 
estimate the total bufadienolide load per toad to be of 50 – 200 mg. 
 
3.2.2.2 Secretion B – parotoid secretions squeezed into MeOH 
 
Parotoid secretion was squeezed from the left parotoid gland of three adult cane toads into MeOH 
(5 mL) and was left for an hour at room temperature. Two female cane toads weighing, 89 g and 71 
g, respectively and one male toad weighing 67 g were subjected to secretion B analyses, and the 
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crude yellow parotoid secretion in MeOH (5 mL) was dried under N2 at 40 °C yielding 46 mg, 41 
mg, and 38 mg respectively. The dried crude extract was subjected to n-BuOH/H2O partition, and 
the n-BuOH solubles were dried under N2 at 40 °C and weighed to generate 14 mg, 12 mg and 10 
mg, respectively. The n-BuOH solubles were then re-dissolved in MeOH to a standard 
concentration (1 mg/mL) to generate analytes A6 – A8 and were analysed using Method 2 (Chapter 
2) specific for bufagenins and bufotoxins, respectively (Figure 3.11). 
 
 
Figure 3.11 Secretion B – production of analytes A6 – A8 (n-BuOH) and A6* – A8*	  (H2O) 
 
Aliquots (10 µL =10 µg) of A6 – A8 were analysed using HPLC Method 2 as described in Chapter 
2 to yield three HPLC traces (Figure 3.12). Identification of bufagenins (1a) (Figure 3.9) and 
bufotoxins (1c, 2c, 3c, 5c and 8c) was performed as mentioned above (Figure 3.10). The area under 
each peak was quantified to generate relative bufadienolide percentages in A6 – A8  (Table 3.3).  
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Figure 3.12 HPLC chromatogram (298 nm) of Secretion B analytes A6-A8 analysed using Method 2 (see Chapter 2). 
Marinobufotoxin (1c), telocinobufotoxin (2c), bufalitoxin (3c), resibufotoxin (4c), hellebritoxin (5c), marinobufagenin 
pimeloyl-L-arginine (8c) and marinobufagenin (1a) 
 
Table 3.3 Relative composition (%) of bufadienolides in secretion B 
 
Compound 
no. A6 (%) A7 (%) A8 (%) 
1c 65.2 65.2 70.3 
2c 4.1 4.2 5.5 
3c 7.5 7.2 6.8 
4c 0.8 0.7 3.9 
5c 9.2 9.5 3.5 
8c 11.8 11.9 6.8 
1a 1.5 1.2 3.0 
 
Surprisingly, HPLC-DAD analysis (298 nm) of secretion B samples showed the presence of 
bufotoxins predominantly (98%), with marinobufotoxin (1c) exhibiting the highest concentration 
followed by bufalitoxin (3c) and telocinobufotoxin (2c), while marinobufagenin (1a) was the only 
bufagenin identified (Figure 3.10).  
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The area under each peak in the HPLC traces (Figure 3.12) was also compared against standard 
curves for marinobufagenin (Chapter 2, Figure 2.16) and marinobufotoxin (Chapter 2, Figure 2.18), 
to calculate the µg/peak per HPLC trace per compound. Table 3.4 uses these qualitative measures to 
calculate the weight (mg) of each bufadienolide in each secretion B sample. 
 
Secretion B contains an approximately 99:1 ratio (amount) of bufotoxins to bufagenins, with 
marinobufotoxin (1c) as the dominant bufotoxin followed by telocinobufotoxin (2c), bufalitoxin 
(3c) and hellebritoxin (5c), and marinobufagenin (1a) was the dominant bufagenin with no traces of 
other bufagenins. 
 
In light of the significant differences observed in the bufotoxin:bufagenin ratios in secretion A and 
secretion B, we were keen to analyze and quantify the levels of free suberoyl-L-arginine (1d) (and 
homologs). Standards outlined in chapter 2 provided authentic standards and suitable analytical 
methods. 
 
The H2O solubles from the n-BuOH/ H2O of secretion B partition were dried in vacuo and 
derivatized with 2,4-pentanedione. The resulting reaction product was dried in vacuo, dissolved in 
MeOH to a standard concentration (1 mg/mL) to generate analytes A6*-A8* which were analysed 
using the HPLC-DAD method (Method 3, refer section 2.4.7) described above. Comparison of 
HPLC retention times and HPLC-MS data for all peaks in the traces with authentic standards (See 
Chapter 2) confirmed the presence of derivatized suberoyl-L-arginine (1e) (Figure 3.13). 
Interestingly, only trace amounts of suberoyl-L-arginine were identified in secretion B (Figure 
3.14).  
 
 
Figure 3.13 Derivatized arginyl amide identified in Secretion B preparation 
 
The area under derivatized suberoyl-L-arginine in the HPLC traces (Figure 3.14) was compared 
against standard curves for suberoyl-L-arginine (Chapter 2, Figure 2.16), to calculate the µg/peak 
per HPLC trace per compound. Table 3.4 uses these qualitative measures to calculate the weight 
(mg) of suberoyl-L-arginine in each secretion B H2O solubles. Levels of bufotoxins in secretion B 
correlated with the total mass of bufadienolides sampled from toads 6 – 8 with less/negligible 
amounts of bufagenins (<0.1 mg). Moreover, only negligible amount of suberoyl-L-arginine (<0.1 
mg) was identified in secretion B. From the above analysis the total weight of bufadienolides per 
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secretion B was calculated across toads 6 – 8 to be 11 mg, 10 mg and 7 mg respectively, with the 
bufagenin to bufotoxin ratio in male and female toads being similar.  
 
 
 
 
Figure 3.14 HPLC chromatogram (320 nm) of Secretion B analytes A6*-A8* analysed using Method 3 (see Chapter 2). 
Dehydrobufotenine (1.6), derivatized suberoyl-L-arginine (1e) 
 
 
Table 3.4 Absolute amounts of bufadienolides and arginyl amides in secretion B 
 
Compound 
no. 
A6  
(mg) 
A7  
(mg) 
A8  
(mg) 
1c 7.4 6.5 4.9 
2c 0.6 0.4 0.4 
3c 1.0 0.7 0.5 
4c 0.3 0.3 0.3 
5c 1.0 0.9 0.3 
8c 1.2 1.2 0.5 
1a <0.1 <0.1 <0.1 
1e <0.1 <0.1 <0.1 
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3.2.2.3 Secretion C – parotoid secretions squeezed into H2O 
 
Parotoid secretion was squeezed from the right parotoid gland of three adult cane toads into H2O (5 
mL), homogenized using a vortex and was left for an hour at room temperature to deliver a creamy 
yellow solution. Two female cane toads weighing, 89 g and 71 g, respectively and one male toad 
weighing 67 g were subjected to secretion C analyses. The crude yellow parotoid secretion in H2O 
(5 mL) was dried under N2 at 40 °C yielding 44 mg, 39 mg, and 37 mg respectively. The dried 
crude extract was subjected to n-BuOH/H2O partition, and the n-BuOH solubles were dried under 
N2 at 40 °C and weighed to generate 15 mg, 11 mg and 9 mg, respectively. The n-BuOH solubles 
were then re-dissolved in MeOH to a standard concentration (1 mg/mL) to generate analytes A9 – 
A11 and which were analysed using Method 1 (Chapter 2) specific for bufagenins, respectively 
(Figure 3.15).  
 
Figure 3.15 Secretion C – production of analytes A9 – A11 (n-BuOH) and A9* – A11*	  (H2O) 
 
Aliquots (10 µL =10 µg) of A9 – A11 were analysed using HPLC Method 2 as described in Chapter 
2 to yield three HPLC traces (Figure 3.16). Identification of bufagenins (1a, 2a, 3a, 4a and 5a) 
(Figure 3.9) was performed as mentioned above. The area under each peak was quantified to 
generate relative bufadienolide percentages in A9 – A11  (Table 3.5).  
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Figure 3.16 HPLC chromatogram (298 nm) of Secretion C analytes A9-A11 analysed using Method 1 (See Chapter 2). 
Marinobufagenin (1a), telocinobufagenin (2a), bufalin (3a), resibufagenin (4a) 
 
Table 3.5 Relative composition (%) of bufadienolides in secretion C 
 
Compound 
no. 
A9  
(%) 
A10  
(%) 
A11  
(%) 
1a 84.3 84.5 84.9 
2a 5.0 4.8 5.4 
3a 7.8 7.5 6.8 
4a 1.8 1.9 2.5 
5a 1.0 1.2 0.5 
 
 
Secretion C contains >99 % bufagenins compared to bufotoxins, with marinobufagenin (1a) as the 
dominant bufagenin followed by bufalin (3a), telocinobufagenin (2a), resibufagenin (4a), and 
hellebrigenin (5a). The area under each peak in the HPLC traces (Figure 3.16) was also compared 
against standard curves for marinobufagenin (Chapter 2, Figure 2.16), to calculate the µg/peak per 
HPLC trace per compound. Table 3.6 uses these qualitative measures to calculate the weight (mg) 
of each bufadienolide in each secretion C sample. 
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As detailed above, the H2O soluble phase from the n-BuOH:H2O partitions of secretion C were 
prepared and derivatized to yield analytes A9*-A11* which were analysed for suberoyl-L-arginine 
(1d) (and homologues) using the methodology outlined in chapter 2. Comparison of HPLC 
retention times and HPLC-MS data for all peaks, with comparison to authentic standards (See 
Chapter 2), confirmed the presence of derivatized arginyl amides (1e and 3e) (Figure 3.17). 
 
 
               
                        derivatized suberoyl-L-arginine  (1e)                         derivatized pimeloyl-L-arginine (3e) 
 
Figure 3.17 Derivatized arginyl amides detected in Secretion C preparation 
 
 
The area under derivatized arginyl amides peaks in the HPLC traces (Figure 3.18) was quantified to 
calculate the weight (mg) of arginyl amides in each Secretion C sample, which was dominated by 
suberoyl-L-arginine (1e) with trace amounts of pimeloyl-L-arginine (3e). From the above analysis 
the total weight of bufadienolides per Secretion C was calculated across all toads 1-3 to be ~ 9 mg, 
7 mg and 5 mg, respectively with the bufagenin to bufotoxin ratio in male and female toads being 
similar and dominated by bufotoxins (>99.9%) 
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Figure 3.18 HPLC chromatogram (320 nm) of 2 Secretion C analytes A9*-A11* analysed using Method 3 (see Chapter 
2). Dehydrobufotenine (1.6), derivatized pimeloyl-L-arginine (3e) and derivatized suberoyl-L-arginine (1e)  
 
Table 3.6 Absolute amounts (mg) of bufadienolides and arginyl amides in secretion C  
 
Compound 
no. 
A9  
(mg) 
A10  
(mg) 
A11  
(mg) 
1a 7.6 5.7 4.6 
2a 0.4 0.3 0.2 
3a 0.6 0.4 0.3 
4a <0.1 <0.1 0.1 
5a <0.1 <0.1 <0.1 
1e 6.8 4.9 3.8 
3e 0.8 0.5 0.3 
 
3.2.2.4 Toxin A – microgland extracted with MeOH 
 
Two male cane toads weighing 102 g and 99 g, respectively and one female toad weighing 104 g 
were subjected to toxin A analyses. To investigate the composition of bufadienolides present in the 
parotoid toxin stored in situ, left parotoid glands of three adult cane toads were excised and three 
parotoid microglands from each parotoid gland filled with toxin were dissected, washed with PBS, 
weighed and immersed in MeOH (1 mL). Large well-developed parotoid microglands with an 
average mass of 3.4±0.4 mg (n = 9) were selected for toxin A analysis to minimize handling errors. 
The parotoid microglands in MeOH were homogenized using a pipette tip and left for an hour at 
room temperature. The crude yellow toxin A sample was dried under N2 at 40 °C, and dried crude 
extract subjected to n-BuOH/H2O partition. The dried n-BuOH solubles were dried under N2 at 40 
°C and were re-dissolved in MeOH (50 µL) and were analysed using method 2 (Chapter 2) specific 
for bufagenins and bufotoxins, respectively (Figure 3.19). 
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Figure 3.19 Toxin A – production of analytes A12 – A20 (n-BuOH) and A12’ – A20’	  (H2O) 
 
Aliquots (10 µL) of A12 – A20 were analysed using HPLC Method 2 as described in Chapter 2 to 
yield nine HPLC traces (Figure 3.20). Identification of bufotoxins (1c, 2c, 3c, 4c, 5c, 8c and 9c) and 
bufagenins (1a) (Figure 3.9) was performed as mentioned above (Figure 3.10). The area under each 
peak was quantified to generate relative bufadienolide percentages in A12 – A20  (Table 3.7). 
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Figure 3.20 HPLC chromatogram (298 nm) of Toxin A analytes A12-A20 analysed using Method 2 (see Chapter 2). 
Marinobufotoxin (1c), telocinobufotoxin (2c), bufalitoxin (3c), hellebritoxin (5c), marinobufagenin pimeloyl-L-arginine 
(8c) 
HPLC-DAD analysis (298 nm) of Toxin A revealed that they were dominated by >99% bufotoxins, 
with only trace levels of bufagenins (<1%). Bufotoxins were dominated by marinobufotoxin (1c) 
(66%) and the lone bufagenin identified was marinobufagenin (1a) (<1%) (Figure 3.10). This 
observation confirms that in situ cane toad toxin is composed of bufotoxins and that secretions can 
be prone to hydrolysis to deliver bufagenins and arginyl amides (as evidenced in secretion A and 
secretion C).  
 
The area under each peak in the HPLC traces of Toxin A samples (Figure 3.20) was also compared 
against standard curves for marinobufagenin (Chapter 2, Figure 2.16) and marinobufotoxin 
(Chapter 2, Figure 2.18), to calculate the µg/peak per HPLC trace per compound. Table 3.7 uses 
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these qualitative measures to calculate the weight (mg) of each bufadienolide in each Toxin A 
sample. 
 
Table 3.7 Relative composition (%) of bufadienolides in toxin A 
 
Compound 
no. 
A12 
(%) 
A13 
(%) 
A14 
(%) 
A15 
(%) 
A16 
(%) 
A17 
(%) 
A18 
(%) 
A19 
(%) 
A20 
(%) 
1c 64.5 64.6 64.5 65.3 64.0 65.0 64.5 64.6 64.3 
2c 5.7 5.4 6.1 5.8 5.6 4.8 5.7 5.8 5.7 
3c 13.3 13.1 12.0 13.0 13.5 11.5 13.3 12.1 12.0 
4c 0.8 0.8 0.7 0.8 0.7 0.6 0.7 0.6 0.7 
5c 2.8 2.9 2.9 2.9 3.0 5.4 3.0 4.4 4.7 
8c 9.0 9.5 9.1 9.0 9.4 9.0 9.6 9.4 9.7 
9c 1.7 1.8 1.7 1.7 1.8 1.2 1.7 1.9 1.8 
1a 2.0 1.5 2.0 2.0 2.0 2.5 1.5 1.0 1.0 
 
Total bufadienolides per parotoid microgland was between 50 – 250 µg depending on the size of the 
microgland and % bufadienolide per parotoid microgland was between 2.6 – 5.2% (Table 3.8). The 
bufadienolide content per microgland is broadly correlated with the weight of the microgland 
(Figure 3.21, r2 = 0.9647). The nine microglands used in this study were among the larger 
encountered in the ~80 – 100 microglands found per parotoid gland. Based on these 
approximations, it is possible to estimate that the yield of bufadienolides per toad to be between 10 
– 50 mg.  
Table 3.8 Total amounts (µg) of bufadienolides in toxin A 
 
 A12 A13 A14 A15 A16 A17 A18 A19 A20 
A 
(µg) 
50 250 90 82 180 74 203 143 216 
 
B 
(%) 
2.6 4.8 3.5 3.4 4.1 3.2 5.2 4.2 4.7 
A (µg) – calculated as total mass of bufadienolides per microgland 
B (%) – calculated as mass of total bufadienolides per mass of microgland 
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Figure 3.21 Plot between mass of microgland (mg) and total bufadienolides per microgland (µg)  
 
Analysis of the arginyl amide content in the H2O solubles from toxin A proceeded as described 
earlier.  The dried H2O soluble partitioned from each microgland was derivatized with 2,4-
pentanedione, and the reaction product dried in vacuo and dissolved in MeOH (50 µL) to yield 
analytes A12*-A20*, which were analysed using the HPLC-DAD method (Method 3, refer section 
2.4.7) described above. Negligible levels of arginyl amides were detected in the parotoid 
microgland contents confirming that arginyl amides in the parotoid secretion are a by-product of the 
hydrolysis of bufotoxins in situ and importantly, that surplus arginyl amides are not stored 
(accumulated) in microglands (Figure 3.22).  
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Figure 3.22 HPLC chromatogram (298 nm) of Toxin A analytes A12*-A20* analysed using Method 3 (see Chapter 2). 
Dehydrobufotenin (1.6) and suberoyl-L-arginine (1e) 
 
3.2.2.5 Toxin B – microgland extracted into H2O 
 
Two male cane toads weighing 102 g and 99 g, respectively and one female toad weighing 104 g 
were subjected to toxin B analyses. Right parotoid glands of three adult cane toads were excised 
and three parotoid microglands from each parotoid gland filled with toxin we dissected, weighed 
and immersed into H2O (1 mL). The parotoid microglands were then homogenized using a pipette 
tip and were left for an hour at room temperature to deliver a pale yellow solution. The crude 
yellow parotoid toxin B in MeOH (1 mL) was dried under N2 at 40 °C. The dried crude extract was 
subjected to n-BuOH/H2O partition and the n-BuOH solubles comprising bufadienolides were dried 
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under N2 at 40 °C and re-dissolved in MeOH (50 µL) to deliver analytes A21-A29, which were 
analysed using Method 2 (Chapter 2) specific for bufagenins and bufotoxins, respectively (Figure 
3.23). 
 
Figure 3.23 Toxin B – production of analytes A21 – A29 (n-BuOH)  
 
Aliquots (10 µL) of A21 – A29 were analysed using HPLC Method 2 (see Chapter 2) to yield nine 
HPLC traces (Figure 3.24). Identification of bufotoxins (1c, 2c, 3c, 4c, 5c, 8c and 9c) and 
bufagenins (1a) (Figure 3.9) was performed as mentioned above (Figure 3.10). The results obtained 
from the analysis were identical to toxin A (microgland treated in MeOH) where the bufadienolides 
composition was dominated with bufotoxins (>98%) and trace amounts of marinobufagenin was 
detected.  The observation also indicated the absence of hydrolytic activity associated with in situ 
parotoid toxin. 
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Figure 3.24 HPLC chromatogram (298 nm) of Toxin B analytes A21*-A29* analysed using Method 2 (see Chapter 2). 
Marinobufotoxin (1c), telocinobufotoxin (2c), bufalitoxin (3c), hellebritoxin (5c), marinobufagenin pimeloyl-L-arginine 
(8c), bufalin pimeloyl-L-arginine (9c), marinobufagenin (1a), bufalin (3a) and resibufagenin (4a) 
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3.2.3 Rate of hydrolysis of bufotoxins  
 
During our analysis on handling of parotoid secretions, hydrolysis of bufotoxins to bufagenins and 
suberoyl-L-arginine was well established. To investigate whether the bufotoxins hydrolysis is time-
dependent, the rate of hydrolysis of bufotoxins was calculated at different time intervals.  
 
3.2.3.1 Rate of hydrolysis of bufotoxins – Secretion D 
 
To identify the rate of conversion of bufotoxins into bufagenins, parotoid secretion from three cane 
toads was squeezed into H2O (5 mL) followed by rapid mixing using a vortex to obtain a 
homogenous solution. Aliquots of this homogenous solution (500 µL) were quenched with MeOH 
(500 µL) at various time intervals ranging from 5, 10, 15, 20 and 30 min. A 0 min reading was 
obtained by squeezing parotoid secretions directly into MeOH (5 mL) to immediately inhibit the 
bufotoxin hydrolysis. All MeOH solutions were dried under N2 at 40 °C, triturated with MeOH (1 
mL), dried under N2 at 40 °C and re-dissolved in MeOH to a standard concentration (1 mg/mL) to 
generate analytes A30-A50, respectively and analysed using Method 2 (Figure 3.25).  
 
Figure 3.25 Secretion D – production of analytes A30 – A50 (n-BuOH)  
 
Aliquots (10 µL = 10 µg) of A30 – A50 were analysed using HPLC Method 2 (see Chapter 2) of 
which seven representative traces are shown below (Figure 3.26). Identification of bufotoxins (1c, 
2c, 3c, 4c, 5c and 8c) (Figure 3.9) and bufagenins (1a, 2a, 3a, 4a and 5a) (Figure 3.10) was 
performed as mentioned above.  
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Figure 3.26 HPLC chromatograms (298 nm) representative of Secretion D analytes A30-A50 analysed using Method 2 
(see Chapter 2). Marinobufotoxin (1c), telocinobufotoxin (2c), bufalitoxin (3c), hellebritoxin (5c), marinobufagenin 
pimeloyl-L-arginine (8c), marinobufagenin (1a), telocinobufagenin (2a), bufalin (3a), resibufagenin (4a) and 
hellebrigenin (5a). 
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The area under peaks corresponding to marinobufotoxin (representing bufotoxin) and 
marinobufagenin (representing bufagenin) was quantified to generate relative bufadienolide 
percentages in A30 – A50 and was interpreted as a graph as shown below (Figure 3.27). A curve 
was plotted between % of marinobufotoxin and marinobufagenin against each time interval (X axis, 
min) with two rows of Y-axis corresponding to hydrolysis of marinobufotoxin (green) and 
formation of marinobufagenin (blue). 
 
 
Figure 3.27 Conversion of marinobufotoxin (1c) to marinobufagenin (1a) over 30 min. Green line indicating the 
breakdown of bufotoxins (left Y axis), blue line indicating the formation of bufagenins (right Y axis) 
 
From the graph (Figure 3.27, One phase decay, non-linear fit, r2 = 0.9806) it is evident that the rate 
of hydrolytic activity in the parotoid secretion is rapid. The curve obtained from the percentage 
conversion of bufotoxins and bufagenins was linear until 5 min and reached the maximum (100%) 
through further time intervals. Rapid mixing using vortex resulted in a homogenous solution that 
distributed the chemistry of the parotoid secretion uniformly throughout the solution. The 
hydrolytic activity in the parotoid secretion resulted in the conversion of about 94% of bufotoxins 
into bufagenins in 5 min and then reached complete conversion (>99%) after 10 min.  
 
From this observation, it can be determined that cane toad parotoid secretions are subject to ex situ 
hydrolysis and this reaction is rapid and converts bufotoxins into bufagenins and arginyl amides. 
Our previous observation of bufagenins dominating the parotoid secretion (secretion C), which was 
analyzed using method 1 also coincides with our current observation. The above experiment 
indicated that handling of cane toad parotoid toxins during the chemical analysis would play a 
major role in the determination of the toxin constituents. From our observations it is evident that 
exposure of cane toad parotoid toxin to H2O (moisture) would increase the hydrolysis and result in 
rapid and quantitative conversion of bufotoxins to bufagenins. These results suggest that a 
hydrolase is co-secreted with the parotoid secretion.  
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3.2.4 Identification of bufotoxin hydrolysis in parotoid microglands – chemical 
approach 
 
3.2.4.1 Toxin C – investigation of co-localization of hydrolase 
 
An experiment was performed to identify whether the hydrolase activity detected in cane toad 
secretion is co-localized with bufotoxins within the microglands. In our preliminary investigations 
with parotoid microglands (Toxin A and Toxin B), parotoid microglands were gradually detached 
from their basal epithelium using micro-tweezers. However, in the current investigation, individual 
microglands from the parotoid glands of a male and a female toad were dissected using micro-
scissors and were cut angular to the basal epithelium of the parotoid gland, as this approach would 
provide access to surrounding epithelium which could also contain hydrolase (Figure 3.28). During 
this process access to an individual microgland was gained by destroying surrounding microglands 
and after dissection the microgland was washed twice with PBS buffer.  
 
 
Figure 3.28 Comparison of dissection strategies adopted in previous analyses, Toxin A, Toxin B and Toxin C 
 
Following dissection, the microglands were homogenized using a sterile pipette tip in the presence 
of H2O (500 µL) and was left at room temperature for 60 min and dried in vacuo and triturated with 
MeOH (1 mL) to solubilize all the bufadienolides. The MeOH soluble fraction was then dried in 
vacuo and was re-dissolved in MeOH to a standard concentration (1 mg/mL) to generate analytes 
A51-A54 which were analysed using Method 2 (Figure 3.29).  
connective tissue
I
II III IV V
A B
A - dissection of microgland by detaching from basal epithelium (II;Toxin A and Toxin B)
B - dissection of microgland by cutting through surrounding connective tissue by destroying adjacent microglands(III, IV and 
V;Toxin C)
	   155	  
 
Figure 3.29 Toxin C – production of analytes A51 – A54 (n-BuOH)  
 
Aliquots (10 µL) of A51 – A54 were analysed using HPLC Method 2 as described in Chapter 2 to 
yield four HPLC traces (Figure 3.30). Identification of bufotoxins (1c, 2c, 3c and 5c) (Figure 3.9) 
and bufagenins (1a, 2a, 3a and 4a) (Figure 3.10) was performed as mentioned above.  
  
  
Figure 3.30 Identification of hydrolase activity in different modes of dissection. (green – microgland detached from 
basal epithelium, blue – microgland cut across basal epithelium), marinobufotoxin (1c), marinobufagenin (1a) 
 
Interestingly, the analysis showed the conversion of bufotoxins into bufagenins in Toxin C prepared 
from microglands detached from the basal epithelium, differed from those of Toxin B which was 
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prepared from microglands cut from the basal epithelium, indicating that the mode of dissection is 
critical. Hydrolysis of bufotoxins to bufagenins in Toxin C was not as rapid as observed in parotoid 
Secretion D. For example, after 60 min >20% of bufotoxins in toxin C were unhydrolysed, however 
Secretion D showed >99% hydrolysis of bufotoxins after only 10 min. The analysis indicates that 
the amount of hydrolase present in Toxin C was far less than that in Secretion C, and more than in 
the Toxin A or Toxin B. These observations could be explained if the hydrolase was localized 
external to the parotoid microglands within the surrounding tissues, especially towards basal 
epithelium (just above the microglands). An imaging of parotoid microglands with different modes 
of dissection was applied to identify the localization of enzymes (Chapter 4). 
 
3.2.5 Why bufotoxins? – Multi-faceted stability investigations 
  
 
The preliminary analysis on cane toad parotoid toxin and secretion indicated a change in the levels 
of bufadienolides and arginyl amides during the secretion of parotoid gland contents. This 
observation also leads to insights into the significance of adapting a complex mechanism of 
biosynthesising a conjugated bufadienolide and hydrolysing during the secretion of the toxin. 
Several key features were investigated to identify the advantages of bufotoxin accumulation in 
parotoid glands. One of the major reasons was the stability of bufotoxins. Stability in this regard is 
classified into various types such as physical stability (formation of secondary structures such as 
micelles or liposomes for better packaging), chemical stability (resistance to proteins or other 
macromolecules in bodily fluids such as plasma), microbiological stability (resistance to microbial 
biotransformation) and toxicological stability (resistance to self-poisoning) (Figure 3.31). This 
chapter will focus on physical and chemical stabilities of bufotoxins while microbiological (Chapter 
5) and biological stabilities (Chapter 7) will be discussed later. 
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Figure 3.31 Storage of bufotoxins serves several benefits such as physical, chemical, biological and toxicological 
stabilities 
 
3.2.6 Physical stability - Storage of toxins and their particle stability 
 
Following the dissection of parotoid gland and parotoid microgland, storage of parotoid toxin 
within the parotoid microgland was investigated. The parotoid toxin within the microgland was 
reported to have shown positive reaction to Alcian blue stain by Jared et al2 Since the toxin is rich 
in bufadienolides, a lipid specific stain such as Nile red would be significant in determining the 
storage of toxins and possibly the structure of lipid stores. To perform microscopy, a microgland 
was dissected from the parotoid gland of a cane toad and was stained with Nile red and mounted on 
a glass slide and fixed with 50% glycerol. Imaging was performed using confocal microscopy and 
the emission was detected using red and green filters.  
 
The emission spectrum of Nile red stain is based on its environment, and fluorescence is observed 
in lipid-rich regions. Polar lipids appear bright red7 while neutral lipid structures appears green,8 
and hence the detection filters are green and red. Since bufotoxins are polar lipids (based on the 
conjugation), they appeared bright red with the lipid particles resembling a ring or droplet like 
structures (Figure 3.32). A lipid (bufotoxin) rich environment was observed within the parotoid 
microgland. 
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Figure 3.32 Parotoid toxin exiting from a parotoid microgland as identified by confocal microcopy stained with Nile 
red. A) Charged lipid bodies (bufotoxins) appear red as marked by an arrow, B) neutral lipids appear green as marked 
by an arrow. pm – parotoid microgland, e – epithelium, pt – parotoid toxin, ed – exit duct. Bars – 900 µm 
 
On investigating the green emission spectra, the neutral lipid-rich region was identified to be the 
apical portion of the parotoid microgland, which is further connected to the toxin exit duct. The 
neutral lipids could be attributed to the presence of cholesterol or triglycerides, which are the major 
constituents of large secondary structures such as liposomes or lipid droplets.8 Presence of 
secondary structures such as liposomes or lipid droplets in parotoid microglands were expected, 
providing the surface area required for the storage of high amounts of bufotoxins. High resolution 
imaging such as electron microscopy would reveal the presence of such secondary structures within 
the parotoid microglands. Investigation of the storage of parotoid toxin using confocal imaging 
indicated that the lipid rich regions within the parotoid microgland contained polar lipids (such as 
bufotoxins) as well as neutral lipids. 
 
3.2.6.1 Physical properties of cane toad of parotoid toxins 
 
Physical stability of toxin is essential as high amounts of parotoid toxin is distributed and stored 
within the parotoid gland (10’s to 100’s of mg levels of bufotoxins) and this requires the formation 
of stable particles. The stability of the bufotoxin particles (in situ toxin) must be high to package 
substantial amounts of steroids, and this could be achieved by forming secondary structures such as 
liposomes or micelles. Since bufotoxins possess a hydrophobic region attributed by steroidal rings 
and a hydrophilic region formed by the guanidine of the diacid arginyl amide, they could 
significantly form stable micelles or liposomes. While imaging the storage of toxins within the 
parotoid gland using Nile red stain, which is specific for lipids, particles (ring like) about 5 µm 
diameter were identified (Figure 3.33). These particles had a droplet like appearance with the 
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periphery stained red. Since positively charged lipids appear bright red when stained with Nile red, 
bufotoxins bearing the hydrophilic guanidine appeared red on the circumference of the lipid-droplet 
like structures while neutral lipids such as cholesterol appear green. Bufotoxins stored in the 
parotoid glands are possibly trapped within large lipid bodies such as lipid droplets, facilitating the 
storage of large toxin reserves and delivery upon a predatory attack. Lipid droplets are large 
globules containing rich amounts of fatty acids and sterol esters and they range from 20 nm to 100 
µm.9  
  
Figure 3.33 Confocal image of toxin stored within the parotoid microgland showing the structure of lipid structures. A 
–lipid droplet like structures with dense polar lipids (red), B – lipid structures also contains neutral lipids (green). ls – 
lipid structures. 
 
 
Further characterization of the particle storage of parotoid toxin rich in bufotoxin was performed 
using electron microscopy. A transmission electron microscopy of a whole individual microgland 
showed insights into the packaging of bufotoxins. Lipid structures ranging from few nm to µm size 
were identified (Figure 3.34). Since a large amount of toxin had to be packaged and delivered 
through an efficient vehicle, the cane toad parotoid glands possess an effective usage of lipid 
droplet like structures. The small lipid structures could be disintegrated particles of large lipid 
structures or they could also be the precursors of large droplets. Formation of lipid droplets had 
been identified in human adipocytes as a storage and delivery vehicle for fatty acid esters/lipids.10 A 
cane toad parotoid gland could also be compared to adipocytes due to the storage and delivery of 
high amounts of fatty acids including steroids (as steroidal esters). Presence of numerous fibrous 
particles on the lipid structures was also identified. The large lipid structures possessed significant 
amount of fibrilar structures compared to the small droplets exhibiting a regular pattern. From the 
previous observations based on Nile red staining of parotoid microgland, it is evident that 
bufotoxins (positively charged lipids) are attached to the lipid structures. Cane toad parotoid glands 
contain microglands that act as storage vesicles for toxin in the form of bufotoxins. Bufotoxins can 
potentially self assemble as micelle/lipid droplets to facilitate storage and delivery (secretion) as a 
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defense agent (Figure 3.35). Micellar structures reported in the literature have been identified to 
form cylindrical structures when observed under a high-resolution microscope such as TEM.11  
 
 
Figure 3.34 Lipid droplets observed within an individual parotoid microgland using transmission electron microscopy. 
L – lipid droplet, VW – microgland wall. Bar – 5 µm 
 
Figure 3.35 Cylindrical structures within lipid droplets, which are proposed to be micelles within an individual parotoid 
microgland using transmission electron microscopy. Bar – 200 nm 
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A combined approach of confocal imaging and electron microscopy showed some evidence of 
secondary structures formed within the parotoid gland for the storage of toxins. No such description 
of such a controlled toxin delivery system has been reported in any species other than Bufo. Since 
the toxin consists of steroidal esters (bufotoxins), a mechanism that is commonly known to deliver 
fatty acid esters in adipocytes could also have been adopted in Bufo toads.  
 
Bufagenins such as bufalin (3a) and resibufagenin (4a) have been demonstrated to form highly 
stable structures when trapped within synthetic liposomes.12,13 Considering the chemical stability of 
bufotoxins within the parotoid microglands, they could therefore likewise form highly stable 
bufotoxin-loaded lipid structures. Thus the in situ stored bufotoxins would be a much more practical 
storage mechanism than storing hydrolysed particles (ex situ). It is likely that the volume required 
to store the toxin would be much smaller for bufotoxins compared to bufagenins. In summary, 
storage of bufadienolides as bufotoxins enables a highly physically stable environment for in situ 
toxin storage aiding in the accumulation of concentrated amounts of bufadienolides within the 
parotoid gland. 
3.2.7 Chemical stability of toxins to plasma and saliva 
 
During a predatory attack on a cane toad significant amounts of bufotoxins would be released into 
the buccal cavity and gut of the predator where the bufotoxins would be hydrolysed into bufagenins 
upon exposure to body fluids such as saliva and plasma. The generated bufagenins would 
eventually find their way to the target cells expressing Na+/K+ ATPase, and in the process are 
exposed to body fluids such as saliva and plasma (increased plasma protein concentration). 
Shimada et al, reported the metabolism of marinobufotoxin (1a) and marinobufagenin (1c) after 
being exposed to enzymatic hydrolysis using rat or human liver cytosolic fraction.14 About 20% of 
1a was converted into 3-dehydromarinobufagenin and 10% into 3-epimarinobufagenin after 3 h. 
Also, 10% of 1c was converted into 1a after 3 h, but the expected compound, marinobufagenin-3-
suberate (1b) was not detected.  
 
The bufotoxins, however, would most likely hydrolyze on contact with saliva and/or plasma before 
being metabolized by the liver since both saliva and plasma possess complex mixtures of proteins 
(enzymes including hydrolases). Hence, the chemical stability of parotoid secretion in plasma 
and/or saliva would indicate the hydrolysis of bufotoxins without the aid of hydrolase. The rate of 
formation of bufagenin would provide insights into understanding of the chemical stability of 
bufotoxins. If enzymes in the buccal cavity or plasma of predators could rapidly hydrolyse 
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marinobufotoxin (1c), the role of enzyme(s) co-secreted with parotoid secretions requires further 
analysis to determine its ecological function. Chemical stability of bufotoxins to hydrolases in 
plasma and/or saliva would indicate the need of an effective enzyme(s) being co-secreted to initiate 
rapid hydrolysis of bufotoxins for immediate activity against predators. Chemical stability of 
bufotoxins was investigated by determining the susceptibility of bufotoxins to body fluids such as 
plasma or saliva.  
3.2.7.1 Stability of toxins to plasma  
 
To determine the chemical stability of bufotoxins in plasma, a known concentration of 1c (100 µM) 
was subjected to transformation in the presence of human plasma for 0 – 4 h at 37 °C. The 
enzymatic activity at each time interval (0, 1 and 4 h) was investigated by inhibiting the reaction, 
using n-BuOH, forming a bi-phasic mixture. The organic phase was dried, re-dissolved in MeOH 
(50 µL) and analysed using HPLC-DAD (Method 1).  
 
Figure 3.36 HPLC chromatogram (298 nm) of 100 µM of marinobufotoxin (1c) (green) in the presence of human 
plasma after 4 h. Marinobufagenin (1a) (blue) and marinobufagenin-3-hemisuberate (1b) (gold) 
 
Analysis of 1c subjected to plasma at 37 °C showed the formation of the hemi-ester, 1b in higher 
amounts and minute amounts of 1a (Figure 3.36). This is an interesting observation, as even after 4 
h of exposure only 30% of bufotoxin was converted to 1b. Only 1% of 1a was observed, showing 
that the hydrolysis of bufotoxins to bufagenins in plasma is not efficient. The formation of 1a from 
1c could be directly by the hydrolysis of C-3 suberoyl-L-arginine or 1c could be converted into 1c 
and further hydrolysed to form 1a. The latter could be a two-step process: 
 
1) proteolysis at C-9’ releasing marinobufagenin hemisuberate and 
2) hydrolysis at C-3 releasing marinobufagenin 
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Breakdown of amide at C-9’ could be attributed to the proteolytic activity of peptidases/proteinases 
(proteases). The hemi-ester that was formed following protease attack was more stable to hydrolytic 
activity in the plasma, which could be the reason for the presence of less/negligible amounts of 1a.  
Another reason for the production of hemi-ester instead of releasing free steroid could be that the 
former is less toxic than the latter. This could also be explained from the toxicity studies published 
in the literature that 1a is a potent cytotoxin as well as cardiotoxic agent.15 Hydrolysis of several 
esters has been reported in human plasma but esters of bufotoxins are more stable and the toads 
have developed a complex mechanism for their hydrolysis.16, 17 We hypothesize that 1c is converted 
into 1b in the plasma as it is less toxic (inhibition of Na+/K+ ATPase) compared to 1a, which causes 
severe toxicity by inhibiting Na+/K+ ATPase (Phase 1 metabolism).  
 
Shimada et al, reported that when 1c was subjected to biotransformation with mouse/human liver 
cytosolic fraction, resulted in the production of 1a without forming 1b, however, only 10% of 1a 
was produced after 3 h exposure at 37 °C showing the high stability of 1c from being metabolized 
by liver.14 Half-life of marinobufotoxin in human plasma was determined by the above mentioned 
method with more time intervals (0, 1, 2, 4, 6, 8, 10, 12, 14, 20 and 24 h) included. The reaction 
was monophasic resulting in the production of 1b while 1a appeared in minute amounts (<5%) even 
after 20 h of exposure to human plasma. This clearly indicates that 1c is highly stable against 
hydrolysis in the plasma (Figure 3.37). The half-life (t1/2) of 1c was calculated by plotting the 
percentage of 1c remaining in plasma at different time intervals (h). The t1/2 of 1c was determined to 
be 7.9 h (One phase decay; r2 = 0.9920) after exposure to human plasma for 24 h. 
 
Figure 3.37 Stability of 100 µM of marinobufotoxin (1c) in the presence of human plasma for 24 h 
 
The longer t1/2 of 1c in human plasma suggests that bufotoxins are chemically stable molecules 
against proteolytic activity, interestingly, they are even more stable against hydrolysis. This could 
0 5 10 15 20 25
0
50
100
time (h)
%
 m
bt
x 
re
m
ai
ni
ng
	   164	  
be the reason for bufotoxins hydrolysing into bufagenins during the release of the parotoid gland 
contents by a complex mechanism, while it should also be noted that previous studies have 
determined bufagenins more toxic than bufotoxins are.18  
3.2.7.2 Stability of toxins to saliva 
 
Stability of 1c in saliva was also determined since during the predatory attack bufotoxins are first 
exposed to saliva containing mixture of proteins (such as lysozymes and other hydrolases), which 
could result in breakdown of bufotoxins to bufagenins and other derivatives. To determine the 
chemical stability of bufotoxins in saliva, a known concentration of 1c (100 µM) was subjected to 
biotransformation in the presence of human saliva for 0 – 1 h at 37 °C. The enzymatic activity at 
each time interval (0, 15 min and 1 h) was investigated by inhibiting the reaction, using n-BuOH, to 
form a bi-phasic mixture. The organic phase was investigated using HPLC-DAD (Method 1). 
 
 
Figure 3.38 Stability of 100 µM of marinobufotoxin (1c) (green) in the presence of human saliva for 1 h. 
Marinobufagenin (1a) (blue) and marinobufagenin-3-hemisuberate (1b) (gold) 
 
Similar to our observation in plasma experiment, the bufotoxin was highly stable to hydrolysis of 
the ester (<5%) (Figure 3.38). Another interesting observation was that the bufotoxins were also 
stable to proteolytic activity since negligible amounts of 1b was identified using HPLC-DAD based 
detection. This observation suggests that 1c is a stable molecule, which is not degraded by enzymes 
in saliva. Considering the rapid pace of lethal events that occurs during the predatory attack,19 the 
conversion of bufotoxins into bufagenins must be at a higher rate. Hence, it is evident that the in 
situ parotoid gland hydrolase play an inevitable role in the hydrolysis of bufotoxins into bufagenins 
during the secretion of cane toad toxins.  
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3.2.8 Discussion – parotoid secretions vs parotoid toxins 
 
The results described above reveal a level of molecular complexity associated with the chemical 
composition of cane toad parotoid toxin that has gone unnoticed for over 100 years. New found 
knowledge of cane toad parotoid toxin has implications for our understanding of cane toad chemical 
ecology, with possible flow on benefits in regards to control of the invasive pest. Figure 3.39 
illustrates our key findings to date, which can be summarized as follows; 
 
1. Cane toad parotoid toxin is localized in situ within the parotoid gland in ~ 80 – 100 
microglands.  
2. Cane toad parotoid toxin in situ is dominated by bufotoxins while the secretions contains 
bufagenins and arginyl amides (Figures 3.40 and 3.41).  
3. The chemical composition of microgland toxin is remarkably simple, being dominated by a 
single bufotoxin, marinobufotoxin, with trace amounts of closely related bufotoxins (Figure 
3.42).  
4. During a predatory attack (or on manual compression) up to 50% of parotoid microglands 
will secrete their toxins via a duct, exuding a milky yellow liquid. 
5. Bufotoxins are co-secreted with a hydrolase that rapidly transforms bufotoxins into 
bufagenins and arginyl amides. 
6. Microglands do not store bufagenins and arginyl amides. 
7. The bufadienolide localization and composition of male and female cane toad parotoid toxin 
is effectively the same. 
8. The total levels of bufotoxins within the cane toad parotoid gland is ~ 50 – 200 mgs.  
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Figure 3.39 Summary on investigations of storage and delivery of cane toad parotoid toxins 
 
 
  
Figure 3.40 Scheme of analysis of parotoid secretions with different handling approaches yielding different 
composition of bufagenins vs bufotoxins 
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Figure 3.41 Scheme of analysis of parotoid toxin with different handling approaches yielding different composition of 
bufagenins vs bufotoxins 
 
 
Figure 3.42 Chemical composition of parotoid toxins vs parotoid secretions. Bufotoxins (green), bufagenins (blue) and 
arginyl amides (red) 
 
Although dominated by marinobufotoxin, parotoid toxin contains a range of closely related 
bufotoxins, all of which can be viewed as derivatives of marinobufotoxin (1c). These relationships 
are illustrated in Figure 3.43. While we can speculate conversion of bufotoxins to bufagenins is 
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achieved via a co-secreted hydrolase, the structure and properties of the hydrolase have to be 
studied, and will be explored in detail in Chapter 4. Marinobufotoxin (1c) could possibly be a 
precursor scaffold from which all the other bufotoxins are derived by in situ metabolic processing, 
including oxido-reductive enzymes. Another possibility is that marinobufotoxin could be subjected 
to in situ biotransformation by microbes. Such microbial transformations (degradation) were first 
reported in our laboratory in 2008.20 The possibility that other microbes may inhabit the parotoid 
gland and facilitate the transformation of marinobufotoxin into one or more of other bufotoxins 
detected within the microglands is worthy of further investigation. Our efforts in the area will be 
described in Chapter 5.  
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Figure 3.43 Plausible oxidation-reduction in in situ parotoid glands to form various bufotoxin analogues from 
marinobufotoxin (1c) and the action of hydrolase to form bufagenins from respective bufotoxins 
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3.3 Conclusion  
 
Our preliminary investigation on the handling of cane toad parotoid secretions suggested the 
presence of bufotoxins in the parotoid secretions (chapter 2). Further investigation on the storage 
and delivery of cane toad parotoid toxins using the analytical methodology previously developed 
specifically for bufadienolide classes and arginyl amides, revealed that in situ parotoid toxins are 
stored as bufotoxins and upon release they are converted into bufagenins and arginyl amides, 
constituting ex situ parotoid secretions. Matured parotoid microglands are filled with bufotoxins and 
upon release, are inflated and filled with blood. This observation was also justified by the ratio of 
absolute amounts of bufotoxins:arginyl amides in the parotoid toxin and bufagenins:arginyl amides 
in the parotoid secretion analysed using our standard quantification methods. Quantification studies 
also showed that typical bufotoxin content in adult cane toads range between 25 – 100 mg. Also, the 
rapid hydrolysis of bufotoxins when the parotoid gland contents were squeezed into H2O suggested 
the presence of hydrolyzing agents such as hydrolase co-secreted with the parotoid toxin. A 
differential dissection analysis exhibited the absence of in situ hydrolase within the microgland and 
is localized in the vicinity of the basal epithelium to which microglands are attached.  
 
Based on our imaging studies, it was identified that bufotoxins in the parotoid gland could form 
highly stable particles and could be packaged around lipid structures. Chemical stability analysis 
using plasma/saliva indicated that bufotoxins are highly stable compounds against hydrolysis from 
bodily fluids. These observations suggested the possible mechanism for the hydrolysis of 
bufotoxins could be primarily due to the presence of some enzymes that are co-secreted, resulting in 
rapid hydrolysis in the presence of H2O to release one equivalent of bufagenin and an arginyl amide 
each for one equivalent of bufotoxin. The proposed event that occurs during the manual 
compression of parotoid glands is summarized below (Figure 3.44).  
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Figure 3.44 A diagrammatic representation of storage and release of parotoid toxin from a parotoid microgland based 
on recent findings. The secretion majorly comprised of bufagenins, however, the in situ toxin contains bufotoxins 
predominantly 
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3.4 Experimental  
 
3.4.1 Micro-dissection of parotoid microglands 
 
Parotoid glands were dissected from cane toad parotoid glands using a sterile tweezer and surgical 
scissors. The excised parotoid gland was washed with distilled H2O/PBS to wash off any blood or 
tissues and also to maintain the moisture within the gland. Incisions were made on the ventral side 
of the gland to remove the thin epithelium gradually to expose the parotoid microglands that were 
held together by the external thin epithelium. Images of the parotoid gland and parotoid microgland 
were taken using Zeiss light microscope. Individual microglands were detached from the basal 
epithelium by the use of tweezers.  
 
3.4.2 Secretion A – parotoid secretion squeezed onto glass plate (Figure 3.7) 
 
Parotoid secretion from three toads (six parotoid glands) was manually squeezed onto a sterile glass 
plate and left for 60 min. The total secretion was collected dissolving in MeOH (10 mL) into a vial. 
This was followed by drying the crude parotoid secretion in MeOH under N2 at 40 °C. The dried 
crude parotoid secretion was subjected to partition with n-BuOH/ H2O, n-BuOH layers were dried 
under N2 at 40 °C, re-dissolved in MeOH (1 mg/mL) to a standard concentration.  
 
3.4.3 Secretion B – parotoid secretions squeezed into MeOH (Figure 3.11) 
 
Parotoid glands (three) from three cane toads were squeezed to obtain the parotoid secretions 
directly into a vial containing MeOH (5 mL) mimicking the parotoid toxin, left for 60 min. The 
parotoid toxin was then dried under N2 at 40 °C, partitioned between n-BuOH and H2O. The dried 
n-BuOH layer solubles was resuspended in MeOH to a standard concentration (1 mg/mL). The 
dried H2O solubles were subjected to derivatization with 2:1 ratio of 2,4-pentanedione and pyridine 
for 6 h at reflux, dried under N2 at 40 °C and resuspended in MeOH to a standard concentration (1 
mg/mL). 
 
3.4.4 Secretion C – parotoid secretions squeezed into H2O (Figure 3.15) 
 
Parotoid glands (three) from three cane toads were squeezed to obtain the parotoid secretions 
directly into a vial containing H2O (5 mL), gradually mixed until the solution is partially 
homogenized and left for 60 min. The parotoid secretion was then dried under N2 at 40 °C, 
partitioned between n-BuOH and H2O. The dried n-BuOH layer solubles was resuspended in 
MeOH to a standard concentration (1 mg/mL). The dried H2O layer solubles was subjected to 
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derivatization with 2:1 ratio of 2,4-pentanedione and pyridine for 6 h at reflux, dried under N2 at 40 
°C and resuspended in MeOH to a standard concentration (1 mg/mL). 
 
3.4.5 Toxin A – microgland extracted in MeOH (Figure 3.19) 
 
Individual parotoid microglands were dissected from parotoid glands, washed with PBS, weighed 
and were directly immersed into a vial containing MeOH (500 µL). The microgland was disrupted 
using a pipette tip to release the parotoid toxin into MeOH and left for 60 min, dried under N2 at 40 
°C, partitioned between n-BuOH and H2O. The dried n-BuOH layer solubles was resuspended in 
MeOH to (50 µL). The dried H2O layer solubles was subjected to derivatization with 2:1 ratio of 
2,4-pentanedione and pyridine for 6 h at reflux, dried under N2 at 40 °C and resuspended in MeOH 
(50 µL). 
 
3.4.6 Toxin B - microgland extracted in H2O (Figure 3.23) 
 
Individual parotoid microglands were dissected from parotoid glands, washed with PBS, weighed 
and were directly immersed into a vial containing H2O (500 µL). The microgland was disrupted 
using a pipette tip to release the parotoid toxin into H2O and left for 60 min, dried under N2 at 40 
°C, partitioned between n-BuOH and H2O. The dried n-BuOH layer solubles was resuspended in 
MeOH (50 µL). 
 
3.4.7 Secretion D – rate of hydrolysis of bufotoxin (Figure 3.25) 
Left parotoid glands (three) from three cane toads were squeezed to obtain the parotoid secretions 
directly into a vial containing H2O (5 mL), gradually mixed until the solution is partially 
homogenized. An aliquot of sample (500 µL) was obtained for each time interval ranging 5, 10, 15, 
20 and 30 min and quenched with MeOH (500 µL). 0 min reading was obtained by squeezing the 
right parotoid gland into a vial containing MeOH (5 mL). The parotoid secretion was then dried 
under N2 at 40 °C, partitioned between n-BuOH and H2O. The dried n-BuOH layer solubles was 
resuspended in MeOH to a standard concentration (1 mg/mL). 
 
3.4.8 Toxin C – co-localization of hydrolase within microgland (Figure 3.29) 
 
Parotoid glands were excised and individual microglands were cut using micro-scissors from the 
basal epithelium by destroying surrounding microglands, washed with PBS and were directly 
immersed into a vial containing H2O (500 µL). The microgland was disrupted using a pipette tip to 
	   174	  
release the parotoid toxin into H2O and left for 60 min, dried under N2 at 40 °C, partitioned between 
n-BuOH and H2O. The dried n-BuOH layer solubles was resuspended in MeOH (50 µL). 
3.4.9 Imaging in situ parotoid toxin in parotoid microglands (Confocal imaging) 
 
Parotoid microglands were dissected from parotoid glands as mentioned above, washed twice with 
sterile H2O and were directly immersed in cold PBS solution containing 4% formaldehyde. Parotoid 
microglands were later immersed into a solution of Nile red stain (10 µg/mL; 300 µL) and 
incubated for 10 min. Nile red treated parotoid microglands were then washed twice with PBS to 
remove excess nile red and was fixed using a cover slip with 50% glycerol. The sample was then 
observed using a confocal microscope (Zeiss, Australia).  
 
3.4.10 Imaging in situ parotoid toxin in parotoid microglands (Electron 
microscopy) 
Parotoid microglands were dissected from parotoid glands as mentioned above and were washed 
with 4% formaldehyde solution in PBS and immersed in sodium cacodylate buffer containing 3% 
glutaraldehyde.  
3.4.11 Stability of marinobufotoxin in plasma 
 
Human plasma was kindly provided by Dr. Abishek Iyer (Prof Fairlie Group, IMB, UQ). 
Marinobufotoxin (100 µM) was made up to 1 mL with human plasma (450 µL) and incubated for 
various time intervals (0 – 60 min) at 37 °C. The enzymatic activity at each time interval was 
investigated by the addition of n-BuOH to form a bi-phasic mixture and the organic layer was 
extracted (2x). The organic layers were combined and dried under a stream of N2 at 40 °C, re-
dissolved in MeOH (50 µL).  
3.4.12 Half-life of marinobufotoxin in plasma 
 
Human plasma was kindly provided by Dr. Abishek Iyer (Prof Fairlie Group, IMB, UQ). 
Marinobufotoxin (100 µM) was made up to 1 mL with human plasma (450 µL) and incubated for 
various time intervals (1, 2, 4, 6, 8, 10, 12, 16, 20 and 24 h) at 37 °C. The enzymatic activity at each 
time interval was investigated by inhibiting the reaction, n-BuOH was added to form a bi-phasic 
mixture and the organic layer was extracted (2x). The organic layers were combined and dried 
under a stream of N2 at 40 °C, re-dissolved in MeOH (50 µL).  
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Graphpad Prism was used to generate t1/2 curves (One phase decay) for marinobufotoxin (1c) with 
area under the peak calculated at different concentrations. Relative amounts of marinobufotoxin 
(1c) were determined by calculating the area under the peak analysed using HPLC-DAD.  
3.4.13 Stability of marinobufotoxin in saliva 
 
Human saliva was collected from the research candidate (Mr. Venkatanambi Kamalakkannan). 
Marinobufotoxin (100 µM) was made up to 1 mL with human saliva (450 µL) and incubated for 
various time intervals (0 – 60 min) at 37 °C. The enzymatic activity at each time interval was 
investigated by inhibiting the reaction, n-BuOH was added to form a bi-phasic mixture and the 
organic layer was extracted (2x). The organic layers were combined and dried under a stream of N2 
at 40 °C, re-dissolved in MeOH (50 µL).  
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Chapter 4: Isolation, identification and characterization of 
enzyme mediating toxin hydrolysis 
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4.1 Introduction 
 
The in situ parotoid toxin is rapidly converted into bufagenins in secretions obtained after manual 
compression, most likely by the action of a co-secreted bufotoxin hydrolase (BtH). Chemical 
analysis of the parotoid microglands (Chapter 3) clearly indicated if a BtH is present it is localized 
in the vicinity of the basal epithelium to which the microglands are attached, and that during manual 
compression of the parotoid gland or predatory attack BtH is likely to be co-secreted with toxin. 
Toledo et al has previously reported the anatomy of B. marinus parotoid gland and commented on 
the presence of proteins, along with bufadienolides and biogenic amines.1  Likewise, Jared et al 
detected protein-like substances in specialized glands (differentiated granular glands) in the vicinity 
of the parotoid microglands in Rhinella jimi (Brazilian toad),2 situated just above the parotoid 
glands near the exit pore, which would allow for co-secretion of protein (BtH) with the parotoid 
toxin.2   
 
Although new to our understanding of toad chemical ecology, the concept of an enzyme-toxin co-
secretion model has been reported as a part of the defense mechanism exhibited by bombardier 
beetles. In that instance, the substrate hydrogen peroxide is stored in a separate chamber which is 
then mixed with the catalase/peroxidase to produce free oxygen, which in turn oxidizes, 
hydroquinone to p-quinone resulting in a highly exothermic reaction reaching about 100 °C.3, 4 
While there are no reports describing the co-secretion of hydrolases and cardiotonic steroids as a 
defense mechanism, the identification of such a hydrolase in B. marinus would provide valuable 
insights into the ecological role and chemo-anatomy of the parotoid gland. For example, that a 
hydrolase (BtH) could convert a storage protoxin (bufotoxin) to a defensive toxin (bufagenins) 
represents an intriguing possibility.   
 
Parotoid secretions reported in chapter 3 suggested localization of an in situ parotoid gland 
hydrolase (BtH). To detect in situ as well as ex situ BtH we explored the use of a fluorescent stain 
and subjecting parotoid gland preparations to fluorescent imaging. We also employed 
transcriptomics analyses to acquire the RNA sequence dataset from which we translated protein 
sequence information. Purification of BtH from parotoid secretions was achieved using gel filtration 
chromatography with the help of a fluorescent indicator. Structure-activity-relationship studies on 
BtH were performed using various bufadienolide substrates, to determine substrate specificity. 
Kinetics studies showed rapid hydrolysis of bufotoxin by BtH as identified previously in Chapter 3. 
Purified BtH was also subjected to peptide mass fingerprint analysis, which was correlated with 
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protein sequence information from transcriptome analyses, to characterize the complete sequence of 
BtH (Scheme 4.1).  
 
 
Scheme 4.1 Identification and characterization of parotoid gland hydrolase 
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4.2 Results and discussion 
 
4.2.1 Fluorescein aided detection of hydrolase activity in parotoid secretions  
 
The preliminary experiments on cane toad toxin suggested that a hydrolyzing enzyme (BtH) in the 
parotoid gland was co-secreted during manual compression resulting in rapid hydrolysis of 
bufotoxins into bufagenins and arginyl amides. For easy and rapid detection of hydrolase activity in 
situ (localization of hydrolase) and ex situ (isolation of hydrolase) a highly reactive fluorescent 
stain, fluorescein diacetate (FdA) (which is often used to detetect hydrolases) was used. We 
anticipated and confirmed that bufotoxin hydrolase (BtH) would accept fluorescein diacetate (FdA) 
as a substrate and release the fluorescent dye, fluorescein (Figure 4.1).  
 
 
Figure 4.1 Conversion of fluorescein diacetate to fluorescein by the hydrolase in the presence of H2O 
 
FdA could be hydrolysed by the parotoid secretion suggesting a hydrolase enzyme with broad 
specificity was present in the secretion. Having fluorescent diacetate (FdA) as a BtH responsive 
dye, we analyzed the location, biochemistry and structure of BtH. Parotoid secretion from an adult 
cane toad was collected in a vial containing PBS (pH 7.4) and mixed gently using a vortex.  An 
aliquot (1 mL) was centrifuged to remove non-polar substances (including bufadienolides) and the 
supernatant was collected and reacted with a solution of FdA (50 µg/mL; 100 µL) and left for 15 
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min. The supernatant exhibited strong fluorescence activity within 5 min of incubation indicating 
that BtH did accept FdA as a substrate (Figure 4.2). Due to its specificity and rapid reaction time 
with BtH, FdA was seen as a useful reagent that could be used to visualize the localization BtH 
within the parotoid gland.  
 
 
Figure 4.2 Reaction of crude parotoid secretions pellet with fluorescein diacetate exhibiting no fluorescence (left) and 
supernatant exhibiting strong fluorescence (right) 
 
 
4.2.2 Identification of BtH 
 
4.2.2.1 Structure of parotoid gland and microglands 
 
Parotoid glands are large secretory glands that store parotoid toxin, and on manual compression 
release the stored toxin through numerous pores. Several anatomical studies have been reported on 
parotoid glands, describing their physical as well as biochemical features. Several lipids, proteins, 
carbohydrates and cell wall components have been described by Toledo et al,1 Jared et al2 and 
Hutchinson et al,5 in an effort to better understand the storage of toxin within the parotoid gland. 
Notwithstanding prior studies, we elected to reexamine this matter – particularly in light of our 
revelations regarding bufotoxin hydrolysis. We explored the histology of the parotoid gland and its 
cellular/organelle components using several imaging techniques, including those listed in Table 4.1. 
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Table 4.1 List of stains and specificity 
 
Stain Specificity 
Trichrome cells, connective tissue and cytoplasm 
PAS polysaccharides (eg. glycogen) and mucinous 
substances (eg. Mucous and glycoproteins) 
 
Alcian blue acidic polysaccharides (eg. 
glycosaminoglycans) 
and mucinous substances 
 
DAPI DNA 
Congo red cytoplasm and erythrocytes 
Mucicarmine Microorganisms (cell wall components) 
 
A trichrome staining of the parotoid gland revealed the structure of distinct parotoid microglands 
(pm), small granulated glands (gg) and a rich structural framework of collagen and cells scattered 
upon different regions (Figure 4.3). The contents of parotoid microglands (rich in bufotoxins) did 
not show any positive reaction to trichrome stain indicating the absence of cells or connective tissue 
within the parotoid microglands.  
 
  
Figure 4.3 Trichrome staining of B. marinus parotoid gland, bright red – nuclei, pinkish red – cytoplasm, green – 
connective tissue. A – basic structures of parotoid gland exhibiting parotoid microgland (pm), differentiated granular 
glands (dg), connective tissue (CT), granular gland (g), mucinous glands (m), bar – 500 µm. B – expansion of the toxin 
exit duct (texd) connecting ductal epithelium (d) of parotoid microgland to the pore on parotoid skin, bar – 10 µm. 
 
This staining showed that the basic anatomy of the B. marinus parotoid gland consists of a 
structural framework similar to the Brazilian toad, Rhinella jimi. The main structures of the parotoid 
gland include those listed in Table 4.2. 
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Table 4.2 List of anatomical structures in parotoid gland  
 
Code Structure Description 
pm large parotoid 
microglands   
bottle shaped glands containing parotoid toxin 
d ductal epithelium    duct at the apex of the parotoid microgland with dense 
cellular material  
gg granular glands   small granulated glands containing secretory material  
dg differentiated 
granular glands 
large granulated glands at the apex of parotoid microgland 
adjacent to the ductal epithelium and  
c connective tissue thick dense connective tissue consisting of collagen fibers 
ed exit duct duct connecting the microgland to the toxin exit pore 
s secretion secretory material within dg 
m mucous glands scattered glands with mucinous secretions along the dermis 
e epidermis thick calcified epidermis 
n nuclei   nucleus within cells  
ge glandular epithelial 
cell 
epithelial cells present within differentiated granular glands 
me myo-epithelial cells epithelial cells distributed in the surface of parotoid 
microglands  
k keratinocyte keratin containing cells present in the proximity of 
epidermis 
 
Histology of large parotoid microglands with Alcian blue, PAS, H&E and mucicarmine stains 
showed the secretion is highly positive to Alcian blue (Figure 4.4A) and mucicarmine while 
negative to PAS and H&E. These investigations clearly indicated the presence of polysaccharides 
(eg. mucopolysaccharides) within the parotoid microgland. This observation also indicated that 
substances such as carbohydrates are present in substantial amounts in the parotoid microglands, 
however, their function is currently unknown. The walls of the parotoid microgland showed the 
presence of high amounts of nucleated cells (thick red portion, Figure 4.3A). Hostetle et al had 
previously proposed that such cells were responsible for the biosynthesis of bufadienolides, 
although there is no direct evidence to support this hypothesis.6 Alcian blue (Figure 4.4A) and 
Congo red (Figure 4.4B) revealed that parotoid microglands have foam like internal structures.  
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Figure 4.4 Differential staining of parotoid microglands exhibiting foam like appearances. A – Alcian blue staining, B 
– Congo red staining. Bars – 20 µm  
 
The differentiated granular glands (dg) present adjacent to the ductal epithelium (Figure 4.3) were 
structurally different from the mucous (m) and the granular glands (gg) (Figure 4.5 E). The 
differentiated granular glands consist of four glands that are arranged in a circular form around the 
ductal epithelium. Some of these glands exhibited secretions positive to PAS staining (Figure 4.5B, 
Figure 4.5F), however, the nuclei of the cells (n) in the surrounding epithelium exhibited positive 
DAPI (Figure 4.5A), Congo red (Figure 4.5D) and Alcian blue staining. A trichrome staining of 
differentiated granular glands (dg) clearly indicated the presence of secretory material (s) and 
surrounded by secretory epithelium with two different cell types, nucleated and non-nucleated 
epithelial cells (Figure 4.5C). The differentiated granular glands were also previously proposed to 
contain proteins based on their reaction with bromophenol blue by Almeida et al and Toledo et al, 
however no biochemical characterization of the proposed proteins were performed.1,7 The function 
of these differentiated granular glands is largely unknown. This was of major interest to our 
investigation to detect and identify the tissue locality of a potential BtH. Based on the location of 
these glands, we hypothesized that BtH is stored in and co-secreted from differentiated granular 
glands along with the toxins upon manual pressure on the parotoid glands.  
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Figure 4.5 Imaging of parotoid glands using various stains. Clockwise, A – DAPI staining of parotoid gland exhibiting 
parotoid microgland (pm) devoid of cells, ductal epithelium (d) and differentiated accessory glands (dg) at the apex of 
the parotoid microgland, bar – 500 µm. B – PAS stain positive secretion (s) in the differentiated accessory gland with 
possibly two different cell types, the surrounding glandular epithelial cells (ge) and cells with nuclei (n), bar – 50 µm. C 
– parotoid gland stained with trichrome displaying islets of differentiated accessory glands (dg) filled with cytoplasmic 
secretion (s) and dense connective tissue (c), bar – 100 µm. D – differentiated accessory glands stained with Congo red 
exhibiting two cell types as with other stains, PAS and trichrome, bar – 50 µm, E – a trichrome staining indicating 
granular gland (gg) and small mucous gland just below the epidermis filled with secretion (s) and differentiated cells 
(n), bar – 50 µm, F – wall of the parotoid microgland stained with Congo red indicating the myo epithelium (me) and 
abundance of cell types (n) in the inter-vesicular space. 
 
4.2.2.2 Localization of BtH  
 
The presence of a potential BtH within the parotoid gland was investigated using fluorescent 
microscopy and FdA. Sections of parotoid gland was cut using a microtome and mounted on glass 
slides and were treated with FdA (10 µg/mL; 1% DMSO), followed by imaging using a confocal 
microscope with the long pass filter set for an emission wavelength of 505 and 560 nm.  
 
A transmission (transmitted light image) exposure showed the presence of the vesicle containing 
toxin with four differentiated granular glands arranged in a circular form adjacent to the apex of the 
vesicle (narrow passage) filled with secretion as described above (Figure 4.6A). The presence of 
collagen around the parotoid glands and mucous glands lying under epidermis were also identified. 
The differentiated granular glands (dg) contain thick epithelial cells and secretion that was also 
highly reactive to PAS (Figure 4.6B).  
 
Staining with FdA exhibited fluorescence of the secretion contained within the differentiated 
granular glands (Figure 4.6B). The surrounding layer filled with collagen around parotoid 
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microglands exhibited fluorescence, probably due to the leakage from the differentiated glands 
while preparing the tissue sections, or due to BtH non-specific fluorescence. Since the differentiated 
glands containing BtH is present in a close vicinity to the parotoid microgland and the toxin exit 
duct (attached to the pore), it is ideally positioned for the co-secretion with parotoid toxin. Auto-
fluorescence of the tissues was also investigated, to confirm that the fluorescence exhibited by the 
secretion within the differentiated glands is not an artifact (due to non-specific fluorescence by 
FdA) or associated with some tissues (such as collagen, extracellular matrix, etc.) which can exhibit 
auto-fluorescence without addition of any fluorescent stain.8 An auto-fluoresence image (without 
addition of FdA) clearly indicated fluorescence exhibited by the in situ secretion is not an artifact, 
even though the secretory epithelial cells (Figure 4.6C) within the differentiated glands exhibited 
some auto-fluorescence.  
 
 
Figure 4.6 Confocal image of differentiated granular glands in the parotoid gland containing granulated cells and in situ 
secretion. A – transmission exposure, B – staining with fluorescein diacetate (arrow indicates the localized 
fluorescence), C – auto fluorescence. Bars – 900 µm 
 
4.2.3 MALDI imaging on parotoid glands 
 
Spatial localization of bufotoxins within the parotoid microglands was identified by imaging mass 
spectrometry, using a MALDI mass spectrometer fitted with a light microscope. Parotoid glands 
from two toads were excised and immediately snap frozen with liquid nitrogen followed by 
treatment with formalin and fixation using microwave to deactivate any enzymatic activity. 
Enzymatic activity was disrupted to inhibit the conversion of bufotoxins to bufagenins during the 
handling of the parotoid glands. Sections of parotoid gland were cut using a microtome, mounted on 
a MALDI-plate (CHCA matrix) and subjected to simultaneous imaging using mass spectrometry 
and a light microscope (imaging mass spectrometry). Overlapping the ionization pattern with the 
image obtained showed the spatial distribution of bufadienolides in the parotoid microglands 
(Figure 4.7).  
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The major ion detected in the total positive ion current corresponded to marinobufotoxin (1c) (713.2 
Da, [M+H]+) (Figure 4.7B), which correlated with our previous studies on the chemical profiling of 
the parotoid toxin. Marinobufotoxin was identified as the most abundant bufadienolide within the 
parotoid microgland. The second most abundant ion (699.2 Da, [M+H]+) (Figure 4.7C) correlated to 
bufalitoxin (3c), and was also identified to be present around the same regions as marinobufotoxin, 
indicating the storage of bufotoxins is evenly distributed within the parotoid microglands. 
Interestingly, the observation is also in agreement with our earlier findings where marinobufotoxin 
(1c) was identified as the most abundant bufotoxin followed by bufalitoxin (3c) (Chapter 3). 
 
 
 
Figure 4.7 Imaging mass spectrometry of parotoid glands with in situ parotoid toxin rich in bufotoxins. A – light 
microscopy image, B – spatial distribution of marinobufotoxin (1c) C – spatial distribution of bufalitoxin (3c), D – 
spatial distribution of marinobufagenin (1a). Bars – 100 µm 
 
By contrast, the search for the mass of marinobufagenin (1a) (401.2 Da, [M+H]), the dominant 
bufagenin in the secretion, showed a spatial distribution outside of the parotoid microgland just 
above the toxin exit duct (Figure 4.8). This observation was consistent with BtH mediated 
hydrolysis of residual bufotoxin during the handling of the parotoid gland while preparing sections 
using microtome.  
Imaging mass spectrometry showed different spatial distribution of bufotoxins and bufagenin within 
the parotoid gland, supporting our earlier findings on the storage and delivery of the parotoid toxin. 
This observation along with confocal imaging (Figure 4.6) suggests that BtH is localized in 
individual glands, physically separated from the parotoid microglands.  
A B 
C D 
	   189	  
4.2.4 Isolation of BtH from B. marinus parotoid secretions 
 
Scheme 4.2 Preparation of analytes A55 – A58 
Parotoid secretions from each parotoid gland of two cane toads were squeezed into phosphate 
buffer saline (PBS). The parotoid secretion C (see Chapter 3) was subjected to homogenization 
(syringe) followed by ultrasonication to rupture any vesicles and generate analyte A55. A55 was 
centrifuged to remove tissue and cell debris, and the supernatants were separated as A56, while the 
cellular pellet was re-suspended in PBS to generate A57. A solution of FdA (50 µg/mL; 1% 
DMSO) in H2O was prepared as a reagent to detect and purify BtH.  
 
Proposed BtH mediated fluorescence was detected in the supernatants (A56), whereas pellet 
suspensions (A57) exhibited very little fluorescence. A56 was subjected to ultrasonication (5 min) 
after which it was concentrated using Amicon filters (10 kDa cut off) to remove molecules <10 kDa 
(eg. bufadienolides and biogenic amines) to generate analyte A58. Fluorescence generated by FdA 
hydrolysis was mediated by a potential hydrolase that was present in fractions A56 and A58 
(Scheme 4.2). An SDS PAGE fractionation of all the analytes A55 – A58 was performed on a 
12.5% SDS (sodium dodecyl sulfate) gel using Tris buffer at pH 7.4 (Figure 4.8) to separate the 
proteins based on charge and molecular masses. Samples were applied with a loading dye to help 
track the protein mixture. A molecular mass standard was also included to compare the molecular 
mass of proteins in the analytes. This analysis revealed bands at 10 kDa, 25 kDa, 50 kDa, 100 kDa 
and 150 kDa as prominent in all analytes. The concentrated fraction (A58) which exhibited 
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hydrolytic activity (<5 min) contained three prominent bands correlating to molecular masses of 25 
kDa, 50 kDa and 100 kDa. 
 
Figure 4.8 SDS PAGE analysis of analytes A55 – A58 in Tris buffer 
 
A58 was then subjected to size exclusion chromatography to separate the proteins based on their 
size (or molecular mass), using a Superdex S-200 column containing 150 mM NaCl, 20 mM 
Na2HPO4 at pH 7.4. The fractions collected from gel filtration chromatography of A58 generated 
analytes A59 – A64 (Scheme 4.3). The analytes were subjected to SDS-PAGE as well as FdA 
monitoring to identify the active fraction containing BtH. The active fraction was further purified 
by gel filtration chromatography (Scheme 4.3). 
 
Scheme 4.3 Preparation of analytes A59 – A65 and their biochemical analysis 
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Figure 4.9 Chromatogram showing the absorbance of various proteins present in the parotoid secretions using gel 
filtration chromatography, S-200 column. A59 – A64 denotes the fractions that were collected. Blue – absorbance at 
210 nm, green – absorbance at 280 nm 
 
Six fractions were collected during the gel-filtration based purification (Figure 4.9) and all of them 
were investigated for the hydrolase activity using FdA. The fluorescence was detected using a UV 
transilluminator at an excitation wavelength of 254 nm. BtH mediated hydrolase activity was 
localized in A62 (Figure 4.10). A62 was concentrated using an Amicon filter (10 kDa cut off) to 
remove any residual small molecules (including bufadienolides and biogenic amines) and was 
subjected to SDS PAGE analysis to reveal a mixture of three proteins (Figure 4.11). Although, A61 
and A62 eluted close to each other on gel filtration chromatography (Figure 4.9), A61 did not show 
any hydrolytic activity when treated with FdA. Furthermore, SDS-PAGE analysis revealed the 
presence of a 100 kDa band in A62, not seen in A61. From this data we hypothesize that the 100 
kDa band observed in A62 is BtH.  
 
 
Figure 4.10 Fluorescence exhibited by A62 (left) and A61 (right) measured using FdA as the substrate after incubation 
for 10 min at 37 °C.  
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Figure 4.11 SDS PAGE analysis of A61 and A62 collected using gel filtration in Tris buffer. 100 kDa (possibly BtH) 
band is highlighted in red 
 
Further purification of A62 using size exclusion chromatography (S-200 column) fitted to an FPLC-
DAD gave two peaks identified as A62a and A62b. Both peaks were collected and reacted with 
FdA to reveal that only A62b exhibited BtH activity (Figure 4.12).  
 
 
Figure 4.12 Purification of the active protein (A62b) using gel filtration chromatography, S200 column. Blue – 210 nm, 
green – 280 nm 
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Scheme 4.4 Analyses of A62b. 100 kDa band is highlighted in red 
 
 
A62b was subjected to SDS-PAGE (reducing) as well as Native-PAGE (non-reducing) analyses to 
confirm purity (Scheme 4.4). To achieve these analyses, A62b was concentrated using Amicon 
filter (10 kDa cut off) and subjected to SDS – PAGE to reveal two protein bands, corresponding to 
molecular masses 100 kDa and 50 kDa respectively, with the former being more prominent (higher 
concentration) (Figure 4.14). As SDS PAGE analysis involves denaturation/reduction of protein 
prior to analysis this can generate protein bands corresponding to monomeric units of an oligomeric 
protein, leading to the possibility that the 50 kDa was a monomer of a 100 kDa dimer.  
 
To explore this hypothesis, a Native-PAGE (non-reducing) analysis was performed on A62b 
without prior denaturation. Native PAGE analysis clearly showed the presence of only one protein 
with a molecular mass of 100 kDa (Figure 4.15), suggesting that a protein with mass 100 kDa is 
BtH.  
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4.2.5 Hypotheses 
 
Based on the findings shown above we present two working hypotheses:  
 
Hypothesis SDS-PAGE Native-PAGE 
1 
      
 BtH 100 kDa                                               50 kDa  
      dimer                                       monomer 
 
BtH 100 kDa dimer 
2 
  
 
      
 BtH 100 kDa                      50 kDa 
 
BtH 100 kDa                   100 kDa dimer 
 
Figure 4.13 Summary of hypotheses 1 and 2 
 
4.2.5.1 Hypothesis 1  
 
A62b consists of a single protein that can exist in both monomeric (50 kDa) and dimeric (100 kDa) 
forms. Both species are observed under SDS PAGE analysis, but only the dimeric species is evident 
under Native PAGE analysis. The dimeric species exhibits hydrolytic activity and can be 
characterized as BtH (Figure 4.13). 
 
 4.2.5.2 Hypothesis 2  
 
A62b consists of two proteins of molecular weight 100 kDa and 50 kDa. Under SDS-PAGE 
analysis both species can be characterized and the hydrolytic activity associated with BtH is 
uniquely attributed to the 100 kDa protein. Under Native PAGE analysis the 50 kDa protein exists 
exclusively as a dimeric species, which co-elutes with (but is not associated with) BtH (Figure 
4.13).  
 
While we have demonstrated that BtH co-expresses with parotoid secretion and facilitates the 
hydrolysis of bufotoxins to bufagenins, it is interesting to speculate on the possible biosynthetic 
versatility of this protein. It is well established that enzymatic reactions can be reversible, 
suggesting that BtH may also have a role in the biosynthetic conversion of bufagenins to bufotoxins 
(ie. as an esterase) (Figure 4.14). Irrespective of its dual potential (hydrolase/esterase), following 
manual compression and secretion of toxin, there should be an upregulation of the biosynthesis of 
 
 
 
 
 
 
+ 
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both the toxic bufadienolides and BtH. To explore this possibility we turned our attention to a 
transcriptomic analysis. 
 
 
Figure 4.14 Plausible role of BtH in hydrolysis and esterification  
 
4.2.6 Identification of BtH – a proteomic/transcriptomic approach 
 
4.2.6.1 Transcriptomics of parotoid gland 
 
 
Scheme 4.5 Preparation of analytes A66 – A69 
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The left parotoid gland of a female cane toad was subjected to manual compression leading to 
secretion of toxin. This toad was allowed to respond to this insult for 72 h, after which the left 
parotoid gland was excised and processed to generate analyte A66 (Scheme 4.5). As a negative 
control, the right parotoid gland from the same toad was then squeezed and excised immediately to 
generate analyte A67 (Scheme 4.5). RNA from both parotoid glands was isolated using a modified 
protocol from the supplier (Qiagen) followed by mRNA enrichment using immobilized oligo(dT) 
beads to generate analytes A68 and A69 from the left and right parotoid glands, respectively. The 
compressed parotoid gland (A68) would mimic a “stimulated” gland with the biosynthesis of 
bufotoxins and BtH “up-regulated”, whereas the uncompressed parotoid gland (A69) would 
correspond to an “unstimulated” gland with biosynthesis of bufotoxins and BtH unaffected. 
Enriched mRNA were isolated from A68 (19.7 ng/mL) and A69 (16.7 ng/mL) and cDNA libraries 
constructed and subjected to Ion torrent PGM (Life Tech) sequencing. Ion torrent sequencing is one 
of a high throughput sequencing technology where a complementary dNTP (deoxyribonucleotide 
triphosphate) is added to the growing template DNA strand resulting in a release of hydrogen ions 
and pyrophosphate (as by products). Release of H+ interacts with the in-built ion-sensitive sensors 
(eg. ISFET) resulting in an electronic signal, which is then processed by the in-built software to 
determine the nucleotide sequence of the entire library. The transcriptome is a dynamic 
phenomenon and changes over time.  Ion torrent sequencing provides an RNA-seq that indicates the 
status of the transcriptome under study at a given instant. An illustration of the processes as applied 
to cane toad parotoid glands is shown in Scheme 4.6. 
 
Scheme 4.6 Identification of protein sequences exhibiting high expression profiles from parotoid gland transcriptome 
 
The transcriptome from A68 exhibited > 280,000 high quality reads, while A69 exhibited >400,000 
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extending to 500 bp. The transcriptome assembly for A68 and A69 exhibited 2.3Mbp and 3.8Mbp 
consensus length, respectively. Gene ontology and annotations were performed for 5,725 contigs 
from A68 and 9,374 contigs from A69 which were assembled using CLC Genomics workbench 
using standard Ion Torrent assembly parameters. A large set of >1,000 enzymes were identified 
from both transcriptomes, with most involved in common processes such as cell division, transport, 
protein synthesis, etc. A significant differential gene expression pattern for specific enzymes 
involved in the biochemical pathways was observed between both A68 and A69, however, due to 
the vast set of data and limited amount of time, the relationship between the entire parotoid gland 
transcriptome and biochemical pathways is not elaborated in this thesis, which instead focuses on 
the sequence identification of the protein of interest, BtH.  
 
The relative gene expression level was obtained by comparison of the number of reads and 
consensus lengths for each contigs from RNA-seq libraries obtained from A68 and A69. A69 
exhibited high levels of expression of specific contigs (proteins) that we hypothesized may coincide 
with BtH. Tables 4.3 and 4.4 illustrate the contigs that exhibited high levels of expression in A68 
and A69, respectively. The Contig that showed highest expression levels from A68 (contig 22) was 
also observed at higher expression levels in A69 (contig 37), and was attributed to a protein with a 
molecular mass of 100 kDa consistent with that attributed to BtH (Figure 4.15). Of note, A69 
revealed another protein of high abundance (contig 61) with the molecular mass of 50 kDa (Figure 
4.17). Both these high abundance gene sequences were translated to their protein sequence using 
ProteinPilot® and are illustrated in Figure 4.16 (100 kDa) and Figure 4.18 (50 kDa). 
 
Table 4.3 Proteins that exhibited high expression levels in A68 (>2000 reads) 
 
Sequence Number of reads 
Consensus 
length 
Function 
contig 84 7517 1899 type 2 cytoskeletal 75-like 
contig 14 3932 2180 type 1 cytoskeletal 17 
contig 22 2883 2885 Pfam 115-like 
contig 15 5399 1485 heat shock cognate 71kDa 
contig 111 2085 2755 
nicotinamide n-
methyltransferase 
(protein with unknown function highlighted in red) 
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Table 4.4 Proteins that exhibited high expression levels in A69 (>2000 reads) 
 
Sequence Number of reads 
Consensus 
length 
Function 
contig 79 6837 3185 
nicotinamide n-
methyltransferase 
contig 61 5042 1768 galactoside-9 
contig 157 4144 1754 
Eukaryotic translation 
elongation factor 1 α1 
contig 131 3683 1184 type 2 cytoskeletal 75-like 
contig 54 3493 1553 heat shock cognate 71kDa 
contig 46 3452 1809 type 1 cytoskeletal 17 
contig 37* 3406 883 Pfam 115-like 
(protein with unknown function highlighted in red, * represents various isoforms of the protein with different 
expression levels) 
 
CCAACTTGGCTCCTTTTCTTTGAGGATCCTCTCCTCCTGTCCTAAGCTGTGGTACATGATCGCTAATACAATATCATAATTGCCTTACA
TTGTATTGAAGTTTTGGGACAGTTATCAAGAAATCATGTTGACTAATGAAGATTACGCCTCACTTACCAAAGGCATCCAGAATCTGAAT
TTCACAGGAGACAGTATCCCTTGTAGGCTTCTTCTTACTGGTGACACAGCATTCCCAGTACTGGAGACTCCTGCAAACAATGTTCTCAT
TGCTGCATCCAGATACGGCAAGGGACGCTTGGTTGTCATGAGCCATGAATCATATTTGAATGATCCACAATTTATGGATTTTCTGCAGA
ATGCAATATCCTGGTTGAAACCATCCTCAGAAGCAGTAATTGGCATTGAAAACAGCCTAGGTCTTTTGGCAGACACTCTGTCTAACTCT
GGACATAGAATTGACACGACCTCTGGCTTTAAGGAAGATTTGGGAGTGTTCTGCATGACACAATATAATGAAAGCCAGTTATCAGAAGT
TGTGTTATTTTTGAAGGAAGGTGGTGGTCTCCTTATTGGAGCTGAAGCCTGCCATTGGTCTGAAAGCCACCCAGAATTAAATGTTTTCT
TTGATTTTCCTGGAAACAAAATAACATCTGTAGCTGGTGTCTATTTCACTAATAAGACTGGAGAAAATGGGATTTTCCCAGCGAGTGAG
AAACCACCACCATTTCCATCTTTTAATGATGTGGACTTCTCCATGGACCTAAAACAGATCTTCAATGGGCTATCCAGTCTGGATGTTAG
TGGGGATGCTGGTGCATCTGAACTCCTACTACACGGACCTTTGACTTTTCCACTTGGACTGACTAACAGCAACCAATGTTTTTTTGGTG
CTGCATACTATGGCCGAGGACGTGTTGTAGTGGGGCCACATGAAGGCTACATTACAAGACTACAGCTGAAGTCTTTTATCCTGAATGCC
ATTTCGTGGCTGGATGCGGGAAGAAATGGGATGATTGGTGTTCAAAATGCAATGCGAGGCCTGATTCCCATACTGCAGGCTGAGGGTAT
CTCTTGTGCGACGTCCAATGTGAGTTCTGAATTCAGCATTTATTGTTGCAATTCTTATAGTGATGCTGAAGTAGACAAAATCCATCAGT
TTGTTGCAGAAGGAGGAAGTCTTCTCATTGCTGGCCATGCCTGGTACTGGTCTTACTCCCATTCAGATGTTCCTTCTCAGTATCCAGGA
AACAAAATCCTCAATAGATTTGGGATAACCATTCTGGAAAGCACCATAAACAATGGCATTTACAAAGTTCCTGAGTCAACTACTAATTC
ATATCATTTTCTCAGATCAATCTGTCAGTTTCTGAGAGACTTGAAAAATGGAGTGGAGATTAAACCCCCTCTAAGCTCCTGGTTATCAA
AGCTCAGACAAGATGTCGCGACCTATCTGAAGTTGCCTGCCACACCTCTTAGGGTGTCCCTATGGCAAGAACTTTTAAATCTGGTACAA
AATTGTAATTTACCAGAAGTGAGCAAAGAGCATCCAGTGAAAAGCCAATCCAAAGAGGCTTTTCTAATCTGTTTGGCTCAAGAAGTCGA
CTGCTTTTATGACTCATTTCAAGAGGACGCAGGAGAGCTTGATATTCAAGGAGAACCCATACATGTAGATATTGATGGCACAAATCCTG
GTGGTGATGCATGGAGAAGTACAGGGCTATACTTGCCTCCTAACAAAAAAGGAAAACTGGTATTTCCATCCTCAGCTGTGGGAAATGGT
CTCCAGGTACAAATTGGTTGTCAGTCCGATAACCTGAGCGGAGCATCAGAGTATTGTCGTGCTCCAGTGGTTGTACATAGAAAGAATGT
TGTTCGCGAGGAGGTTGTGATATCCTGTATCTGGGGAGGACTTCTTTATGTTATTGTAAAGGGGAAGAGTGAACTGGGAAATATTCCAG
TTACAATTTATGGGGCAGAACCAGCTCCAACATTTATAAATGGACAAACTAATGTTTCTTCGTGGTTGGATACATTACGCACCTCAACA
TCTCCTTGGGCTGAGCTTATTACAGAGGATATTATCCTGACTGTCCCTACTGATAAAGTCCGCTCACTAGAGGATCCTGAATCACTTAT
GTGTTTATGGGACAACATCATGTCTACAATAGCTGATCTGGCAGCTATCCCAAAGAAAATGCCTCGTCCAGAAAGAATTGTGGCCGATG
TTCAGATCTCAGCAGGTTTTATGCATGCTGGATACCCAATAATGTGCCATGTGCCAACATCAACTTCTTTAGTAACTGTTACATCATTG
AAGAGTGGCATGTGGGGGGCTGCACATGAGCTTGGCCACAACCAGCAGAGAGGAGTTTGGGAATTCCCTCCTCACACCACAGAAGCCAC
CTGTAATCTGTGGTCAGTATATGTGCATGAAATCTTGCTGGGGATCCCAAGGGATAAAGCTCATCCTGCTCTCAAGCCGGGAGACAGAG
AACAAAGAACCAAGCAGTATGTGAAGAATGGAGCCAAACTTGATGAGTGGAACGTGTGGACAGCGCTTGAGACTTATCTTCAGCTACAA
GAGGGCTTTGGTTGGGATCCCTTCAAGCGGGTTTTCTCAGAGTATCAAACCATGTCCAACGTCAGTAATAACAAGAATGTTAAGATGAA
TCTTTGGGCAGAGAAGTTCTCTCAAGCAGTTGATAAGAACCTGGCTCCATTCTTTCAGGCCTGGGGATGGCCCATTGATGATGCTACCA
GCAACAAATTATCCACATTAAGTGAATGGGAAGAGAATCCAATGAAGAAATATGTCAGCTAAATTTCATTAAAGAAATATATAAAATGA
TCCTTCTATATTAATAAGCTTTCAGTGGCTTAAGAGG 
 
Figure 4.15 Calculated nucleotide sequence of 100 kDa protein with high expression in A68 (contig 22) and A69 
(contig 37) 
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MLTNEDYASLTKGIQNLNFTGDSIPCRLLLTGDTAFPVLETPANNVLIAASRYGKGRLVVMSHESYLNDPQFMDFLQNAISWLKPSSEA
VIGIENSLGLLADTLSNSGHRIDTTSGFKEDLGVFCMTQYNESQLSEVVLFLKEGGGLLIGAEACHWSESHPELNVFFDFPGNKITSVA
GVYFTNKTGENGIFPASEKPPPFPSFNDVDFSMDLKQIFNGLSSLDVSGDAGASELLLHGPLTFPLGLTNSNQCFFGAAYYGRGRVVVG
PHEGYITRLQLKSFILNAISWLDAGRNGMIGVQNAMRGLIPILQAEGISCATSNVSSEFSIYCCNSYSDAEVDKIHQFVAEGGSLLIAG
HAWYWSYSHSDVPSQYPGNKILNRFGITILESTINNGIYKVPESTTNSYHFLRSICQFLRDLKNGVEIKPPLSSWLSKLRQDVATYLKL
PATPLRVSLWQELLNLVQNCNLPEVSKEHPVKSQSKEAFLICLAQEVDCFYDSFQEDAGELDIQGEPIHVDIDGTNPGGDAWRSTGLYL
PPNKKGKLVFPSSAVGNGLQVQIGCQSDNLSGASEYCRAPVVVHRKNVVREEVVISCIWGGLLYVIVKGKSELGNIPVTIYGAEPAPTF
INGQTNVSSWLDTLRTSTSPWAELITEDIILTVPTDKVRSLEDPESLMCLWDNIMSTIADLAAIPKKMPRPERIVADVQISAGFMHAGY
PIMCHVPTSTSLVTVTSLKSGMWGAAHELGHNQQRGVWEFPPHTTEATCNLWSVYVHEILLGIPRDKAHPALKPGDREQRTKQYVKNGA
KLDEWNVWTALETYLQLQEGFGWDPFKRVFSEYQTMSNVSNNKNVKMNLWAEKFSQAVDKNLAPFFQAWGWPIDDATSNKLSTLSEWEE
NPMKKYVS 
 
Figure 4.16 Translated protein sequence of 100 kDa protein with high expression in A68 (contig 22) and A69 (contig 
37) 
 
CTTCCTTCGGAGCCTGCAGTGAACGATCTGTAGCGCCCCTGTGGCAGTAGATGGGCTGACTTGTTGGGACTCAATGCTCCTTTATTTTA
AGAAACTCTGAAGTTATCTGTCAGCTTTACCAGTCAAAATGTGTGACGAAATCATCAAGAATCCCCCTGTTCCATACGTCACCCATTTT
CACAGTGGCATCAAGAATGGCAGCGTGTTTGTTATAAGCGGCACCGTCCTTCCCTCGGCCGAAGGGTTTATGGTCGATTTCCAGTGTGG
TACTCTTGGAAATGCTGACATTGCCTTCAATTTCAATCCACGTTTTAATGAAGGACATGTTCTTCTTAACACACGGCAGAACAATGTAT
GGAGCCCAGATGAAAATAGGTACAAGGTGCCATTTGCTAAGGAACAACCTTTTGAAATCCAGGTCCTAGTTACAGACCAAGAATATAAA
GTTTTTGTTAATAAAATATTCTTTTTGGATTATCCTCACAAAATTCCTCTGGCCAAAGTCTGTGCTTTTGGGGTAAAGGGCGATGTGAC
TCTAAGTTGTGTGGAGATCCAACCACAAATGATTGGATTCCATCATCAATATTTTCCAGAAGGACAACAGGAAAACACTCTTCCATTTG
GCACCCAGTTTCCTAGTGAAATCAAAGTTGGCACAGTGTTTATTATCAATGGCACTATCCCTCCATTACCTGACAGGTCTTACATCAAT
TTCATGTGTGGTAGTGACATAGATGATGATATTGCTTTCCATTTCAATCCTCGTTTTGATGAAGAAAAAATCATCTGCAACGCAAAGAG
AAATGGCTTTTATGACGTCAATGAAGAGAGGTCGCCACTGCGACTTAAAAAAGACCAAGCTTTTGAATTCCGGTTCCTAGTTGAAGACC
ATGCATATCAAGTTTCTTTGAATGGAGATGAACTTTTTTATTTTAGTCACAGACTTTCTCCAGACACAGTCAAGAATTTAGTAATAATG
GGCTGTGCTCTTCTGAAAAGCGTTGAGATACAAGCAGAAGCATCTGGATTCCATCATCTTTATTTTCAAGATGAACACATCTCAAAGTC
TGTTCCACTCGTGACCCCGTTTGTGGTTGGCATCAAAGAGGACACCGTGGTTAGGATTCGTGGCACTGTCCTACCAGCGACTAAAAGCT
TCTCCATAGATATCCAATGTGGTGATAAGGACACTGATGACATCGCCTTCCATCTCAATATATTTACTGGTAAAGGACATGTTTCCTGC
AATACAATGGAAAATGAAATCTGGGGGAATGAAGAACTCAAAGAAGAGATGCCATTCAAAAGGGGACAACCTTTTGAAGTCCGGATCCT
ATTCACAAGCCAAGAATACAAAGTTTCTGTGGATAGAAATCGATTTTTGGAATACGGTCACAGAATTCCTATGGAGCGGGTCAACACTT
TGGCAGTACATGGCCGTATTACTGTAAATACTGTGGAGATCAAATCACAAGGGGGTGAATTCCCTTAAAACCTCTCAAAACTGCTGACA
GCTCTGCATAGGTGACGGGAGAGCAGTGTAATCATACCTGGACTGATGGTCATCCATCTTTTATTACCCCTCCCACCGTGATTGCAAGT
GTCCTGGAGGTGGTCCCTTTCTGTTCAGTGCCCTGGCTTCTCTCTACTGAACCGTTCCTTCCTCTCTGCTCTGAATGGCGGCTCTAGCG
TTTTCCTAACTAGCCACTAAAGCTCCATTATGCTGTGCTGATGCAAGAAAATAAATTTAAAAAAAAAATAAAAATAA 
 
Figure 4.17 Calculated nucleotide sequence of 50 kDa protein with high expression in A69 (contig 61)  
 
MCDEIIKNPPVPYVTHFHSGIKNGSVFVISGTVLPSAEGFMVDFQCGTLGNADIAFNFNPRFNEGHVLLNTRQNNVWSPDENRYKVPFA
KEQPFEIQVLVTDQEYKVFVNKTFFLDYPHKIPLAKVCAFGVKGDVTLSCVEIQPQMIGFHHQYFPEGQQENTLPFGTQFPSEIKVGTV
FIINGTIPPLPDRSYINFMCGSDIDDDIAFHFNPRFDEEKIICNAKRNGFYDVNEERSPLRLKKDQAFEFRFLVEDHAYQVSLNGDELF
YFSHRLSPDTVKNLVIMGCALLKSVEIQAEASGFHHLYFQDEHISKSVPLVTPFVVGIKEDTVVRIRGTVLPATKSFSIDIQCGDKDTD
DIAFHLNIFTGKGHVSCNTMENEIWGNEELKEEMPFKRGQPFEVRILFTSQEYKVSVDRNRFLEYGHRIPMERVNTLAVHGRITVNTVE
IKSQGGEFP 
 
Figure 4.18 Translated protein sequence of 50 kDa protein with high expression in A69 (contig 61)  
 
The A68 (contig 22) and A69 (contig 37) were attributed to a protein comprising 897 amino acids 
and a molecular mass of 99 kDa, belonging to an uncharacterized member of the FAM-115 
superfamily of proteins (Figure 4.15). An NCBI blast search of the protein yielded a highest 
homology (88%) hit corresponding to an uncharacterized protein reported from Bufo Bufo 
gargarizans (Asiatic toad) (Figure 4.19).9 A comparison of this protein sequence was performed 
against peptides identified from the shotgun sequencing of BtH (see below), supporting its 
assignment as BtH.  
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Figure 4.19 An NCBI-blast of the highest expressed protein from the stimulated parotoid gland showing similarity to 
Bufo species (as marked in red) 
 
The A69 (contig 61) was attributed to a common protein comprising 454 amino acids and a 
molecular mass of 50 kDa, belonging to lectin superfamily of proteins (Figure 4.15). An NCBI blast 
search of the protein yielded homology hit corresponding to galectin like protein reported from 
Xenopus laevis (African clawed frogs) (Figure 4.20).10 A comparison of this protein sequence was 
performed against peptides identified from the shotgun sequencing of 50 kDa protein (see below), 
supporting its assignment as lectin.  
 
 
Figure 4.20 An NCBI-blast of the highest expressed protein from the stimulated parotoid gland showing similarity to 
galectin like protein from Xenopus laevis 
 
The expression profiles of A69 with two most abundant protein, 100 kDa (BtH) and 50 kDa (lectin) 
correlated with the protein profile of parotoid secretions, A62b (Scheme 4.4). That said, the 
upregulation of BtH post manual compression of the parotoid glands also indicates the plausible 
role played by BtH in the biosynthesis of bufotoxins from bufagenins and arginyl amides. 
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4.2.6.2 Tandem mass spectrometry sequencing of BtH 
 
BtH enriched material (A62b) was fractionated and subjected to shotgun proteomics using mass 
spectrometry. A62b was subjected to SDS PAGE fractionation to resolve two proteins of molecular 
mass 100 kDa and 50 kDa. Both bands were manually cut from the gel and individual gel spots 
from two bands were washed with ultrapure water and destained (40 mM NH4CO3/50% MeCN) 
and dehydrated (100% MeCN). Gel spots were rehydrated in 10 µL of 20 µg/mL proteomics grade 
trypsin (Sigma-Aldrich) and incubated overnight at 37°C. Digests were eluted by washing the gel 
spots for 20 min with each of the following solutions: 20 µL 1% formic acid, followed by 20 µL of 
5% MeCN/0.5% formic acid. Both extracted proteins, 0.75 µg each was processed by LC/MS/MS 
analysis to generate two sets of peptides. MS2 spectra were acquired at a rate of 20 scans/s, with a 
cycle time of 2.3 s, and optimized for high resolution. Precursor ions with m/z between 300 – 1,800 
m/z, a charge of +2 to +5, and an intensity of at least 120 counts/s were selected, with a unit mass 
precursor ion inclusion window of ± 0.7 Da, and excluding isotopes within 2 Da for MS2 spectra. 
MS2 spectra were searched against contigs translated to all six reading frames from both assembled 
transcriptomes (A68 and A69) using Proteinpilot v4.5 (AB Sciex) (Scheme 4.7) which uses a 
sequence template to match experimental MS2 spectra to the theoretical MS2 spectra it has 
generated from the template provided. 
 
 
Scheme 4.7 MS/MS sequencing of 100 kDa and 50 kDa proteins obtained from A62b. 
 
MS/MS sequencing of the tryptic digest of the 100 kDa protein extracted from the SDS PAGE gel 
of A62b revealed 93 individual peptides (Table 4.5) selected using high stringency parameters that 
required >95% sequence confidence (e.g. omitting hits with missed cleavages or ethanoloyl 
modifications) with a predicted mass of 100 kDa. These peptides showed high (100%) sequence 
homology with the putative BtH sequence established by transcriptomic analysis (contig 22, Table 
4.3 and contig 37, Table 4.4), accounting for 65% coverage of the entire sequence (Figure 4.21).  
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Table 4.5 List of peptides generated from tryptic digest of the 100 kDa protein from SDS-PAGE 
fractionation of A62b and LC/MS/MS analysis 
 
 
 
Δ ppm = Theoretical – calculated m/z [M+H] in ppm 
 
 
MLTNEDYASLTKGIQNLNFTGDSIPCRLLLTGDTAFPVLETPANNVLIAASRYGKGRLVVMSHESYLNDP
QFMDFLQNAISWLKPSSEAVIGIENSLGLLADTLSNSGHRIDTTSGFKEDLGVFCMTQYNESQLSEVVLFL
KEGGGLLIGAEACHWSESHPELNVFFDFPGNKITSVAGVYFTNKTGENGIFPASEKPPPFPSFNDVDFSM
DLKQIFNGLSSLDVSGDAGASELLLHGPLTFPLGLTNSNQCFFGAAYYGRGRVVVGPHEGYITRLQLKSF
ILNAISWLDAGRNGMIGVQNAMRGLIPILQAEGISCATSNVSSEFSIYCCNSYSDAEVDKIHQFVAEGGSL
LIAGHAWYWSYSHSDVPSQYPGNKILNRFGITILESTINNGIYKVPESTTNSYHFLRSICQFLRDLKNGVEI
KPPLSSWLSKLRQDVATYLKLPATPLRVSLWQELLNLVQNCNLPEVSKEHPVKSQSKEAFLICLAQEVD
CFYDSFQEDAGELDIQGEPIHVDIDGTNPGGDAWRSTGLYLPPNKKGKLVFPSSAVGNGLQVQIGCQSD
NLSGASEYCRAPVVVHRKNVVREEVVISCIWGGLLYVIVKGKSELGNIPVTIYGAEPAPTFINGQTNVSS
WLDTLRTSTSPWAELITEDIILTVPTDKVRSLEDPESLMCLWDNIMSTIADLAAIPKKMPRPERIVADVQI
SAGFMHAGYPIMCHVPTSTSLVTVTSLKSGMWGAAHELGHNQQRGVWEFPPHTTEATCNLWSVYVHE
ILLGIPRDKAHPALKPGDREQRTKQYVKNGAKLDEWNVWTALETYLQLQEGFGWDPFKRVFSEYQTM
SNVSNNKNVKMNLWAEKFSQAVDKNLAPFFQAWGWPIDDATSNKLSTLSEWEENPMKKYVS 
 
Figure 4.21 Complete sequence of BtH identified from transcriptomics and compared with the data from shotgun 
sequencing of the 100 kDa protein isolated from SDS-PAGE fractionation of A62b. Green – peptides with 99% 
confidence levels, red – peptides with 60% confidence levels, yellow – peptides with <50% confidence levels, grey – 
peptides not identified using shotgun sequencing. 
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With respect to the sequence data attributed to BtH (Figure 4.18), it is interesting to note that no 
known protein family was observed with high sequence homology (blast InterProScan, NCBI). It is 
also interesting to note that the sequence for BtH does not include a “signal peptide” at the N-
terminal, which is normally characterized as a short cleavable peptide sequence to direct proteins 
into the necessary secretory pathway. 
 
A majority of the proteins contain a “signal peptide” at the N-terminal end for targeted delivery. 
Surprisingly, the translated sequence of BtH was lacking an N-terminal signal peptide indicating 
that it could possibly belong to the class of “leaderless secretory proteins”.11 Selected group 
secretory proteins including FGF-1, IL-1 and galectins belong to this class of proteins.11-13 
Eukaryotic proteins are usually secreted through classical secretory pathways involving transport 
and post-translational modifications in endoplasmic reticulum and Golgi.14 Leaderless proteins are 
secreted via non-classical secretory pathway, which is independent of the secretory mechanism 
involving ER-Golgi network.14 The fact that BtH lacks an N-terminal signal that guides its 
intracellular trafficking could suggest that BtH does not traffic intracellularly but is an extra cellular 
protein. This would be consistent with our investigation on the localization of BtH within the 
parotoid gland (Figure 4.6B).  
 
MS/MS sequencing of the tryptic digest of the 50 kDa protein extracted from the SDS-PAGE gel of 
A62b revealed 68 individual peptides selected using high stringency parameters that required >95% 
sequence confidence (Table 4.6) with a predicted mass of 50 kDa. When correlated with the high 
frequency contigs from the transcriptomic analyses of cane toad parotoid gland both pre (A69) and 
post secretion (A68) using Protein Pilot, these peptides showed high sequence homology (100%) 
with a 50 kDa protein, detected in A69 (contig 61, Table 4.4) with 78% coverage of the entire 
sequence (Figure 4.22).  
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Table 4.6 List of peptides generated from tryptic digest of the 50 kDa protein from SDS-PAGE 
fractionation of A62b and LC/MS/MS analysis 
 
 
Δ ppm = Theoretical – calculated m/z [M+H] in ppm 
 
MCDEIIKNPPVPYVTHFHSGIKNGSVFVISGTVLPSAEGFMVDFQCGTLGNADIAFNFNPRFNEGHVLLNTR
QNNVWSPDENRYKVPFAKEQPFEIQVLVTDQEYKVFVNKIFFLDYPHKIPLAKVCAFGVKGDVTLSCVEI
QPQMIGFHHQYFPEGQQENTLPFGTQFPSEIKVGTVFIINGTIPPLPDRSYINFMCGSDIDDDIAFHFNPRF
DEEKIICNAKRNGFYDVNEERSPLRLKKDQAFEFRFLVEDHAYQVSLNGDELFYFSHRLSPDTVKNLVIM
GCALLKSVEIQAEASGFHHLYFQDEHISKSVPLVTPFVVGIKEDTVVRIRGTVLPATKSFSIDIQCGDKDTD
DIAFHLNIFTGKGHVSCNTMENEIWGNEELKEEMPFKRGQPFEVRILFTSQEYKVSVDRNRFLEYGHRIP
MERVNTLAVHGRITVNTVEIKSQGGEFP 
 
Figure 4.22 Complete sequence of 50 kDa protein identified from transcriptomic analysis and compared with shotgun 
sequencing of the 50 kDa protein isolated from SDS-PAGE fractionation of A62b. Green – peptides with 99% 
confidence levels, red – peptides with 60% confidence levels and grey – peptides not identified using shotgun 
sequencing. 
 
On performing an NCBI-BLAST search for the identified sequence, it returned several homologous 
to lectin reported from Xenopous laevis. An Interpro search for the identification of the function of 
the protein revealed the major part of the sequence showed homology to carbohydrate recognition 
domain of galectins and also to concanavalin A like lectins (Figure 4.23). A literature search 
performed on lectins showed their ability to form dimers that exhibit galactoside-binding activity.15, 
16 The presence of lectin proteins in the parotoid glands in situ could be attributed to the presence of 
rich amounts of polysaccharides6 since lectins bind to carbohydrates. This observation clearly 
identified the mixture of another protein present along with BtH. The sensitiveness and reliability of 
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transcriptomics combined with proteomic analysis played a vital role in identifying the co-eluting 
protein.  
 
 
Figure 4.23 Complete sequence of the 50 kDa protein identified from partial sequencing, transcriptomics and 
comparison with InterProScan protein database showing part of the sequence similarity to lectin like superfamily  
 
4.2.6.3 Further purification of A62b 
 
The protein mixture was concentrated to 1 mg/mL in Tris buffer at pH 8.0 and was injected to an 
anion exchange resin column (Mono S HR 5/5), with a linear gradient of 100 – 1000 mM NaCl. 
Identification of two distinct peaks would have indicated the presence of two different proteins as 
determined by our transcriptomic analysis. Surprisingly, only one narrow peak was observed. From 
the UV absorbance, the sample was thought to contain just one protein, 100 kDa. However, an SDS 
PAGE analysis of the single peak exhibited two bands, 100 kDa and 50 kDa, respectively. The 
observation clearly indicated the presence of two proteins co-eluting again on the anion exchange 
resin. A search on ExPasy database (ProtParam) for BtH and the lectin protein sequences returned 
the theoretical pI of the proteins to be 5.28 and 5.48, respectively. Since both the proteins had 
similar pI it was difficult to separate the proteins based on ion exchange chromatography (Figure 
4.24).  
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Figure 4.24 Purification of the active fraction of BtH containing 100 kDa and 50 kDa proteins using anion exchange 
chromatography at pH 8.0 
 
4.2.7 Phylogenetic analysis 
 
Homologous sequences from different species identified by BLAST were correlated with BtH 
sequence information to identify the phylogenetic relationship. Since there is not much information 
about the BtH protein family, a phylogenetic analysis would be significant in two ways: (1) 
identification of homologs (similar proteins) from various species – to identify species specific 
distribution of the homologs and (2) grouping of homologs based on age as well as function – this 
analysis would lead us to identify any functional relationship with other known proteins from 
different/same species.  
 
There was no species-specific clustering of the sequence homolog identified from the phylogenetic 
analysis, with several species ranging from birds, amphibians and mammals exhibiting a match with 
BtH (Figure 4.22). A sequence homolog is the part of the query protein sequence that exhibits 
homology with BtH and it is ranked based on the degree of homology (%):  
 
• Closely related species are shown in the first cluster consist of the Asiatic toad (Bufo 
gargarizans) and a frog (Xenopus silurana), (i.e. amphibians) (homology score of 100%). 
An unknown protein from B. gargarizans showed the closest match followed by a FAM115-
like protein from Xenopus silurana (Figure 4.25). 
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Figure 4.25 First cluster of phylogenetic tree for BtH 
 
• Closely related species shown in the second cluster (homology score 99%) includes the 
orders Cetaceae, Carnivora, Artiodactyla, Perissodactyla and Rodentia (Figure 4.26).  
 
 
Figure 4.26 Second cluster of phylogenetic tree for BtH 
 
• Closely related species shown in the third cluster (homology score 85 – 100%) include 
Primates (i.e. orangutan, chimpanzee, human, gorilla, marmoset and monkey) (Figure 4.27).     
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Figure 4.27 Third cluster of phylogenetic tree for BtH 
 
Majority of the hits that showed sequence homology to BtH were exclusively identified to be 
member of the FAM115 protein family, which have only been predicted by genome sequencing. 
The full-length protein sequence homology exhibited by the matched hits was only in the range of 
43 – 58%, except for an unknown protein identified by gene sequencing from B. gargarizans 
(88%). Such low homology levels also indicated that BtH could belong to new class of protein and 
the current investigation also indicates the high sequence conservation in BtH. The phylogenetic 
tree was generated with Danio rerio  (Zebrafish) sequence (NP_001082796.1) as the root while all 
the other homologs were matched based on the sequence similarity with the BtH. No other known 
protein family showed a match with BtH. 
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Figure 4.28 Phylogentic analysis of BtH showing matches with conserved sequences reported from different species 
exhibiting sequence homology and phylogenetic distance from the related homologs. 
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4.2.8 Kinetics of BtH – measurement of Vmax and Km values for the hydrolysis of 
bufotoxins by in situ hydrolase 
 
Previous observations showed the BtH mediated hydrolysis of bufotoxins to bufagenins was rapid. 
To quantify this process we set out to determine the rate kinetics of Vmax and Km, where Vmax 
denotes the maximum rate of the reaction at maximum substrate concentration, while Km denotes 
the substrate concentration at which half maximal Vmax is achieved. Subsequently the values were 
calculated to be Vmax = 22.0 µmoles/min/mg of BtH and Km = 182 nM.  
 
As the BtH substrate (bufotoxin) is non-fluorescent and the substrate (bufotoxins) and the product 
(bufagenins) have virtually identical UV-Vis spectra, we elected to use HPLC-DAD methodology 
to determine the rate of BtH hydrolysis of bufotoxins to bufagenins. The BtH hydrolysis of the 
marinobufotoxin (1c) was measured at specific time points by quenching BtH activity by the 
addition of MeOH to the reaction mixture. Each time point reaction mixture was dried, re-dissolved 
in MeOH to a standard concentration (50 µL) and analysed using HPLC-DAD Method 1 (see 
Chapter 2). The conversion of marinobufotoxin (1c) to marinobufagenin (1a) was determined by 
calculating the area under the curve as described in Chapter 2 and Chapter 3. All BtH hydrolysis 
reactions were performed at 37 °C using A62b fraction (containing lectin). Hence the actual kinetics 
of BtH must be higher than the value measured using the cuurent assay system.  
 
Firstly, the rate kinetics of BtH was determined by monitoring the hydrolysis of 1c into 1a time 
period by various concentrations of hydrolase. Final assay volume was 200 µL and the triplicates 
for each concentration of BtH was maintained with time intervals ranging from 0 – 10 min. A 
standard minimum concentration of marinobufotoxin (1c) was determined (62.5 µM) based on the 
UV absorbance using Method 1 as previously determined (Chapter 2).  For each time interval 50 µL 
of the reaction was obtained and immediately quenched with MeOH (100 µL) to inhibit the 
hydrolysis. The resulting mixture was dried under N2 at 40 °C and was re-dissolved in MeOH (500 
µL) and filtered and again dried under N2 at 40 °C and was re-dissolved in MeOH (50 µL) and 
analysed using Method 1.  
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Figure 4.29 Rate kinetics of parotoid gland hydrolase (BtH) for the hydrolysis of marinobufotoxin (1c) at various 
concentrations 
 
Number of moles of 1a formed post the hydrolysis of 1c was calculated for every 10 min (Figure 
4.29). A graph was plotted between the number of moles of 1a formed by various concentrations of 
BtH and the slope corresponded to the half maximal value, which was 0.4 µg/mL for 62.5 µM of 
1c. Concentration slightly lower than half maximal value was selected because at lower 
concentrations of BtH, saturation of binding sites could be achieved by increasing concentrations of 
substrate, 1c. Hence, 0.2 µg/mL of BtH was the optimum concentration to determine the rate 
kinetics of the bufotoxin hydrolysis (in triplicates). 
 
A constant concentration of BtH (0.2 µg/mL) was exposed to varying concentrations of 1c and the 
hydrolysis was monitored for various time intervals (0 – 60 h). Rate of hydrolysis of 1c was 
determined for about 10 time intervals with triplicates for each. Various concentrations of 1c was 
exposed to hydrolysis, with concentrations ranging between 0 – 125 µM. Final assay volume was 1 
mL and for each time point 50 µL of reaction mixture was pipetted out into 100 µL of MeOH to 
inhibit the hydrolysis. The resulting mixture was dried under N2 at 40 °C and was triturated with 
MeOH (500 µL) and filtered and again dried under N2 at 40 °C and was re-dissolved in MeOH (50 
µL) and analysed using HPLC-DAD using Method 1. 
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Figure 4.30 Calculation of Km and Vmax value for the BtH (parotoid gland hydrolase) for the hydrolysis of 
marinobufotoxin (1c) at various concentrations 
 
The specific activity of BtH was calculated for each concentration of 1c by determining the number 
of moles of marinobufagenin (1a) formed per min per mg of BtH (Figure 4.30). The number of 
moles of 1a formed from 1c was determined by calculating the area under the peaks from the 
chromatogram (298 nm) obtained from HPLC-DAD. From the graph the Vmax was 22.0 
µmoles/min/mg of BtH and Km value was calculated to be 182 nM. A low Km value suggests the 
high affinity of BtH for the substrate, while high Vmax value determines the high rate of reaction. 
Preliminary analysis of hydrolysis observed in cane toad secretions also showed high rate of 
hydrolysis as 94% of bufotoxin in the parotoid secretions converted into bufagenins in 5 min, which 
is consistent with the current observation  
 
4.2.9 Structure-activity-related studies on BtH 
 
Parotoid gland hydrolase (BtH) was investigated for structure activity related studies with various 
bufadienolide moieties to understand and compare substrate specificity for bufotoxins and related 
structures. Reactivity of BtH with marinobufagenin esters with varying side chain lengths including 
marinobufagenin-3-acetate (8b), marinobufagenin-3-succinate (9b), marinobufagenin-3-suberate 
(1b), bufolipin A (1h) (isolation from eggs, described in chapter 6) and marinobufotoxin (1c) was 
investigated. A known amount of substrate (50 µg) was incubated with BtH (2 µg) for 60 min at 
room temperature and the reaction was stopped by the addition of MeOH. The reaction mixture was 
then dried under N2 at 40 °C, subjected to n-BuOH/H2O partition and the n-BuOH layer was 
collected and dried under N2 at 40 °C, re-dissolved in MeOH and analysed using Method 1.  
Surprisingly, following 60 min of incubation with BtH, 87% of marinobufagenin-3-hemisuberate 
(1b) (Figure 4.31A) was hydrolysed to marinobufagenin (1a) and 94% of marinobufotoxin (1c) was 
hydrolysed to marinobufagenin (1a) (Figure 4.31B). Only 2% of marinobufagenin-3-acetate (8b) 
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was hydrolysed to form marinobufagenin indicating that shorter chain length at C-3 would hinder 
the function of BtH (Figure 4.32). In the case of marinobufagenin-3-succinate (9b) (Figure 4.33A) 
and long chain fatty acid ester, bufolipin A (1h) (Figure 4.33B), no hydrolysis was observed with 
BtH even after incubation for 60 min indicating that both short and long chain esters are resistant to 
hydrolysis by BtH.  
 
 
   
Figure 4.31 HPLC chromatograms (298 nm) indicating the structure based hydrolase activity of BtH with (A) 
marinobufagenin-3-suberate (1b) (B) marinobufotoxin (1c) 
 
 
Figure 4.32 HPLC chromatogram (298 nm) indicating the structure based hydrolase activity of BtH with 
marinobufagenin-3-acetate (8b) 
 
 
By comparison the analogues featuring a suberate moiety, marinobufagenin-3-suberate (1b) and 
marinobufotoxin (1c) alone exhibited high levels of hydrolysis (>90%) to form marinobufagenin 
(1a). These analyses clearly indicate that BtH exhibits specificity for substrates with suberate 
moieties (1b and 1c) (n = 6) possessing 6 methylenes, but disfavours substrates with lesser/higher 
chain lengths such as acetate (n = 1), succinate (n = 2) and a long chain fatty acid (n = 13) (Figure 
4.34). 
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Figure 4.33 HPLC chromatograms (298 nm) indicating the structure based hydrolase activity of BtH with (A) 
marinobufagenin-3-succinate (9b) and bufolipin A (1h) 
 
 
Figure 4.34 structure activity based relationship activity exhibited by BtH on various bufotoxin analogues with short 
and long chain variants 
 
 
4.2.9.1 Inhibition of hydrolase activity by suberoyl-L-arginine 
 
Preliminary investigations on the structure activity based function of BtH indicated that bufotoxins 
possessing suberoyl-L-arginine conjugate at the C-3 exhibited high specificity. This could be 
possibly due to the binding properties exerted by the suberoyl-L-arginine moiety on BtH, and 
suggests that free suberoyl-L-arginine may be a competitive inhibitor of BtH (Figure 4.35).  
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Figure 4.35 Hypothesis – suberoyl-L-arginine influences the binding characteristics of bufotoxins on BtH 
 
To test the hypothesis, BtH was first incubated with suberoyl-L-arginine and/or arginine to compete 
for the binding sites in BtH, followed by the addition of marinobufotoxin (1c). Inhibition of the 
hydrolysis of 1c would demonstrate whether suberoyl-L-arginine or L-arginine were competitive 
inhibitors of BtH. A UV absorption minimum was previously determined for the detection of 
marinobufotoxin (1c) (62.5 µM) using HPLC-DAD at various concentrations. The ideal 
concentration of hydrolase (10 µg/mL) for the hydrolysis of bufotoxins was also previously 
established.  
 
Suberoyl-L-arginine (100 µL) and L-arginine (100 µL) at various concentrations, ranging from 7.8 
µM (0.125× bufotoxin) to 1.25 mM (20× bufotoxin) were added to BtH (10 µg/mL) in duplicate 
and incubated for 15 min at 37 °C followed by the addition of 62.5 µM (100 µL) of 
marinobufotoxin (1c). The reaction was incubated for another 15 min at 37 °C. The hydrolase 
reaction was stopped by the addition of MeOH (300 µL) and the reaction mixture was dried in 
vacuo and triturated with MeOH (500 µL) to solubilize bufadienolides. The MeOH soluble fraction 
was dried in vacuo and re-dissolved in MeOH to a standard concentration (1 mg/mL) and analysed 
using Method 1 (Figure 4.36). 
 
The HPLC-DAD based analysis of inhibition of BtH showed that suberoyl-L-arginine (1d) was a 
competitive inhibitor of BtH mediated hydrolysis of 1c while L-arginine failed to inhibit 1c 
hydrolysis (Figure 4.36). This observation suggests that during the hydrolysis of bufotoxins the 
released suberoyl amides could downregulate BtH hydrolysis of bufotoxins, however, in an 
ecological context it remains questionable whether this is likely to impede the conversion of 1c to 
1a.  
 
O
O
O
O
H
H
OHH
N
O
O CO2H
NH
NH2H2N
BtH
	   216	  
 
Figure 4.36 Inhibition of BtH mediated hydrolysis of marinobufotoxin (1c) in the presence of suberoylarginine (1d) 
and L-arginine (L-arg). Ctrl – 1c + BtH, arrows point to the hydrolysis product, 1a. 
 
 
4.2.10 Formation of bufotoxins by BtH (a hydrolase acting as an esterase) 
 
BtH mediated esterification of marinobufagenin (1a) with suberoyl-L-arginine (1d) to form 
marinobufotoxin (1c) would likely be impacted by several factors including substrate, temperature, 
pH, co-factors, hydrophobicity, etc. BtH mediated esterification trailed: 
 
• Substrate ratio – ratios of marinobufagenin (1a) and suberoyl-L-arginine (1d) (1:1, 1:10 and 
1:100). 
• Temperature – 14 °C, 26 °C and 37 °C  
• pH – pH 4, pH 6, pH 7 and pH 9  
• co-factors – with and without co-enzyme A  
• Hydrophobicity – 30%, 50%, 80% and 100% n-hexane/H2O 
 
None of the above experiments exhibited detectable levels of conversion of marinobufotoxin (1c) 
into marinobufagenin (1a). This could be due to various factors such as absence of cofactors 
necessary for the enzymatic activity such as ATP and NADPH or metals such as Cu, Mn, Fe, Zn 
while BtH could theoretically esterify bufagenins, however, our investigations, failed to 
demonstrate conditions under which this esterification could be detected. 
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4.3 Conclusion 
 
Preliminary chemical analysis on cane toad toxins showed insights into the hydrolysis of in situ 
parotoid toxin during manual compression of the parotoid gland and that there is a hydrolase(s) co-
secreted with the parotoid secretions. The key findings included evidence that BtH; 
 
1. Is localized in situ at the apex of parotoid microgland  
2. Co-secreted during the manual compression of the parotoid gland  
3. Mediates rapid hydrolysis of marinobufotoxin  
4. Exhibits high substrate specificity for bufotoxins (marinobufotoxin). 
5. Is upregulated post secretion of toxin from the parotoid gland. 
6. belongs to unreported class of proteins. 
7. Is a 99 kDa protein with 897 amino acids with a sequence as shown in Figure 4.21. 
 
The current studies on the cane toad parotoid gland and the toxins has widened the traditional 
understanding (Figure 4.37 & Figure 4.38) and showed insights into some of the complex 
mechanism involved during the secretion of parotoid toxin. To our knowledge the cane toad 
parotoid chemistry is the first of its kind to accumulate steroidal toxins as “protoxin” that are 
rapidly converted into free steroidal “toxin” by co-secretion of a specific hydrolase.  
 
 
Figure 4.37 Summary on investigations of storage and delivery of cane toad toxins 
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Figure 4.38 A diagrammatic representation of storage and release of parotoid toxin from a parotoid microgland based 
on recent findings 
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4.4 Experimental  
 
4.4.1 Reaction with fluorescein diacetate 
 
A solution of fluorescein diacetate in PBS (50 µg/mL) in 1% DMSO was prepared. Parotoid 
secretions were squeezed into a vial containing PBS (5 mL). An aliquot of parotoid secretion in 
H2O was subjected to centrifugation (4000 rpm) and the supernatant was collected and reacted with 
FdA (100 µL). 
 
4.4.2 Histology of parotoid gland 
 
Parotoid glands from four cane toads were excised and cut into three or four pieces longitudinally 
and were fixed with 4% formaldehyde (pH 7.4, PBS) and embedded in paraffin sections (5 µm) 
stained with Mallory trichome, Haematoxylin Eosin, PAS, Alcian Blue, Congo red and DAPI 
stains. Images were obtained using an Olympus light microscope fitted with a 12 M-pixel digital 
camera.  
 
4.4.2.1 Imaging of BtH 
 
Parotoid glands from a cane toad were dissected and cut into thin sections after exposure to liquid 
nitrogen (−78 °C). The tissue sections were stained with fluorescein diacetate (10 µg/mL in 1% 
DMSO/H2O) for 5 min and were washed three times with PBS to remove excess stain. The tissues 
were fixed with 70% EtOH/H2O followed by washing with xylene. The dry tissues were mounted 
onto wax slides and then cut into 5 µm sections using a vibratome and were imaged under a 
confocal microscope. Confocal microscopy was performed on a Zeiss LSM510 confocal laser-
scanning microscope equipped with a Zeiss 63x/1.4NA oil-immersion objective. Confocal 
microscopy samples were measured with emissions filtered through a 505 nm and 560 nm long-
pass filters. Images were accessed using Image J software (NIH). Images were processed using 
Image J (USA).  
 
4.4.3 Imaging mass spectrometry  
 
Parotoid glands excised from three cane toads were snap frozen in liquid nitrogen (−78 °C). The 
frozen glands were then fixed with RCL/EtOH using a microwave based fixation for 2 min 
followed by stepwise treatment with 70% EtOH/H2O, 100% EtOH and xylene before embedding in 
paraffin. Sections (7 µm) were cut, layered in Indium-Tin Oxide slides (Bruker Daltonics, 
Germany), sprayed with 7 mg/mL α-cyano-4-hydroxycinnamicacid (CHCA) in 50% MeCN and 
	   220	  
0.2% TFA. Spectra were acquired using an Ultraflex III ToF/ToF mass spectrometer (Bruker, 
Germany) using linear positive mode, mass range 0.2 – 8 kDa and a resolution of 80 µm. Images 
were visualized using manufactureser’s inbuilt software, Fleximaging 2.1 (Bruker Daltonics).  
 
4.4.4 Isolation of BtH from parotoid secretions 
 
Parotoid secretions from each parotoid gland of two cane toads squeezed into phosphate buffer 
saline (70 mL) were dispensed into two falcon tubes (35 mL each). The contents of one were 
homogenized using syringes (18 G, 23 G and 30 G), while the contents of the remaining tube were 
ultrasonicated for 2 min. Both the syringe and ultrasonicated fractions were centrifuged at 5000 rpm 
for 15 min and the supernatants collected in separate clean flacon tubes, while the pellets were re-
suspended in PBS. Fluorescein diacetate (50 µg/mL; 1% DMSO) in H2O was prepared to detect the 
hydrolytic activity during the purification of the hydrolase. Supernatant fractions were concentrated 
using an Amicon filter (10 kDa cut off) to workable volume (20 – 30 mL) and an aliquot (1 mL) of 
the concentrated supernatants purified by HPLC (Superdex S-200 column, Isocratic, Phosphate 
buffer comprising 150 mM NaCl, 20 mM Na2HPO4 at pH 7.4, 0.5 mL/min). Proteins were collected 
based on UV absorbance and hydrolytic activity determined by treatment with FdA detected at 500 
nm.  
 
The hydrolytically (FdA) active protein fraction (A62b) was later subjected to purification using a 
gel filtration column (Superdex S-200) fitted to an HPLC-DAD (Superdex S-200 column, Isocratic, 
Phosphate buffer comprising 150 mM NaCl, 20 mM Na2HPO4 at pH 7.4, 1 mL/min) was used to 
isolate active protein from a mixture of proteins. The isolated protein fraction was again subjected 
to reaction with FdA. 
 
The hydrolytically active protein fractions (A62b) were subsequently subjected to purification using 
an anion exchange column fitted to an HPLC-DAD (Mono S HR 5/5 column, linear gradient, 0.1 – 
1 M NaCl in 30 min, Tris buffer comprising 1M NaCl, 100 mM Tris, pH 8.0, 1 mL/min) was used 
to isolate active protein from a mixture of proteins. The isolated protein fraction was again 
subjected to reaction with FdA. Protein concentration was determined by measuring the absorbance 
at 280 nm using a Nanodrop and also by Bradford assay.  
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4.4.5 Kinetics of BtH 
 
4.4.5.1 Optimization of BtH concentration 
 
An aliquot of 62.5 µM of marinobufotoxin (1c) (50 µL) and BtH at different concentrations (0.09, 
0.19, 0.38. 0.76, 1.50 and 3 µg/mL; 50 µL) was added to phosphate buffer to a final assay volume 
to 200 µL and the hydrolysis reaction was allowed to proceed at 37 °C with an aliquot (50 µL) 
collected at 10 min intervals (quenched with MeOH (100 µL) followed by drying under N2 at 40 
°C). The dried reaction mixture was triturated in MeOH (200 µL). The MeOH solubles were 
transferred into a new eppendorf tube and was again dried under N2 at 40 °C, re-dissolved in MeOH 
(50 µL) and analysed using Method 1.  
 
4.4.5.2 Determination of Vmax and Kd values for BtH 
 
An aliquot of BtH (0.2 µg/mL; 250 µL) and marinobufotoxin (1c) at different concentrations (15.6, 
31.3, 62.5, and 125 µM; 250 µL) was added to phosphate buffer to a final assay volume to 1 mL 
and the hydrolysis reaction was carried out at 37 °C with an aliquot (50 µL) collected for each 
minute between 0 – 10 min (quenched with MeOH (100 µL) followed by drying under N2 at 40 °C). 
The dried reaction mixture was triturated in MeOH (200 µL). The MeOH solubles were transferred 
into a new eppendorf tube and was again dried under N2 at 40 °C, re-dissolved in MeOH (50 µL) 
and analysed using Method 1.  
 
Graphpad Prism was used to generate standard curves for individual bufadienolides and amides 
(Section). Relative amounts of bufadienolides and amides were determined by calculating the area 
under the peak using Agilent Chemstation software.  
 
4.4.6 Inhibition of BtH by amides 
 
Suberoylarginine (100 µL) and L-arginine (100 µL) in PBS at various concentrations ranging from 
9.5, 19, 39, 78.5, 156, 312.5, 625, 1250 µM were added to BtH (10 µg/mL; 50 µL) in duplicate 
experiments after incubating for 15 min at 37 °C. Marinobufotoxin (62.5 µM; 100 µL) was added to 
the reaction mixture and was incubated for another 15 min at 37 °C, after which BtH was quenched 
by the addition of MeOH (300 µL) and the reaction mixture was dried under N2 at 40 °C. The 
triturated MeOH (500 µL) solubles at a standard concentration (1 mg/mL) were analysed by 
Method 1 (Figure 4.36). 
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4.4.7 Transcriptomics of parotoid gland 
 
Sample was prepared for sequencing using the Ion Torrent RNA Seq kit, v1, as per the 
manufacturers protocol. In brief, the RNA was fragmented using RNAse III treatment, adaptor 
ligated, reverse transcribed and amplified, and size selected to a median size of ~200bp. 
Templating and sequencing used the Ion Torrent 200 sequencing kits, v2.  Sample was sequenced 
on a 314 chip and the final FASTQ file provided. 
 
4.4.8 Tandem mass spectrometry sequencing of BtH 
 
BtH was subjected to SDS PAGE analysis. Gel spots were washed with ultrapure water, destained 
(40 mM NH4CO3/50% MeCN) and dehydrated (100% MeCN). Gel spots were rehydrated in 10 µL 
of 20 µg/ml proteomics grade trypsin (Sigma-Aldrich) and incubated overnight at 37 °C. Digests 
were eluted by washing the gel spots for 20 min with each of the following solutions: 20 µL 1% 
formic acid, followed by 20 µL of 5% MeCN/0.5% formic acid, followed by LC-MS/MS analysis 
(stable bond C18 column (2.1 mm × 100 mm, 1.8 µm particle size, 300 Å pore size) at a flow of 400 
µL/min and a gradient of 1–40% solvent B (90% MeCN, 0.1% formic acid) in 0.1% formic acid 
over 5 min on a Shimadzu Nexera UHPLC coupled with an AB SCIEX 5600 mass spectrometer 
equipped with a Turbo V ion source heated to 450 °C). Peptide sequences identified by 
fragmentation patterns and assembled using Protein Pilot™ (AB Sciex), were compared with the 
transcriptome of the parotoid gland, with alignment of the protein sequences manually optimized 
using CLC Main Workbench software (CLC bio, Aarhus, Denmark). Sequence similarity and 
function information of proteins was investigated using Inter-Pro science, NCBI-BLAST and 
UniProt databases.  
 
4.4.9 Phylogenetic analysis 
 
Sequences showing similarity to BtH were previously extracted from NCBI database. The final 
dataset contained about 110 sequences. The sequence alignment was performed using MAFFT 
(algorithm). The alignment of the protein sequences were manually optimized using CLC Main 
Workbench software (CLC bio, Aarhus, Denmark). The phylogenetic tree was viewed and 
annotated using Figtree.  
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Chapter 5: The ecological role of microbial biotransformation 
of cane toad toxins 
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5.1 Introduction  
 
Bufagenins are the active ingredients of the Chinese traditional medicine Chansu, which is known 
for several medicinal properties including potent cardiotonic1 and anticancer activity.2 Since the 
bufagenins are potent inhibitors of cardiac Na+/K+ ATPase,3 novel bufagenin analogues that are less 
toxic yet therapeutically significant are highly valued.  
 
Biotransformation of bufadienolides has been widely reported by various bacteria4-6 and plant 
cells7. For instance, cinobufagenin (32a) when exposed to the fungi, Alternaria alternata exhibited 
6 biotransformation products including four oxidized compounds8 while in the presence of 
Syncephalastrum racemosum, 32a yielded 5 products9 and in the presence of Mucor spinosus 32a 
yielded two oxygenated, six hydroxylated and one acetylated product.10  
 
Resibufagenin (4a) when exposed to the cultures of Mucor subtilissimus was converted into 11 
products,4 while exposure to Pseudomonas aeruginosa produced a single product, 3-
oxoresibufogenin.5 In another experiment, resibufagenin (4a) when exposed to Mucor 
polymorphosporus produced 22 biotransformation products.11 Other bufagenins that are included in 
the biotransformation experiment includes marinobufagenin (1a), bufalin (3a) and cinobufagenin 
(32a).  
 
Biotransformation of bufalin (3a) by Mucor spinosus yielded 12 analogues of bufalin.12 
Interestingly, biotransformation of bufadienolides was mostly reported in fungi and one notable 
actinomycetes, Nocardia sp. Tables 5.1 and 5.2 lists literature accounts bufagenin substrates, 
biotransforming organisms and biotransformation products: 
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Figure 5.1 Biotransformation of cinobufagenin (31a) by Alternaria alternata and Mucor spinosus (Bhatti et al., 2012) 
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Table 5.1 List of bufagenins, biotransforming fungi and biotransformation products 
 
Substrate Fungi No of Products Reference 
bufalin (3a) Mucor spinosus 12 12 
 Cunninghamella 
blakesleana 
4 11 
 Alternaria alternata 4 13 
 Penicillium aurantigriseum 2 14 
 Fusarium solani AS 3.1829 1 15 
resibufagenin (4a) Mucor polymorphosporus 22 11 
 Mucor polymorphosporus 18 16 
 Alternaria alternata 2 13 
 Pseudomonas aeruginosa 1 6 
 Pseudomonas aeruginosa 1 5 
 Mucor subtilissimus 1 17 
 Fusarium solani AS 3.1829 1 15 
 Penicillium aurantigriseum 2 14 
bufotalin (30a) Alternaria alternata 3 18 
cinobufagenin (32a) Alternaria alternata 6 8 
 Alternaria alternata 3 13 
 Alternaria alternata 1 19 
 Aspergillus niger 7 10 
 Mucor spinosus 9 5 
 Fusarium solani AS 3.1829 1 15 
 Penicillium aurantigriseum 5 14 
 Syncephalastrum 
racemosum 
5 9 
 
 
Table 5.2 List of bufagenins, biotransforming bacteria and biotransformation products 
 
Substrate Bacteria No of Products References 
resibufagenin (4a) Nocardia sp. 2 20 
cinobufagenin (32a) Nocardia sp 1 20 
marinobufagenin (1a) Comamonas testorsteroni 4 21 
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Figure 5.2 Modifications observed in biotransformation of bufagenins 
 
Reported biotransformations of bufagenins exhibit a similarity as is evident from the 
biotransformation products. For instance, the most commonly observed biotransformation products 
are bufagenins that are 12β-hydroxylated and/or 7β-hydroxylated. Other frequent modifications 
include epimerization or oxidation at C-3, reduction/oxidation at C-5 and oxidation at C-15.  
 
In an ecological context, the biotransformation of bufadienolides offers the potential to broaden the 
chemical diversity of the bufadienolides in the parotoid gland. However, most of the previous 
(published) biotransformation experiments were performed with microbes (fungi) which were not 
sourced from cane toads and hence, the biotransformation products previously reported are absent 
in parotoid secretions. In a recent report, our laboratory described the biotransformation of 
marinobufagenin (1a) by bacteria isolated from the cane toad parotoid secretion.21 In that study, 
bacterial strains from the parotoid gland, ovary, tongue and stomach of a mature female cane toad 
were recovered and grown in liquid cultures in the presence of 1a. The biotransforming strains were 
identified as Comomonas testosteroni, Flavobacterium sp. (both from parotoid gland) and 
Acinetobacter johnsonii (from the ovary).21 C. testosteroni is a gram-negative bacterium that 
utilizes C19 – C27 steroids as its carbon source for growth.22-24 Exposure of marinobufagenin (1a) to 
liquid cultures of Comomonas testosteroni for 96 h, followed by solvent extraction and HPLC-
DAD-ESI-MS analysis, yielded 3-epi-marinobufagenin (17a), 3-oxomarinobufagenin (18a), Δ1,4-3-
oxoresibufogenin (19a) and Δ1,4-3-oxobufalin (20a) (Figure 5.3).  
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This observation supports the hypothesis that bacteria present in the parotoid gland may manipulate 
bufadienolide diversity. This process has the potential to be both advantageous, or disadvantageous 
to toad survival. For example, biotransformation could make the toxin more effective against range 
of predators and/or make it function in both aquatic and terrestrial environments. Alternatively, 
biotransformation could degrade bufadienolide reserves, rendering the toad less able to defend itself 
against predatory attacks. 
 
Figure 5.3 Biotransformation of marinobufagenin (1a) by Comamonas testosteroni. 3-epi-marinobufagenin (17a), 3-
oxomarinobufagenin (18a), Δ1,4-3-oxoresibufogenin (19a), Δ1,4-3-oxobufalin (20a) (Hayes et al., 2009).21   
 
 
Studies described earlier in the thesis revealed that parotoid toxins are stored as bufotoxins and are 
subjected to ex situ hydrolysis by BtH to form bufagenins and arginyl amides. In situ 
biotransformation of bufotoxins by bacteria is also worthy of investigation and are the basis of this 
chapter.  
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5.2 Results and discussion  
5.2.1 Biotransformation of marinobufagenin 
The capacity of Comomonas testosteroni (from parotoid gland) and Acinetobacter johnsonii 
(isolated from cane toad ovaries) to biotransform marinobufagenin (1a) was re-examined.21  The 
strains were cultivated in nutrient broth (section 5.4.1.1) in the presence of 1a and aliquots extracted 
with EtOAc at 24, 48 and 72 h intervals were dried under N2 at 40 °C and re-dissolved in MeOH to 
a standard volume (500 µL) to generate analytes A70 – A72 (Scheme 5.1). These analytes were 
analysed using HPLC-DAD Method 1 (see Chapter 2) (Figure 5.4). Marinobufagenin (1a) extracted 
from nutrient broth was used as a negative control.  
 
 
 
Scheme 5.1 Preparation of analytes A70 – A72 
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Figure 5.4 HPLC traces (298 nm) of analytes A70 - A72 analysed using Method 1. Marinobufagenin (1a), 3-
epimarinobufagenin (17a), 3-oxomarinobufagenin (18a), Δ1,4-3-oxobufalin (19a) and Δ1,4-3-oxoresibufogenin (20a). 
  
C. testosteroni transformed marinobufagenin (1a) into four products, 3-oxomarinobufagenin (18a), 
Δ1,4-3-oxoresibufogenin (19a), 3-epiresibufogenin (17a) and trace amounts of Δ1,4-3-oxobufalin 
(20a) (based on DAD response) as observed previously (Figure 5.4). The HPLC trace of analytes 
A70 - A72 showed marinobufagenin (1a) been depleted with simultaneous increase in the 
concentration of biotransformation products gradually over 72 h.  
 
A. johnsonii strains were cultivated under the same condition as described above for C. testosteroni 
in the presence of marinobufagenin (1a) with sampling at 24, 48 and 72 h intervals generating 
analytes A73 – A75 (Scheme 5.2). Marinobufagenin (1a) extracted from uninoculated nutrient 
broth was used as a negative control. These analytes were analysed using the HPLC-DAD Method 
1 (see Chapter 2) (Figure 5.5). A. johnsonii was found to transform marinobufagenin (1a) into three 
different products, 3-epimarinobufagenin (17a), 3-oxomarinobufagenin (18a) and Δ1,4-3-oxobufalin 
(20a) (Figure 5.5), concurred with the results obtained previously by Hayes et al.21 
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Figure 5.5 HPLC traces (298 nm) of analytes A73 - A75 analysed using Method 1. Marinobufagenin (1a), 3-
epimarinobufagenin (17a), 3-oxomarinobufagenin (18a) and Δ1,4-3-oxoresibufogenin (19a). 
 
 
                               marinobufotoxin (1c)                                    marinobufagenin-3-suberate (1b) 
 
marinobufagenin (1a) 
 
5.2.2 Biotransformation of marinobufotoxin (1c) 
The objective of this study was to determine if Comomonas testosteroni (from parotoid gland) and 
Acinetobacter johnsonii (from ovaries) could biotransform marinobufotoxin (1c).21  C. testosteroni 
strains were cultivated in nutrient broth (as described above) in the presence of marinobufotoxin 
(1c) (10 mg/mL; 50 µL) with n-BuOH extracts prepared at 24, 48 and 72 h intervals dried under N2 
at 40 °C and re-dissolved in MeOH to a standard volume (500 µL) to generate analytes A76 – A78 
(Scheme 5.3). These analytes were analysed using the HPLC-DAD Method 1 (see Chapter 2) 
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(Figure 5.6). Since bufagenins were the expected biotransformation products, Method 1 was applied 
instead of Method 2, which is specific for bufotoxins.  
 
Scheme 5.3 Preparation of analytes A76 – A78 
 
Figure 5.6 HPLC traces (298 nm) of analytes A76 – A78 analysed using Method 1. Marinobufotoxin (1c), 
marinobufagenin hemisuberate (1b) and marinobufagenin (1a). 
 
C. testosteroni cultures exposed to marinobufotoxin (1c) did not show significant biotransformation 
to 1a. A small percentage of 1c was converted into marinobufagenin hemisuberate (1b) (11%) and 
marinobufagenin (1a) (3%) (Figure 5.6). This result suggests that C-3 suberoylarginine conjugates 
are resistant to bacterial biotransformation.  
 
A. johnsonii strains were cultivated in nutrient broth (as described above) in the presence of 
marinobufotoxin (1c) (10 mg/mL; 50 µL) with n-BuOH extracts prepared at 24, 48 and 72 h 
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Method 1 (see Chapter 2) (Figure 5.7). Marinobufotoxin (1c) extracted from uninoculated nutrient 
broth was used as negative control. 
 
 
Scheme 5.4 Preparation of analytes A79 – A81 
 
 
Figure 5.7 HPLC traces (298 nm) of analytes A79 – A81 analysed using Method 1. Marinobufotoxin (1c). 
 
 A. johnsonii cultures did not show biotransformation against 1c (Figure 5.7). These analyses clearly 
indicate that bufotoxins are largely resistant to microbial biotransformation by the two bacterial 
isolates recovered from the parotoid gland.  
 
The above observations suggest that biotransforming bacteria present in the parotoid glands are 
opportunistic as the bacteria could possibly utilize bufagenins in parotoid secretions (post predatory 
attack) as a source of carbon for growth. This observation does not favour the previous hypotheses 
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diversification of parotoid chemistry. However, identification of microbes that could transform 
bufagenins into other bufagenin analogues found in parotoid secretions would be the key to suggest 
diversification of cane parotoid chemistry.  
5.2.3 Biotransformation of marinobufagenin-3-suberate (1b) 
During the biotransformation of marinobufotoxin (1c) by C. testosteroni, it was observed that a 
small fraction was converted into 1b and a much smaller amount into 1a. This raised the possibility 
that if C. testosteroni cultures was exposed to marinobufotoxin (1c) for an extended time period, 
this may convert 1b into 1a. To test this hypothesis, synthetic marinobufagenin hemisuberate (1b) 
(see Chapter 2), was subjected to biotransformation by C. testosteroni (Figure 5.8) and A. johnsonii 
(Figure 5.9). C. testosteroni strains cultivated in nutrient broth (as described above) in the presence 
of 1b (10 mg/mL; 50 µL) were extracted with n-BuOH at 24, 48 and 72 h intervals, and the extracts 
were dried under N2 at 40 °C and re-dissolved in MeOH to a standard volume (500 µL) to generate 
analytes A82 – A84 (Scheme 5.5). These analytes were analysed using HPLC-DAD Method 1. 
Marinobufagenin-3-suberate (1b) extracted from uninoculated nutrient broth was used as a negative 
control. 
 
Scheme 5.5 Preparation of analytes A82 – A84 
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Figure 5.8 HPLC traces (298 nm) analytes A82 – A84 analysed using Method 1.marinobufagenin hemisuberate (1b), 
marinobufagenin (1a), 3-oxomarinobufagenin (18a) and * contaminant.  
 
C. testosteroni cultures exposed to marinobufagenin-3-suberate (1b) did not show significant 
biotransformation (Figure 5.8). The HPLC trace also shows the formation of trace amounts of 1a 
and 18a, the latter as a biotransformation product of 1a (as shown earlier).  
 
A. johnsonii strains cultivated in nutrient broth (as described earlier) in the presence of 1b (10 
mg/mL; 50 µL) were extracted with n-BuOH at 24, 48 and 72 h intervals and the extracts dried 
under N2 at 40 °C and re-dissolved in MeOH to a standard volume (500 µL) to generate analytes 
A85 – A87 (Scheme 5.6). The analytes A85 – A87 were analysed using HPLC-DAD Method 1 
(Figure 5.9). Marinobufagenin-3-suberate (1b) extracted from uninoculated nutrient broth was used 
as a negative control. A. johnsonii cultures exposed to 1b failed to show significant 
biotransformation,  with 14% conversion to 1a over 72 h compared to 15% in the case of C. 
testosteroni.  
 
Scheme 5.6 Preparation of analytes A85 – A87 
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Figure 5.9 HPLC traces (298 nm) of analytes A85 – A87 analysed using Method 1. Marinobufagenin hemisuberate 
(1b), marinobufagenin (1a) and * contaminant. 
 
5.2.4 Biotransformation of other bufagenins 
5.2.4.1 Biotransformation of telocinobufagenin (2a) 
 
As the microbial biotransformation of cane toad bufagenins by the bacteria isolated from parotoid 
glands and ovaries resulted in significant degradation of marinobufagenin we investigated the effect 
on other bufagenins, namely bufalin (3a) and telocinobufagenin (2a). These are the second and 
third most dominant bufadienolides in the cane toad parotoid secretions.  
 
A. johnsonii strains cultivated in nutrient broth (as described earlier) in the presence of 
telocinobufagenin (2a) were extracted with EtOAc at 72 h and the extracts dried under N2 at 40 °C 
and re-dissolved in MeOH to a standard volume (500 µL) to generate analyte A88 (Scheme 5.7). 
Analyte A88 was analysed using HPLC-DAD Method 1 (Figure 5.10). Telocinobufagenin (2a) 
extracted from uninoculated nutrient broth was used as a negative control.  
 
Scheme 5.7 Preparation of analyte A88 
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Biotransformation of 2a (m/z (M+H)+, 403) after 72 h showed the presence of two degradation 
products with m/z (M+H) values 401 and 383 respectively (Figure 5.11). Since 2a is also a similar 
bufagenin to 1a, we anticipated a similar microbial biodegradation. Therefore, the peak 
corresponding to m/z 401 was attributed to the C-3 oxidation product, 3-oxotelocinobufagenin (21a) 
while m/z 383 was attributed to Δ4,5-3-oxobufalin (22a). Hence the biotransformation steps for 2a 
possibly involve the typical oxidation/dehydration products as observed previously for 1a (Figure 
5.12).   
 
 
Figure 5.10 HPLC trace (298 nm) of analyte A88. Telocinobufagenin (2a), 3-oxotelocinobufagenin (21a), Δ4,5-3-
oxobufalin (22a) 
 
Figure 5.11 Single ion-extraction of analyte A88. Telocinobufagenin (2a), 3-oxotelocinobufagenin (21a), Δ4,5-3-
oxobufalin (22a) 
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Figure 5.12 Proposed scheme and biotransformation products of telocinobufagenin (2a) by A. johnsonii. 
Telocinobufagenin (2a), 3-oxotelocinobufagenin (21a), Δ4,5-3-oxobufalin (22a) 
 
5.2.4.2 Biotransformation of bufalin (3a) 
 
Following the successful biotransformation of 2a by A. johnsonii, a sample of bufalin (3a) was 
subjected to degradation by A. johnsonii. A. johnsonii strains cultivated in nutrient broth (as 
described earlier) in the presence of bufalin (3a) were extracted with EtOAc after 72 h, dried under 
N2 at 40 °C and re-dissolved in MeOH to a standard volume (500 µL) to generate analyte A89 
(Scheme 5.8). The analyte A89 was analysed using HPLC-DAD Method1 (Figure 5.13). Bufalin 
(2a) extracted from uninoculated nutrient broth was used as a negative control.  
 
 
Scheme 5.8 Preparation of analyte A89 
 
Biotransformation of 3a (m/z (M+H)+, 387) showed the presence of two degradation products with 
m/z (M+H) values of 387 and 385 respectively (Figure 5.13). A total ion current (negative mode) 
indicated the presence of two bufagenins eluting at the same time with the m/z 385 (Figure 5.14A). 
A single ion extraction revealed the presence of a bufagenin with m/z 387 (Figure 5.14B). Since, 3a 
is structurally similar to 1a, we anticipated a similar response to microbial biotransformation (as 
mentioned above), which permits assignment of m/z 387 as 3-epibufalin (23a). Of note, 3-
epibufalin (23a) was previously reported as a degradation product in the biotransformation of 3a 
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with Penicllium aurantigriseum and Mucor spinosus as well as treatment with human plasma.12, 14, 
25 The second degradation product, which corresponded to m/z 385 was attributed to 3-oxobufalin 
(24a), as observed previously in the biotransformation of 1a and 2a, and an oxidation product of 
either 3a or 3-epibufalin (23a). The biotransformation products of 3a by A. johnsonii matched with 
the biotransformation products of 3a with the fungi Penicillium aurantigriseum.14 Hence the 
biotransformation steps for 3a possibly involve the typical oxidation products as observed with 1a 
(Figure 5.15). 
 
 
Figure 5.13 HPLC traces (298 nm) of A89 analysed using Method 1. Bufalin (3a), 3-oxobufalin (24a) 
 
 
 
Figure 5.14 A – HPLC-DAD-MS analysis revealing total ion current (negative reflectron mode) indicating the presence 
of bufalin (3a), 3-epibufalin (23a) and 3-oxobufalin (24a). B - HPLC-DAD-MS analysis revealing single ion-extraction 
of analyte A89. Bufalin (3a) and 3-oxobufalin (24a) 
 
 
Figure 5.15 Proposed scheme and biotransformation products of bufalin (3a) by A. johnsonii. Bufalin (3a) and 3-
oxobufalin (24a) 
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5.2.4.3 Discussion – biotransformation of bufagenins, bufotoxins and bufagenin-3-suberate 
 
Biotransformation of 1c and 1b by biotransforming bacteria did not show significant modification 
(as in the case of 1a) but a small fraction was transformed into marinobufagenin (1a). This may 
indicate that, only a sub-population of biotransforming bacteria is active against bufotoxins, or that 
the kinetics are very slow and inefficient. This observation also shows why biotransformation 
products of 1a (such as 17a, 18a, 19a and 20a) are not identified in parotoid toxin. Several 
advantages of biosynthesizing toxins as bufotoxins have been considered (see Chapter 3) but one of 
the major concerns was the stability of the toxins to microbial biodegradation. Since the bufotoxins 
are resistant to microbial biotransformation, it is possible that cane toads have developed a strategy 
to resist/overcome the microbial biodegradation of the parotoid toxins by storing bufadienolides as 
bufotoxins. If toxins were stored as bufagenins, the steroid-degrading microbes would thrive in a 
steroid-rich environment leading to the degradation of stored toxins, and adversely impacting the 
chemical defence of the cane toad.  
 
5.2.5 Identification of new bufagenin transforming microbes from parotoid 
gland and secretions 
 
Given the success in documenting the biotransforming properties of the cane toad microbes (C. 
testosteroni and A. johnsonii), an effort was made to isolate additional biotransforming microbes. 
More specifically, consideration was given to isolation and characterization of microbes that could 
modify and diversify the structure of bufadienolides without causing degradation, as such microbes 
would be potent and beneficial to the cane toad.  
 
Parotoid secretion from one of the parotoid glands from two toads was directly squeezed into sterile 
water and an aliquot was directly plated onto a nutrient agar plate and incubated at 26.5 °C for 7 
days. The other parotoid gland from two toads were excised and an incision was made using fine 
scissors on the ventral side and a swab of the cut side was applied to a nutrient agar plate and 
incubated for 26.5 °C for 7 days. Microbial flora on the surface of the parotoid gland were isolated 
using the former approach while the latter method retrieved microbial flora present within parotoid 
gland. A 7-day incubation was deemed estimal as it would reveal both bacteria (unicellular as well 
as sporulating) as well as fungi. Individual colonies were selected and plated on a nutrient agar 
medium and incubated for 2 days for unicellular bacteria, 3 days for spore-producing bacteria and 7 
days for fungi at 26.5 °C. A total of 68 strains were isolated including bacteria (63) and fungi (5) 
based on the morphology of the colonies. 
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Previously, all the biotransformation experiments with bufagenin, bufotoxins and bufagenin 
suberates were performed using microbial culture tubes (5 mL) on the previously isolated two 
active biotransforming strains, C. testosteroni and A. johnsonii. To explore the biotransforming 
potential of a library of 68 strains required a semi-high throughput technique. Hence, a 24-well 
micro bioreactor approach was used to assess such strains capable of transforming marinobufagenin 
(1a). This micro bioreactor based approach was previously optimized by Dr Zeinab Khalil from the 
Capon group. Micro bioreactors are valuable replacements of a traditional shaker flask for the 
cultivation of microbes in low volumes. Various compartments of micro bioreactor is illustrated in 
Figure 5.16. 
 
 
 
 
Figure 5.16 Applikon bioreactor system; (A) traditional shake flasks, (B) 24-well microbioreactor plate, (C) stainless 
steel cover, (D) sandwitch covers, (E)- plate holder 
 
Micro bioreactors consist of a 24 well plate for cultivation of microbes over which goes the 
sandwich covers providing space for aeration. The whole set up is held together by a stainless steel 
cover following which the micro reactors are clamped to a support, which is then subjected to 
constant shaking. Micro bioreactors were previously used for cultivating microorganisms in small 
volumes, however, the growth characteristics and secondary metabolism production is comparable 
with shaker flasks. 17 Hence, the micro bioreactor based cultivation of microbes was performed in 
the presence of a bufagenin while microbes cultured without a bufagenin served as a negative 
New Strategy: Applikon microbioreactor 
(A)  (B) 
(C) 
(D) 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control.  A single colony from the agar plate was picked and cultured onto a nutrient broth in a 
micro bioreactor, sealed with a lid. Marinobufagenin (1a) (15 mg/mL; 3 µL) was added to the 
cultures after 12 h of incubation and further incubated for 36 h for bacteria and 84 h for fungi 
followed by extraction with EtOAc. The EtOAc extracts were dried in vacuo and re-dissolved in 
MeOH (50 µL) to generate analytes A90 – A157, which were analysed using Method 1 (Scheme 
5.9). 
 
 
Scheme 5.9 Preparation of analytes A90 – A157 
 
Only 4 out of 68 strains exhibited an ability to biotransform 1a with two strains (CMB-TD-29 and 
CMB-TD-59) showing significant levels of biotransformation, and the remaining two only 
moderate levels. Interestingly, the two strains that showed highest biotransformation activity were 
isolated from the ventral part of the parotoid gland (in situ) and exhibited similar biotransformation 
products. The morphology of two strains resembled bacteria, one with rough colonies (white) while 
the other with rough to smooth colonies (off-white). Taxonomic classification remains a work-in-
progress. In the former two closely eluting peaks with the same m/z (M+H) value of 417 were 
detected, along with m/z 363 (25a) and m/z 345 (27a) (Figure 5.17). The peak m/z 417 was identical 
to arenobufagenin (6a, m/z 417) previously identified by Hayes et al and confirmed with co-
injection with an authentic standard (in-house library).21 The UV profile of all biotransformed 
	   244	  
products exhibited a characteristic bufadienolide spectrum. Another peak eluting closer to 6a was 
tentatively identified as the C-3 epimer 23a, a biotransformation seen in earlier studies. The two 
bacterial strains also significantly transformed 1a to 6a (44%) and also exhibited moderate 
conversion of 1a to 26a (12%).  
 
 
Figure 5.17 HPLC traces (298 nm) of analytes A119 (green) and A148 (blue) analysed using Method 1. 
Arenobufagenin (6a), m/z 363 Da (25a), m/z 417 (26a) 
 
 
                                                      arenobufagenin (6a)              3-epiarenobufagenin                     
                                                                                                        (possible 26a)                        
 
 
Two bacterial strains, isolated from the exterior of the parotoid gland (ex situ) (CMB-TD22) (A109) 
and the inner part of the parotoid gland (in situ) (CMB-TD37) exhibited moderate and low levels of 
biotransformation of marinobufagenin, respectively. The strains also exhibited the same 
biotransformation products as indicated by the retention of the compounds, m/z values and the UV 
profiles (Figure 5.18). Three compounds were detected but surprisingly all the compounds 
exhibited the same molecular mass, m/z 419 (Figure 5.18). CMB-TD22 (A109) showed moderate 
levels of biotransformation to yield uncharacterized metabolites 28a (11%), 29a (7%) and 30a 
(12%), while CMB-TD37 (A124) exhibited lower levels of transformation to yield 28a (2%), 29a 
(4%) and 30a (4%). 
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Figure 5.18 HPLC trace (298 nm) of A109 derived from CMB-TD22 analysed using Method 1. m/z 419 (28a), m/z 419 
(29a), m/z 419 (30a) 
 
A fungal strain (CMB-TD-42), isolated form the skin of the parotoid gland was cultivated in the 
presence of 1a resulting in lower levels of biotransformation (Figure 5.19). Two biotransformation 
products, 6a and 31a, were identified based on the retention time, m/z values and the UV profile. 
Also, the UV profile of the biotransformation products exhibited a characteristic bufadienolide 
spectrum. The retention time and the m/z value of the peak at tR = 5.7 min also matched with the 
retention time of 6a. 31a was also m/z 417, which tentatively identified as an epimer of 6a as 
described with bufagenins.  
 
Figure 5.19 HPLC trace (298 nm) of A129 derived from CMB-TD42 analysed using Method 1. Arenobufagenin (6a), 
m/z 417 (31a) 
 
Comparison of these most recent biotransformation trial with those reported by Hayes et al. clearly 
indicated the presence of bufagenin degrading microbes in the parotoid glands (from within and 
surface), however, the biotransformation products and the mechanism of degradation of the newly 
isolated microbes were different from that previously described.  
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Figure 5.20 Proposed role of biotransforming microbes in parotoid glands 
 
Based on our observations two types of biotransforming microbes are proposed to be present within 
the parotoid gland, types 1 and 2 (Figure 5.20). Type 1 microbes are proposed to play a role in the 
degradation of bufagenins as reported by Hayes et al.21 That said type 1 microbes are possibly 
opportunistic as they consume bufagenins as carbon source for growth and may also protect toads 
from accumulation of toxic bufagenins. Type 2 microbes are organisms that can potentially 
biotransform bufotoxins such as marinobufotoxin (1c) to yield other bufotoxin analogues such as 
telocinobufotoxin (2c), bufalitoxin (3c) and arenobufotoxin (6c). These microbes could possibly 
play a role in diversification of chemical diversity thereby improving the efficacy to cane toad 
parotoid toxins against diverse predatory species.  
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5.3 Conclusion 
 
• Microbial degradation of bufadienolides by bacteria/fungi from parotoid gland and ovaries 
suggested that bufagenins are prone to biotransformation 
• Bufotoxins are resistant to microbial degradation  
• Identification of bacteria from in situ parotoid gland capable of diversifying bufagenin 
analogues suggesting possible role in the formation of various bufadienolide scaffolds in the 
parotoid toxin 
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Figure 5.21 A diagrammatic representation of storage and release of parotoid toxin from a parotoid microgland based 
on recent findings. In situ bufotoxins are converted to ex situ bufagenins and amides by co-secretion of BtH. The 
converted bufagenins on the surface of the parotoid glands are biotransformed by the steroid-degrading microbes. 
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5.4 Experimental 
5.4.1 Biotransformation of bufadienolides 
5.4.1.1 Materials 
Composition of nutrient agar medium: Peptone (Bacto) 4 g/L, NaCl (Univar) 1.5 g/L and Agar 
(Sigma) 18 g/L in H2O. 
Composition of nutrient broth: D-glucose (Sigma) 10 g/L, peptone (Bacto) 2 g/L, yeast extract 
(Bacto) 4 g/L and NaCl (Univar) 1.5 g/L in H2O.  
5.4.1.2 Growth of previously isolated biotransforming strains 
Biotransforming strains, C. testosteroni. (from parotoid gland) and A. johnsonii (from ovary) were 
previously were stored at −80 °C in 10% aqueous glycerol. The glycerol stocks were thawed at 
room temperature and were streaked onto freshly prepared nutrient agar plates, which were 
incubated at 26.5 °C for 48 h. 
5.4.1.3 Growth of bacterial strains in liquid medium 
A single colony from the previously grown nutrient agar plate was selected and cultured in nutrient 
broth (10 mL) and incubated at 26.5 °C with shaking at 150 rpm until visible turbidity was achieved 
(24 h). 
5.4.2 Biotransformation of marinobufagenin (1a) 
Marinobufagenin in acetone (10 mg/mL; 50 µL) was added to each overnight culture (5 mL) of C. 
testosteroni and Acinetobacter johnsonii which were then incubated at 26.5 °C for further 72 h. 500 
µL of cultures were extracted for every 0 h, 24 h, 48 h and 72 h time period respectively, with equal 
volumes of ethyl acetate (2 × 500 µL) and the organic layers were reduced to dryness under a 
stream of N2 at 40 °C. The residues were redissolved in methanol (100 µL), filtered using 0.45 µm 
PTFE filter and analysed by HPLC-DAD-ESI-MS.  
 
5.4.3 Biotransformation of marinobufotoxin (1c) 
Marinobufotoxin in acetone (10 mg/mL; 50 µL) was added to each overnight culture (5 mL) of C. 
testosteroni and A. johnstoni which were then incubated at 26.5 °C for further 72 h. 500 µL of 
cultures were extracted for every 0 h, 24 h, 48 h and 72 h time period respectively, with equal 
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volumes of ethyl acetate (2 × 500 µL) and the organic layers were reduced to dryness under a 
stream of N2 at 40 °C. The residues were redissolved in methanol (100 µL), filtered using 0.45 µm 
PTFE filter and analysed by HPLC-DAD-ESI-MS.  
5.4.4 Biotransformation of marinobufagenin hemisuberate (1b) 
Marinobufagenin hemisuberate in acetone (10 mg/mL; 50 µL) was added to each overnight culture 
(5 mL) of C. testosteroni and A. johnsonii which were then incubated at 26.5 °C for further 72 h. 
500 µL of cultures were extracted for every 0 h, 24 h, 48 h and 72 h time period respectively, with 
equal volumes of ethyl acetate (2 × 500 µL) and the organic layers were reduced to dryness under a 
stream of N2 at 40 °C. The residues were redissolved in methanol (100 µL), filtered using 0.45 µm 
PTFE filter and analysed by HPLC-DAD-ESI-MS.   
5.4.5. Biotransformation of telocinobufagenin (2a) 
Telocinobufagenin in acetone (10 mg/mL; 50 µL) was added to each overnight culture (5 mL) of C. 
testosteroni, Acinetobacter johnsonii, Acinetobacter sp. and Flavobacterium sp. which were then 
incubated at 26.5 °C for further 72 h. 500 µL of cultures were extracted for every 0 h, 24 h, 48 h 
and 72 h time period respectively, with equal volumes of ethyl acetate (2 × 500 µL) and the organic 
layers were reduced to dryness under a stream of N2 at 40 °C. The residues were redissolved in 
methanol (100 µL), filtered using 0.45 µm PTFE filter and analysed by HPLC-DAD-ESI-MS.  
5.4.6 Biotransformation of bufalin (3a) 
Bufalin in acetone (10 mg/mL; 50 µL) was added to each overnight culture (5 mL) of C. 
testosteroni, Acinetobacter johnsonii, Acinetobacter sp. and Flavobacterium sp. which were then 
incubated at 26.5 °C for further 72 h. 500 µL of cultures were extracted for every 0 h, 24 h, 48 h 
and 72 h time period respectively, with equal volumes of ethyl acetate (2 × 500 µL) and the organic 
layers were reduced to dryness under a stream of N2 at 40 °C. The residues were redissolved in 
methanol (100 µL), filtered using 0.45 µm PTFE filter and analysed by HPLC-DAD-ESI-MS 
 
5.4.7 Isolation of microbes from the surface and the interior of the parotoid 
gland 
Parotoid secretions from two (left) parotoid glands of two matured cane toads were directly 
squeezed onto sterile water, gently mixed and immediately an aliquot (50 µL) was added onto a 
nutrient agar plate and incubated for 5 days at 26.5 °C. Cane toads were then euthanized and 
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dissected to obtain two parotoid glands (right). An incision was made on the ventral portion of the 
parotoid gland and was directly swabbed onto a nutrient agar plate using a sterile tweezer followed 
by incubation for 5 days at 26.5 °C. 
 
5.4.8 Biotransformation of marinobufagenin (1a) using micro bioreactors 
The micro bioreactors and its accessories (including the sieved lid and the seal) were initially 
sterilized using autoclave. Sterile nutrient broth (2 mL) was added to each well of the 24-well plate 
micro bioreactor. A single colony of each microbe isolated from the parotoid secretions and 
parotoid gland was inoculated onto the broth and incubated for 12 h at 26.5 °C for unicellular 
bacterial colonies and 24 h for fungal and sporulating bacterial colonies. Marinobufagenin (15 
mg/mL; 3 µL) was added to the cultures and was further incubated for 2 days for at 26.5 °C for 
unicellular bacterial colonies while 4 days for fungal and sporulating bacterial colonies. Cultures 
were extracted with equal volumes of ethyl acetate (2 × 2 mL) and the organic layers were filtered 
using 0.45 µm PTFE filter and reduced to dryness under a stream of N2 at 40 °C. The residues were 
redissolved in methanol (50 µL) and analysed by HPLC-DAD-ESI-MS (Table 5.3). 
 
Table 5.3 Biotransformation of marinobufagenin by newly isolated strains from parotoid glands 
Strain code Biotransformation products 
Retention 
time (min) 
Molecular 
mass (m/z) 
CMB-TD29 arenobufagenin (6a) 5.81 417 
 25a 6.28 363 
 3-epi-arenobufagenin (26a) 5.74 417 
CMB-TD49 arenobufagenin (6a) 5.81 417 
 3-epi-arenobufagenin (26a) 5.74 417 
 27a 6.25 345 
CMB-TD22 28a 5.70 419 
 29a 6.32 419 
 30a 6.46 419 
CMB-TD42 arenobufagenin (6a) 5.81 417 
 31a 6.61 417 
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Chapter 6: Characterization of the cane toad egg extracts, 
with the emphasis on bufadienolides (bufolipins) 
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6.1 Introduction 
 
The aim of this chapter is to characterize the bufadienolide composition of the eggs of B. marinus. 
B. marinus eggs have been reported to contain cardiotonic activity similar to that of adult parotoid 
secretions,1  with eggs (pre-laying) removed from oviducts in 1994 reported to contain poly-
hydroxylated bufagenins such as  11α-hydroxymarinobufagenin (10a), 11α,19-
dihydroxymarinobufagenin (11a), 11α-hydroxytelocinobufagenin (12a), 19-
hydroxytelocinobufagenin (13a), 11α,19-dihydroxytelocinobufagenin (14a) (Figure 6.1).1 A 
subsequent 1998 report described telocinobufagenin (2a), hellebrigenin (5a), arenobufagenin (6a) 
and 5β-hydroxyarenobufagenin (15a) and three bufolipins, 11α, 19-dihydroxytelocinobufagenin-3-
(14-hydroxy-7-tetradecanoic acid) ester (bufolipin A* (1h)), 11α, 19-dihydroxytelocinobufagenin-
3-(14-hydroxytetradecanoic acid) ester (bufolipin B* (2h)) and 11α, 19-
dihydroxytelocinobufagenin-3-(12-hydroxydodecanoic acid) ester (bufolipin C* (3h)) from oviducts 
of B. marinus.2 Interestingly, in a recent finding by Crossland et al, bufolipin A (1h) was isolated 
from laid eggs while several other bufolipins and bufagenins were also identified.3 
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                                     11α19-dihydroxy                 19-hydroxy                5β-hydroxyarenobufagenin (15a) 
                                  telocinobufagenin (13a)    telocinobufagenin (14a) 
 
 
bufolipin A (1h)          
 
        
bufolipin B (2h)                              
 
  
bufolipin C (3h) 
 
Figure 6.1 Bufagenins and bufolipins found in eggs/ovaries of the cane toad 
* Bufolipins terminology is coined by our group to describe the unique class of bufadienolides identified in B. marinus 
eggs 
 
In this study all bufadienolides from B. marinus eggs including bufagenins and bufolipins will be 
isolated and characterized using analytical, preparative and semi-preparative HPLC-DAD, HPLC-
DAD-MS, NMR and HRMS.  
 
HPLC-DAD analytical methods used for the isolation and identification of bufolipins were 
developed with the use of bufagenin esters standards (comprising varying lengths of diacid esters) 
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previously synthesized (see Chapter 2). B. marinus eggs were subjected to trituration with hexane 
and n-BuOH, with bufadienolides (bufagenins and bufolipins) solubilized by n-BuOH. n-BuOH 
solubles were then subjected to fractionation using HPLC-DAD methods specific for bufagenins 
and bufolipins. Following isolation the bufadienolides were subjected to structure elucidation using 
NMR and HRMS.  
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6.2 Results and discussion 
 
6.2.1 Analytical methodology for bufagenin esters 
 
An HPLC-DAD based analytical methodology was developed specific for bufagenin esters (i.e. 
bufolipins) by identifying suitable reverse phase HPLC conditions. Synthetic bufagenin ester 
standards were prepared and subjected to analytical method development using several reverse 
phase columns (e.g. C3, C8, C18, CN and phenyl) with C8 providing the best resolution as previously 
observed by Crossland et al.3 Solvent conditions including MeOH/H2O, MeCN/H2O at varying 
gradients (linear/isocratic) with (Method 4) and without (Method 5) TFA as modifier (0.01%) were 
considered, however, a linear gradient of MeCN/H2O with TFA (0.01%) showed the best resolution 
(Figure 6.2). HPLC-DAD analysis without TFA showed broad peaks, however, since TFA could 
possibly react with bufagenin esters (as previously observed with bufotoxins), reverse-phase HPLC 
condition without TFA was considered as a suitable analytical methodology. For direct 
identification of compounds in crude egg extracts reverse phase HPLC condition with TFA was 
applied.  
 
 
 
 
Figure 6.2 HPLC chromatograms and UV-Vis spectrum of synthetic bufolipins, marinobufagenin-3-succinate (8b), 
marinobufagenin-3-pimelate (5b) and marinobufagenin-3-suberate (1b) using Method 4. 
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Synthetic bufagenin esters exhibited analytical characteristics comparable to hydrophobic 
compounds due to the C-3 fatty acid ester linkage. As expected, the longer the fatty acid chain the 
more the hydrophobicity as evidenced from retention times.  
 
An alternative analytical methodology (Method 5) for egg extracts was also developed using 
synthetic bufolipins. Since, the egg extracts consists of a mixture of bufagenins, bufotoxins and 
bufolipins along with significant amounts of fatty acids (Crossland et al),3 a specific methodology 
to retain bufolipins (ie. bufagenin esters) for a longer time period on the C8 reverse phase column 
was optimized using MeCN/H2O gradient without the use of TFA. Solvent conditions of Method 5 
were optimized to begin with 90% H2O/MeCN and increasing the organic phase to 50% 
H2O/MeCN in only 5 min to separate all the polar compounds from the hydrophobic bufolipins. 
Followed by gradual increase of organic phase from 50% H2O/MeCN to 30% H2O/MeCN over 15 
min over which is the expected range of retention time for the bufolipins. As expected, synthetic 
bufagenin esters showed retention times from 6.7 to 8.5 min using Method 5 (Figure 6.3).  
 
 
 
 
Figure 6.3 HPLC chromatograms and UV-Vis spectrum of synthetic bufolipins, marinobufagenin-3-succinate (8b), 
marinobufagenin-3-pimelate (5b) and marinobufagenin-3-suberate (1b) using Method 5. 
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6.2.2 Partitioning of egg extracts 
 
 
 
Scheme 6.1 Preparation of analytes A158 – A190. 
 
A single wild harvested B. marinus egg mass was freeze-dried and extracted with MeOH to 
solubilize all bufadienolides, along with other structure classes including fatty acids, nucleic acids 
and lipids. The MeOH extract was concentrated in vacuo and then subjected to trituration with 
water and n-BuOH to generate fractions A158 and A159, respectively. The n-BuOH fraction 
(A159) solubilized all bufadienolides including bufolipins and fatty acids. To further concentrate 
bufolipins, A159 was concentrated in vacuo and then triturated with hexane followed by n-BuOH to 
generate fractions A160 and A161 respectively. The n-hexane solubilized fatty acids along with 
some bufolipins (A160), however, n-BuOH solubilized mostly bufolipins (A161). Fraction A161 
was then subjected to preparative HPLC to yield fractions A162 – A186, of which, only two 
fractions, A172 and A173 were identified to contain bufolipins based on the UV response and 
HPLC-DAD-MS (Scheme 6.1). These two fractions were subsequently purified by semi-preparative 
HPLC to isolate two known and a mixture of five new bufolipins. 
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6.2.3 Identification of bufadienolides based on HPLC-DAD-MS analysis 
 
A sample of A159 was dried in vacuo, re-dissolved in MeOH to a standard concentration (3 
mg/mL) and subjected to HPLC-DAD-MS analysis using the above mentioned analytical 
methodology, Method 4 (Figure 6.4).  
 
 
Figure 6.4 HPLC chromatogram of A159 analysed using Method 4. 
 
Sharp peaks corresponding to bufadienolides were detected between the retention times 5 - 12 min 
based on the UV absorbance. Identification of bufadienolides was performed by isolation of 
individual peaks using preparative and semi-preparative HPLC, supported by MS and NMR 
analyses. An HPLC-DAD-MS analysis and comparison with bufadienolide standards previously 
described in Chapter 2 was also performed to identify bufadienolides in B. marinus eggs. 
Interestingly, no bufotoxins were identified in the B. marinus egg extracts, however, high amounts 
of bufagenins (5.2 – 10.1 min) and moderate to low amounts of bufolipins (10.5 – 11.8 min) were 
detected. Significant amounts of hydrophobic molecules (possibly bufolipins) (12.5 – 16.5 min) 
were also detected (Figure 6.5).  Ionization of bufagenins was better than bufolipins while the 
hydrophobic molecules exhibited poor ionization.  
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Figure 6.5 HPLC-DAD-MS chromatogram of A161 analysed using Method 4 exhibiting the presence of bufagenins 
(blue), bufolipins (yellow) and hydrophobic molecules (aqua) 
 
Single mass ion extraction for each HPLC peak was performed to identify bugafenins and 
bufolipins based upon their range of molecular masses. Bufagenins showed ionization in the 
positive ESI mode and exhibited a m/z in the range between 400-440 while bufolipins showed 
better ionization in the negative ion ESI mode with a m/z >600 (Figure 6.6a, bufagenins 
(highlighted in blue), Figure 6.6b, bufolipins (highlighted in yellow)).  
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Figure 6.6a HPLC-DAD-ESI(+)-MS of A161 exhibiting single ion extraction of bufagenins  
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Figure 6.6b HPLC-DAD-ESI(-)-MS of A161 exhibiting single ion extraction of bufolipins  
 
6.2.4 Isolation of bufagenins 
 
The n-BuOH solubles of B. marinus eggs (A161) were subjected to purification using preparative 
HPLC-DAD (Figure 6.7) and individual peaks corresponding to bufadienolides were collected and 
subjected to characterization studies using HPLC-DAD-MS, HRMS and NMR.  
 
 
Figure 6.7 Purification of A161 using preparative HPLC-DAD 
 
Previous published reports of bufagenins and bufolipins relied on a sampling of 182 toads yielding 
2 – 20 mg of each bufadienolide (total >2g), whereas our studies was performed on a wild harvested 
egg mass from one cane toad.1 Hence, characterization was performed on sub milligram scale on an 
individual and/or mixture of bufadienolides, employing sensitive tools like HRMS, NMR and LC-
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MS. Using this approach, some of the fractions collected from preparative HPLC contained two or 
three bufagenins, making characterization difficult, however, previous reports of bufadienolides 
from eggs and ovaries of B. marinus provided helpful information. As fatty acids adsorbed on to the 
reverse phase C8 column (during multiple injections) all the isolated bufagenins and bufolipins were 
contaminated with trace amounts of fatty acid. Subsequent purification of bufagenins using semi-
preparative HPLC was difficult as the amount of bufadienolides (individual or mixture) recovered 
from preparative-HPLC were in the range of only 200 – 600 µg. That said co-injection of bufagenin 
standards (see Chapter 2) was also performed to identify some bufagenins present in B. marinus 
eggs.  
 
Characterization of 11α,19-dihydroxy telocinobufagenin (13a) from Japanese B. marinus eggs has 
been previously reported.1 In our study, 13a was obtained as a pale white solid with HR(+)ESIMS 
analysis revealing a quasi-molecular ion (m/z 457.2193 [M+Na]+) consistent with the molecular 
formula C24H34O7 (Δmmu 0.85).1 The UV-vis spectrum of 13a exhibited the characteristic α-pyrone 
ring absorbance. All of the above indicated that 11α,19-dihydroxytelocinobufagenin (13a) was 
present in our egg extract.  
 
Characterization of 11α,19-dihydroxymarinobufagenin (12a) from Japanese B. marinus eggs has 
been previously reported.1 In our study 12a was obtained as a pale white solid with HR(+)ESIMS 
analysis revealing a quasi-molecular ion (m/z 455.2040 [M+Na]+) consistent with the molecular 
formula C24H32O7 (Δmmu 0.85).1 The UV-vis spectrum of 12a exhibited the characteristic α-pyrone 
ring absorbance. All of the above indicated that 11α,19-dihydroxymarinobufagenin (12a) was 
present in our egg extract.  
 
Characterization of 11α-hydroxymarinobufagenin (10a) from Japanese B. marinus eggs has been 
previously reported.1 In our study 10a was obtained as a pale white solid with HR(+)ESIMS 
analysis revealing a quasi-molecular ion (m/z 439.2100 [M+Na]+) consistent with the molecular 
formula C24H32O6 (Δmmu -2.07).1 The UV-vis spectrum of 10a exhibited the characteristic α-
pyrone ring absorbance. All of the above indicated that 11α-hydroxymarinobufagenin (10a) was 
present in our egg extract.  
 
Characterization of hellebrigenin (5a) from Japanese B. marinus ovaries has been previously 
reported.2 In our study 5a was obtained as a pale white solid with HR(+)ESIMS analysis revealing a 
quasi-molecular ion (m/z 439.2193 [M+H]+) consistent with the molecular formula C24H32O6 
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(Δmmu 1.45).2 The 1H NMR (CD3OD) data for 5a was identical to the literature data (see Chapter 
2). The UV-vis spectrum of 5a exhibited the characteristic α-pyrone ring absorbance, and on 
HPLC-DAD co-injection proved identical to an authentic standard of 5a (see Chapter 2). All of the 
above confirmed hellebrigenin (5a) was present in our egg extract. 
 
Characterization of telocinobufagenin (2a) from Japanese B. marinus ovaries has been previously 
reported.2 In our study 2a was obtained as a pale white solid with HR(+)ESIMS analysis revealing a 
quasi-molecular ion (m/z 403.2479 [M+H]+) consistent with the molecular formula C24H34O5 
(Δmmu -2.98).2 The 1H NMR and 13C NMR (CD3OD) data for 2a was identical to the literature data 
(see Chapter 2). The UV-vis spectrum of 2a exhibited the characteristic α-pyrone ring absorbance 
and on HPLC-DAD co-injection proved identical to an authentic standard of 2a  (see Chapter 2). 
All of the above confirmed telocinobufagenin (2a) was present in our egg extract. 
 
Characterization of marinobufagenin (1a) from Australian cane toad parotoid secretions has been 
previously reported.4 In our study 1a was obtained as a pale white solid with HR(+)ESIMS analysis 
revealing a quasi-molecular ion (m/z 401.2323 [M+H]+) consistent with the molecular formula 
C24H32O5 (Δmmu 2.32).4 The 1H NMR and 13C NMR (CD3OD) data for 1a was identical to the 
literature data (see Chapter 2). The UV-vis spectrum of 1a exhibited the characteristic α-pyrone 
ring absorbance and on HPLC-DAD co-injection proved identical to an authentic standard of 1a  
(see Chapter 2). All of the above confirmed marinobufagenin (1a) was present in our egg extract. 
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                                   marinobufagenin (1a)        telocinobufagenin (2a)               hellebrigenin (5a) 
Figure 6.8 Bufagenins identified in A161 
 
Due to the very low yields, two additional bufagenins detected in our egg extract (A161) could not 
be well characterized. Nevertheless, a single ion extraction for m/z 419 [M+H]+ exhibited two peaks 
that we speculate may be due to 11a and 14a, both of which have previously been reported from 
Japanese B. marinus eggs.1 In our study these two bufagenins exhibited HR(+)ESIMS quasi-
molecular ions (m/z 441.2204 [M+Na]+ and m/z 441.2224 [M+Na]+), consistent with the molecular 
formula C24H34O6,1 and UV-vis spectra with characteristic α-pyrone ring absorbances. All of the 
above indicated that 11α-hydroxytelocinobufagenin (11a) and 19-hydroxytelocinobufagenin (14a) 
were present in our egg extract. Further analysis of HPLC-DAD-MS data for A161 indicated the 
presence of three additional isomeric bufagenins (tR = 5.8, 6.2 and 6.8 min; Method 4), with UV-vis 
spectra characteristic of α-pyrone ring absorbance. At this time the structure of these bufagenins 
remains unknown.  
 
6.2.5 Identification of bufolipins 
 
Characterization of bufolipin A (1h) from Japanese B. marinus oviducts has been previously 
reported.2 In our study 1h was obtained as a pale white solid with HR(+)ESIMS analysis revealing 
a quasi-molecular ion (m/z 660.4216 [M+H]+) consistent with the molecular formula C38H60O9 
(Δmmu 0.65).2 The UV-vis spectrum of 1h exhibited the characteristic α-pyrone ring absorbance 
and on HPLC-DAD co-injection proved identical to an in-house authentic standard of 1h  
(previously isolated by Dr Angela Salim).3 All of the above confirmed that bufolipin A (1h) was 
present in our egg extract.  
 
Characterization of bufolipin B (2h) from Japanese B. marinus oviducts has been previously 
reported.2 In our study, 2h was obtained as a pale white solid with HR(+)ESIMS analysis revealing 
a quasi-molecular ion (m/z 658.4220 [M+H]+) consistent with the molecular formula C38H58O9 
(Δmmu 0.50).2 The UV-vis spectrum of 2h exhibited the characteristic α-pyrone ring absorbance. 
All of the above indicated that bufolipin B (2h) was present in our egg extract.  
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bufolipin A (1h)          
 
        
bufolipin B (2h)                              
 
Figure 6.9 Bufolipins identified in A161 
 
 
Figure 6.10 HPLC-DAD-MS profile of analytes A187 and A188 
 
Further analysis of HPLC-DAD-MS data for A189 and A190 indicated the presence of four 
additional bufolipins (tR = 12.0, 12.1, 12.4 and 13.2 min) (Method 4) with m/z  [M+Cl]- at 691, 655, 
667 and 721, respectively, and with UV-vis spectra characteristic of α-pyrone ring absorbance. 
Figure 6.11 illustrates the mixture of unknown bufolipins  present in A189 and A190 respectively.  
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Figure 6.11 HPLC-DAD-MS profile of unknown bufolipins in fractions 4h and 5h 
 
 
6.2.6 Discussion on bufadienolides from B. marinus eggs 
 
Literature reports described of six bufagenins from pre-laid eggs obtained from 182 cane toads,1 
and two bufagenins and 3 bufolipins from the oviducts of 180 cane toads.2 In our studies 8 known 
bufagenins and 2 bufolipins were identified from a single mass of eggs laid by one cane toad. 
Additional bufadienolides were detected but insufficient material was available to characterize and 
assign molecular structures. This study, demonstrated that the chemical diversity present in eggs is 
higher than previously reported.  
 
6.2.7 Hydrolysis of bufolipins 
 
Adult cane toad parotoid toxins are stored as bufotoxins and during the manual compression of the 
parotoid glands, bufotoxins are co-secreted with BtH and hydrolyzed into bufagenins. To identify 
the potential for BtH mediated hydrolysis of bufolipins in eggs. Pure bufolipin A (50 µg) was 
subjected to hydrolysis by BtH (2 µg) for 1 and 48 h time intervals, after which it was quenched 
with MeOH (500 µL), dried and re-dissolved in MeOH (50 µL) to generate analytes A191 and 
A192, respectively (Scheme 6.2). These analytes were then analysed using HPLC-DAD Method 1 
(see Chapter 2).  
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Scheme 6.2 Preparation of analytes A191 and A192. 
 
Bufolipin A (1h) exposed to BtH for 1 h exhibited no hydrolysis. However, HPLC-DAD (Method 
1) (see Chapter 2) analysis after 48 h (Figure 6.12) revealed moderate levels (28%) of hydrolysis to 
yield the bufagenin, 11α,19-dihydroxy telocinobufagenin (13a) and the fatty acid 14-
hydroxytetradecanoic acid (5.1). Marinobufotoxin (1c) was used as a control (refer Figure 4.31B). 
 
Figure 6.12 HPLC chromatogram (298 nm) of A192 analysed using Method 1   
 
HPLC-DAD-MS confirmed the presence of 11α,19-dihydroxytelocinobufagenin (13a) (m/z 435, 
[M+H]), bufolipin A (1h) (m/z 659, [M+H]) and 14-hydroxytetradecanoic acid (5.1) (m/z 225, 
[M+H]) (Figure 6.13).  
 
  
Figure 6.13 HPLC-DAD-MS analysis of A192 describing the single ion extraction for 11α,19-
dihydroxytelocinobufagenin (13a) and 14-hydroxytetradecanoic acid (5.1) 
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6.2.8 Bufolipins as B. marinus tadpole attractants 
 
Previous studies by Crossland et al showed that bufagenins and bufolipins attracted cane toad 
tadpoles, and can be used as toad specific baits.3 These studies also determined that bufagenin baits 
lacked longevity as the bufagenins rapidly diffused into surrounding water with t1/2 48 h (data not 
shown). Bufolipins on the other hand are more hydrophobic than bufagenins and offer the prospect 
of longer lived baits. For practical reasons baits that continue to operate effectively for prolonged 
periods are deemed superior. Not withstanding their value, commercial supply of bufolipins from 
cane toad eggs is not practical. Hence, ‘semi-synthetic bufolipin mimics’ were synthesized from 
bufagenins recovered in high amounts from parotoid secretions. These bufolipin mimics were 
synthesized by esterification of bufagenins (e.g. 1a) with long chain saturated fatty acids (e.g. 
octanoic acid) in a two-step reaction (Scheme 6.3). Synthetic bufolipins marinobufagenin-3-
octanoate (6h) prepared as shown above showed better results (longevity) in cane toad tadpole 
attractant experiments (data not shown). Substantial amounts of synthetic bufolipins are required for 
field trials and required sourcing of large amounts of bufagenins.   
 
 
 
Scheme 6.3 Synthesis of bufolipins with octanoic acid (5.1) as example. (a) – reflux for 1 h with octanoic acid chloride 
and DMAP in pyridine 
 
 
 
Figure 6.14 HPLC chromatogram of marinobufagenin-3-octanoate (6h) analysed using Method 4 
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6.2.8.1 Isolation of large amounts of bufagenins 
 
Parotoid glands from 220 frozen cane toads were dissected, washed with H2O and blended with 
MeOH using a tabletop blender. MeOH solubles along with tissue debris was subjected to filtration 
using Celite resin (Celite 545) to yield a mixture of bufadienolides and biogenic amines that was 
dried in vacuo to yield an oily residue, 11.2 g. This residue was subjected to sequential solvent 
trituration to yield n-hexane (1.6 g), EtOAc (5.8 g), n-BuOH (686 mg), MeOH (458 mg) and H2O 
(3 g) solubles (Scheme 6.4). All samples were subjected to HPLC-DAD analysis using Method 1 
(see Chapter 2) (Figure 6.14).  
 
Scheme 6.4 Preparation of analytes A193 – A198. 
 
EtOAc solubles (A195) contained only bufagenins and constituted more than 60% of parotoid 
secretions (based on mass recovery). n-BuOH solubles (A196) exhibited a mixture of bufotoxins 
(37%) and bufagenins (63%) with higher quantities of bufagenins (Figure 6.15). MeOH solubles 
(A197) consisted significant amount of bufotoxins (58%) followed by bufagenins (42%). Analysis 
of n-hexane solubles (A194) revealed the absence of bufadienolides. Armed with significant supply 
of bufagenins (>5.8 g) synthetic bufolipins can be synthesized as mentioned previously (Scheme 
6.3) to support large scale field trials. These studies are ongoing. 
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Figure 6.15 HPLC traces (298nm) of analytes A192 – A195 analysed using Method 1. Marinobufagenin (1a), 
telocinobufagenin (2a), bufalin (3a), resibufagenin (4a), arenobufagenin (5a), marinobufotoxin (1c) and 
dehydrobufotenin (1.6) 
 
 
 
6.3 Conclusion 
 
• Bufolipins were detected and isolated from B. marinus eggs using analytical methodologies 
developed using bufagenin ester standards 
• B. marinus eggs contain bufagenins, bufolipins and hydrophobic molecules (such as fatty 
acids) 
• Eight known bufagenins and two unknown bufagenins were identified in B. marinus eggs 
• Two known and five uncharacterized bufolipins were detected in B. marinus eggs 
• Synthetic bufolipins have previously been shown to attract B. marinus tadpoles at a similar 
potency to natural bufolipins. These synthetic bufolipins can be prepared by esterification of 
bufagenins obtained from extraction of adult can toad parotoid secretions. This current study 
has generated gram quantities of bufagenins for future elaboration in to synthetic bufolipins 
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6.4 Experimental 
6.4.1 analytical methodologies for detection and isolation of bufolipins 
 
Table 6.1 Analytical methods for the detection of bufolipins 
 
 Method Structure class Conditions 
HPLC-DAD Method 4 bufolipins 
 
Zorbax C8 column, 150 × 4.6 mm, 5 µm, 1 mL/min, 
gradient from 90% H2O/ MeCN to 100% MeCN over 
15 min, hold at 100% MeCN over 5 min, with constant 
0.01% modifier (TFA). 
HPLC-DAD Method 5 bufolipins 
 
Zorbax C8 column, 150 × 4.6 mm, 5 µm, 1 mL/min, 
gradient from 90-50% H2O/ MeCN over 5 min, 50-
30% H2O/ MeCN over 15 min, 30% H2O/ MeCN to 
100% MeCN over 5 min, holding 100% MeCN for 5 
min, with constant 0.01% modifier (TFA). 
 
 
6.4.2 Isolation and identification of bufagenins and bufolipins from B. marinus 
eggs 
 
A single clutch of B. marinus eggs from one cane toad was collected (USyd), lyophilized, 
solubilized in MeOH, filtered and the filtrate reduced to dryness under vacuum. The MeOH 
solubles were sequentially triturated with n-BuOH and H2O and the n-BuOH solubles concentrated 
in vacuo and subjected to sequential trituration with n-hexane and n-BuOH. n-BuOH solubles was 
reduced to dryness under vacuum and subjected to preparative HPLC (Phenomenox, Luna C8 
column, 250×21.2 mm, 10 µm, gradient from 90% H2O/ MeCN to 100% MeCN over 15 min, 
holding 100% MeCN over 5 min and wash with 90% H2O/ MeCN for 5 min, no TFA) to collect 25 
fractions. Two fractions containing bufolipins were combined and purified using semi-preparative 
HPLC (Zorbax C8 column, 250 × 9.4 mm, 5 µm, 1 mL/min, gradient from 90-50% H2O/ MeCN 
over 5 min, 50-30% H2O/ MeCN over 15 min, 30% H2O/ MeCN to 100% MeCN over 5 min, hold 
at 100% MeCN for 5 min, no TFA).  
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6.4.3 Synthesis of octanoic acid chloride 
 
A solution of octanoic acid (200 mg, 1.30 mmol) in thionyl chloride (3 mL) was refluxed for 6 h 
following which octanoic acid chloride was carefully obtained by distilling off the reaction mixture 
using Kugelrohr.  
 
6.4.4 Synthesis of marinobufagenin-3-octanoate (6h) 
 
A solution of marinobufagenin (1a) (5 mg, 12.5 µmol) is refluxed with octanoic acid chloride (25 
µL) in the presence of DMAP (0.6 mg, 4.9 µmol) in pyridine (3 mL) for 1 h with constant stirring 
following which the reaction mixture was dried under N2 at 40 °C and subjected to purification 
using semi-preparative HPLC (Zorbax C18 column, 250 × 9.4 mm, 5 µm, 1 mL/min, gradient from 
90% H2O/ MeCN to 100% MeCN over 15 min, holding 100% MeCN over 5 min, with constant 
0.01% modifier (TFA)) to yield marinobufagenin-3-octanoate (1.2 mg) (Appendix Fig S30).  
 
1H NMR (CD3OD, 600 MHz) δH 0.76 (s, H-18), 0.92 (s, H-19), 1.38 (m, H-3’-­‐	  H-7’), 2.72 (m, H-
17), 2.78 (s, H-8’), 3.60 (s, H-15), 6.46 (dd, H-23), 7.42 (d, H-22), 7.94 (d, H-21) ppm. (Appendix 
Figure S30). colourless oil; [α]21D +37.8 (c 0.1, CHCl3); HRESI(+)MS m/z 549.3187 (M+Na)+ 
(calcd for C32H46O6, 549.3180). 
 
6.4.5 Isolation of bufagenins from parotoid secretions 
 
Parotoid glands from 220 frozen toads were dissected and disrupted in a blender containing MeOH 
to release all the secretions. The MeOH solubles along with tissue debris was collected and was 
subjected to filtration using Celite resin (Celite 545) and the flow through was collected, reduced to 
dryness under vacuum and was triturated with n-hexane, EtOAc, n-BuOH, MeOH and H2O.  
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Chapter 7: Comparative analysis of the pharmacological 
properties of individual cane toad toxins 
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7.1 Introduction 
 
7.1.1 Cane toad toxins and toxicity 
 
The aim of the chapter is to investigate the toxicological/pharmacological properties of cane toad 
bufadienolides and arginyl amides. The language pertaining to cane toad toxins in the literature is 
often vague and inaccurate. For example, parotoid secretions are often described as venoms which 
conjures a particular view of there use as effective weapons. As venoms are typically injected by a 
specialized fang or spine, this description is quite inappropriate when applied to cane toads, which 
lack any such apparatus. Quite the opposite, cane toad toxin is only released involuntarily following 
physical pressure during a predatory attack – in which the toad is the victim not the aggressor.  
 
This confusion also extends to attempts to use in vitro experiments to characterize the toxicity of 
cane toad toxins.  Assays carried out on crude toxins1,2 are of questionable value for a range of 
reasons; For example, as the diversity and ratio of chemicals present within a toxin sample can vary 
depending on the individual toad, the method of extraction, the method of handling and the method 
of storage, any assays carried out on uncharacterized toxin cannot be reproduced. Furthermore, the 
prospect that different chemical components could exert additive, complementary and/or synergistic 
effect needs to be considered.2  
 
Finally, the choice of assay is critical as it underlines the relevance, reproducibility and reliability of 
any interpretation. Regrettably, many literature accounts of cane toad toxicity use poorly 
documented or questionable methodology, and extrapolate to conclusions that are not well 
defended. Consider the following SWOT analysis of some of the most common assays – Na+/K+ 
ATPase and cytotoxicity assays.  
 
7.1.2 Conventional assays: a critique 
 
Na+/K+ ATPase, an ion channel responsible for the transport of Na+ and K+, is expressed in various 
tissues as different isoforms, and bufadienolide toxicity is often correlated with inhibition of cardiac 
Na+/K+ ATPase. Although, Na+/K+ ATPase inhibition by bufadienolides had been described since 
1960’s, the typical assay system employs Na+/K+ ATPase isolated from pigs (liver or brain).3, 4 For 
practical reasons the more ecologically relevant cardiac Na+/K+ ATPase sourced from crocodiles, 
snakes, quolls, is not available, which means published account of bufadienolide Na+/K+ ATPase 
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toxicity lack ecological relevance and yet they are often used to infer ecological significance! 
Several researchers have performed Na+/K+ ATPase inhibition assays using various assay 
platforms.2, 4, 5 The most common assay platform is displacement of radio labeled ouabain by 
analytes such as bufadienolides where ouabain is viewed as a positive control. Again the ecological 
relevance is questionable as ouabain is a cardenolide glycoside not a bufadienolide, and the assay 
measures a ligand displacement not a loss of function. Perhaps an even larger risk is the willingness 
by some researchers to make quantitative comparisons between assay results obtained in different 
enzyme preparations, in different labs, using different protocols, such unqualified comparisons are 
of very little value.   
 
ouabain (1.10) 
Table 7.1 List of pharmacological properties reported on various bufadienolide structure classes 
isolated from B. marinus reported from various countries (reused from Table 1.2) 
 
Pharmacological 
properties (cell/tissue types) 
bufagenins bufotoxins bufolipins bufagenin 
sulfates 
bufagenin 
glycosides 
Na+/K+ ATPase inhibition      
human kidney3 1a, 2a     
C7-MDCK cells2 1a, 3a 1c, 2c    
dog Kidney/pig brain4 3a     
guinea pig heart6 1a, 2a 1c, 2c, 8c    
guinea pig heart5 1a 1c  1f 1g 
dog kidney7   1h, 2h, 3h   
Cytotoxicity      
PLC/PRF/5 cells8 1a, 2a, 3a, 
4a, 5a 
    
HL-60, HCT-8, SF295, 
MDA-MB435, PBLS9 
1a, 2a, 3a, 
5a 
    
A549, U373, HS683, MCF-
710 
   2f  
Antibiotic – E. coli and S. 
aureus11 
1a, 2a     
 
A list of bufadienolides submitted for various Na+/K+ ATPase inhibition assays from various 
sources and cell types and different read outs are listed in Table 7.1. Since the assays had several 
different parameters it is difficult to compare their outcomes. For example, a study performed by 
O
OH
OH
O
O
HO
HO
HO
O
OH
OH
OHMe
H
H
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Shimada et al in 1985 reported marinobufotoxin (1c) is more potent than marinobufagenin (1a) 
while Akimova et al in 2005 reported the opposite.2, 5 The former assay was performed on guinea 
pig Na+/K+ ATPase and the read out was monitored using HPLC analysis while the latter was 
performed on MDCK cell lines using a ouabain radio labeled displacement assay system. 2, 5 
Although the radio ligand displacement assay is generally accessible and provides a measure of 
binding affinity, the fact that it does not address functionality, and that it lacks a consistent 
cell/tissue derived Na+/K+ ATPase (e.g. varying across pigs and dogs), and meaningful positive 
control, make the assay highly questionable.  
 
Cytotoxicity exhibited by bufadienolides performed in vitro is often compared to the toxicity of 
cane toad toxins.10 Cytotoxicity is mostly performed on mammalian cancer cell lines, which are 
ecologically irrelevant assay systems. Moreover, cytotoxicity exhibited by bufadienolide is not 
entirely due to Na+/K+ ATPase inhibition as several pathways could be potential targets. Also 
cytotoxicity could possibly vary for each cell types contradicting the results, as some bufadienolides 
could be cytotoxic to one cell type while non-cytotoxic to others. A list of bufadienolides subjected 
to various cytotoxicity assays including various cell types are listed in Table 7.1. As mentioned 
previously comparative SAR studies including all bufadienolide structure classes is difficult as 
different bufadienolides were subjected to cytotoxicity studies with different cell types. Strengths of 
cytotoxicity assays include accessibility, feasibility and direct measurement of toxicity exhibited 
against selected cell types. Lack of relevant cell/tissues from relevant source organism and 
difference in readouts based on cell types are the weaknesses. Opportunities include inclusion of 
various bufadienolide structure classes in a single assay platform for comparative studies. Threat 
includes the correlation of in vitro assay to an ecological context.  
 
7.1.3 Cane toad toxicity – pharmacological or ecological 
 
Both in vitro Na+/K+ ATPase inhibition and cytotoxicity are attributed to the pharmacological 
properties of bufadienolides and are difficult to link to an ecological role due to lack of relevant 
assay systems. In addition, the oral bioavailability of cane toad parotoid secretions plays a critical 
role in the ecological significance of bufadienolides. Predators that present with lower 
bufadienolide oral bioavailability could possibly survive being poisoned by cane toads.  
Only one study on antibiotic activity of bufadienolides is reported.11 The assay system included 
pathogenic bacteria like Escherichia coli and Staphylococcus aureus. It is highly unlikely to 
correlate the assay results to relevant ecological context since the assay did not include toad-
	   282	  
specific pathogenic strains. Hence the antibiotic activity is correlated to the pharmacological 
properties of bufadienolides and cannot be translated into ecological relevance.  
 
In summary, “toxicity” of cane toad parotoid secretions could be differentiated into 
pharmacological and ecological toxicity. Pharmacological toxicity includes Na+/K+ ATPase 
inhibition, cytotoxicity and antimicrobial properties of bufadienolides under in vitro conditions 
while ecological toxicity indicates a relevant assay (in vivo) performed on cane toad predators. 
However, given the constraints in obtaining Na+/K+ ATPase from tissue samples from predators 
such as crocodiles, quolls, lizards or snakes and the ethics approval for performing such assays 
made it difficult to pursue such studies.  
 
Owing to the strengths of pharmacological toxicity listed above, cytotoxicity and antimicrobial 
properties of bufadienolides have been detailed in this chapter. Although this approach includes 
some weaknesses one of the additional strengths of the current investigation is inclusion of various 
bufadienolide structure classes for a comparative study. Cytotoxicity of bufadienolides in this 
context refers to the cell toxicity exhibited on mammalian cells while the antimicrobial property 
indicates the toxicity against certain gram positive and gram-negative bacteria. In either case it is 
the toxicity exhibited by cane toad toxins on mammalian and prokaryotic cells and does not solely 
refer to analysis of drug like characteristics. Due to the lack of time toxicity exhibited against fungal 
cells could not be performed.  Investigations on cardiotoxicity of bufadienolides are significant 
however an assay to selectively inhibit cardiomyocytes (cardiac muscle cells involved in 
conduction of action potential) and a read out to quantify the inhibition is currently unavailable. 
Steps were taken to establish such an assay involving human cardiomyocytes and selective ion 
channel stains to quantitatively represent the inhibition of Na+/K+ ATPase, however, due to lack of 
time the assay could not be completed. That said a future work (in collaboration with Dr Ivan 
Birros, GE Health Sciences) has been planned to establish cardiomyocytes assay. Hence, the 
toxicity studies described in the current chapter represents pharmacological toxicity and this cannot 
be extended to ecological context.  
 
During our investigations on bufadienolide pharmacological properties arginyl amides were also 
included in various pharmacological studies (such as cytotoxicity and antimicrobial properties) 
(Scheme 7.1).  
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Scheme 7.1 Investigations of pharmacological activities of bufadienolides and arginyl amides 
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7.2 Results and discussion  
 
7.2.1 Pharmacological toxicity studies on bufadienolides 
 
Pharmacological toxicity studies on bufadienolides was performed by investigating the toxicity 
exhibited on prokaryotes (bacteria) and mammalian cells (cancer cell lines) by various structure 
classes of bufadienolides. Table 7.2 illustrates the bufadienolides and their pharmacological 
toxicity. 
 
Table 7.2 Prokaryotic and mammalian cell toxicities of bufadienolides 
 
Bufadienolide Prokaryotic cytotoxicity* Mammalian cytotoxicity** 
marinobufagenin (1a) ✕ ✓ 
telocinobufagenin (2a) ✕ ✓ 
bufalin (3a) ✕*** ✓ 
hellebrigenin (5a) ✕ ✓ 
bufalin-3-acetate (7a) ✕ ✓ 
marinobufagenin-3-suberate (1b) ✕ ✕ 
telocinobufagenin-3-suberate (2b) ✕ ✕ 
bufalin-3-suberate (3b) ✕ ✓ 
marinobufagenin-3-pimelate (5b) ✕ ✕ 
marinobufagenin-3-succinate (9b) ✕ ✓ 
marinobufotoxin (1c) ✕ ✓ 
telocinobufotoxin (2c) ✕ ✓ 
bufalitoxin (3c) ✕ ✓ 
bufolipin A (1h) ✕ ✓ 
bufolipin B (2h) ✕ ✓ 
 
*performed with Bacillus subtilis, Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus (strains 
ATCC 550 & ATCC 1900) 
** performed with human SW 620 (colon cancer) and SF-295 (glioblastoma) cell lines 
***moderate activity against P. aeruginosa 
✓ MIC less than 64 µg/mL; IC50 less than 30 µM 
✕ No antimicrobial; No cytotoxicity 
 
Interestingly none of the bufadienolide structure classes were antibiotic to the pathogenic bacteria 
investigated in vitro. However, bufadienolides showed significant cytotoxicity against the 
mammalian cancer cell lines. Toxicity against mammalian cells is consistent with previous 
literature.8 Bufadienolide structure classes exhibited a range of cytotoxicity levels based on 
substitutions at C-3, which are discussed in sections below.  
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7.2.2 Cytotoxicity of bufadienolides – An SAR study 
 
7.2.2.1 Cytotoxicity of bufagenins 
 
Bufagenins subjected to cytotoxicity assays against SW 620 (colon cancer) and SF-295 
(glioblastoma) cell lines included marinobufagenin (1a), telocinobufagenin (2a), bufalin (3a) and 
hellebrigenin (5a) (Figure 7.1). The IC50 values exhibited by each bufagenin represented the half 
maximal inhibition of the growth of cells, which is indicated by the stain, MTT. The IC50 curves are 
illustrated in Figure 7.2 and the values in Table 7.3. 
 
marinobufagenin (1a)                     telocinobufagenin (2a)                           bufalin (3a) 
 
hellebrigenin (5a)                              
Figure 7.1 Bufagenins subjected to cytotoxicity assays 
 
   
Figure 7.2 Cytotoxicity (IC50) of bufagenins from parotoid secretions for SW 620 and SF-295 cell lines 
 
The IC50 for bufagenins in the current investigation is in agreement with Kamano et al where 
bufalin (3a) was determined to be the most cytotoxic bufagenin followed by telocinobufagenin with 
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sub-nano molar potency.8 A striking similarity of bufalin and telocinobufagenin is the hydroxyl at 
C-14, which could play a major role in the potent cytotoxicity. Cytotoxicity of hellebrigenin 
reduced to micromolar concentrations possibly due to an aldehyde substitution at C-10.   
 
7.2.2.2 Cytotoxicity of bufagenin esters 
 
Bufagenin esters subjected to cytotoxicity assays against SW 620 (colon cancer) and SF-295 
(glioblastoma) cell lines included bufalin-3-acetate (7a), marinobufagenin-3-suberate (1b), 
telocinobufagenin-3-suberate (2b), bufalin-3-suberate (3b), marinobufagenin-3-pimelate (5b) and 
marinobufagenin-3-succinate (9b) (Figure 7.3). The IC50 curves are illustrated in Figure 7.4 and the 
values in Table 7.3. 
bufalin-3-acetate (7a)       marinobufagenin-3-succinate (9b)                    marinobufagenin-3-pimelate (5b) 
 
marinobufagenin-3-suberate (1b)                telocinobufagenin-3-suberate (2b) 
 
bufalin-3-suberate (3b) 
Figure 7.3 Bufagenin esters subjected to cytotoxicity assays 
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Figure 7.4 Cytotoxicity (IC50) of bufagenin esters from parotoid secretions and synthetic analogues for SW 620 and SF-
295 cell lines 
 
Comparison of IC50 values of bufagenin esters in the current investigations indicated that shorter the 
chain length of the ester at C-3 the higher is the cytotoxicity. Similarly, among marinobufagenin 
analogues, marinobufagenin-3-succinate (8b) with the shortest chain length (n=2) at C-3 showed 
IC50 of 16.16 µM while other analogues are non-cytotoxic. Among the bufagenin esters subjected to 
cytotoxicity, bufalin analogues are more cytotoxic than marinobufagenin and telocinobufagenin 
analogues, which is consistent with previous investigations with bufagenins.8  
 
7.2.2.3 Cytotoxicity of bufotoxins 
 
Bufotoxins subjected to cytotoxicity assays against SW 620 (colon cancer) and SF-295 
(glioblastoma) cell lines included marinobufotoxin (1c), telocinobufotoxin (2c) and bufalitoxin (3c) 
(Figure 7.5). The IC50 curves are illustrated in Figure 7.6 and the values in Table 7.3. 
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bufalitoxin (3c) 
 
Figure 7.5 Bufotoxins subjected to cytotoxicity assays 
 
  
Figure 7.6 Cytotoxicity (IC50) of bufotoxins for SW 620 and SF-295 cell lines 
 
 
Cytotoxicity levels of bufotoxin in the current investigations revealed interesting findings, the 
dominant bufotoxin (>75%) in parotoid toxins in situ, marinobufotoxin (1c) showed the least 
cytotoxicity against SW 620 and SF-295, with a significant difference compared to other 
bufotoxins. The cytotoxicity levels comparison within the bufotoxin scaffold was similar to 
bufagenin and bufagenin esters scaffolds.  
 
7.2.2.4 Cytotoxicity of bufolipins 
 
Bufolipins subjected to cytotoxicity assays against SW 620 (colon cancer) and SF-295 
(glioblastoma) cell lines included bufolipin A (1h) and bufolipin B (2h) (Figure 7.7). The IC50 
curves are illustrated in Figure 7.8 and the values in Table 7.3. 
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bufolipin A (1h)          
 
        
bufolipin B (2h)                              
  
Figure 7.7 Bufolipins subjected to cytotoxicity assays 
 
  
Figure 7.8 Cytotoxicity (IC50) of bufolipins for SW 620 and SF-295 cell lines 
 
Interestingly, cytotoxicity levels of bufolipins in the current investigations are also comparable to 
bufotoxins, such as bufalitoxin and telocinobufotoxin. In the case of bufagenin esters it was 
determined that long chain esters at C-3 could deter cytotoxicity levels, however, cytotoxicity levels 
of bufolipins clearly suggests the importance of terminal hydroxyl at C14’ of the fatty acid ester. 
Another important observation is that both bufolipin A and bufolipin C has C14 hydroxyl as in the 
case of bufalin and telocinobufagenin scaffolds, thus exhibiting higher cytotoxicity.  
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7.2.2.5 Discussion – SAR studies on cytotoxicity of bufadienolides 
 
Table 7.3 IC50 values of bufadienolides against mammalian cancer cells 
 
Structure class Bufadienolide IC50 (µM) 
SW620 SF-295 
bufagenin marinobufagenin (1a) 0.44 0.68 
bufagenin telocinobufagenin (2a) 0.07 0.07 
bufagenin bufalin (3a) 0.01 0.01 
bufagenin hellebrigenin (5a) 2.67 4.74 
bufagenin ester bufalin-3-acetate (7a) 0.35 0.44 
bufagenin ester marinobufagenin-3-suberate (1b) >30 >30 
bufagenin ester telocinobufagenin-3-suberate (2b) >30 >30 
bufagenin ester bufalin-3-suberate (3b) 11.3 7.53 
bufagenin ester marinobufagenin-3-pimelate (5b) >30 >30 
bufagenin ester marinobufagenin-3-succinate (9b) 16.16 24.04 
bufotoxin marinobufotoxin (1c) 14.92 20.26 
bufotoxin telocinobufotoxin (2c) 0.37 0.63 
bufotoxin bufalitoxin (3c) 0.23 0.38 
bufolipin  bufolipin A (1h) 0.29 0.35 
bufolipin bufolipin B (2h) 0.58 0.38 
 
The current investigation of SAR studies of cytotoxicity exhibited by bufadienolide structure 
classes including bufagenins, bufagenin esters, bufotoxins and bufolipins suggests that bufagenins 
are the most cytotoxic class of bufadienolides followed by bufolipins and bufotoxins (Table 7.3). A 
cross comparison of marinobufagenin scaffolds of bufadienolides indicates that marinobufagenin 
(1a) is the most toxic scaffold followed by bufolipins (1h and 2h) and marinobufotoxin (1c) (Figure 
7.9). We hypothesize that bufotoxins, besides providing physical, chemical and microbiological 
stabilities, also provides biological stability from self-intoxication. On the other hand, bufagenins 
exhibiting high to very high cytotoxicity are potent molecules generated from the pool of 
bufotoxins, similar to that of a “pro-drug” to “drug” metabolism. Bufolipins could also provide 
better solubility characteristics (hydrophobicity) and with a better cytotoxicity profiles they could 
be ideal bufadienolide delivery vehicles adopted by B. marinus eggs.  
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Figure 7.9 Structure activity relationship of bufadienolide structure classes based on cytotoxicity 
 
7.2.2.6 Cytotoxicity of arginyl amides 
 
Arginyl amides subjected to cytotoxicity assays against SW 620 (colon cancer) and SF-295 
(glioblastoma) cell lines included suberoyl-L-arginine (1d), adipoyl-L-arginine (2d), pimeloyl-L-
arginine (3d) and azeloyl-L-arginine (1d) (Figure 7.10). None of the arginyl amides exhibited 
cytotoxicity activity (Figure 7.11).  
 
                          
                         adipoyl-L-arginine (2d)                                                                     pimeloyl-L-arginine (3d)
           
                        suberoyl-L-arginine  (1d)                                                                   azeloyl-L-arginine (4d) 
Figure 7.10 Arginyl amides subjected to cytotoxicity assays 
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Figure 7.11 Cytotoxicity (IC50) of arginyl amides for SW 620 and SF-295 cell lines 
 
Arginyl amides such as suberoyl-L-arginine (1d) and pimeloyl-L-arginine (3d) are identified in 
parotoid secretions and are present in significant amounts (see Chapter 3). However, the absence of 
cytotoxicity observed with arginyl amides does not necessarily indicate an absence of ecological 
significance. Arginyl amides may act independently (possibly different targets) compared to 
bufadienolides. Figure 7.12 illustrates the relationship between the cytotoxicity values of 
marinobufotoxin (1c) and its hydrolysis products in our current investigation. 
 
 
Figure 7.12 Cytotoxicity profiles of marinobufotoxin (1c) and its hydrolysis products 
 
7.2.2.7 Synergism of bufagenins and suberoyl-L-arginine (1d)  
 
Bufagenins and arginyl amides constituting parotoid secretions possibly exhibit synergistic activity 
on same or multiple targets.  Hence both the structure classes were subjected to cytotoxicity assays 
at equimolar concentrations and no changes were observed. Following cytotoxicity studies 
investigation of another target, stimulation of nitric oxide (NO) production by arginyl amides.  
SW 620
0.001 0.010 0.100 1 10 100
0
20
40
60
80
100
120
140
Concentration of pure compound (μM)
Pe
rce
nt
 vi
ab
ilit
y (
%
)
3d
2d
1d
4d
SF-295
0.001 0.010 0.100 1 10 100
0
20
40
60
80
100
120
140
Concentration of pure compound (μM)
Pe
rce
nt
 vi
ab
ilit
y (
%
)
3d
2d
1d
4d
	   293	  
7.2.3 Possible role of nitric oxide synthase in cane toad toxicity 
 
For assessing the biological activity of arginyl amides we also investigated the possibility of 
activation of mammalian nitric oxide synthase (NOS). Nitric oxide synthase is an enzyme complex 
required to synthesize nitric oxide (NO) from L-arginine. There are three types of mammalian NOS 
(mNOS) expressed in nervous system (nNOS), immune system (iNOS in lungs) and endothelial 
cells (eNOS).12 Endothelial NOS (eNOS) play a major role in generating NO, which mediates 
vasodilation of blood vessels resulting in increased blood flow.13 eNOS utilizes L-arginine substrate 
to synthesize NO in the presence of co-factors such as Ca-calmodulin (Ca2+ bound calmodulin), 
FMN (flavin mononucleotide), FAD (flavin adenine dinucleotide), Heme and BH4 
(tetrahydrobiopterin) (Figure 7.13).14  The NO biosynthesis is also inhibited by the synthetic agents 
N-nitro-L-arginine, N-methyl-L-arginine and N-nitro-arginine-methyl-ester.14  
 
Since arginyl amides contain L-arginine we speculated that their presence may mediate NO 
production. For example, arginyl amides could possibly act as a substrate for eNOS leading to the 
production of NO with associated increases in blood flow. Such an event may accelerate the 
transport of cardiotoxic bufagenins leading to a more rapid (and effective) poisoning.  
 
 
Figure 7.13 Description of NOS pathway in an endothelial cell indicating the substrates, co-factors for NO production 
as well as the inhibitors. Reproduced from Feletou et al 2006. 
 
7.2.4 mNOS activation of arginyl amides 
 
The arginyl amides suberoyl-L-arginine (1d), pimeloyl-L-arginine (3d), adipoyl-L-arginine (2d) and 
azeloyl-L-arginine (4d) were tested at four concentrations (5 mM, 1 mM, 100 µM and 10 µM) were 
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subjected to mNOS activation assay. Of the four arginyl amides subjected to mNOS activation, only 
suberoyl- L-arginine (1d) and pimeloyl- L-arginine (3d) that are naturally occurring analogues with 
1d, are present in substantial levels in the parotoid secretions. The assay was carried out using two 
cancer cell lines, SW620 (RPMI) and KB31 (DMEM) as a model for qualitatively assessing NOS 
activation of arginyl amides. The cell lines were cultivated from the frozen stock and maintained at 
a constant temperature of 15 °C. SW620 and KB31 exhibited about 70% confluence after 48 h of 
incubation. Arginyl amides were added to the cells aliquoted on to a 96-well plate and were 
incubated for 20 min followed by the addition of NO detection reagent and incubated for further 10 
min as described by the manufacturer’s protocol. NO detection reagent is a non-fluorescent 
substrate and reacts with the induced NO to generate a red fluorescent product, which is then 
detected using confocal microscopy. In a negative control an NO scavenger was added to the cells 
prior to the addition of NO detection reagent, to quench NO and associated fluorescence. Cells 
treated with L-arginine and NO detection reagent exhibited fluorescence and this represented the 
positive control. No fluorescence was detected with cells treated only with NO detection reagent.  
 
7.2.4.1 Effect of suberoyl-L-arginine and pimeloyl-L-arginine compared to L-arginine 
 
Cell lines, SW620 and KB31 treated with L-arginine exhibited high fluorescence at 1 mM and 5 
mM concentrations which is in consistent with the values previously determined in-house assays by 
Dr Zeinab Khalil (Capon group). Surprisingly, suberoyl-L-arginine exhibited high fluorescence 
indicating the activation of mNOS at 100 µM compared to L-arginine in SW620 as well as KB31 
cells (Figure 7.14 and Figure 7.15).  
 
Pimeloyl-L-arginine (3d) on the other hand exhibited less mNOS activation compared to L-arginine 
at about 1 mM. Suberoyl-L-arginine exhibited mNOs activation at lower levels even at 10 µM in 
KB31 and SW 620 cell lines. Although the current investigation is a qualitative measure of mNOS 
activation, 1d exhibited more activation than L-arginine based on the fluorescence observed at 
various concentrations (Figure 7.15).  
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Figure 7.14  mNOS activation identified in KB31 cells post treatment with A – KB31 cells with NO detection reagent, 
B – 1mM suberoyl-L-arginine (1d) with NO detection reagent and C – 1mM suberoyl-L-arginine (1d) with NO 
scavenger, D – 1mM L-arginine with NO detection reagent, E – 1mM L-arginine with NO scavenger . Bars – 0.6 µm. 
 
 
 
Figure 7.15 mNOS activation identified in SW620 cells post treatment with A – SW620 cells with NO detection 
reagent, B – 1mM suberoyl-L-arginine (1d) with NO detection reagent and C – 1mM suberoyl-L-arginine (1d) with NO 
scavenger, D – 1mM L-arginine with NO detection reagent, E – 1mM L-arginine with NO scavenger . Bars – 0.6 µm. 
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7.2.4.2 SAR studies on mNOS activation of arginyl amides 
 
Arginyl amides with varying chain lengths including suberoyl-L-arginine (1d), adipoyl-L-arginine 
(2d), pimeloyl-L-arginine (3d) and azeloyl-L-arginine (4d) were subjected to mNOS activation in 
SW 620 and KB-31 cancer cell lines as explained above (Figure 7.16). Adipoyl-L-arginine and 
pimeloyl-L-arginine exhibited moderate mNOS activation and are comparable to L-arginine at 100 
µM concentration. However, suberoyl-L-arginine and azeloyl-L-arginine showed higher 
fluorescence even at 10 µM levels. This observation suggests that longer the fatty acid ester, the 
higher the mNOS activation.  
 
 
Figure 7.16 mNOS activation identified in KB-31 cells post treatment with 1mm A – adipoyl-L-arginine (2d), B – 
pimeloyl-L-arginine (3d), C- suberoyl-L-arginine (1d) and D - azeloyl-L-arginine (4d). Bars – 0.6 µm. 
 
Fatty acid chain of arginyl amides plays a role in the activation of mNOS. The hydrophobicity of 
arginyl amides contributed by fatty acid could facilitate the transport through the cell membrane 
resulting in increased intake compared to L-arginine.  
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7.2.4.3 Discussion – mNOS activation by arginyl amides 
 
Our analyses on mNOS activation suggests that arginyl amides, especially suberoyl-L-arginine (1d), 
the major arginyl amide in the parotoid secretions exhibits significant activation compared to the 
positive control, L-arginine. During a predatory attack, 1d present in the parotoid secretions would 
lead to increased NO production resulting in a plausible vasodilation. It is speculated that this 
would result in increased transport/accessibility of the hydrophobic bufagenins into the cardiac 
region resulting in inhibition of cardiac Na+/K+ ATPase further leading to cardiac arrest (Figure 
7.17).  
Toxin delivery in cane toads follow a typical protoxin to toxin conversion mediated by BtH with 
bufagenins resulting in intoxication of predators while arginyl amides could possibly playing a role 
in intoxication by improving the bufagenin cardiotoxicity.  
 
 
Figure 7.17 Proposed scheme of events following a predatory attack on cane toads 
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7.2.5 Antibacterial activity of bufadienolides and arginyl amides 
 
Cane toad toxins including bufagenins, bufotoxins and arginyl amides were subjected to 
antimicrobial assays with various gram-positive and gram-negative strains including, Bacillus 
subtilis (ATCC 6633), Escherichia coli (ATCC11775), Pseudomonas aeruginosa (ATCC 10145), 
and Staphylococcus aureus (strains ATCC 9144 & ATCC 25923). The list of bufagenins (Figure 
7.1), bufagenin esters (Figure 7.3), bufotoxins (Figure 7.5) and arginyl amides (Figure 7.18) 
subjected to bacterial cytotoxicity assays are mentioned above.  
 
None of the bufadienolides and arginyl amides exhibited prokaryotic cytotoxicity against any of the 
bacteria subjected to the analysis. However, bufalin (3a) exhibited moderate antimicrobial activity 
against the Gram-negative bacteria Pseudomonas aeruginosa with a MIC of 1 µg/mL (Figure 7.14).   
 
 
Figure 7.18 MIC (antilog) curve exhibited by bufalin (3a) on Pseudomonas aeruginosa 
 
Cane toad toxins lack antimicrobial properties against pathogenic bacteria under current 
investigation. These results could not be directly compared to the antimicrobial properties of 
bufadienolides in parotoid gland in situ as the microbes experienced in vivo could be different from 
the current investigation. However, the in situ bufotoxins also provides resistance to microbial 
biotransformation as mentioned earlier in Chapter 5. These observations are consistent with out 
previous findings that in situ storage of bufotoxins provides multiple benefits to the cane toad 
parotoid glands including microbiological stability.  
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7.3 Conclusion 
 
Toxicity of cane toads is a relative terminology as there are no relevant functional assays that 
explore targets (such as Na+/K+ ATPase) in a predatory species (such as crocodile, snakes, quolls 
etc) comparing bufadienolides (bufagenins, bufolipins and bufotoxins) and arginyl amides. 
However, some reports describe binding assays with bufadienolides and Na+/K+ ATPase from non-
predatory species such as pigs. Our current investigations explored the cytotoxicity of cane toad 
chemical diversity and mNOS activation of arginyl amides as a measure of toxicity and identified 
that: 
 
• Bufagenins are more cytotoxic (>30 fold) than bufotoxins and arginyl amides in our 
investigations 
 
• Cytotoxicity of bufolipins are comparable to bufagenins 
 
• Cane toad chemical diversity did not show antibacterial activity 
 
• Arginyl amides are modest activators of mNOS  
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7.4 Experimental 
 
7.4.1 Cytotoxicity 
 
7.4.1.1 Cell lines and Cell Culture 
The human colon cancer cell line SW620 and the human glioblastoma cell line SF-295 were 
provided by Susan E. Bates and Robert W. Robey of the National Cancer Institute (NCI), Bethesda, 
MD. These two cell lines were cultured in RPMI medium 1640 (Invitrogen, Carlsbad, CA). 
 
7.4.1.2 Cytotoxicity Assay (MTT) 
 The MTT assay was used to evaluate the cytotoxicity of compounds against cancer cell lines 
(SW620 and SF295) as previously described15. Briefly, cells (2,000/well in 180 µL of RPMI 1640 
supplemented with 10% FBS) were seeded evenly in a 96-well micro-plate which was then 
incubated for 18 h (37 °C; 5% CO2) for attachment of cells. Compounds to be tested were dissolved 
in 5% DMSO (v/v) and diluted from a range of concentrations (0.001 µM to 3 µM for 3a and 0.01 
µM to 30 µM for all other compounds). Aliquots (20 µL) of each dilution (or of 5% DMSO for 
control wells) were added to the plate in duplicate. After 68 h incubation (37 °C; 5% CO2), a 
solution of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma, USA) in 
PBS was added to each well to a final concentration of 0.4 mg/mL and the plate was incubated for a 
further 4 h (37 °C; 5% CO2). The medium was then carefully aspirated and precipitated formazan 
crystals were dissolved in DMSO (100 µL/well). Finally, the absorbance of each well at 580 nm 
was measured with a PowerWave XS Microplate Reader from Bio-Tek Instruments Inc. (Vinooski, 
VT). IC50 values (the concentration of the compound required for 50% inhibition of the cancer cells) 
were calculated using Prism 5.0 from GraphPad Software Inc. (La Jolla, CA). 
7.4.2 mNOS activation assay 
 
7.4.2.1 Reagents preparation according to manufacturer’s instructions 
 
The nitric oxide detection kit (ENZ-51013) including the NO scavenger 2-(4-carboxyphenyl)-
4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide (c-PTIO) and matching 10×wash buffer was 
purchased from Enzo Life Sciences. 
 
1. Dilution of NO detection reagent: An aliquot of the NO detection reagent (2.5 µL) was diluted 
1:400 with pre-warmed culture medium (1 mL) immediately prior to use.  
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2. Positive control: The NO inducer (L-arginine) was supplied as a stock (100 mM) in deionized 
water. A final concentration per well is 1 mM. Therefore 2 µL of the stock is transferred to 198 µL 
of the cell culture medium. 
3. Negative control: The NO Scavenger (c-PTIO) was supplied as lyophilized powder, which was 
dissolved in dry DMF (100 µL) to produce a stock solution of 4 mM.  
4. 1X Wash buffer: The wash buffer was supplied as a 10X solution, which was diluted 1/10 with 
deionized water to give a 1X working concentration. 
 
7.4.2.2 Cell Preparations 
 
Two cell lines were chosen for the assay, KB-31 (adherent epithelial like, human cervix carcinoma) 
and SW620 (adherent epithelial like, human colorectal carcinoma). Both cells, KB-31 and SW620 
were cultivated in 96 well plates 3 d prior to the experimental day to ensure 50-70% confluency in 
the day of the experiment. The cells were seeded in the plates in 2 different concentrations. KB-31 
was seeded in plates to give final concentration 4000 cells/well, while SW620 was seeded in the 
plates to give final concentration 2000 cells/well. The plates were incubated at 37 °C for 3 d. On the 
day of the experiment, KB-31, 8000 cells/well gave confluency around 60% and for SW620, 8000 
cells/well gave approx. confluency of 70% and the media used were DMEM for KB-31 and 
RPMI1640 for SW620 supplemented with L-glutamine and no phenol red. Cells were harvested and 
treated with compounds in 4 different concentrations (5 mM, 1 mM, 100 µM and 10 µM; 20 
µL/well). Confocal microscopy was performed on a Zeiss LSM510 confocal laser-scanning 
microscope equipped with a Zeiss 63x/1.4NA oil-immersion objective. Confocal microscopy 
samples, in 12 mm coverglass bottom culture dishes (ProSciTech), were excited with a 543 nm He 
Ne laser and measured emissions filtered through a 560 nm long-pass filter. Images were accessed 
using Image J software (NIH).  
 
7.4.3 Antimicrobial assay 
 
MICs against all bacteria were measured by broth microdilution according to the Clinical and 
Laboratory Standards Institutes (CLSI) M7-A7 methodology. Briefly, serial two-fold dilutions of 
each compound was added into Costar non-treated polystyrene 96-well plates, and each well 
inoculated with 50 µL of bacterial strain including Bacillus subtilis, Pseudomonas aeruginosa, 
Staphylococcus aureus strain 9144, Staphylococcus aureus strain 25923 and Escherichia coli in 
MHB with a final concentration of approximate 5×105 CFU/ml. The MIC was the lowest antibiotic 
concentration that showed no visible growth after 24 h of incubation at 37 °C. Plates were subjected 
to spectrophotometric analysis (OD600nm) using POLARstar Omega (BMG Labtech).  
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8. Conclusion 
 
The current thesis describes cane toad parotoid glands and parotoid toxins, their storage and 
delivery, regulation of toxin levels, enzyme mediating toxin regulation, toxin distribution across 
adults and eggs and relationship with bacteria. Addressing all these domains required inputs from 
various disciplines including organic chemistry, analytical chemistry, biochemistry, proteomics and 
transcriptomics, imaging and microbiology. Profiling of cane toad toxins started in 1930’s and it 
was always thought that cane toad parotoid glands contained bufagenins and secereted upon manual 
compression. In 1970’s parotoid glands were studied and parotoid microglands containing parotoid 
toxins were identified, however, individual microglands were not dissected and studied until 2012. 
In 2008 bufagenin degrading bacterial strains were identified and the relationship between parotoid 
secretions and biotransforming bacteria was questioned.  
 
Studies carried on in the current thesis further extended our existing knowledge on cane toad 
parotoid glands, parotoid toxin, parotoid secretions and the relationship with bacteria. A clear 
distinction between parotoid toxins and parotoid secretions was addressed with the help of chemical 
profiling, dissection analysis and microscopy. Identification of a protoxin to toxin conversion with 
the aid of in situ BtH exhibited significant understanding of a rare type of toxin storage and release 
mechanisms in Bufo species. Accordingly, the cytotoxicity studies correlated with the in situ 
bufotoxins being less cytotoxic compared to highly cytotoxic ex situ bufagenins. Another 
interesting finding is the identification of significant amounts of arginyl amides in parotoid 
secretions and their mNOS activation in mammalian cells. Distinction of bufagenin degrading 
strains and biotransforming strains is significant in understanding the relationship between bacteria 
and the parotoid glands. Also, existence of several new bufolipins was identified from B. marinus 
eggs, which also extends our undersanding of B. marinus chemical diversity. Figure 8.1 illustrates 
the trends in the understanding of cane toad parotoid secretions before and after the commencement 
of the current thesis.  
 
The current findings may help us identify strategies to develop cane toad control solutions in 
Australia by exploiting our studies on BtH, bufagenin degrading bacteria and bufolipins (used as 
attractant pheromones).  
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9. Future work 
 
Investigation in the current thesis has led to new insights into the understanding of cane toad toxins 
resulting in interesting outcomes. Following are the list of future work: 
 
• Protein crystallization – As discussed in chapter 4, isolation and identification of BtH 
protein sequence were performed. Since BtH belong to novel class of enzymes, structural 
information is significant. Parotoid secretions from 20 cane toads (40 parotoid glands) were 
collected and a large-scale purification of BtH (30 mg) was performed as mentioned before. 
Following this BtH will be subjected to crystal studies and the resulting crystals will be 
submitted to X-ray crystallography to identify the BtH crystal structure. This work is being 
performed in collaboration with A/Prof. Brett Collins (Institute for Molecular Biosciences) 
and is currently in progress.  
• Bufolipins – Large scale synthesis of bufolipins (g scale) from previously isolated parotoid 
secretions (se Chapter 5) will be performed and submitted to toad tadpole attractant field 
trials which is being performed in collaboration with Prof. Rick Shine in Northern Territory. 
• Identification of biotransforming bacteria – Biotransforming strains that were found to 
transform marinobufagenin (1a) into arenobufagenin (6a) will be subjected to identification 
using PCR based investigation. Also the ability of the strains to transform marinobufotoxin 
(1c) to arenobufotoxin (6c) (oxidations at steroidal C ring) will be performed as the strains 
were isolated from parotoid glands and identification of in situ biotransformation of 
bufotoxins would be significant. Also ability of such strains to biotransform other steroids 
including cholesterol and progesterone will be performed as modifications at C-10 and C-11 
of steroidal C-ring would be a significant investigation.  
• Pharmacology studies – antifungal assays for bufadienolides and arginyl amides using in-
house fungi species such as Candida albicans and Aspergillus niger. A cardiomyocyte 
(Na+/K+ ATPase) inhibition of various structure classes of bufadienolides and arginyl 
amides.  
• Attractant pheromones – bufagenins obtained from parotoid secretions would be subjected 
to microbial biotransformation to produce bufagenin-like structures found in eggs. These 
egg bufagenins would then be converted to bufolipins using established partial synthesis. 
These bufolipins would then be subjected to field trials for the identification of better 
attractant pheromone properties. 
 
 
